<SEC-DOCUMENT>0001193125-23-144211.txt : 20230515
<SEC-HEADER>0001193125-23-144211.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515080104
ACCESSION NUMBER:		0001193125-23-144211
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Benitec Biopharma Inc.
		CENTRAL INDEX KEY:			0001808898
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39267
		FILM NUMBER:		23918501

	BUSINESS ADDRESS:	
		STREET 1:		3940 TRUST WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 780-0819

	MAIL ADDRESS:	
		STREET 1:		3940 TRUST WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d214466d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:bntc="http://www.benitecbiopharmainc.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P07_01_2022To03_31_2023">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="hidden78952390" contextRef="P07_01_2022To03_31_2023">84-4620206</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P07_01_2022To03_31_2023">2023</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P07_01_2022To03_31_2023">Q3</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P07_01_2022To03_31_2023">0001808898</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P07_01_2022To03_31_2023">--06-30</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bntc-20230331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_11_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecIpHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >bntc:LabEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >bntc:LabEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:SeriesTwoWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_08_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_08_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_07_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_07_2022_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PurchaseWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-22</xbrli:startDate> <xbrli:endDate>2020-04-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-15</xbrli:startDate> <xbrli:endDate>2022-09-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-15</xbrli:startDate> <xbrli:endDate>2022-09-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:Series2WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-15</xbrli:startDate> <xbrli:endDate>2022-09-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-17</xbrli:startDate> <xbrli:endDate>2022-10-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-27</xbrli:startDate> <xbrli:endDate>2022-10-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2022To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-30</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;;font-size: .83em;"><br/></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);;text-indent: 0px;">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);;text-indent: 0px;">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">WASHINGTON, D.C. 20549 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P07_01_2022To03_31_2023">10-Q</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Mark One) </div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P07_01_2022To03_31_2023" format="ixt:date-monthname-day-year-en">March 31, 2023</ix:nonNumeric> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Commission File Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P07_01_2022To03_31_2023">001-39267</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 24pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P07_01_2022To03_31_2023">BENITEC BIOPHARMA INC.</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Exact name of registrant as specified in its charter) </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden78952390">84-462-0206</span></div></div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(IRS Employer</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Identification No.)</div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P07_01_2022To03_31_2023">3940 Trust Way</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P07_01_2022To03_31_2023">Hayward</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P07_01_2022To03_31_2023">94545</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices&#160;&amp; zip code) </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P07_01_2022To03_31_2023">510</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P07_01_2022To03_31_2023">780-0819</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Registrant&#8217;s telephone number including area code) </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Title of each class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Trading</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Symbol(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of each exchange</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">on which registered</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P07_01_2022To03_31_2023">Common Stock, par value $0.0001</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P07_01_2022To03_31_2023">BNTC</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P07_01_2022To03_31_2023">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P07_01_2022To03_31_2023">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Emerging&#160;growth&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P07_01_2022To03_31_2023" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;or&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P07_01_2022To03_31_2023" format="ixt:fixed-false">&#9746;</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">We had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn05_11_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">27,981,161</ix:nonFraction> shares of our common stock outstanding as of the close of business on Ma<div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">y 11, 2</div>023. </div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);;text-indent: 0px;">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;text-indent: 0px;"><br/></div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">BENITEC BIOPHARMA INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center" id="toc">INDEX TO FORM <span style="white-space:nowrap">10-Q</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:8%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:88%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_1">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_2">PA RT <span style="white-space:nowrap">I-FINANCIAL</span> INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;1.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_3">Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_4">Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and June 30, 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_5">Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended March 31, 2023 and 2022 (Unaudited)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_6">Consolidated Statements of Stockholders&#8217; Equity for the Nine Months Ended March 31, 2023 and 2022 (Unaudited)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_7">Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2023 and 2022 (Unaudited)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_8">Notes to Consolidated Financial Statements (Unaudited)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;2.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_9">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;3.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_10">Quantitative and Qualitative Disclosures About Market Risk</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;4.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_11">Controls and Procedures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_11a">PA RT <span style="white-space:nowrap">II-OTHER</span> INFORMATION </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;1.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_13">Legal Proceedings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;1A.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_14">Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;2.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_15">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;3.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_16">Defaults Upon Senior Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;4.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_17">Mine Safety Disclosures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;5.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_18">Other Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&#160;6.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_19">Exhibits</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc214466_20">SIGNATURES </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center" id="toc214466_1">SPECIAL NOTE REGARDING <span style="white-space:nowrap">FORWARD-LOOKING</span> STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Report contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. Our forward-looking statements relate to future events or our future performance and include, but are not limited to, statements concerning our business strategy, future commercial revenues, market growth, capital requirements, new product introductions, expansion plans and the adequacy of our funding. All statements, other than statements of historical fact included in this Report, are forward-looking statements. When used in this Report, the words &#8220;could,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; or the negative of these terms, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of our plans to develop and potentially commercialize our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of the initiation and completion of preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and sufficiency of patient enrollment and dosing in any future clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of the availability of data from clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and outcome of regulatory filings and approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated delays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales, marketing, manufacturing and distribution requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market competition and the acceptance of our products in the marketplace; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments in the United States of America, France and Canada; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the development of novel AAV vectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the plans of licensees of our technology; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a &#8220;one shot&#8221; cure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our dependence on our relationships with collaborators and other third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors, including our capital structure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to continue as a going concern; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to meet the Nasdaq listing standards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our intellectual property position and the duration of our patent portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of local, regional, and national and international economic conditions and events; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of the current <span style="white-space:nowrap">COVID-19</span> pandemic, the disease caused by the <span style="white-space:nowrap">SARS-CoV-2</span> virus, which may adversely impact our business and preclinical and future clinical trials; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as other risks detailed under the caption &#8220;Risk Factors&#8221; in this Report and in other reports filed with the SEC. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Report, we caution you that these statements are based on a combination of facts and important factors currently known by us and our expectations of the future, about which we cannot be certain. We have based the forward-looking statements included in this Report on information available to us on the date of this Report or on the date thereof. Except as required by law we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including annual reports on Form <span style="white-space:nowrap">10-K,</span> quarterly reports on Form <span style="white-space:nowrap">10-Q</span> and current reports on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All forward-looking statements included herein or in documents incorporated herein by reference are expressly qualified in their entirety by the cautionary statements contained or referred to elsewhere in this Report. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="bntc-20230331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="toc214466_2" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PART I&#8212;FINANCIAL INFORMATION </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td id="toc214466_3" style="width:9%;vertical-align:top;text-align:left;">ITEM&#160;1.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Financial Statements </div></td></tr></table><div id="toc214466_4" style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">BENITEC BIOPHARMA INC. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Balance Sheets </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(in thousands, except par value and share amounts) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">June&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">(Unaudited)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,062</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,820</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">771</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities and stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">429</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,153</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,532</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, less current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,507</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,091</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies (Note 11)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn06_30_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">160,000,000</ix:nonFraction></ix:nonFraction></div> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">27,981,161</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and June&#160;30, 2022, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,791</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">163,228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">148,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">853</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,882</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="toc214466_5" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">BENITEC BIOPHARMA INC. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Statements of Operations and Comprehensive Loss </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(in thousands, except share and per share amounts)<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine Months Ended</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue:</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing revenues from customers</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total revenues</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,588</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,096</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,011</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,508</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,599</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,341</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,116</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (loss):</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency transaction gain (loss)</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">229</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense, net</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income, net</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on investment</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income (loss), net</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,901</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income:</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized foreign currency translation gain (loss)</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">392</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt; height: 13pt;">
<td style="vertical-align: middle; width: 64%; height: 13pt; padding: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other comprehensive income (loss)</div></td>
<td style="vertical-align: middle; width: 3%; height: 13pt; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">&#160;</td>
<td style="vertical-align: middle; width: 3%; height: 13pt; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">233</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">)&#160;</td>
<td style="vertical-align: middle; width: 3%; height: 13pt; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">392</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">&#160;</td>
<td style="vertical-align: middle; width: 3%; height: 13pt; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: middle; height: 13pt; padding: 0pt;">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive loss</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,352</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,508</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,509</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,901</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share:</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.16</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.40</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.67</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.61</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 64%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding: basic and diluted</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">27,981,161</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">22,090,191</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements.</div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="toc214466_6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENITEC BIOPHARMA INC. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Stockholders&#8217; Equity </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Common&#160;Stock</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accumulated</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amount</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Capital</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deficit</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Loss</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June 30, 2021</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">130,119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation gain</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at September 30, 2021</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">135,164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P10_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P10_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December 31, 2021</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">139,985</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,273</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,836</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at March&#160;31,2022</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">143,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,506</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 49%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June 30, 2022</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">148,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,882</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, and common warrants sold for cash, net of offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrants" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,637,843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,015</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">302</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">302</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation gain</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">507</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">507</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr>
<td style="vertical-align: bottom; width: 49%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at September 30, 2022</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,809,533</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,768</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">153,420</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,613</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WarrantsExercisedDuringThePeriod" contextRef="P10_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,171,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P10_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P10_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P10_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P10_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 49%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December 31, 2022</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">27,981,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,720</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">158,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">898</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,994</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation gain</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 49%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 49%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt; height: 13pt;">
<td style="vertical-align: middle; width: 44%; height: 13pt; padding: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; text-align: left;">Balance at March&#160;31, 2023</div> </td>
<td style="vertical-align: top; width: 2%; height: 13pt; text-align: left;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt; text-align: left;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">27,981,161</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt; text-align: left;">&#160;</td>
<td style="vertical-align: top; width: 2%; height: 13pt; text-align: left;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; text-indent: 0px; height: 13pt;"><div style="letter-spacing: 0px; top: 0px; text-align: left;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt; text-align: left;">&#160;</td>
<td style="vertical-align: top; width: 2%; text-indent: 0px; height: 13pt; text-align: left;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; text-indent: 0px; height: 13pt;"><div style="letter-spacing: 0px; top: 0px; text-align: left;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,791</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt; text-align: left;">&#160;</td>
<td style="vertical-align: top; width: 2%; height: 13pt; text-align: left;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; text-indent: 0px; height: 13pt;"><div style="letter-spacing: 0px; top: 0px; text-align: left;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">163,228</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt; text-align: left;">)&#160;</td>
<td style="vertical-align: top; width: 2%; height: 13pt; text-align: left;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; text-indent: 0px; height: 13pt;"><div style="letter-spacing: 0px; top: 0px; text-align: left;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">853</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt; text-align: left;">)&#160;</td>
<td style="vertical-align: top; width: 2%; height: 13pt; text-align: left;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; text-indent: 0px; height: 13pt;"><div style="letter-spacing: 0px; top: 0px; text-align: left;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,713</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; height: 13pt; text-align: left;">&#160;</td> </tr>
<tr>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div> </td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr> </table> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements.</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><br/></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </div> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="toc214466_7" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">BENITEC BIOPHARMA INC. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Statements of Cash Flows </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(in thousands) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine&#160;Months<br/> Ended&#160;March&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash flows from operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,901</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AmortizationOfRightOfUseAssets" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AmortizationOfRightOfUseAssets" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on investment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">325</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">702</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expense and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IncreasedecreaseInAccountsAndOtherPayables" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IncreasedecreaseInAccountsAndOtherPayables" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">512</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:IncreaseDecreaseInLeaseLiabilities" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:IncreaseDecreaseInLeaseLiabilities" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,044</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash flows from financing activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, and common warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,884</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,015</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase (decrease) in cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,489</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash, beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash, end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Supplemental disclosure of cash flow information:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="toc214466_8" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">BENITEC BIOPHARMA INC. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Notes to Consolidated Financial Statements </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited) </div><ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Business </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (the &#8220;Company&#8221;) is a corporation formed under the laws of Delaware, United States of America, on <ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P07_01_2022To03_31_2023" format="ixt:date-monthname-day-year-en">November 22, 2019</ix:nonNumeric> and listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April 15, 2020. On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June 30, 2021, the Company completed an organization restructuring as part of the commercial desire to provide a more efficient structure for the future as the Company transitioned its operations to the United States. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; are to our fiscal year end June 30 of that calendar year. </div><ix:nonNumeric name="bntc:ScheduleOfEntitiesInControlTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Principal&#160;place&#160;of<br/> business/country&#160;of<br/> incorporation</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">Australia</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Australia Proprietary Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">Australia</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">United Kingdom</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RNAi Therapeutics, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tacere Therapeutics, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec IP Holdings, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To03_31_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr></table></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true" continuedAt="TextSelection_78952198"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Basis of Presentation and Summary of Significant Accounting Policies </div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basis of Presentation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June 30, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principles of Consolidation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P07_01_2022To03_31_2023" escape="true" continuedAt="TextSelection_78952359"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use of Estimates </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>6</ix:exclude></div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_78952359" continuedAt="TextSelectionAppend_78952359_1"><ix:continuation id="TextSelection_78952198" continuedAt="TextSelectionAppend_78952198_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_1" continuedAt="TextSelectionAppend_78952198_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_2" continuedAt="TextSelectionAppend_78952198_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78952198_3" continuedAt="TextSelectionAppend_78952198_4"><ix:continuation id="TextSelectionAppend_78952359_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, allowance for uncollectable receivables, foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates, and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.&#160;<br/></div> </div></ix:continuation><ix:nonNumeric name="bntc:RisksAndUncertainitiesPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Risks and Uncertainties </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single- source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third <div style="display:inline;">parties.</div> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Segment Reporting </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Other comprehensive income (loss) for all periods presented consists entirely of foreign currency translation gains and losses. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>7</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_78952198_4" continuedAt="TextSelectionAppend_78952198_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_5" continuedAt="TextSelectionAppend_78952198_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_6" continuedAt="TextSelectionAppend_78952198_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78952198_7" continuedAt="TextSelectionAppend_78952198_8"><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair Value Measurements </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with GAAP using ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:7%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</td></tr></table></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and Cash Equivalents </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. There were no cash equivalents or bank overdrafts as of March 31, 2023 and June 30, 2022. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concentrations of Risk </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and Other Receivables </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and Equipment </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. <ix:nonNumeric name="bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true" continuedAt="TextSelection_78952285">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </ix:nonNumeric></div><ix:continuation id="TextSelection_78952285"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:82%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2022To03_31_2023_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2022To03_31_2023_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">4</ix:nonNumeric></div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">7</ix:nonNumeric></div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P07_01_2022To03_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</ix:nonNumeric></td></tr></table></ix:continuation></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment of Long-Lived Assets </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>8</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_78952198_8" continuedAt="TextSelectionAppend_78952198_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_9" continuedAt="TextSelectionAppend_78952198_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_10" continuedAt="TextSelectionAppend_78952198_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78952198_11" continuedAt="TextSelectionAppend_78952198_12"><ix:nonNumeric name="bntc:TradeAndOtherPayablesPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and other payables </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leases </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and Diluted Net Loss Per Share </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of March 31, 2023, and June 30, 2022, there were <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">40,684,965</ix:nonFraction> and <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">845,159</ix:nonFraction> potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true" continuedAt="TextSelection_78951891"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue Recognition </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue by applying the following steps: </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing revenues </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method and is constrained to the extent that it is probable that a significant reversal will not occur. Revenue is recognized as or when the performance obligations are satisfied. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>9</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_78951891" continuedAt="TextSelectionAppend_78951891_1"><ix:continuation id="TextSelectionAppend_78952198_12" continuedAt="TextSelectionAppend_78952198_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_13" continuedAt="TextSelectionAppend_78952198_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952198_14" continuedAt="TextSelectionAppend_78952198_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78952198_15"><ix:continuation id="TextSelectionAppend_78951891_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Services revenue </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div> </ix:continuation><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and Development Expense </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed when incurred. Research and development expenses relate primarily to the cost of conducting clinical and preclinical trials. Preclinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain preclinical and clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with preclinical and clinical trial contracts are based on the number of animal subjects, samples or tissues requiring analyses, patients, drug administration cycles, the type of treatment and the outcome since the length of time before actual amounts can be determined will vary depending on the total samples requiring primary and repeated analyses, the length of the patient cycles and the timing of the invoices by the preclinical and clinical trial partners. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based Compensation Expense </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the shorter of the service period or the vesting period. The Company determines employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation based on the grant-date fair value using the Black-Scholes Option Pricing Model. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income Taxes </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to Australia and United States income tax laws. The Company follows ASC 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent Accounting Pronouncements </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> Financial Instruments&#8212;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. </div> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="bntc:GoingConcernDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true" continuedAt="TextSelection_78952192"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Going Concern </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended March 31, 2023, and 2022, the Company incurred a net loss of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">14.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">13.1</ix:nonFraction>&#160;million and used cash of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">13.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">11.0</ix:nonFraction>&#160;million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>10</ix:exclude></div> </ix:nonNumeric></div> <ix:continuation id="TextSelection_78952192" continuedAt="TextSelectionAppend_78952192_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78952192_1" continuedAt="TextSelectionAppend_78952192_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952192_2" continuedAt="TextSelectionAppend_78952192_3"><ix:exclude> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78952192_3"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s business focuses on the development of novel genetic medicines and, at this stage in the Company&#8217;s development, the Company has not established a source of revenue to cover its full operating costs, and as such, is dependent on funding operations through capital financing activities. As of March 31, 2023, the Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.6</ix:nonFraction>&#160;million in cash and cash equivalents. The Company has performed a review of its cash flow forecasts and has concluded that substantial doubt exists as to its ability to continue as a going concern. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future.</div> </ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">4. Cash, cash equivalents, and restricted cash </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">June&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at bank</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DueFromBanks" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DueFromBanks" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,062</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:OtherAssetsDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">5. Prepaid and other assets</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/>2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">332</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">871</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses&#8212;OPMD Program</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:CreditMemo" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">546</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:MarketValueOfListedShares" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:MarketValueOfListedShares" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">879</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">6. Pr<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operty and equipment, net</div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 457.391px;"></td>
<td style="vertical-align: bottom; width: 33.9062px;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 28.375px;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/>2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,343</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,343</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,403</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,404</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation and amortization</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,297</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,182</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">106</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and </div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">amortization</div> expense was $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction>&#160;thousand and for the three and nine months ended March 31, 2023, and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction>&#160;thousand, respectively, for the same periods in 2022. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">7. Trade and other payables </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March&#160;31,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;30,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">422</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedLicenceFeesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">116</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedLicenceFeesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued OPMD project costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedOpmdProjectCostsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedOpmdProjectCostsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued consultant fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedConsultantFeesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedConsultantFeesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;">11</div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always;text-indent: 0px;"></div> </div> </div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Leases </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2025. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. </div> <ix:nonNumeric name="bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the nine months ended March 31, 2023: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Operating<br/> lease&#160;right-<br/> of-<br/> use&#160;assets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">771</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Operating<br/> lease<br/> liabilities</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">811</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">623</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, the Company&#8217;s operating lease has a remaining lease term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn03_31_2023" format="ixt-sec:duryear">2.21</ix:nonNumeric> years and a discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn03_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.67</ix:nonFraction>%. The maturities of the operating lease liabilities are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March&#160;31,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">292</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">657</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">623</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded lease liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#8217;s incremental borrowing rate. Rent expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million for the three and nine months ended March 31, 2023, respectively, and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million for the same periods in 2022. </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12</div> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true" continuedAt="TextSelection_78952210"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">9. Stockholders&#8217; equity </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Common Stock </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December 8, 2021, the stockholders of the Company approved an amendment (the &#8220;Charter Amendment&#8221;) to the Company&#8217;s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock of the Company from <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_08_2021_MinimumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_08_2021_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction>. On December 7, 2022, the stockholders of the Company approved another amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_07_2022_MinimumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction> to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_07_2022_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">160,000,000</ix:nonFraction>. The Charter Amendment was filed with the Secretary of State of the State of Delaware and became effective December 9, 2022. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Warrants </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December 6, 2019, certain investors (the &#8220;Investors&#8221;) were issued <ix:nonFraction name="bntc:NumberOfSeriesWarrantsIssued" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4</ix:nonFraction> Purchase Warrants that were exercisable into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">214,190</ix:nonFraction> fully paid shares of common stock should the Purchase Warrants be exercised in full (&#8220;Purchase Warrants&#8221;). The exercise price for the Purchase Warrants is US$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.50</ix:nonFraction> per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (<ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en">December 6, 2024</ix:nonNumeric>). On April 22, 2020, the Company issued <ix:nonFraction name="bntc:CashlessExerciseOfPurchaseWarrants" contextRef="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">37,417</ix:nonFraction> shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">107,095</ix:nonFraction> shares of common stock. </div> <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The activity related to warrants during the nine months ended March 31, 2023, is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Common</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Price</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Stock from</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">(per</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Warrants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">share)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">107,095</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants issued September&#160;15, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P07_01_2022To09_30_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,171,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfPreFundedWarrantsIssued" contextRef="P07_01_2022To09_30_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series 2 Warrants issued September&#160;15, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:ClassOfWarrantOrRightsIssuedDuringPeriod" contextRef="P07_01_2022To09_30_2022_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,809,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" contextRef="P07_01_2022To09_30_2022_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.66</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at September&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">42,088,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:ClassOfWarrantOrRightsExercised" contextRef="P10_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,171,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" contextRef="P10_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">39,916,566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:ClassOfWarrantsOrRightsExcercisable" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">39,916,566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On September 15, 2022, we closed an underwritten public offering in which we issued and sold (i) <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,637,843</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) <ix:nonFraction name="bntc:ClassOfWarrantOrRightsIssuedDuringPeriod" contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,171,628</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, with each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant immediately exercisable for one share of common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share until exercised in full and (iii) <ix:nonFraction name="bntc:ClassOfWarrantOrRightsIssuedDuringPeriod" contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,809,471</ix:nonFraction> common warrants, the Series 2 Warrants, with each common warrant accompanying each issued share of common stock and/or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant and exercisable for one share of common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_15_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.66</ix:nonFraction> per share. The Series 2 warrants sold in the offering became exercisable commencing December 9, 2022, the date on which the Company had both (a)&#160;received approval from its stockholders to increase the number of shares of common stock it is authorized to issue and (b)&#160;effected such stockholder approval by filing with the Secretary of State of the State of Delaware a certificate of amendment to its <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Amended and Restated Certificate of Incorporation, and will expire on the fifth anniversary of such</div> initial exercise date. The combined purchase price for each share of common stock and accompanying common warrant was $<ix:nonFraction name="bntc:IssueOfCommonStockAndWarrantPricePerShare" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">0.60</ix:nonFraction>, which was allocated as $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.59</ix:nonFraction> per share of common stock and $<ix:nonFraction name="bntc:ClassOfWarrantsOrRightsIssuePricePerUnit" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per common warrant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On October 17, 2022 and October 27, 2022, investors exercised <ix:nonFraction name="bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod" contextRef="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,004,961</ix:nonFraction> and <ix:nonFraction name="bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod" contextRef="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">166,667</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, respectively, at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of March 31, 2023, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">39,916,566</ix:nonFraction> warrants outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Equity Incentive Plan </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Employee Share Option Plan </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In connection with its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> to the United States in April 2020, the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Share Option Plan&#8221;). This includes the Company&#8217;s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date for three years. If an employee dies, retires, or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. Since the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> no new options have been or will be issued under the Share Option Plan. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Equity and Incentive Compensation Plan </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December 9, 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2020 Equity and Incentive Compensation Plan and, on December 8, 2021, the Company&#8217;s stockholders approved an amendment to increase the maximum number of shares that may be issued under such plan to 1,850,000 (as amended, the &#8220;2020 Plan&#8221;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are issued under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#8217;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date for three years. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> director options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on the day prior to each of the Company&#8217;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Future equity grants will be made under the 2020 Plan. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>13</ix:exclude></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_78952210" continuedAt="TextSelectionAppend_78952210_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78952210_1" continuedAt="TextSelectionAppend_78952210_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78952210_2" continuedAt="TextSelectionAppend_78952210_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78952210_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Equity Awards </div><ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related to equity awards, which are comprised of stock options during the nine months ended March 31, 2023 is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Remaining</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Aggregate</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Contractual</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Intrinsic</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Price</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Term</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Value</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June&#160;30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">738,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P06_30_2022To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">7.18</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">45.92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">36,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">9.93</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">768,399</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.64</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">456,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.46</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Share-Based Compensation Expense </div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The classification of share-based compensation expense is <div style="display:inline;">summarized </div>as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;">Nine&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March 31, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">224</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">478</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">325</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">702</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of March 31, 2023, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. </div> </ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">10. Income taxes </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three and nine months ended March 31, 2023, and March 31, 2022 respectively, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.</div></div><br/> </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">11. Commitments and contingencies </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Contract commitments </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Contingencies </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P07_01_2022To03_31_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">12. Related party transactions </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">During the nine months ended March 31, 2023, the Company did not enter into any related party transactions. As of March 31, 2022, the Company had entered into a related party transaction with Francis Abourizk Lightowlers for legal fees totaling $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P07_01_2022To03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;thousand. Peter Francis, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director at the Company, is a partner at Francis Abourizk Lightowlers. As of March 31, 2022 amounts due to this related party of $<ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;thousand were included in trade and other payables on the accompanying consolidated balance sheet. </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;">14</div> </div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="toc214466_9">Item&#160;2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the following discussion and analysis of financial condition and operating results together with our consolidated financial statements and the related notes and other financial information included elsewhere in this document. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Overview</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (&#8220;Benitec&#8221; or the &#8220;Company&#8221; or in the third person, &#8220;we&#8221; or &#8220;our&#8221;) is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called <span style="white-space:nowrap">DNA-directed</span> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease- causing genes following a single administration. The Company is developing a ddRNAi-based therapeutic <span style="white-space:nowrap">(BB-301)</span> for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is a ddRNAi-based genetic medicine currently under development by Benitec. <span style="white-space:nowrap">BB-301</span> is an AAV-based gene therapy designed to simultaneously silence the expression of the mutant, disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and replace the mutant gene with a wild type gene (to drive restoration of function in diseased cells). This fundamental therapeutic approach to disease management is called &#8220;silence and replace&#8221;. The silence and replace mechanism offers the potential to restore the normative physiology of diseased cells and tissues and to improve treatment outcomes for patients suffering from the chronic, and potentially fatal, effects of OPMD. <span style="white-space:nowrap">BB-301</span> has been granted Orphan Drug Designation in the United States and the European Union. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The targeted gene silencing effects of RNAi, in conjunction with the durable transgene expression achievable via the use of modified viral vectors, imbues the silence and replace approach with the potential to produce long-term silencing of disease-causing genes along with simultaneous replacement of wild type gene function following a single administration of the proprietary genetic medicine. We believe that this novel mechanistic profile of the current and future investigational agents developed by Benitec could facilitate the achievement of robust and durable clinical activity while greatly reducing the frequency of drug administration traditionally expected for medicines employed for the management of chronic diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the achievement of long-term gene silencing and gene replacement may significantly reduce the risk of patient <span style="white-space:nowrap">non-compliance</span> during the course of medical management of potentially fatal clinical disorders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline"><span style="white-space:nowrap">COVID-19</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">COVID-19</span> has been declared a pandemic by the World Health Organization and has spread to nearly every country, including Australia and the United States. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted in, and will likely continue to result in, significant disruptions to businesses and capital markets around the world. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and its variants, and the actions to contain the coronavirus or treat its impact, including the effectiveness and adoption of vaccines for the virus, among others. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain elements of our research and development efforts are conducted globally, including the ongoing development of our silence and replace therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to complete preclinical studies and initiate clinical studies despite the ongoing <span style="white-space:nowrap">COVID-19</span> pandemic. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we endeavor to complete our development programs, including the ongoing Toxicology and Biodistribution and Natural History studies for <span style="white-space:nowrap">BB-301,</span> we are in close contact with our principal investigators, contract research organizations, and preclinical trial sites, which are located in the United States, Canada, and France, and are assessing the impact of <span style="white-space:nowrap">COVID-19</span> on our studies and the expected development timelines and costs on an ongoing basis. In light of developments relating to the <span style="white-space:nowrap">COVID-19</span> global pandemic since the beginning of the outbreak, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s industry guidance for conducting clinical trials, we have experienced delays to the original timeline regarding the initiation and anticipated completion of the ongoing <span style="white-space:nowrap">BB-301</span> Clinical Trial Application (CTA)-enabling and Investigational New Drug Application (IND)-enabling development work. The initiation of the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study in Beagle dogs, which represents a key component of the <span style="white-space:nowrap">CTA-</span> enabling and <span style="white-space:nowrap">IND-enabling</span> work, was delayed by several months, however, the study has been completed without incident. The acquisition of chemical reagents, biological reagents and laboratory supplies which are essential for the conduct of basic laboratory research, the conduct of nonclinical studies and the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">completion of GMP manufacturing of <span style="white-space:nowrap">BB-301,</span> has also become challenging due to the disruption of global supply chains inherent to the production of these materials. We will continue to evaluate the impact of the <span style="white-space:nowrap">COVID-19</span> pandemic on our business and we expect to reevaluate the timing of our anticipated preclinical and clinical milestones as we learn more and the impact of <span style="white-space:nowrap">COVID-19</span> on our industry becomes clearer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also implemented a halt of <span style="white-space:nowrap">non-essential</span> business travel and a rotation system whereby staff work from home and attend the laboratory on designated days which may result in a reduction of laboratory work. As we transition our employees back to our premises, there is a risk that <span style="white-space:nowrap">COVID-19</span> infections occur at our offices or laboratory facilities and significantly affect our operations. Additionally, if any of our critical vendors are impacted, our business could be affected if we become unable to procure essential equipment in a timely manner or obtain supplies or services in adequate quantities and at acceptable prices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Public Equity Offering</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 15, 2022, we closed an underwritten public offering in which we issued and sold (i) 17,637,843 shares of the Company&#8217;s common stock, (ii) 12,171,628 <span style="white-space:nowrap">pre-funded</span> warrants, with each <span style="white-space:nowrap">pre-funded</span> warrant immediately exercisable for one share of common stock at an exercise price of $0.0001 per share until exercised in full and (iii) 29,809,471 common warrants, with each common warrant accompanying each issued share of common stock and/or <span style="white-space:nowrap">pre-funded</span> warrant and exercisable for one share of common stock at an exercise price of $0.66 per share (the &#8220;September 2022 Capital Raise&#8221;). The common warrants sold in the offering became exercisable on December 9, 2022, the date by which the Company (a)&#160;received approval from its stockholders to increase the number of shares of common stock it is authorized to issue and (b)&#160;effected such stockholder approval by filing with the Secretary of State of the State of Delaware a certificate of amendment to its amended and restated certificate of incorporation, and will expire on the fifth anniversary of such initial exercise date. The combined purchase price for each share of common stock and accompanying common warrant was $0.60, which was allocated as $0.59 per share of common stock and $0.01 per common warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds to the Company from the public offering were approximately $16&#160;million, after deducting underwriting discounts and commissions and public offering expenses payable by the Company, and excluding any proceeds the Company may receive upon exercise of the <span style="white-space:nowrap">pre-funded</span> warrants or the common warrants. The Company currently intends to use the net proceeds for the clinical development of <span style="white-space:nowrap">BB-301,</span> including the natural history <span style="white-space:nowrap">lead-in</span> study and the Phase 1b/2a <span style="white-space:nowrap">BB-301</span> treatment study, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities. The Company will have broad discretion in determining how the proceeds of the public offering will be used, and its discretion is not limited by the aforementioned possible uses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Nasdaq Listing</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 6, 2022, we received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying us that the minimum bid price per share for our common stock fell below $1.00 for a period of 30 consecutive business days and therefore we did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The letter also states that we will be provided 180 calendar days, or until March 6, 2023, to regain compliance with the minimum bid price requirement. In accordance with Rule 5810(c)(3)(A), we can regain compliance if at any time during the <span style="white-space:nowrap">180-day</span> period the closing bid price of our common stock is at least $1.00 for a minimum of 10 consecutive business days. On March 7, 2023, Nasdaq notified the Company in writing that while the Company had not regained compliance with the minimum bid price requirement, it was eligible for an additional 180 calendar day period, or until September 5, 2023, to regain compliance with the minimum bid price requirement. Nasdaq&#8217;s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement and on the Company&#8217;s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company&#8217;s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement. These options include completing a reverse stock split of our common stock for the purpose of meeting the closing bid price requirement. We received stockholder approval to effect a reverse stock split at our Annual Meeting of Stockholders on December 7, 2022 but currently have no plans to proceed. Such approval allows our board of directors, in its discretion, to elect to implement such reverse stock split at any time prior to December 7, 2023. Completing a reverse stock split will not, in of itself, cause us to remain in compliance with Nasdaq&#8217;s listing standards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Development Programs</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Pipeline </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the current product candidate and the development status: </p> <p style="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table 1. Pipeline: Oculopharyngeal Muscular Dystrophy </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g214466g20n20.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">BB-301</span> for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). <span style="white-space:nowrap">BB-301</span> is the lead investigational agent under development by Benitec, and the key attributes of OPMD and <span style="white-space:nowrap">BB-301</span> are outlined in Figure 3. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 3. Overview of the <span style="white-space:nowrap">BB-301</span> Program </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g214466g21n21.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is a <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-class</span></span> genetic medicine employing the &#8220;silence and replace&#8221; approach for the treatment of OPMD. OPMD is an insidious, autosomal- dominant, late-onset, degenerative muscle disorder that typically presents in patients at <span style="white-space:nowrap"><span style="white-space:nowrap">40-to-50</span></span> years of age. The disease is characterized by progressive swallowing difficulties (dysphagia) and eyelid drooping (ptosis). OPMD is caused by a specific mutation in the poly(A)-binding protein nuclear 1 gene (PABPN1). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OPMD is a rare disease, however, patients have been diagnosed with OPMD in at least 33 countries. Patient populations suffering from OPMD are well- identified, and significant geographical clustering has been noted for patients with this disorder. Each of these attributes could facilitate efficient clinical development and global commercialization of <span style="white-space:nowrap">BB-301.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PABPN1 is a ubiquitous factor that promotes the interaction between the poly(A) polymerase and CPSF (cleavage and polyadenylation specificity factor) and, thus, controls the length of mRNA poly(A) tails, mRNA export from the nucleus, and alternative poly(A) site usage. The characteristic genetic mutation underlying OPMD results in trinucleotide repeat expansion(s) within exon 1 of PABPN1 and results in an expanded poly-alanine tract at the <span style="white-space:nowrap">N-terminal</span> end of PABPN1. The mutation generates a protein with an <span style="white-space:nowrap">N-terminal</span> expanded poly-alanine tract of up to 18 contiguous alanine residues, and the mutant protein is prone to the formation of intranuclear aggregates designated as intranuclear inclusions (INIs). The INIs that sequester wildtype PABPN1 may contribute to the &#8220;loss of function&#8221; phenotype associated with OPMD. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No therapeutic agents are approved for the treatment of OPMD. Additionally, there are no surgical interventions available to OPMD patients that modify the natural history of the disease, which is principally comprised of chronic deterioration of swallowing function. <span style="white-space:nowrap">BB-301</span> has received Orphan Drug Designation in the United States and the European Union and, upon achievement of regulatory approval for <span style="white-space:nowrap">BB-301</span> in these respective jurisdictions, the Orphan Drug Designations would provide commercial exclusivity independent of intellectual property protection. While OPMD is a rare medical disorder, we believe the commercial opportunity for a safe and efficacious therapeutic agent in this clinical indication exceeds $1&#160;billion over the course of the commercial life of the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec has previously outlined the core <span style="white-space:nowrap">CTA-enabling</span> and <span style="white-space:nowrap">IND-enabling</span> studies required by global regulatory agencies to support the initiation of <span style="white-space:nowrap">BB-301</span> clinical trials in OPMD patients, and these studies include a <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study (the &#8220;Pilot Dosing Study&#8221;) in large animals and a classical <span style="white-space:nowrap">12-week</span> GLP Toxicology and Biodistribution Study for <span style="white-space:nowrap">BB-301.</span> In these large animal studies, <span style="white-space:nowrap">BB-301</span> is directly injected into the pharyngeal muscles known to underlie the morbidity and mortality which characterizes the natural history of OPMD in human subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As referenced above, the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study in large animals was the first of two <span style="white-space:nowrap">CTA-enabling</span> and <span style="white-space:nowrap">IND-enabling</span> studies conducted by Benitec. This study was carried out under the guidance of the scientific team at Benitec, with key elements of the design and execution of the study conducted in close collaboration with a team of experts in both medicine and surgery that have been deeply engaged in the treatment of OPMD patients for decades. The <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study and the GLP Toxicology and Biodistribution Study for <span style="white-space:nowrap">BB-301</span> were conducted in canine subjects in order to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Support the validation and optimization of the newly designed route and method of <span style="white-space:nowrap">BB-301</span> administration, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Confirm the efficiency of vector transduction and transgene expression in the key tissue compartments underlying the morbidity and mortality that comprises the natural history of OPMD, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Confirm the optimal <span style="white-space:nowrap">BB-301</span> doses in advance of initiation of human clinical studies, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Facilitate the observation of key toxicological data-points. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study was designed as an <span style="white-space:nowrap">8-week</span> study in Beagle dogs to confirm the transduction efficiency of <span style="white-space:nowrap">BB-301</span> upon administration via direct intramuscular injection into specific anatomical regions of the pharynx through the use of an open surgical procedure. This new method and route of <span style="white-space:nowrap">BB-301</span> administration was developed in collaboration with key surgical experts in the field of Otolaryngology, and this novel method of <span style="white-space:nowrap">BB-301</span> dosing will significantly enhance the ability of treating physicians to accurately administer the AAV-based investigational agent to the muscles that underlie the characteristic deficits associated with disease progression in OPMD. It is important to note that prior <span style="white-space:nowrap">BB-301</span> <span style="white-space:nowrap">non-clinical</span> studies have reproducibly validated the robust biological activity achieved following direct intramuscular injection of the AAV-based agent. As an example, direct injection of <span style="white-space:nowrap">BB-301</span> into the tibialis anterior muscles of A17 mice facilitated robust transduction of the targeted skeletal muscle cells and supported complete remission of the OPMD disease phenotype in this animal model. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec conducted the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study in Beagle dog subjects to demonstrate that direct intramuscular injection of BB-301 via the use of a proprietary dosing device in an open surgical procedure could safely achieve the following goals: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Biologically significant and dose-dependent levels of <span style="white-space:nowrap">BB-301</span> tissue transduction (i.e., delivery of the multi-functional BB-301 genetic construct into the target pharyngeal muscle cells), </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Broad-based and dose-dependent expression of the three distinct genes comprising the <span style="white-space:nowrap">BB-301</span> gene construct within the pharyngeal muscle cells, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Biologically significant levels of target gene knock-down (i.e., inhibition of the expression of the gene of interest) within the pharyngeal muscle cells. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Pilot Dosing Study evaluated the safety and biological activity of two concentrations of <span style="white-space:nowrap">BB-301</span> (1.0+E13 vg/mL and 3.0+E13 vg/mL) across three distinct doses (1.0+E13 vg/mL and 3.0+E13 vg/mL with a low injection volume, and 3.0+E13 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">vg/mL with a high injection volume) following direct intramuscular injection into the Hypopharyngeus (HP) muscles and the Thyropharyngeus (TP) muscles of Beagle dogs via the use of a proprietary delivery device employed in an open surgical procedure. The HP muscle in Beagle dogs corresponds to the Middle Pharyngeal Constrictor muscle in human subjects, and the TP muscle in Beagle dogs corresponds to the Inferior Pharyngeal Constrictor muscle in human subjects. <span style="white-space:nowrap">BB-301</span> was injected only on Day 1 of the Pilot Dosing Study, and the corresponding canine pharyngeal muscles were harvested for molecular analyses after 8 weeks of observation post-injection. <span style="white-space:nowrap">BB-301</span> dosing was carried out independently by a veterinary surgeon and an Otolaryngologist with extensive experience regarding the provision of palliative surgical care for OPMD patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Molecular analyses have been completed for the canine subjects treated in the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study. Key interim data-sets derived from the analyses of pharyngeal muscle tissues isolated from 16 Beagle dog subjects (of the <span style="white-space:nowrap">24-subject</span> Beagle dog study population) are highlighted below. The final <span style="white-space:nowrap">data-set</span> derived from the completed molecular analyses of the pharyngeal muscle tissues of the canine subjects treated on the Pilot Dosing Study will be presented in a peer-reviewed format. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key interim data-sets are summarized below: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 4. Pharyngeal Muscle Tissue Transduction Levels Achieved by <span style="white-space:nowrap">BB-301</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g214466g23n23.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding Gene Expression Levels Observed for <span style="white-space:nowrap">BB-301</span> Within the Pharyngeal Muscle Tissues (Figure 5, Figure 6, Figure 7): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> encodes two distinct siRNA species (i.e., siRNA13 and siRNA17) which are each, independently, capable of inhibiting (i.e., &#8220;silencing&#8221;) the expression of the mutant form of the PABPN1 protein and the wild type (i.e., endogenous) form of the PABPN1 protein (importantly, the mutant form of the PABPN1 protein underlies the development, and progression, of OPMD). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> also codes for a wild type version of the PABPN1 protein whose intracellular expression is unaffected by the inhibitory activities of siRNA13 and siRNA17; this &#8220;codon optimized&#8221; transcript drives the expression of a PABPN1 protein (i.e., coPABPN1) which serves to replenish the endogenous form of the PABPN1 protein and to replace the mutant form of PABPN1 that underlies the development and progression of OPMD in diseased tissues. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For comparative purposes, it should be noted that the average range of expression for wild type PABPN1 within the pharyngeal muscle cells of Beagle dogs is 4.5 copies per <span style="white-space:nowrap"><span style="white-space:nowrap">cell-to-7.8</span></span> copies per cell. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 5. siRNA13 Expression Levels Achieved by <span style="white-space:nowrap">BB-301</span> within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g214466g24n01.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 6. siRNA17 Expression Levels Achieved by <span style="white-space:nowrap">BB-301</span> within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g214466g24n02.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 7. coPABPN1 Expression Levels Achieved by <span style="white-space:nowrap">BB-301</span> within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g214466g25n25.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding Wild Type PABPN1 Silencing (i.e., target &#8220;knock-down&#8221;) Observed for <span style="white-space:nowrap">BB-301</span> Within the Pharyngeal Muscle Tissues (Figure 8): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As noted above, <span style="white-space:nowrap">BB-301</span> encodes two distinct siRNA species (i.e., siRNA13 and siRNA17) which are each, independently, capable of inhibiting (i.e., &#8220;silencing&#8221;) the expression of all forms of the PABPN1 protein (siRNA13 and siRNA17 silence the expression of both wild type PABPN1 [wtPABPN1] and mutant PABPN1). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">While the Beagle dog subjects treated in the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study do not express mutant PABPN1, the level of <span style="white-space:nowrap"><span style="white-space:nowrap">BB-301-driven</span></span> gene silencing for the PABPN1 target can be indirectly assessed in these study subjects due to the equivalent inhibitory effects of siRNA13 and siRNA17 on both wtPABPN1 and mutant PABPN1. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Thus, the wtPABPN1 silencing activity observed in the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study serves as a surrogate for the silencing activity that would be anticipated in the presence of mutant PABPN1. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> has been evaluated in prior <span style="white-space:nowrap">non-clinical</span> studies in animals that express mutant PABPN1 and, as a result, manifest the symptomatic phenotype of OPMD; in the symptomatic animal model of OPMD (i.e. the A17 mouse model), the achievement of PABPN1 silencing levels of 31% inhibition (or higher) following <span style="white-space:nowrap">BB-301</span> administration led to resolution of OPMD disease symptoms and the elimination of the histopathological hallmarks of OPMD. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 8. PABPN1 Silencing (i.e., &#8220;target knock-down&#8221;) Achieved by <span style="white-space:nowrap">BB-301</span> within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g214466g26n01.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are key methodological distinctions between the current <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study conducted by Benitec as compared to the prior <span style="white-space:nowrap">BB-301</span> Beagle dog dosing study carried out independently by the previous <span style="white-space:nowrap">BB-301</span> licensee. The <span style="white-space:nowrap">BB-301</span> dosing study conducted by the prior <span style="white-space:nowrap">BB-301</span> licensee employed <span style="white-space:nowrap">non-ideal</span> routes and methods of <span style="white-space:nowrap">BB-301</span> administration to the target pharyngeal muscle tissues and employed similarly limited analytical methods at the completion of the dosing phase of the study. Subsequently, the Benitec team worked to optimize the route and method of administration of <span style="white-space:nowrap">BB-301</span> and to refine the core analytical methods employed following the completion of dosing of the large animal subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current proprietary method of <span style="white-space:nowrap">BB-301</span> delivery to the key pharyngeal muscles of study subjects, and the proprietary molecular analytical methods employed to assay the pharyngeal muscle tissues of study subjects, with both methods having been developed by the Benitec team, led to the observation of broad-based transduction of the targeted pharyngeal muscle tissues (Figure 9, represents individual sections of the TP muscle following <span style="white-space:nowrap">BB-301</span> dosing). Critically, the Benitec-developed methods also facilitated the achievement of a <span style="white-space:nowrap">228-fold</span> improvement (+22,647%) in <span style="white-space:nowrap">BB-301</span> transduction of the HP muscle and a <span style="white-space:nowrap">113-fold</span> improvement (+11,163%) in <span style="white-space:nowrap">BB-301</span> transduction of the TP muscle relative to the levels of <span style="white-space:nowrap">BB-301</span> transduction observed by the previous <span style="white-space:nowrap">BB-301</span> licensee at identical <span style="white-space:nowrap">BB-301</span> doses in identical canine study populations (Figure 10). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 9. <span style="white-space:nowrap">BB-301</span> Transduction Levels Achieved for Individual Sections of the TP Muscle Following <span style="white-space:nowrap">BB-301</span> dosing </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g214466g26n02.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 10. Impact of the Methodological Improvements to the <span style="white-space:nowrap">BB-301</span> Large Animal Dosing Study Design on the Relative Pharyngeal Muscle Tissue Transduction Levels Achieved by Benitec vs. the Former <span style="white-space:nowrap">BB-301</span> Licensee </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g214466g27n27.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the disclosure of the positive interim <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study results, Benitec completed <span style="white-space:nowrap">pre-CTA</span> and <span style="white-space:nowrap">pre-IND</span> meetings with regulatory agencies in France, Canada, and the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summary of Regulatory Interactions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Benitec successfully completed the regulatory interactions required to support initiation of the OPMD clinical development program in 2022 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Successful regulatory engagement comprised the completion of the following meetings: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">Pre-Clinical</span> Trial Application <span style="white-space:nowrap">(Pre-CTA)</span> Consultation Meeting with Health Canada </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Scientific Advice Meeting with The National Agency for the Safety of Medicines and Health Products in France (L&#8217;Agence nationale de s&#233;curit&#233; du m&#233;dicament et des produits de sant&#233; or &#8220;ANSM&#8221;) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Type C Meeting with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022 Benitec began screening OPMD subjects at the first clinical trial site in the United States in support of the OPMD clinical development program. In January 2023 Benitec disclosed the enrollment of the first OPMD subject into the Natural History Study (i.e., the <span style="white-space:nowrap">6-month</span> <span style="white-space:nowrap">pre-treatment</span> observation period described below). Enrollment of OPMD subjects into the Natural History Study at the U.S. clinical trial site is proceeding at a rapid pace and supports our central clinical development goals of: (1)&#160;administering <span style="white-space:nowrap">BB-301</span> to OPMD subjects in 2H2023, and (2)&#160;disclosing interim safety and efficacy data in 2H2023 for one or more subjects that have received <span style="white-space:nowrap">BB-301.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summary of the <span style="white-space:nowrap">BB-301</span> Clinical Development Program: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The <span style="white-space:nowrap">BB-301</span> clinical development program began in 2022, and the conduct of the development program will comprise approximately <span style="white-space:nowrap">76-weeks</span> of <span style="white-space:nowrap">follow-up</span> for each OPMD study participant, inclusive of: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">6-month</span> <span style="white-space:nowrap">pre-treatment</span> observation periods employing quantitative radiographic imaging techniques for evaluation of the baseline disposition and natural history of OPMD-derived dysphagia in each study participant </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1 day of <span style="white-space:nowrap">BB-301</span> dosing to initiate participation in the Phase 1b/2a <span style="white-space:nowrap">single-arm,</span> open-label, sequential, dose escalation cohort study </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">52-weeks</span> of post-dosing <span style="white-space:nowrap">follow-up</span> for conclusive evaluation of the primary and secondary endpoints of the Phase 1b/2a <span style="white-space:nowrap">BB-301</span> treatment study </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The screening of OPMD subjects for enrollment into the OPMD Natural History Study began in December 2022, with the first OPMD subject being formally enrolled in January 2023 and brisk enrollment having continued over the subsequent months. This observational study will facilitate the characterization of OPMD patient disposition at baseline and assess subsequent rates of progression of dysphagia (swallowing impairment) in subjects with OPMD via the use of quantitative radiographic measures of global swallowing function and pharyngeal constrictor muscle function along with clinical assessments and patient-reported self-assessments of swallowing function </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Videofluoroscopic Swallowing Studies (VFSS) will be conducted to complete the following methodological assessments: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Dynamic Imaging Grade of Swallowing Toxicity Scale (DIGEST) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Pharyngeal Area at Maximum Constriction (PhAMPC) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Pharyngeal Constriction Ratio (PCR) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Clinical measures of global swallowing capacity and oropharyngeal dysphagia </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Patient-reported measures of oropharyngeal dysphagia </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The natural history of dysphagia observed for each OPMD study participant in the Natural History Study, as characterized by the quantitative radiographic measures and the clinical and patient self-reported assessments outlined above, will serve as the baseline for comparative assessments of safety and efficacy of <span style="white-space:nowrap">BB-301</span> upon rollover of OPMD study subjects from the Natural History Study onto the Phase 1b/2a <span style="white-space:nowrap">BB-301</span> treatment study </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Upon the achievement of <span style="white-space:nowrap">6-months</span> of <span style="white-space:nowrap">follow-up</span> in the Natural History Study, OPMD Natural History Study participants can become eligible for enrollment onto the Phase 1b/2a treatment study with the investigational genetic medicine, <span style="white-space:nowrap">BB-301,</span> which uses an <span style="white-space:nowrap">AAV9-based</span> gene therapy approach for the treatment of OPMD-derived dysphagia </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">This <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> (FIH) clinical trial will be a Phase 1b/2a, open-label, dose escalation study to evaluate the safety and clinical activity of intramuscular doses of <span style="white-space:nowrap">BB-301</span> administered to the pharyngeal muscles of subjects with OPMD </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Upon rollover from the Natural History Study onto the Phase 1b/2a <span style="white-space:nowrap">BB-301</span> treatment study, the <span style="white-space:nowrap">follow-up</span> of OPMD study participants will continue for <span style="white-space:nowrap">52-weeks,</span> and the primary endpoints (safety) and secondary endpoints (comprising the quantitative radiographic measures of global swallowing function and pharyngeal constrictor muscle function, and the clinical and patient-reported assessments noted above) will be evaluated during each <span style="white-space:nowrap">90-day</span> period following Day 1 (Day 1 represents the day of <span style="white-space:nowrap">BB-301</span> intramuscular injection). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Royalties, milestone payments and other license fees</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to pay royalties, milestone payments and other license fees in connection with our licensing of intellectual property from third parties, including as discussed below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have collaborated with Biomics Biotechnologies Co., Ltd., or Biomics, pursuant to several collaboration agreements in relation to single-stranded RNA and shRNA sequences for treatment of hepatitis B. In July 2015, we entered into an <span style="white-space:nowrap">earn-out</span> agreement with Biomics which confirmed Benitec&#8217;s ownership of certain patents resulting from the collaboration in exchange for an upfront payment and equity issuance to Biomics and a share of certain future licensing revenue received by Benitec. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">October 2020 Capital Raise</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 6, 2020, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents. The Company received gross proceeds of approximately $11.5&#160;million and net proceeds of approximately $9.9&#160;million from the offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">April 2021 Capital Raise</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 30, 2021, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents. The Company received gross proceeds of approximately $14.3&#160;million and net proceeds of approximately $12.7&#160;million from the offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">September 2022 Capital Raise</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 15, 2022, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents. The Company received gross proceeds of approximately $17.9&#160;million and net proceeds of approximately $16.0&#160;million from the offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Results of Operations</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Revenues</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not generated any revenues from the sales of products. Revenues from licensing fees are included in the revenue from customers line item on our consolidated statements of operations and comprehensive loss. Our licensing fees have been generated through the licensing of our ddRNAi technology to biopharmaceutical companies. The Company recognized licensing fee revenues totaling $68&#160;thousand and $73&#160;thousand during the nine months ended March 31, 2023 and March 31, 2022, respectively. Licensing fee revenue for the three-month periods ended March&#160;31, 2023 and March&#160;31, 2022 totaled $54&#160;thousand and $48&#160;thousand, respectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties and License Fees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties and license fees consist primarily of payments we are required to remit for royalties and other payments related to <span style="white-space:nowrap">in-licensed</span> intellectual property. Under our <span style="white-space:nowrap">in-license</span> agreements, we may pay <span style="white-space:nowrap">up-front</span> fees and milestone payments and be subject to future royalties. We cannot precisely predict the amount, if any, of royalties we will owe in the future, and if our calculations of royalty payments are incorrect, we may owe additional royalties, which could negatively affect our results of operations. As our product sales increase, we may, from time to time, disagree with our third-party collaborators as to the appropriate royalties owed, and the resolution of such disputes may be costly, may consume management&#8217;s time, and may damage our relationship with our collaborators. Furthermore, we may enter into additional license agreements in the future, which may also include royalty, milestone and other payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and Development Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and preclinical trials. Preclinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and Administrative Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries, related benefits, travel, and equity-based compensation expense. General and administrative expenses also include facility expenses, professional fees for legal, consulting, accounting and audit services and other related costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses may increase as the Company focuses on the continued development of the preclinical OPMD program. The Company also anticipates an increase in expenses relating to accounting, legal and regulatory-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and other similar costs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables sets forth a summary of our expenses for each of the periods: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:70%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">Three&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">Nine&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center">(US$&#8217;000)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 8,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,011</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three and nine months ended March 31, 2023, we incurred $3.2&#160;million and $9.6&#160;million in research and development expenses, respectively, as compared to $2.2&#160;million and $8.1&#160;million for the comparable periods ended March 31, 2022. Research and development expenses relate primarily to the OPMD project. The year-over-year increases for the nine-month period reflect conclusion of the BB-301 Regulatory Toxicology Study and the Parallel Assay Method Development, Qualification, and Validation project, and the continuation of the GMP manufacturing project and Natural History Study. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense totaled $1.2&#160;million and $5.0&#160;million for the three and nine months ended March 31, 2023, compared to $1.3&#160;million and $5.1&#160;million for the comparable periods ended March 31, 2022. The year-over-year decrease for the three-month periods ended March 31 relates to lower listing and filing fees and stock-based compensation. See Note 9 of the Notes to Consolidated Financial Statements included in this Quarterly Report on Form <span style="white-space:nowrap">10-Q.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other Income (Loss) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables sets forth a summary of our other income (loss) for each of the periods: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">Three&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">Nine&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center">(US$&#8217;000)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Income (Loss):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency transaction gain (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(391</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on investment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (loss), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (loss), net during the three and nine months ended March 31, 2023, which consists of foreign currency transaction gain (loss), interest expense, other income, and unrealized loss on investment, totaled $(56) thousand and $(370) thousand, respectively. During the three and nine months ended March 31, 2022, respectively, other income (loss) totaled $185&#160;thousand and $(25) thousand. The swings to foreign currency transaction losses during the three- and nine-month month periods ended March 31 reflect changes in foreign exchange rates. Other income for the nine-month period ended March&#160;31, 2023 relates to recognition of a refund. Unrealized loss on investment decreased for the three- and nine- month periods ended March 31, 2023, compared to the same prior year periods. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Liquidity and Capital Resources</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred cumulative losses and negative cash flows from operations since our predecessor&#8217;s inception in 1995. The Company had accumulated losses of $163&#160;million as of March 31, 2023. We expect that our research and development expenses may increase due to the continued development of the OPMD program. It is also likely that there will be an increase in the general and administrative expenses due to the obligations of being a domestic public company in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had no borrowings as of March 31, 2023 and do not currently have a credit facility. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, we had cash and cash equivalents of approximately $6.6&#160;million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the net cash flow activity for each of the periods set forth below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">Nine Months Ended</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">(US$&#8217;000)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,917</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,044</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(95</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,139</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating activities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the nine months ended March 31, 2023 and 2022 was $13.9&#160;million and $11.0&#160;million, respectively. Net cash used in operating activities was primarily the result of our net loss, partially offset by <span style="white-space:nowrap">non-cash</span> expenses, and changes in working capital, including an increase in payables. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financing activities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $16.0&#160;million and $0 for the nine months ended March 31, 2023 and 2022, respectively. Cash from financing activities during the nine months ended March 31 2023, was related to the issuance of common stock, <span style="white-space:nowrap">pre-funded</span> warrants, and Series 2 warrants, including $17.9&#160;million in gross proceeds from the September 2022 Capital Raise, partially offset by $1.9&#160;million in share issuance costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future of the Company as an operating business will depend on its ability to manage operating costs and budgeted amounts and obtain adequate financing. While we continue to progress discussions and advance opportunities to engage with pharmaceutical companies and continue to seek licensing partners for ddRNAi in disease areas that are not our focus, there can be no assurance as to whether we will enter into such arrangements or what the terms of any such arrangement could be. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have established some licensing arrangements, we do not have any products approved for sale and have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless and until we establish significant revenues from licensing programs, strategic alliances or collaboration arrangements with pharmaceutical companies, or from product sales, we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of product candidates and begin to prepare to commercialize any product that receives regulatory approval. We are subject to the risks inherent in the development of new gene therapy products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The Company has performed a review of its cash flow forecasts and has concluded that substantial doubt exists as to its ability to continue as a going concern. The Company does not have sufficient liquidity to fund its operations for the next twelve months without raising additional funds and the success of raising such additional capital is not solely within the Company&#8217;s control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and costs of our planned clinical trials for our ddRNAi and silence and replace product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and costs of our planned preclinical studies for our ddRNAi and silence and replace product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and characteristics of product candidates that we pursue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, timing, and costs of seeking regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">revenue received from commercial sales of any of our product candidates that may receive regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms and timing of any future collaborations, licensing, consulting, or other arrangements that we may establish; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which we need to <span style="white-space:nowrap">in-license</span> or acquire other products and technologies. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contractual Obligations and Commercial Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 1, 2016, the Company entered into an operating lease for office space in Hayward, California that originally expired in April 2018. The Company has entered into lease amendments that extended the lease through June 2025. See Note 8 of the Notes to Consolidated Financial Statements included in this Quarterly Report on Form <span style="white-space:nowrap">10-Q.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Critical Accounting Policies and Significant Accounting Estimates</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of the Notes to Consolidated Financial Statements included in this Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A critical accounting policy is defined as one that is both material to the presentation of the Company&#8217;s consolidated financial statements and requires management to make difficult, subjective, or complex judgments that could have a material effect on the Company&#8217;s financial condition or results of operations. Specifically, these policies have the following attributes: (1)&#160;the Company is required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2)&#160;different estimates the Company could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on the Company&#8217;s financial condition or results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimates and assumptions about future events and their effects cannot be determined with certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as the Company&#8217;s operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, management is periodically faced with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section above entitled &#8220;Risk Factors.&#8221; Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that the Company&#8217;s consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States of America and provide a meaningful presentation of the Company&#8217;s financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes that the following are critical accounting policies: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and Development Expense </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and preclinical trials. Preclinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based Compensation Expense </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based employee compensation awarded to employees and <span style="white-space:nowrap">non-employees</span> to be recorded as an expense over the shorter of the service period or the vesting period. The Company determines employee and <span style="white-space:nowrap">non-employee</span> share-based compensation based on grant-date fair value using the <span style="white-space:nowrap">Black-Scholes</span> Option Pricing Model. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting Standards recently adopted </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Accounting Standards and Interpretations not yet mandatory or early adopted </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASU <span style="white-space:nowrap"><span style="white-space:nowrap">2016-13-In</span></span> June 2016, the FASB issued ASU <span style="white-space:nowrap">No.&#160;2016-13:</span> &#8220;Financial Instruments-Credit Losses (Topic 326)&#8221;. This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <span style="white-space:nowrap">2019-10:</span> &#8220;Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&#8221; amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_10">Item&#160;3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Quantitative and Qualitative Disclosures About Market Risk </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a smaller reporting company, we are not required to provide the information pursuant to this Item. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_11">Item&#160;4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Controls and Procedures </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established disclosure controls and procedures (as defined in Rules <span style="white-space:nowrap">13a-15(e)</span> and <span style="white-space:nowrap">15d-15(e)</span> under the Securities Exchange Act of 1934, as amended). As of the end of the period covered by this Report we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule <span style="white-space:nowrap">13a-15</span> of the Securities and Exchange Act of 1934, as amended. Based upon that evaluation, our principal executive officer and principal financial and accounting officer concluded that our disclosure controls and procedures are effective. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes in our internal controls over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center" id="toc214466_11a">PART II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">OTHER INFORMATION </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_13">Item&#160;1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Legal Proceedings </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently not a party to any material legal proceedings. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="toc214466_14">Item&#160;1A.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Risk Factors </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no material changes to the risk factors disclosed in Item 1A of the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended June 30, 2022 other than as set forth below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may fail to continue to meet the listing standards of The Nasdaq Capital Market and our failure to maintain the listing of our common stock with a U.S. national securities exchange could adversely affect the liquidity off our common stock. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is currently listed on The Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards, including maintaining a minimum share price. For example, the current continued listing requirements of Nasdaq provide, among other things, that a company may be delisted if the bid price of its stock drops below $1.00 for a period of 30 consecutive business days. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 6, 2022, we received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying us that the minimum bid price per share for our common stock fell below $1.00 for a period of 30 consecutive business days and that therefore we did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The letter stated that we will be provided 180 calendar days, or until March 6, 2023 to regain compliance with the minimum bid price requirement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 7, 2023, Nasdaq notified the Company in writing that while the Company had not regained compliance with the minimum bid price requirement, it was eligible for an additional 180 calendar day period, or until September 5, 2023, to regain compliance with the minimum bid price requirement. Nasdaq&#8217;s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement and on the Company&#8217;s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company&#8217;s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company does not regain compliance by September 5, 2023, then Nasdaq will provide written notification that the Company&#8217;s common stock will be delisted, at which point the Company may appeal Nasdaq&#8217;s determination to a Hearings Panel. The Company would remain listed on Nasdaq pending the Hearings Panel&#8217;s decision. There can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the Hearings Panel, that such appeal would be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a delisting, we would take actions to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our common stock from dropping below the Nasdaq minimum share price requirement or prevent future <span style="white-space:nowrap">non-compliance</span> with Nasdaq&#8217;s listing requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement. These options include completing a reverse stock split of our common stock for the purpose of meeting the closing bid price requirement. Our stockholders approved a reverse stock split at our stockholder meeting on December 7, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our common stock were to be delisted from Nasdaq, our common stock could begin to trade on one of the markets operated by OTC Markets Group, including OTCQX, OTCQB or OTC Pink (formerly known as the &#8220;pink sheets&#8221;), as the case may be. In such event, our common stock could be subject to the &#8220;penny stock&#8221; rules which, among other things, require brokers or dealers to approve investors&#8217; accounts, receive written agreements and determine investor suitability for transactions and disclose risks relating to investing in the penny stock market. Any such delisting of our common stock could have an adverse effect on the market price of, and the efficiency of the trading market for our common stock, not only in terms of the number of shares that can be bought and sold at a given price, but also through delays in the timing of transactions and less coverage of us by securities analysts, if any. Also, if in the future we were to determine that we need to seek additional equity capital, it could have an adverse effect on our ability to raise capital in the public or private equity markets. In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to continue our efforts to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain capital when needed may negatively impact our ability to continue as a going concern. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing ddRNAi products is expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates in preclinical studies and in future clinical trials and as we undertake preclinical studies of new product candidates. As of March&#160;31, 2023, our cash and cash equivalents were $6.6&#160;million. We estimate that without additional financing, our existing cash and cash equivalents will not be sufficient to fund our operations for the next twelve months and the success of raising such additional capital is not solely within the Company&#8217;s control. Our operating plan may require changes and delays as a result of such liquidity issues. We may need to seek additional funds sooner than planned, through public or private equity or debt financings, government grants or other third-party funding, strategic alliances and licensing arrangements or a combination of these approaches. In addition, because the length of time and activities associated with successful development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. In any event, we will require additional capital to obtain regulatory approval for our product candidates and to commercialize any product candidates that receive regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may compromise our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. If we incur indebtedness we may be required to agree to restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could compromise our ability to conduct our business. We could also seek financing through arrangements with collaborative partners at an earlier stage than would otherwise be desirable and we may be required to relinquish rights to some or all of our technologies or product candidates or otherwise agree to terms unfavorable to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any approved product candidates. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_15">Item&#160;2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unregistered Sales of Equity Securities and Use of Proceeds </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_16">Item&#160;3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Defaults Upon Senior Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_17">Item&#160;4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mine Safety Disclosures </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_18">Item&#160;5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Other Information </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc214466_19">Item&#160;6.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center">Number</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Description of Document</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;31.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d214466dex311.htm">Statement of CEO Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;31.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d214466dex312.htm">Statement of CFO Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;32.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d214466dex321.htm">Statement of CEO Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002** </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;32.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d214466dex322.htm">Statement of CFO Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002** </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Calculation Linkbase Document*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Label Linkbase Document*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Presentation Linkbase Document*</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File&#8212;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Furnished, not filed. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center" id="toc214466_20">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Benitec Biopharma Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dated: May&#160;15, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Jerel Banks</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Chairman and Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">(principal executive officer)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Megan Boston</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Director (principal financial and accounting officer)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d214466dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXHIBIT 31.1</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Statement Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Principal Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Regarding Facts and Circumstances Relating to Exchange Act Filings </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">I, Jerel Banks, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma
Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;15, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Chairman and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d214466dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXHIBIT 31.2 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Statement Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 by </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Principal Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Regarding Facts and Circumstances Relating to Exchange Act Filings </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Megan Boston, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma
Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;15, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Director (principal financial and accounting officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d214466dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXHIBIT 32.1 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Statement Pursuant to Section&nbsp;906 the Sarbanes-Oxley Act of 2002 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">By </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Principal Executive Officer
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Regarding Facts and Circumstances Relating to Exchange Act Filings </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: May 15, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Jerel
Banks, Chief Executive Officer of Benitec Biopharma Inc., hereby certify, to my knowledge, that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the accompanying Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma
Inc. for the three month period ended March 31, 2023 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or 15(d), as applicable, of the Securities and Exchange Act of 1934, as amended; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of Benitec Biopharma Inc. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has executed this Statement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Chairman and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d214466dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXHIBIT 32.2 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Statement Pursuant to Section&nbsp;906 the Sarbanes-Oxley Act of 2002 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">By </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Principal Financial Officer
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Regarding Facts and Circumstances Relating to Exchange Act Filings </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: May&nbsp;15, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I,
Megan Boston, Executive Director (principal accounting officer) of Benitec Biopharma Inc., hereby certify, to my knowledge, that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. the
accompanying Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma Inc. for the three month period ended March 31, 2023 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or
15(d), as applicable, of the Securities and Exchange Act of 1934, as amended; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of Benitec Biopharma Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the
undersigned has executed this Statement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Director (principal financial and accounting officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>bntc-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-May-2023 [10:37:53] {AM}-->
<schema targetNamespace="http://www.benitecbiopharmainc.com/20230331" elementFormDefault="qualified" xmlns:bntc="http://www.benitecbiopharmainc.com/20230331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
<link:definition>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Business" id="Business">
<link:definition>1008 - Disclosure - Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" id="GoingConcern">
<link:definition>1010 - Disclosure - Going concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash" id="CashCashEquivalentsAndRestrictedCash">
<link:definition>1011 - Disclosure - Cash, cash equivalents, and restricted cash</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" id="PrepaidAndOtherAssets">
<link:definition>1012 - Disclosure - Prepaid and other assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1013 - Disclosure - Property and equipment, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
<link:definition>1014 - Disclosure - Trade and other payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Leases" id="Leases">
<link:definition>1015 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1016 - Disclosure - Stockholders' equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1017 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1018 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1019 - Disclosure - Related party transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" id="BusinessTables">
<link:definition>1021 - Disclosure - Business (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables" id="CashCashEquivalentsAndRestrictedCashTables">
<link:definition>1023 - Disclosure - Cash, cash equivalents, and restricted cash (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" id="PrepaidAndOtherAssetsTables">
<link:definition>1024 - Disclosure - Prepaid and other assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1025 - Disclosure - Property and equipment, net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
<link:definition>1026 - Disclosure - Trade and other payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" id="LeasesTables">
<link:definition>1027 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1028 - Disclosure - Stockholders' equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" id="BusinessSummaryOfEntitiesInControlDetail">
<link:definition>1029 - Disclosure - Business - Summary of entities in control (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" id="BusinessAdditionalInformationDetail">
<link:definition>1030 - Disclosure - Business - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<link:definition>1031 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" id="GoingConcernAdditionalInformationDetail">
<link:definition>1033 - Disclosure - Going concern - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" id="CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail">
<link:definition>1034 - Disclosure - Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" id="PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<link:definition>1035 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<link:definition>1036 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Property and equipment, net - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" id="TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<link:definition>1038 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<link:definition>1039 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Leases - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" id="LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<link:definition>1041 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" id="StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<link:definition>1042 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" id="StockholdersEquityScheduleOfEquityAwardsDetail">
<link:definition>1043 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" id="StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1044 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1045 - Disclosure - Stockholders' equity - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1046 - Disclosure - Related party transactions - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
<import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
<element name="BasicAndDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BasicAndDilutedEarningsPerShareAbstract" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WarrantsExercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceAndExerciseOfPrefundedAndCommonWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" substitutionGroup="xbrli:item" />
<element name="IncreasedecreaseInAccountsAndOtherPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreasedecreaseInAccountsAndOtherPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreaseDecreaseInLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmortizationOfRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AmortizationOfRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfEntitiesInControlAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherPayablesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_TradeAndOtherPayablesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RisksAndUncertainitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RisksAndUncertainitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BenitecLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecAustraliaProprietaryLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecAustraliaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLlcMember" substitutionGroup="xbrli:item" />
<element name="TacereTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_TacereTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedBblMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedBblMember" substitutionGroup="xbrli:item" />
<element name="BenitecIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecIncMember" substitutionGroup="xbrli:item" />
<element name="RnaiTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_RnaiTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="BenitecIpHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecIpHoldingsIncMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlLineItems" substitutionGroup="xbrli:item" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="MarketValueOfListedShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_MarketValueOfListedShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CreditMemo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_CreditMemo" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedOpmdProjectCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedOpmdProjectCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedConsultantFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedConsultantFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedLicenceFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedLicenceFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PreFundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PreFundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfPreFundedWarrantsIssued" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantOrRightsExercised" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsExcercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsExcercisable" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightsIssuedDuringPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" substitutionGroup="xbrli:item" />
<element name="Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" substitutionGroup="xbrli:item" />
<element name="SeriesTwoWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SeriesTwoWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
<element name="IssueOfCommonStockAndWarrantPricePerShare" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_IssueOfCommonStockAndWarrantPricePerShare" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsIssuePricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" substitutionGroup="xbrli:item" />
<element name="CashlessExerciseOfPurchaseWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_CashlessExerciseOfPurchaseWarrants" substitutionGroup="xbrli:item" />
<element name="NumberOfSeriesWarrantsIssued" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_NumberOfSeriesWarrantsIssued" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsExcercisedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="Series2WarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_Series2WarrantsMember" substitutionGroup="xbrli:item" />
<element name="PurchaseWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PurchaseWarrantsMember" substitutionGroup="xbrli:item" />
<element name="FrancisAbourizkLightowlersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_FrancisAbourizkLightowlersMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>bntc-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-May-2023 [10:37:52] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DepositAssets" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" xlink:label="loc_BNTC_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_BNTC_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_BNTC_AmortizationOfRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_AmortizationOfRightOfUseAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" order="15" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="loc_us-gaap_DueFromBanks" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_BNTC_AccruedLicenceFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedLicenceFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_BNTC_AccruedOpmdProjectCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedOpmdProjectCostsCurrent" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedConsultantFeesCurrent" xlink:label="loc_BNTC_AccruedConsultantFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedConsultantFeesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_BNTC_MarketValueOfListedShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_BNTC_MarketValueOfListedShares" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_CreditMemo" xlink:label="loc_BNTC_CreditMemo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_BNTC_CreditMemo" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>bntc-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-May-2023 [10:37:53] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CashCashEquivalentsAndRestrictedCash" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CashCashEquivalentsAndRestrictedCashTables" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PrepaidAndOtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PrepaidAndOtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_StatementTable_747523" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1701632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1701632" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1701631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasic_1701631" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WarrantsExercisedDuringThePeriod" xlink:label="loc_bntc_WarrantsExercisedDuringThePeriod_814197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_WarrantsExercisedDuringThePeriod_814197" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StatementTable_747147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecIpHoldingsIncMember" xlink:label="loc_bntc_BenitecIpHoldingsIncMember_1701733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIpHoldingsIncMember_1701733" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_StatementTable_748057" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_StatementTable_748512" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701200" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:label="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsExercised" xlink:label="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_StatementTable_1701197" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" xlink:to="loc_bntc_PreFundedWarrantsMember_1701203" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701198" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701198" xlink:to="loc_us-gaap_ClassOfStockDomain_1701199" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701199_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701198" xlink:to="loc_us-gaap_ClassOfStockDomain_1701199_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SeriesTwoWarrantsMember" xlink:label="loc_bntc_SeriesTwoWarrantsMember_1701944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" xlink:to="loc_bntc_SeriesTwoWarrantsMember_1701944" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:label="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_StatementTable_768325" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember_1701170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_Series2WarrantsMember_1701170" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PreFundedWarrantsMember_1701949" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember_1282099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PurchaseWarrantsMember_1282099" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1282103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1282103" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1282104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1282103" xlink:to="loc_us-gaap_EquityComponentDomain_1282104" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1282104_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1282103" xlink:to="loc_us-gaap_EquityComponentDomain_1282104_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1282105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1282104" xlink:to="loc_us-gaap_CommonStockMember_1282105" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1282937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_srt_RangeAxis_1282937" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1282938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1282937" xlink:to="loc_srt_RangeMember_1282938" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1282938_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1282937" xlink:to="loc_srt_RangeMember_1282938_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1282939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1282938" xlink:to="loc_srt_MaximumMember_1282939" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1282940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1282938" xlink:to="loc_srt_MinimumMember_1282940" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1282968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_PlanNameAxis_1282968" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1282970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1282968" xlink:to="loc_us-gaap_PlanNameDomain_1282970" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1282970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1282968" xlink:to="loc_us-gaap_PlanNameDomain_1282970_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1282935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1282935" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1170879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_LegalFees_1170879" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember_1170883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_FrancisAbourizkLightowlersMember_1170883" use="optional" order="7" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bntc-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-May-2023 [10:37:53] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Principal place of business/country of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Initial measurement at July&#160;1, 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset at March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Less:&#160;non-current&#160;portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositAssets" xml:lang="en-US">Deposit Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepositAssets" xml:lang="en-US">Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at end</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities, less current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Less: non-current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 11)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value-160,000,000 shares authorized; 27,981,161 shares and 8,171,690 shares issued and outstanding at March 31, 2023 and June 30, 2022, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liabilities, current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion at March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Amount due to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock Par Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_bntc_BasicAndDilutedEarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" xml:lang="en-US">Basic and Diluted Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" xml:lang="en-US">Weighted average number of shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" xml:lang="en-US">Basic and diluted earnings per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Total other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized foreign currency translation gain (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign currency transaction gain (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized loss on investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized loss on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (loss), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Licensing revenues from customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Total revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WarrantsExercisedDuringThePeriod" xlink:label="loc_bntc_WarrantsExercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WarrantsExercisedDuringThePeriod" xml:lang="en-US">Warrants Exercised During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_WarrantsExercisedDuringThePeriod" xml:lang="en-US">Exercise of&#160;pre-funded&#160;warrants, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WarrantsExercisedDuringThePeriod" xlink:to="lab_bntc_WarrantsExercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WarrantsExercisedDuringThePeriod" xml:lang="en-US">Warrants exercised during the period.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xml:lang="en-US">Issuance And Exercise Of Prefunded and Common Warrants Net Of Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xml:lang="en-US">Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:to="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xml:lang="en-US">Issuance and exercise of pre-funded and common warrants, net of transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at end (In shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at the beginning (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xml:lang="en-US">Issuance and exercise of prefunded and common warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xml:lang="en-US">Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:to="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xml:lang="en-US">Issuance and exercise of pre-funded and common warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments For Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Shares and pre-funded warrant issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Increase Decrease in Accounts and Other Payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:to="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Increase (decrease) in accounts and other payables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expense and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Accrued employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase Decrease In Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_bntc_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase decrease In lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in provided by operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of Right of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AmortizationOfRightOfUseAssets" xlink:to="lab_bntc_AmortizationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of right-of-use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Re-measurement of operating lease right-of-use assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" xlink:label="loc_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" xml:lang="en-US">Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" xml:lang="en-US">Proceeds from issuance of common stock, pre-funded warrants, and common warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" xlink:to="lab_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" xml:lang="en-US">Proceeds from issuance of common stock pre funded warrants and common warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Effects of exchange rate changes on cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlAbstract" xml:lang="en-US">Schedule Of Entities In Control [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract" xlink:to="lab_bntc_ScheduleOfEntitiesInControlAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernAbstract" xlink:to="lab_bntc_GoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_GoingConcernAbstract" xml:lang="en-US">Going concern</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going Concern Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernDisclosureTextBlock" xlink:to="lab_bntc_GoingConcernDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going concern disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Translation and Other Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Basic and Diluted Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:to="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xml:lang="en-US">Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xml:lang="en-US">Trade and Other Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:label="loc_bntc_RisksAndUncertainitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks And Uncertainities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks and Uncertainties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:to="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks and uncertainities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Schedule Of Entities In Control [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Summary of entities in control</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Schedule of entities in control.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Schedule of property plant and equipment useful lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Summary of other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Summary of supplemental balance sheet information related to leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of maturities of the operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of equity-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Schedule of equity awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTable" xml:lang="en-US">Schedule Of Entities In Control [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecLimitedMember" xml:lang="en-US">Benitec Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecLimitedMember" xml:lang="en-US">Benitec Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLimitedMember" xlink:to="lab_bntc_BenitecLimitedMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecAustraliaProprietaryLimitedMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecLlcMember" xml:lang="en-US">Benitec LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecLlcMember" xml:lang="en-US">Benitec LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLlcMember" xlink:to="lab_bntc_BenitecLlcMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_TacereTherapeuticsIncMember" xml:lang="en-US">Tacere Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_TacereTherapeuticsIncMember" xml:lang="en-US">Tacere Therapeutics, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TacereTherapeuticsIncMember" xlink:to="lab_bntc_TacereTherapeuticsIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited BBL [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited ("BBL") [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecIncMember" xml:lang="en-US">Benitec Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecIncMember" xml:lang="en-US">Benitec, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecIncMember" xlink:to="lab_bntc_BenitecIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xml:lang="en-US">RNAi Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xml:lang="en-US">RNAi Therapeutics, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RnaiTherapeuticsIncMember" xlink:to="lab_bntc_RnaiTherapeuticsIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecIpHoldingsIncMember" xlink:label="loc_bntc_BenitecIpHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecIpHoldingsIncMember" xml:lang="en-US">Benitec IP Holdings Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_BenitecIpHoldingsIncMember" xml:lang="en-US">Benitec IP Holdings, Inc.[Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecIpHoldingsIncMember" xlink:to="lab_bntc_BenitecIpHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_BenitecIpHoldingsIncMember" xml:lang="en-US">Benitec IP Holdings, Inc.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlLineItems" xml:lang="en-US">Schedule Of Entities In Control [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems" xlink:to="lab_bntc_ScheduleOfEntitiesInControlLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation Date Of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer hardware [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LabEquipmentMember" xlink:to="lab_bntc_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary of significant accounting policies [Table].</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary of significant accounting policies [Line Items].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromBanks" xml:lang="en-US">Due from Banks</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromBanks" xml:lang="en-US">Cash at Bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromBanks" xlink:to="lab_us-gaap_DueFromBanks" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value Of listed shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value of listed shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MarketValueOfListedShares" xlink:to="lab_bntc_MarketValueOfListedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value of listed shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Total other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_CreditMemo" xlink:label="loc_bntc_CreditMemo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CreditMemo" xml:lang="en-US">Credit Memo</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_CreditMemo" xml:lang="en-US">Prepaid expenses&#8212;OPMD Program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CreditMemo" xlink:to="lab_bntc_CreditMemo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_CreditMemo" xml:lang="en-US">Credit memo.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_bntc_AccruedOpmdProjectCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued Opmd Project Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued OPMD project costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedOpmdProjectCostsCurrent" xlink:to="lab_bntc_AccruedOpmdProjectCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued Opmd Project Costs Current.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedConsultantFeesCurrent" xlink:label="loc_bntc_AccruedConsultantFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedConsultantFeesCurrent" xml:lang="en-US">Accrued Consultant Fees Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_AccruedConsultantFeesCurrent" xml:lang="en-US">Accrued consultant fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedConsultantFeesCurrent" xlink:to="lab_bntc_AccruedConsultantFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedConsultantFeesCurrent" xml:lang="en-US">Accrued offering costs current.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued Licence Fees Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued license fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedLicenceFeesCurrent" xlink:to="lab_bntc_AccruedLicenceFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued licence fees current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total operating lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities at March 31, 2023</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Initial measurement at July&#160;1, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Operating lease discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating lease has a remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Amortization of right of use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Principal payments on operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre funded Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre-funded warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PreFundedWarrantsMember" xlink:to="lab_bntc_PreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre funded warrants .</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:label="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xml:lang="en-US">Weighted Average Exercise Price Of Pre Funded Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xml:lang="en-US">Pre-funded warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:to="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xml:lang="en-US">Weighted average exercise price of pre funded warrants issued.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsExercised" xlink:label="loc_bntc_ClassOfWarrantOrRightsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantOrRightsExercised" xml:lang="en-US">Class Of Warrant Or Rights Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ClassOfWarrantOrRightsExercised" xml:lang="en-US">Pre-funded warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantOrRightsExercised" xlink:to="lab_bntc_ClassOfWarrantOrRightsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantOrRightsExercised" xml:lang="en-US">Class of warrant or rights exercised.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Weighted Average Exercise Price Of Class Of Warrants Or Rights Issued During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Series 2 Warrants issued September 15, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Weighted average exercise price of class of warrants or rights issued during the period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Pre-funded warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of stock number of shares issued in the transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Exercise price of class of warrants or rights outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Exercise price of class of warrants or rights outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Weighted-average exercise price of class of warrants or rights outstanding.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Exercisable at March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Weighted average exercise price of class of warrants or rights excercisable.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Class Of Warrants Or Rights Excercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Exercisable at March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsExcercisable" xlink:to="lab_bntc_ClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Class of warrants or rights excercisable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding, ending of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Class Of Warrant Or Rights Issued During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Series 2 Warrants issued September 15, 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Class of warrant or rights issued during period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:to="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Class of warrant or rights issued during period.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:label="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xml:lang="en-US">WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xml:lang="en-US">Pre-funded warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:to="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xml:lang="en-US">Weighted average exercise price of class of warrants or rights exercised.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SeriesTwoWarrantsMember" xlink:label="loc_bntc_SeriesTwoWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SeriesTwoWarrantsMember" xml:lang="en-US">Series Two Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_SeriesTwoWarrantsMember" xml:lang="en-US">Series 2 Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SeriesTwoWarrantsMember" xlink:to="lab_bntc_SeriesTwoWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SeriesTwoWarrantsMember" xml:lang="en-US">Series 2 Warrants [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock Options, Outstanding, end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock Options,Outstanding, beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted During Period Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted-average Remaining Contractual Term, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share based compensation arrangement by share based payment award options granted during period weighted average remaining contractual term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Stock Options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Stock Options, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-average Remaining Contractual Term, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise price, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Exercise price, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Exercisable, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock Options, Exercisable, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-average Remaining Contractual Term, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognised share based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" xml:lang="en-US">Issue Of Common Stock And Warrant Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" xml:lang="en-US">Issue of common stock and warrant price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:to="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" xml:lang="en-US">Issue of common stock and warrant price per share.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class Of Warrants Or Rights Issue Price Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class of warrants or rights issue price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:to="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class of warrants or rights issue price per unit.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xml:lang="en-US">Cashless exercise of purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xml:lang="en-US">Cashless exercise of purchase warrants (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CashlessExerciseOfPurchaseWarrants" xlink:to="lab_bntc_CashlessExerciseOfPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xml:lang="en-US">Cashless exercise of purchase warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants convertible into shares of common stock on exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Expiry date of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xml:lang="en-US">Number Of Series Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xml:lang="en-US">Number of series of warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NumberOfSeriesWarrantsIssued" xlink:to="lab_bntc_NumberOfSeriesWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xml:lang="en-US">Number of series warrants issued.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock issue price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xml:lang="en-US">Class Of Warrants Or Rights Excercised During The Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:to="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xml:lang="en-US">Class of warrants or rights excercised during the period.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_Series2WarrantsMember" xml:lang="en-US">Series 2 Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_Series2WarrantsMember" xlink:to="lab_bntc_Series2WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_Series2WarrantsMember" xml:lang="en-US">Series 2 warrants.</label>
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PurchaseWarrantsMember" xml:lang="en-US">Purchase Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PurchaseWarrantsMember" xml:lang="en-US">Purchase warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PurchaseWarrantsMember" xlink:to="lab_bntc_PurchaseWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PurchaseWarrantsMember" xml:lang="en-US">Purchase warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_FrancisAbourizkLightowlersMember" xml:lang="en-US">Francis Abourizk Lightowlers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_FrancisAbourizkLightowlersMember" xlink:to="lab_bntc_FrancisAbourizkLightowlersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_FrancisAbourizkLightowlersMember" xml:lang="en-US">Francis abourizk lightowlers.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bntc-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-May-2023 [10:37:52] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CashCashEquivalentsAndRestrictedCash" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PrepaidAndOtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CashCashEquivalentsAndRestrictedCashTables" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PrepaidAndOtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_747112" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_747113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentType_747113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_747125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AmendmentFlag_747125" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_767989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentQuarterlyReport_767989" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_747252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentTransitionReport_747252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_747133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFileNumber_747133" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_747131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityRegistrantName_747131" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_748326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityTaxIdentificationNumber_748326" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_747126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentPeriodEndDate_747126" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_747127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalYearFocus_747127" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_747128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalPeriodFocus_747128" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_747132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCentralIndexKey_747132" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_747136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CurrentFiscalYearEndDate_747136" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_747140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCurrentReportingStatus_747140" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_747120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityInteractiveDataCurrent_747120" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_747142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFilerCategory_747142" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_747143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntitySmallBusiness_747143" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_747144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityEmergingGrowthCompany_747144" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_747141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityShellCompany_747141" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_748327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityIncorporationStateCountryCode_748327" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_748405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressAddressLine1_748405" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_747160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressStateOrProvince_747160" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_747162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressPostalZipCode_747162" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_748406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CityAreaCode_748406" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_748407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_LocalPhoneNumber_748407" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_747163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_Security12bTitle_747163" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_747165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_TradingSymbol_747165" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_747166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_SecurityExchangeName_747166" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_747167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_747167" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1171705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressCityOrTown_1171705" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_746977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_AssetsAbstract_746977" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_746978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrentAbstract_746978" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_1701133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_RestrictedCashCurrent_1701133" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1170841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1170841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_746983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrent_746983" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_746986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_DepositAssets_746986" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_813025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_813025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_746988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_Assets_746988" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_746991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_746991" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_746995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrent_746995" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_747001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_Liabilities_747001" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747005" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_747013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquityAbstract_747013" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_747014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_CommonStockValue_747014" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquity_747018" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_747045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_747045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_747047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesIssued_747047" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_747049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_747049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_747061" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_747061" xlink:to="loc_us-gaap_StatementTable_747523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_us-gaap_StatementLineItems_747526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1701631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasic_1701631" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1701632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1701632" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747109" xlink:to="loc_us-gaap_StatementTable_747147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementLineItems_747150" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WarrantsExercisedDuringThePeriod" xlink:label="loc_bntc_WarrantsExercisedDuringThePeriod_814197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_WarrantsExercisedDuringThePeriod_814197" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747184" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747185" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747220" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747220" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_747054" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetIncomeLoss_747025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_747028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_747028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets_747029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_bntc_AmortizationOfRightOfUseAssets_747029" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_747033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_ShareBasedCompensation_747033" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2147469667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2147469667" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2147469075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2147469075" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants" xlink:label="loc_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants_1701162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants_1701162" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_747056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_747056" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_747053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_747053" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747055" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747057" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Business">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747291" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747261" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock_747262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747261" xlink:to="loc_bntc_GoingConcernDisclosureTextBlock_747262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747424" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747424" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747548" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747548" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747580" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747580" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747939" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747939" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747292" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_813075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_813075" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_747299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_747299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_813076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_UseOfEstimates_813076" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:label="loc_bntc_RisksAndUncertainitiesPolicyTextBlock_1170843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_RisksAndUncertainitiesPolicyTextBlock_1170843" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_747305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_747305" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessTables">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747293" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747293" xlink:to="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747437" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747437" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747553" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747553" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747587" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747942" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_747946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_747946" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_BenitecIpHoldingsIncMember" xlink:label="loc_bntc_BenitecIpHoldingsIncMember_1701733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIpHoldingsIncMember_1701733" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_747257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_747257" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747899" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747899" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747924" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747924" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747274" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetIncomeLoss_747276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks_747364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_DueFromBanks_747364" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_747365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_RestrictedCashCurrent_747365" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_747366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_747366" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747453" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_747454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_747454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_CreditMemo" xlink:label="loc_bntc_CreditMemo_2147469076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_CreditMemo_2147469076" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares_747458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_MarketValueOfListedShares_747458" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_747459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssets_747459" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_813108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_813108" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_813109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsCurrent_813109" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2147470769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2147470769" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747565" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_747566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_747566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent_747567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedLicenceFeesCurrent_747567" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_bntc_AccruedOpmdProjectCostsCurrent_1701136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedOpmdProjectCostsCurrent_1701136" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_AccruedConsultantFeesCurrent" xlink:label="loc_bntc_AccruedConsultantFeesCurrent_1701921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedConsultantFeesCurrent_1701921" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747631" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1170861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1170861" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_OperatingLeaseLiability_747638" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747645" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747645" xlink:to="loc_us-gaap_StatementTable_748057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_StatementLineItems_748060" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" xlink:to="loc_us-gaap_StatementTable_748512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_StatementLineItems_748515" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747599" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747978" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_StatementTable_1701197" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" xlink:to="loc_bntc_PreFundedWarrantsMember_1701203" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701198" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701198" xlink:to="loc_us-gaap_ClassOfStockDomain_1701199" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_SeriesTwoWarrantsMember" xlink:label="loc_bntc_SeriesTwoWarrantsMember_1701944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" xlink:to="loc_bntc_SeriesTwoWarrantsMember_1701944" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_StatementLineItems_1701200" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsExercised" xlink:label="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:label="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:label="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747990" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747962" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747962" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_768322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_768322" xlink:to="loc_us-gaap_StatementTable_768325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember_1282099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PurchaseWarrantsMember_1282099" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember_1701170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_Series2WarrantsMember_1701170" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PreFundedWarrantsMember_1701949" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1282103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1282103" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1282104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1282103" xlink:to="loc_us-gaap_EquityComponentDomain_1282104" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1282105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1282104" xlink:to="loc_us-gaap_CommonStockMember_1282105" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1282937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_srt_RangeAxis_1282937" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1282938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1282937" xlink:to="loc_srt_RangeMember_1282938" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1282939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1282938" xlink:to="loc_srt_MaximumMember_1282939" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1282940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1282938" xlink:to="loc_srt_MinimumMember_1282940" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1282968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_PlanNameAxis_1282968" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1282970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1282968" xlink:to="loc_us-gaap_PlanNameDomain_1282970" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementLineItems_768328" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1282935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1282935" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230331.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember_1170883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_FrancisAbourizkLightowlersMember_1170883" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_747694" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1170879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_LegalFees_1170879" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g214466g20n20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g20n20.jpg
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M)C;6.8)CP]-$9$96EC=7*#A8X:.4165UE7:&)TD1  $# @,#" 4#$ 0*"@,
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M<4[QT8.:5IIS#N3[?QI.LQ54>0VO4\.?Y'D!HIYYD_2@@T]>*Q\%6OH*CUK
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M5P2]3(I:BI1'#VU$\3S^;AA4\FDM(<,E%#X-5D&7Q)8EQ&DA'G8Z@ $@>;:
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MDMUK^]M6.CM9'1L.VG*O8Z[NCI^K?UJY8Q\AQ!(Q"Y';L_0$VD-CIF2H(4L
M^;%.*CQ 4FHKZ\>@.N:K'(8V2O#25Y%VXEE._P#.QL=E.%1L1>Z^@H$9.E])
M"22A0DN=O,C*G+Q]6)DUO6"X@O>0F_!4#"0QC DBT= J>'[,&4CL$MT 'GPX
M>G%F[Q:RP4$S@JG<N G%K>Q*]U] E*?LP*4#[2C)=J#3CEX"HPWXDU9S0U]P
M_#DR5"VQ;DV>4$M9FY<$#:/A]I _[LLA1X94^8J*^LJ /U< WFU48"Y('WI"
MO\%67S6=B2FT] E3_P!V( +/ F5E-.8[.'$5P[XDU[*,DS\G)08+*=SK!CS2
M-F;GHLUIY[H0TO>8.H+5TWNQ+E;G7684IJ45%A];:TK< ([JRVY0'&2;>'7G
M[99$UNYMC0.\ME>I8IVU= JW'W5]-#ZWGI3LR3)7(^D+[RU*6H#D 5*.*1[R
M:NTT$LC>A,?N?;%M,K:=22;3T!G@.F1;GH"I#E*\ZT IQQ<;P:N75\Z2JS.W
M*LR*Y&=B M70$3WNF)25#GX<@+/]214'%#O'K.<@R/.*@;H6K1ER,H.A VOH
M"Y#ID?)'W1T-I/R4PSXEUJE/,?3J5_@VR(QC8?0D^Y.@1XA7[,B6Z>B;[7UL
M,9KVJ_+,[P\_5SJ?@NU(H(VY>I&JT=  "L_3*"4H''S0/'TURX;\3ZNW#VIW
M9BJ? ]F?T;.Q-&T?#_JRIKIE+?@K\9#R);JLCZ%)6G.D"A 4D'T8H[?'7Z>6
M9W.C&SP54'<2R&(C8#U+,W\="NH[H[=+QTV.W&?-1&BO2%O%(I'C!*%-K(KD
M"$@"O'&7XIUG;YC\U=H%/5R)$FY,!J<K:+$MV7H!<>2ZGIA=2"E(KYPY3F%"
ML<*'(1C0-]-;\L1NGDP^XK1(&X]J75.4%.JM/0"5%*NF1W,*DE,A9)'RA-#A
M3M[M5/Z5]/\ -KH1[DV=*'*F3:N@0J"D],*E#@E)7(77YZIK7"SO1K#OTDA;
MU4]7(G?!5C]SV)0T_P! BJA?3$GZ3O.4D.&H'%)2 #WJ\\1\3ZP,0^0%1\%6
M ^:E(LW0/5M(Z9%!)4GNID/9:4'"E.6&C>'6'C-YLF*@[HVWR<C2WJ6>T[.Z
M&=-N7"59.G QILRW2[9<RMYT%V!*J@-(7EXU2:$8QR:[J_F$AS\"/J]*K\(V
MPP$;*=2P";3T!,M45TP IXE9,GP\V<U[1F":XVMWDU(CQ7):ZFPBM%#=R;&N
M=[6 GDYD3-JZ #0'I@02H&J3-JWE]*25)XXTLWAU4X"Z?E^\J%=VZ5BT4&4>
MA&FQ?#^/%'3$ A(H%*DKJE5>(<(! 3Z#QP.WAU)OA-R_\1*.Y]F_$%M4/=/0
M'F(_9@ %*T,IWA\V2G9A!WAU _ZS)^(E_ ]L3M"1[FZ!"FB>F.@YJ(DNY1QK
MEY#%?B'5Z^&60MY.3ZNI4.X-H<3E-4L6?H <!".F-0\-)S9).95*%)(S ',0
M?EXX/B/6Q^ED(5?H_LN9JR4I[H8DV*W:=D=-[B[):I#DZVPG'<GEGI"2AUR1
M3VTN)40/EQ+-X=6:[.V60..U/9N1:@9"10+#"V= 84#^R^"@4%#,"LI'S&M/
M3BKM;U.4YI)GF3G*GX TPG,<F9/^YN@):_$/3&K,"A*3YT Y5I(6 :5RJ2:'
M%1O%JS,!,_L_PI@W&TUHP:RJ)-GZ 0$A?2YXC;BN2)K@*5H%$A24@ A.4<L-
M=O-JKFBMS)^)59SN-IS7EP# :HA:>@!7%[I@2ARE #+)SU5F-*BJ4U -#BHW
MFU)A\-R1^#3U+1\$:>]HS%J6+7T!$J;7TOAO.$AM29;OBE2"",JT)HE%>RM,
M7.]&JN&-R\_@(;N/I[?DEH1)M?0*W1G]EY+:&_I6TIET"E$DDBB0:@J)/R\<
M4;O%J3"2VX()Z*);]Q;)YJ<IZTE=IZ!'6GD'IC6IE:'1)>:E!:V4(15HI214
MA9YXM\3:I6OM)KU*HW#L1@ VBV&\2^AW4,^!*NO3:Y/?@6N!;XRW%+2ZQ#8:
MRM,*1ER^&VGM&+#>C5 :BY?7GR?55/&Y=F&AN1A ',L*_:^@, A?2^VE3K3J
M$TF%0H5YE!"BFJ0H_)BAWFU1WRKAY_[M*.X]DX_T;.Q1E6CH&4"$]+Z ,Q '
MF%$!*J5 4$T(53C3GB/B75<N7SI"WJIZN14&X^GM-0& J4FT] 820KI=16@2
MG+(<'B$',4@A(X BO#%!O!?M.83O:[[S[*L=S+-V#BVB;5:^@+.LJZ8F@%)!
M6,[BE( KD)(3S(PP;T:F*TN75YZ4[59O#RP=^<&2IQ24V/H%74IZ8P,_?IY@
M)(- %%"2FJ:I2,!WFU5WZ=Y"N[A[9/P>YI0-J^'W5NO2^>\5"A?<.97&A!2G
M*.9PH[WZPP>7[0Z@PV)!W%TQAR49AT)/NGH"% >E\E2:D!4EVJ4JX  T_G8L
MW?'61\FX<,.95^"=-'(SL2O<'0&$I"NE^H2$DI3(6 E*!W4E-!F".SLQI.\N
MISM#I+EYJ/F526;FV,;SDR@UY$7NWH%[RF>F4,J;25(4J44M-U:-2M%*T5X@
MHG[' W>74X\&W#P.B--.YUB[$EM5L=AD]#>GS>'K5TV/,B[P$VN8A$A*TRXT
MA%)+*G  0TX>)3C*[>75,Q_K)#JG[7'LY%LCW"M"T.:X $;%K0L'P_&5-LJZ
M85>7>2XZXI4KQ5EY!)2$FG=2BO#E3%QO1JE*>TFO4J'AUISC5V0E/BU_#_2N
MJ>F%PN@9@I4IS,59 C-F XG*D D'C3%_B?67#_2)"/O*A5.XEBSP9&%HZ$TF
MS= 2P$?LOHKQJGS+@*%*)4H^S4=Y1)^7%?B;6!LN'#T45QN/9@?T;.Q!5AZ
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M#JU_LP*KF2Y7S+I)4W["CW>]D!X5Y8H-Y]5::MN7!W519';DVKC0,9V(_(=
M1HC]F!0)H,WF' !\IRX#O7K!.-V[L5!N1:-PR,J.A!RR] 00M3G3%5*4*)RR
MW:D!)Y"F*.WGU-Y\5R3Z%!W'M3]HSL7JKY797_L_/_@2\K[:O^I7_L_^7[;G
MCPWMLWS_ /W+S/POG+VONB/F']F^S^CFZEQ-\0QQ)W^@("N>@(:"E*U$K/GR
MHMJ1R '/'9W6CC,574S8_76Z\NYP\Q,J0%PL!Z*TXTJ*'Y_7CNR1Q>?ASK!'
M+..<%+ >H,H53L[J_P"@:8>ZY$;BP,! Y5<RSUQ)JDEMRM:G[8&H/KRU-<1[
M<1]H.Q'GS;#5*"@ !W^'R_NX60R4^8<">1'GW'2DDIJ:+>%>- V".7I[<'DQ
M\X[$>;<=*+.."0MQ1!   J1\J#P&%.NIXSY;6U8, LSWSEQ.*64*4.\%\13,
MM"4((H.64\.6*&[N#]HKMDN=E31-TIPJ#44)!JE0]1/,8&Q-D/F/P<<2MC7S
MY:&J4$E9IQK]IXJC]2H3]3AC0RWCY$HW%P#2AHEE"TBBD+(]*VW$5]=4FO'#
M' QX-8#3EHDA\[G$XIFH3V*X\N*B*>K-QPOS';"SU)K73DT-4? ]M*]A)K\^
M%.;&XU=0%-$DPPQ1YN%.R@' 5J/J8FD=* JXGE"S&G+8UJ#4VF-/29+D5F\7
MJ-;7UMJ;0MN-)(SOH! JM [3C+*2''*RHYU!N9:4-<%T[JK8S;B#JO46GM*:
M_O<PZ0TW+ONI/.QXTEJU^73X;#+88\-2O%4>.914!C*;U\?A,8-.A)=/,2=M
M*I3'3"Y+C1EM:E<8AS(=DDVZ8+>7+-.3>60Z['MLQM\R)5Q:IWF4]Q).,YOI
M'&H;12(XG_G'/H\\BC7?IJ]PV^?=+EJ=^WQ[;:USY#$JVM(N:VO>*8#3K+"7
M#FBNI.9->(Q;VV3YJN6Q 8/6V)Z6;7<(^H;I!U6NWVJS1(I#$J,W<)JG56UF
M:9RV6%^:2U)6J@'LBN(]Y/!H8QV*P9"0"9#586T=*LG46I(-JLU]ND2&-/1[
M\_>)-O882') =6XRSF"F5H3EH227*8CWD_\ 5CL4^7!^L6NM=/;+6H=":6FZ
MPAHOVN9-ZCVI*(0%O2_95J2PA^8HAM*YR14H4 LG$'4IAL9@JFZ,?@;BT8 \
MZ1IK8VPRMYK_ +8:FU2_!MVFK-)NNH+M;1&B-1),%I2GXR0LYVT)4."N:L-;
M?SEH.1'MCN4*;9]CM&:R3<EZ$U3=KM"8U)+MD6]2(L,EYN!",E<9,?(42 M8
MRU-5'"7:D6..:$D]2N&,G&9SJ.*V.U=(\BZ"ZIE:M;@JM-KCW9]MRWQC/9,Q
MUP$RHBR'$,M(34 BJ<-9K=,/9SV*QTR%V)>ILCICTQ)TU;)<'43XFWAB&W/F
M^,AV*9/GBRMQE@((#9:9*@!RK@=K <XGR#V*!8V[/#YE**#9.E-K4,YAB%KZ
M*IF;"G3TR1#:5)0B%*3;7&T1R.+*5I*ZY.9]K"'ZJ*5$![$YL-LSY3P?2J_V
M\V3M6IMT-6:+N^ITPM+Z"8+FHK['$5IR3)=>0AE+ZI:S&A(47 !0E9Q=NHSN
M%6LHWZRM2T&Q^"W*\]*\JWR]<,P]0EU&EE1'[67XK*H]ZLT]P!$U^6RK(V^V
MTZDIR^T0,3[PN?FHR6O(_P!:ST'H^>E3YJ%:S\&TPM/VO4$69[M9<NST=Y2&
MW8\BUDJSQ3(<HI62OA\<V)][Y11T-7;*TVE+,5M7,),5JC'37;Y=XV_M=HU1
M-E,:ZMU]?<O#%FBNV=J?9I2T&#"#06XR^YDRJ#IJD8/>[>6 ]B4^*WV^9BM<
MVNV%E;C:PUCH1V_6^PWS2-P\&6Y*9:<:]U,.)S75+A*4*\1(2*#EF.*>]6G$
M0'L5&LBV!_K6]W'ICLFF+G?K3?=829=PMD:PRVIML3"8]VL7NX^70_X4A"F9
M+:V2"G.<E.6#WM3] >Q-]E@<,WF8E,+Z<+$\W,MWOZ[V[4+.M;U88/O6)!93
M>;?;+;[V3-<:""U;VGVR$I>5W%@]W%3JU*_F3V*OLUN,,ZT;;;;#;F_[8ZJW
M*USK&ZZ7:T[?Y.GVF(C<9ME]YMLI8$=*FR[*<6^:+011-,'O<_J3V*/9K>OR
M_6K'<Z48RX&AIK.X4(-ZM$1JTEVW($93%T9<D,JD30I$?SK3= $Y@JOV.-#=
M7.4?F3LYE<1Q# .P6LZNZ<[;HA6IG9FM0[%TXJRQ'R+<TA\JN3HA*"TJ'FC%
M;?025EO+3CFP>]Q2OD'L1Y<7SELF@>G31^J+%J&9>M=29%WBW*5!L3>GI$!V
M!<9$.UF2Q'8=="ENRRX@)<;22D5HGO80[5SF/Y@]BIGD::-KE&Q,RNEMF%IC
M2%\N6NV8TG53L2/&BFULEE%SN2W4-0)4A-/'DMJ%'4$ ).(][_Y$]B/,FZ5D
MG>E"WQ+A)TR[J^,[>H5YM=KGR%):-HL_GVU/%*D-.)7(> 6 E.?A^]Q0ZO)R
M6S3Z$T6C'MSN=1QQ*%GZ0A>=57'2+6XC$>3IL1Y$U<^W(CJ:ARW2TJ0E"RFK
M0H"#S37$>^L<;8UZE8:?$17/ZT3/1\47S5E@D[@069NE[=;9=P;C1DRU.>\W
M%>20W169V)'8&:0^/HFB:*Q8:P#0^017H3!;,:*!YP6H:BV%BZ<VZUGK.7=)
MEREV>RLW.PR(T1B-:E.B9Y1]F<]5PR%.M#Q TT4N5X\L!U4?J#V*?9V?/2?U
M,[:1=L-L]23]=7>W:RW',;W/8@S >;EJGRQ$#BF6DK;3'9DDT<S<6\/;J#W"
MHCH.I(=8PN<7&3$J:CID9E3)]OC:FFS$6[4$BP7&4W#S)@*B1VGDRSX+J0S$
M?!H''0&B?9Q/M\OZL=BK[N@^>FI/3&N,I!G:C:3$BHLK[UXB14/QGF9=R\N[
M'MLQ(69\I3'%3;?B*;^R P>]@,'0$D="SNTZ',3GY4]>=@+#<=;WVPZ2U+':
M8LZ9LMNQR#YV]/O-Q6WG%/P@?!90XVUW5))S+-,'O@#] >Q.;IUOE%7J0OIZ
MTM9M-ZBGW+44CWO 5;A"3)\"V6FU/2V\[WOMMA1F1'T5X"F51PIVK^(_F#V+
M4VV8UH:'F@"P%PV'B6ZP:3NMBEWG6S6KY+;#^I=.OQ6M,:6)E-QWD7<.-N.)
M(=)*A5-48CWM_D#V*?(;\\K97NEMUENZ3)6J!;FK'+<RB1 B)3>8B8BWW)-B
M S>\8B>&5)/=4,,&HW!Q:PAIY%D<^5CRT$D K6K]T]*MEFEZCA7^1>V&7+3$
M;;AP(WB/-712 J3,:3F?@LQ OB[DRKI[6)]XW7S5'FS]*WBZ=(HASH4)G6Z)
M2YMFDRUQH]H;6BD2'%?B(BT#C$LOJ=4FK:BKABK]4E Q9BKNGF#0*E:)KGI[
M9T=HJ^ZH-ZFW"?9'++*F6/RC3*+0Q=TO+7(G^(H2HH)2D NC*:\,;+6\=+3P
M"O4DOGEIRU7,C9*0VT4K[I<<#A0,RDJ!*4FE12AX8VB!CG%YP)*5Y\YV50%:
M#@0:<:DCC\E>&-,<#.<*?-N.4E$<W:4?.@D_5IQQ8Q-K2N"CVB888IP>SP#F
M:G#A1)]:0>RF$&W83R>I-$\M.5)JH=I]) /'UC@<0+9O1V*SIYJ#;L1 &H5V
M@YDUXT5Q(/'M%<,:V-FVB0;F?9C1$.[2A(H30 \ 3SIC8UML6@DBM%'GSE*H
M?WM?J_NX/+M/N>Q++IB:FJ5W^QT#U4Y>KEV8QOMH2XD4I5+,MP#2A197/N95
M]L$.45Z^!IQPT0Q@ 5"CS+CF2,BZ\E#U>CU4/$8MY##S*1).,14'TI]-0!WG
M : 'N)/9RK7CBOD-^H)HGG'/5%E&17\)0DU[K@J>SD@C!DMQM#:]2/-F..*C
M97,A1E6&U-J[RP4BF90''@2*>G$AMK78U'F7'.5[,Y#]T'^KDR>T>?W3Y/7C
MPM(^8?VIZNY=;,__ -/7TKFSKXTYJ:Z[\6^9;;!>KE#CZ,: D6^V2)#"E^(2
M& ^VPI/C!?'G7#=&NXH8VMK1_+VE)G:\S.()I5<2IT-KP)!&B-5)! 4 NW2:
MT/'O QZ@\<>C=?VORC2O.DY'\Z6= ZW(*G-&:B20E*^-DD$D'E5609J_)A?O
M2W'*%'E2'E*(Z#UT*C]!=3*'8OW#*0@ TH0L)XC![SMMM0CR)=M2A^@NNQP&
MC-2T_P#E<_\ WD_S\1[SM.4BJ<V.0- J4/T'U[_S+U.?\63?Z,?%VW]J>:B@
MQ/)VE*&A->&H5HG4F4\Z6V:LD>M'E@,2=5@!R@T 6=T<H/I1#;_7":9=%:B
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g214466g21n21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g21n21.jpg
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M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
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M$[H4AM%2R'"$7^<7EG^1?._]X9_2T^J&(_+S/=]"M'*E$# U(CY$/\XO+/\
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M&GU-2XJ@YDG'.<8U"4H)<G2ZU+[#+?[:25,=Y2RU^V]NLNG\3\0G']Y+F,'
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M@-I[-DD$)Z?1KT1E[#<)=0L<Z2R]<&YH74%0VI9-<-NZ =K3BF,T -DN$?U
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M.MG)SM571%IT:EB5?AAA,KU7WB-<?2FW+.2+;*F9<:7!0U&4W!@+4J5YBTF
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MZ]?PGZ.IVWZ#IJ_=;&,+5F.,!8M.8D!*70OL\ESN5T*RM*@$E&R?>VV]FI5
MT+PR]>'//K8X>Y]ET?"^,Y/E_'RL<JN25.TE N3'76@.XG-P9$AMLEJQ=FST
M3TJW'8VWN>NBE<:R_45ZS*++>>GN2,ESDG'<=<QB;AM'36C&2G&)4!E>&\C8
MTF+#\F,F#:OAJV< +0"2%'8ZJ%T"$$39PMR)ZV:;*:7.+^FRRO9Y!X@CT4C,
M(]%+D/V^?UEI\'3G(7YT?R8%8_2/)=2^M(9<D;!)V.J7;R*;Y;R'Z[, Y5X^
MXDM>0,JI\-K<QERL8Y1RRAE%W*<OERJ^>_B%K&BL+9-#'K)3L1EU1\OL;+J3
MML! M$46SAWJEYRQG+^/K3/,SS?+,9P[G;,JKD%VL8F0HF?5+K[KD6VQ%/W.
M\&ZW F5EF=6**RM@;[[]=2BN7YHO*&6\F8Y@-%@^2YY6\-\LX7$ML7?P/'+=
M]_.LTB9;3+B8U:_#152ZV&BO:\UP;>XT%.G8= 1<C)]0/K,I>/.8I>9V^;BQ
M7%J,%G8)C\ MY#QIE\"R=76WD1:J0"IQ"53166GDMF:M]7:LA(=221:*\.]2
MO)5S5R[;)^7XG+L>37<HVP;K'7(&*&%A#P97B@5':3'1=36T1GHKH4'G#N$C
M1%=_K;S;U+9KQ'P#Q]DTOE&E_G!X3A6JXF'XBY.O,^Y>@Y35,C%\F92VHUL)
MVC[UH#RPE:^Y1 3TT1-'-/K$]74VEC87QXG,X5=QQ6JQ+GG)D8Y-J:K&5)NW
M(59-JK PE73[\>H[%NJBH<8=(([MM$5P<]7_ *C\:X_]&G)=?R%E^49S"P#D
M2&S+Q:#8OXUE]]/J2:%&50YK/FHG,P@Z4.*/:M;0^G1$Q<=>HGFRJ](WJDR9
MRTY=Y'QR->X?3\=YFBL:Q[-JC)LP9KV\M8+;\1TP<;Q?(TJ:<F>64ICE0"NX
MZ(N9\X]7?K"X[PK#[C*L^S1J?E/$>+U-DBKH5QGN/ER\C:@6-[90;&JB(MIU
MG1.;LK2OXI;Q)[#XZ(K9X\SCUC9L]6+K9W),'%[;,*9JOY8@T+4?,<PX>Q1,
MVY(+4ADL5EM8R&4MN.>8'%L*'N^ T15MC7*/J1SWD?%LZN,EYDA\78]GV<T^
M#U]I339AM+[*,!>4G$,V*F8\^VK&;N*^RUV@1X[X+85YJ@G1%+L-YE];$K*V
M,/Q>=R1!S^8&\.S[ TXS(DXKQ]Q\EN%"H\FQ9<QEM+5G(3*>\TE2E (ZCIHB
MZ/Y4YLYXX6]'L%C.N0N0,7EPO5-4<5S>37\<;LLT/%TY=PMZVC5Z B1,CRXH
M\N,^D([7>WM)!V)%4)Y,]?L/C#&.8\:G9Y>V^*1\=Q;#\#E8XI<3(L#MX651
MHN<Y%5-Q1/7;KCP8RPXA)['>X+V&XT1,?'_JS]7N"X#1.7&89)R*CD9ANOQ1
MZNQFPN+RIY0:S".JYH\CGO(=2M=76;]K#(6A,9()4GKHB=*_(/F#V$*=R1*R
MODS[_7@=QR-^I<3'F4T\S/<3YG_53$L(998:7),"YQ"4[*DH0A7=&;0>U6P5
MHB:L*Y;]9/)-U>X;CF;\LU</*K"P:YIR>;BLYF7QGEL24ZB'CF#KM(B%"%(0
M64O$'R]R5  [G1%&.7^;O6+@."1S!HN1*KEN5GM0YB]Q K9,*'F35!*J*Q^J
MNON^):S+J1/;5(\EE#<4O*W2E1">_1%UKZO.<_4G3>JG!,?X;A\A0LB@<:TR
MKV B!.EXK=B_K9<AZVJ8C8?KEN45LD)EKF.@L)2%;!!!)%P_ZA<G]7\+B_*^
M'L_S'F*RQ;-,'F6=)D5=BS]C9Y5R5??"RU8&AN*PER345KRECS@-VTCQ Z:(
MNNN=G_6>S8\=8_Q9D7(N%8UA?"G HKZO'L<2]'FYOE<]FCS\S)R4K7,DTV,H
M3+<:3_>[JRISM5NLD5!YYR1ZJ<@SC'N");7*M](QEK-<,RIRSJ)R8O)6&S9K
MR:[)*Q$=@"%+8@M(+DH@L]?%)ZZ(I54<B^MWB7%XG(4.VY#3B]/+_5_)<;<Q
MM,JIQ?C7#<AH@[<PX:&WERI<K'W'NYY"B70E9\ HI(H-(Y?]77(F;9'R;B61
M\LX_EG,V+VF(<7T\;$_)B_S>4?+2F(V50H$B.@1;25AZO/*YS:'EL;%OO;V.
MB+?LHWJ!Q7F"^DQ49_?Y"<<OL>XXPBTI)%KQ_GUW0W4>0]D]LS&0X6;Z9'1Y
MJEJV1(6/LD;:(LN*<N>LWD>Q9PK!,_Y:EU.99'AE9S+?6F+6<:9Q;GLYJ\:R
M;#\.^*A)B1Z"'#@Q&@I#GF-OJ5N!NE)(O>KT>7?(N2>G'BBPY<8GL\B-41K,
MI<N&OA["QF5EE,B?'28[:6NUR1$BM+V4/VW7VZ(NJ0R $C?8#MZ#<#=(V!V!
M .B)'PK6Q':-CMN-CX!7?L.O0*5U(_;'QWT19$M!.P]B?IW)(]FZE$J5^/?1
M%ET1#1$-$0U!(&E%I2E>X=B-P0/P;ZI8XDP.A8U3[*J3FH=_%F>  $_JO:I[
MA[ (ZE>WIT.NJ_$J;<D$ 675N<ONC/:=]5_V?_PK]FMI'_\ SRR[/^-7//S%
M,1M;[!Z:^KV%/M8S;IDO]#NTGN:;6H'K[I0Y^+;74WW(8+US+VW!)]4V+O7[
M=<<I\.S 9+P+Y<-U>0JG&0KM\UOO*@H!2RI"V]AOV+'VCO\ GU\U)<H4IF,<
M7"T[B^CHJIU7LYLH V160)20" K;V;G;\W8=0QT&@:5ES)KW/)F"#]U(/:"=
MB4_3L@[[_6I(3W:KVF\K1F(CL3O[WX1[OYAMJX PB\1:53M7QLBE]JU=1MUZ
M[^!)W!W)&V_4:D-EZE<!FN$8GD1]B]B   1UVZ;]2?P[;G2[+U+&>^<QQ*(@
MC\.R=]B1N!U&XWV4!I=9J5V7/F$! )4>NP(VV )!1M_L3[I_)JX)+" 5-^8U
MU[<1=H'3J=@KHE/=MW>/T[CZO9JT\,EF*IFSICQOI24G?8(7N !]HI^K?;L.
MRM1"4]H>=)42ILUC0-2-2.WJ>GU;[?\ V?35^3L6"$1%7GSYMV.ZL!6-T@=J
M0M11LX3[WTJ;VV)&L:IDO,]II!%[C;!663ZP-,UP_=#=737I*9:KN5HN7R5K
M;I\;[(S\CM[FURKE[X1A*>T?:04[;;^W7H/P4E5E)F21/K&$2[P-H7E[QZQ.
M374#Z5SQ>NFS45[ZPWA(0PX>H6D%/0I]TI24]#U^R=?3"GGMFRFS&>RYH(7S
MSGTXE37 VF\;4ZME.WU^W68'F$53N0.A)=0E:>G3VG;H?PG;55]N[I1:+L9"
MQLIM"^X *44)*EC??M6H@J6@GQ2=P?HU-]NM$U.X[3O2%R7JJ"\_,A/0)S[D
M5E]R9"2KO:BS'G4+==9;7U2E1(2?#;5!F6V(MYNN80EL)BL=X2A!0E"4MM]B
M4H2&@D (0$I'0;#<;^.JFDNTZ$6)RHA27&%S84>2N)+3)C*DI9>^!DLH6VU,
MCEUI:T+*%D#KL-5Z+$6A*Q#')L?X&;1T\N*5/NB)-K($Z+'<E'>7(#4AAQ"G
M9O@LD$D=/#1%F3C-$&($>/35T9NO0AFJ0S6P S5MM([/+A,J8+<1!;';L@#W
M>GAHB2_C-*^9;C]3#DFP+2[$/UL!Q4LLI"&79Q4R53O)0D)1WE10GIX=-$6X
MBEA(<<EM18J9*FFHZY'P<5+[S$<CX=M;J&@5H8(]P$[(]FVB);U5$>4PZY70
MI#L=POQG)3#3ST9]7VW8?FI7Y"E#VIVWT18%TD!Y$\*KJQQ$[94UMV#&")JO
M:BS1Y7[^$#H#XJ Z[Z(B:H*I,2(Q]VPTL5Z]X+7P<7R&1UZQF$M_P?H2!L 0
M"1X'1%C^XZ=IIR$FFK5PY3JW_@C!C"&Y(4/WU?PGE!E+@WZK4G=9Z^.K9)!1
M-EQ@N)9$PB)>XY4V\92&V/(L*>"^TIB*X'H[0#C!*&6G4A24] "-]+Q1/K-5
M%ALIC18C,2,PRTU%8C1HS,6,VE(3Y:6T-)2V@(]T@=.WIX:N#0BU!CU(PA#;
M-76LLF0IXHA0(;3 >6LK$EQ+;*4^?YGOA?V@OJ#OUT1;"*:K:E/S&H$%$QT!
MN1/$./\ %R.W[*''_+\Q2$GJ!OL#X:(M&]Q>@R",W#R&CJKB U,BV4>':P(\
M^"U8L*):DHA.-N(3(05$A9&VYW\=$6\U51& IIB)%:88;1'B14M1V&6&4=W8
MW'9;92A+;7>KL2=PGN.WB=$6JQC%#'0RS&J*N,U%=7)CH9KH83725DK=EQTI
M9V3*F?\ 7%@=RAT.XT1.9B-O+2DH0A)*@I)'EE3#B2IPM]FW:I;W8I>VW4:(
ML<&MA1"^]'B08KLMSXBQ<B1V6#.DE('Q+X;2D.O+\2H]3HB5)K(4H(+L6.ZX
MQ+:FM%3+"ULRF^C4I+DE#B$.M [I[0%()Z'?1%@771%.JE_!0Y$[M6PU+>83
M\2MHJ_A#,F2L%WR%$>XCN["-NFVB)4FLK+!<8SJ^%+\E9>0+"*P^ME[IV.,%
MQ"NQQ':.U0V( Z'1%G,1I()4REQ:%H\QY;;+CJ@"?(W6I!6I3 /0G<C1%@55
M1ER&Y#D:(J4TVMANQ7&8=EF,ZLK7'\Y;:G$M+7U[00D'P T19EU,%:'&7H;#
ML=\.QY4=]B.]'DL2 7'FWV"V4+2XH^]W E7MWT1:@IJWNBE4&*CX1N0S$WBM
M!<6.L("1 +"$_"I"$ ) V*1T^G1%G?@179#4QR)$<FQP$Q9+C;2I+0\%*8<4
MT5-N$?:*3N/IZ:(L,6H@17G#&@0HOQ,A<N4N-'92J5*<3V.29"PD&0^I/[=6
MZB#HB=4MH:4EMMDI0D>Z $I2E/3=2=AOU[=]$3@/ ;>'LT1#1$-$0T1(*P"1
M_2U9+W14HN\?3^;2^Y$"K<=#JT][DW$UR3VMNI4H!2EI*!O[.F_Y=79#A^EI
M6-/$0J=YXL8U?Q+F8D+"53:277,H2KWERK!/P\=M/@2ON4#MXZZM\3:RE;3W
M;#,A^9;O!Y)E3 _=L*8?N.9_\[_S9_N/[/\ PS\G]E^K6TOC_P".Q55\_P#%
M15OY;C-3E]79T%Y!;F5M@%QY+$A2NQUI38&Z E25)(/T;'6YS9@4C,^'NPZI
MEA\L"%L1IX(+#P+&:G+N,=H4+RR>'1UVPU&(7E]RO\OV2)+\SC.<Q'KW]UIH
MIA6H(W/BQ,>4MUM*2/L]VYUY.S/]NU$][IE"T2RXQTN,.,E>L\H?<=B=(U@K
MW%X:(1(;^8!4T/0GS60/+<JRCM2$GSI2.@ 'V?,&VQ'X]=;S?MWQX3#LI1?+
MC8;;5VD/N5R_-&TJ'79QTBRPK(/0GS;L-EU!_==SCY*?QE1)U;_IWQ[=E.!\
MJG^I++/3\R2?0MS4#MYE0?K[5'\Y>!/Y-7V_;CB[FASBYKCN:E?;]RF6 /XG
M(.9%_F+<U?VRI_K5?W?4_P!-^*])RJ_J6RS\3D]"+_,6YJ_ME3^17]WT_IOQ
M7I.4'[E<L$0,RS@',A_F+<T_VRI_K5?\8T_IOQ7I.0?<IE=H@)EG!Z%D3Z$N
M:2!^^U/Y=O\ [;IJT[[=L88;H+H#>*@_<YEH>K&(X B/H1YLW]Q=8H_0'7$C
M\J7-NOX=6G_;IB[_ &BZ' 4'W-Y8\JR(]"7.*>I^ZQ]7Q3XV_P"V:ML^V_&"
M8 NN<!6,[[H\O"86-DQ W=:6/0MS>3T-3]?>^^H#\'[X=]43_MNQ]L3):Z&N
MU7!]SV /$', "?*+T!\FS[2,G(+.JKJYHH=EO,]SLDL$[+$8.=R I8Z=1N-<
MGRU]ON(TE7)F5LLNT7HQU\*T&8ON?PV;0OI<.:6S(0B+?.NKLMX=POA+BB%!
MQBJ^%<3D^,JL9TYU9D2'A8MN/S),E]Y;8C=20  !OX:[OJ\H8-E-\J<98;-
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MWG;IJMN<\+!@'""J['K]_B"+];<?WW%U7^&W66R>GT$%>KPSEA72"I."XF=
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M(KM_B1C**( @6M8 0 1YS/7;PWV?VU;.><-C80JNRJS441RJ@!W5:U^_U26
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MZXX]U_PM!Z_]UL]/IV][IO\ 5J.^>%](*>QZW?XD!F&.[["VKMS[/BV=^O\
MMM3WSPKI!1V/7;_$LHRW'AL56U;L/#^&,;C?\*M3WRPH_I!3V56:+KDC];*
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M1T*A](^L;> U\^I+"9+VS"8&.[#S+Z+5@:9[;FY#=*4XDA23NE25G8$*3ON
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M!?).P^@B](VUDA*2I*E=J-RC[.^^RM@23VG;VDG1%L:(AHB&B(MM%$ CU2;
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M356?5/)>"T,O(>/Z!FX>R&AG3OU2S)RZLX\>NK*-[M4XY*@QYF[K>ZW"1MT
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M=<6V9U?(-IZ0VW..<CCX^F'%&75B;]42VQ_'%1T5Z;%+$9M3B/+W6H]0=]3
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M*;HA+SM:'E-_N1IU.EZ#4O.0\IO]R-.ITO0:EYR'E-_N1IU.EZ#4O.0\IO\
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M:@KRFU^:0-DH04DMJ"!T)43UUR.DJC.DMU05#PUKB&Q#5Y^<H^KG-*7U'/\
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M;A6(L-]K9D86&U9TR*K%&U)<M*!ZY8@9M91K"*IMV.TN9*0:A'E(4M'F,QR
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MW;4W':U*2J*TL>\I1W!23W[%2#ON@[$>Z0=OIVTN'6B2J*R5=V^Q'3H% $!
M;2#L?>[4#8>P>.EQVM/.E?#M]??^UN".W;<*VW!*0E1&XW\?'KI<=K4I/PK1
MVW43L% ]/M)6.U:5=.J5#H1I<=K1'\,UON%%*NTI2H;[I"@.J=]P%#;<';QT
MV;M:(OA60-@=MTE.X3[VQ!'CUZ[JW_#]732X=:(S$94E2=]@L)[MB!N4[=JC
MOXJ2 /'39NUJ$7PK045=ZB3V@D[D]J-MD=W[D]O7Z=-F[6B5\&UX@;_O:T#J
MH=J7"5+*>NR5DGQ\1[-M+CM:(E,MA/:$$=PZ]O@L=I2 X3NI8[5;=>FIN:RB
M+X9IQ6ZT'N[0%;GW3VE7:>P>Z"GO(!\0#^#4;-VM$HQV^[N)ZA1*1L2E)][?
M8;[=>XD[[C?2X[6B2(K .XV[NOO%&ZAOL-P2.A[4@;^.VFS=K4I?PK)!!VV4
M"%#V*!W)"M]R>I]OA[--F[6H2!':W4H]5>Z._N^VEM2E-MD#8=J5JW&VVFS=
MK1'\(@I20D!0"2/#=/3JD$>*5>T'H=+CM:)(;:;7XE [4[$=WB.TD#?<;**>
MOM^O50E..ZD4 ECVN()WW)*03]&QW'4;=-OHU&R>$1^2SOW;DGH020=MB#TW
MWV"M@#]('747':TM64,M[)ZCW>J>OTD+.^QV.ZAN?KTV;M:+&66-R" >OATV
MW'1)V\!V@=/8-1LW:TB47E,]-NG;U'4'96Q'=U)]X D:FX[6EJ4EM W(&VRB
MI&Q.R-QMNGZ.X>.FS=K18@RT>@40K8CQ'NJ(4@J3T^UVJ(_!I<=K19/AF>TH
MW 2>BDI&P(W!(Z>P[;?@TN.UJ5M)V  [AT '4]>@TV9UI%'T^D?ETV9WDBAT
M^D?EU&S.\D4.GTC\NFS.\D4.GTC\NFS.\D4/QC4[,ZPD4GO1^Z&FS=O)%(\U
M']L1^7_7U;V,[<(@B'FH_MJ/R_Z^FQGHDEQL^#B2?HZ^.I-+>TQ1:KZT):))
M \.TJ\%**^W;;5,R6R4%;+(Z-*H'U"7#=5QGDT9E:5S+CR**)'*MG)4V?(:C
M_"LMGJXI3+NXVW^SKJ/Q"JA64KI4@_O ".)<@P&3LZ@/</5%JDGZI.?N7/\
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M6,U?+R/[P<R7*;XA]U _>1\837XI*03_ +G4[?-/R\C^\',ERF^(?=1;6?\
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8?PZ[#[.WO\GL=/Y<:TFW=_\ DO>5?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g214466g23n23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g23n23.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X00W:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O,#<O,3 M
M,C(Z,#8Z-3,@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0C W130Y1#)%-#DW,3%%1#@P.3!"-T$U0C R
M0D$S0T$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0C W130Y1#%%-#DW
M,3%%1#@P.3!"-T$U0C R0D$S0T$B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IC,6)E,S U82TT-3@V+30Q.&(M8C!F-2TT
M8SAD9#<P9&8V8CDB('-T4F5F.F1O8W5M96YT240](G5U:60Z9C X-30Q-#0M
M-F$X,"TT9CEC+3@R9#4M96)D,3!E,S-D9&0R(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3YR<C8Q,S(W-#PO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M($1R869T(#$P
M42 P-#(S,C-?0E0@8V]M;65N=',@35,@,#0R-3(S34)A8V-E<'0N9&]C>#PO
M<F1F.FQI/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T
M:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R
M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
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M\/C@"0+68@(I\A;2"=.HD]"#G@!BB2,M&B \,B?R95P 5#$25UY@5/P'7Y8
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M?K>B\BQ710,0R9>58R#UIG@ N&-GD4A6<%9GA(MR[7*H27EC0 *\"$$Y$$'
M$@@)42(F2DL1*I1@?35@9%\I$&=:=?G@ I:,$#   +6H%*D!JBF>FIR^6 #O
MPY6A!KJITID/R8 +@AI4T+!:5*Z<JBOFK@ V-@J/1ER.6GI_9. )4"NZ^>A/
M]KF3]M1UP ZA@=00BU)H17J>A->GQP ?!#*XJZ:54U  '4#J>NH_;@!BB/<
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M7  +T,C5B&5:&E#EE4TRP!!0EF()6HKH'W<^N6 ( E0Y)CJ:@U5B:? G0<\
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MEAF95(T@$"@.FH^W]9UP 0L<H2OEJI J"@/P(KZAI7 !VE/3522&K3( TZ9
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M  @$@5P ] 2%\ZC(9=-> !ZMXEJ^.:=?^R8 4W0)E%1E7XQU^?Z=< !2%0Q
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M !-* U'7K7/ "^79Y#4A]K+!0*:2%&709T(RP L_9<@71+-ML=?'*GATSK3
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MV.7B21T\ 3E@3 \BR+ITDD4% /AX# %.I\]3&I\#X?+ '[U'7H 1U\*U_-7
M \A<MK9I%4B@IT!^7V8 %/6AS)R$C@'+XU/QI@ .YA9M(1A0&N2J 2/TAE@"
MA8F"FNFIZG2N?SZ4SP #.*"GB,OS$8 !FIZ8("DUH?*I/PITP JN(0Q;1(Z2
M1D$+6BC5FRJ/@:X  >"03.?24Q*,SJJ?A45)K@!;*?4:BH0.@-%^.7@, 4/$
MA5E,A+!/NDT\.F5.F %,T,2*I:!F.D><N21TSI4@Y9X 331PM)F&Z?\ -TP
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M@ HQ/34%#@9C,F@RK0C(X 8P*- 8@C6X Z^84S'7+IX8 =6T#L<E"@MI(/\
M 1T-:8 /1:JNDU"N48"M?@!4T& #UC?4:(U"?C3\O7P& &5K#(H-5;S=/'^S
M\, .-OC=7(96%1IU!5-023U+"IP X$<FMM*EZK2IH*@4^9&6 #XHV2,J593X
MKEEGT\?# #&S1E0]=1%/T0:9D>!Z8 .CBEJ&*N2#FP5/_P!(5K@!G&"T9(TC
M2X+>8 _"A!!%?E@ N%P#GHR)/QS-/'\F #J$YAD .=,_[. "%A<J#J7,?]4
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MUI*9,QU%%.6> $]SM@:36-RV\  U!:4?'J*'/  $NV0,I#;IM;%J54/* :=
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MN;^7>MQW7=[ZZN+S<=TW"7<;^[W&1;J:[OY!IFNIW5(_UTK E@H5 20H  P
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M*.Z/TX=7^0^5C05WAH\OB*Y?FQS,Y\Q3W22?3)O]9T;Y+2:T5%P4$=&T=5#
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M_P!CG4X 6$9G-_R11T_)F,L "-Z.I@RYU-:HH-:^-!@ >58PZN(@0  3GF/
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M>)$7-:&,Y?'57^#+$Z5%0N[>$%V'U37+3I).1SIBA+XF2OB42ZE;34Y"F($
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M'(QN'CIX**5P 5^N6=XO3],O;Q^B)Q'&K HI5HTC+(A=2"N?0C #2W!50IU
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M.>\5=C.$L:)G+:8>>,?&! ?R =?'+&_UB&;)EET(T2U2O7)2MYJ1J^HC/PZ
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MZY!<R[1NVY6NYS['>65\4]%9XBWIVET2?0B(70A KB),9?XH$_=2]^UTR?\
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MR-&Y#N<B#@"T.9<WW+G>]OR/=+/9;.YO&=&''+'\!MTC#RN\2)I1;E@//E3
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1+]JL[F8>6.XW"!3FXP!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g214466g24n01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g24n01.jpg
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M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
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M #YO^(#^:XH:3ZDH]>FH\9[$%?>/\FQ@!1/S_OFM:L_4HVK/HGC/81&1\/\
M)L' !-CY^_S57#Y_4@R*BH!XSV+J'3[5-N98 =Q_GY_-164Z_4DP?O%)/^;3
M8W0 Y9;;P!6[\_'YJ""K_P!H]%--4:>-=AT().=#MNN "4'Y]OS2%BC_ *BF
MRI0%">.-CI"33W;:I7\N 'B?GP_-(3J*O4C'6%?9!XXV1J1[C3;5#@!VS\]W
MYHSG_P"HZ,:&A_S<[('7,=-M@8 (#YZWS1"XBGJ);*5#HGC;9)3X^/ZO GZ<
M /6?GH?-!4?-ZA:_1QKLCW^S;_NP X_TZ'S.PI-?4.PD5S"^.=F _6!MTTP
M\/SSOF:@T/J$BU_^P6R4_P"].W:C "C7SR/F;J-?WA&:'H!L#8Y'Y3MX5!P
MY;^>3\S+64K]04;I0 [ V2#7W_\ ( SP \:^>#\S)8 5Z@&"JGFIL'90-?H_
M5TX 6/SOOF9"E.?&OM4JK8&R:4KUSL &?T8 5_TWGS, <_4!% K]D[ V45'I
M6G_(-, <J^=_\RO(#GIL4R-=A[*"B?\ &_R=(K@#[_3=_,Q5FGGMNAS%-@;)
M/Y";#@!RU\[?YEVD%?/3?3S*.P]E"BAX4_5TTP M_IMOF4>'/K%/#_(79/\
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M]_FLHS'J5B&B7/\ HTV(-6GH?_%PYY8 &M?Q 'S7JG5ZE89%*@'C78PI[/\
MYLX 3/\ $!_->JYJ]2T-(TU!'&>Q2!E6H_R;]V !G\P=\V(!=/4G$64UI_FT
MV(.G_DVGK3 "'\PE\V0H)_>4AA7_ .&FQ30Y?_5@C+ " _B$_FT9_P#M*PCD
M?^C?8GY:?JQE@!J?XA?YM53_ .TK$ZG_ *--B^W_ .S& $5_Q#'S;@K+U+1
M/_PTV#_AVU7 "*OXAOYMP-/WF(PKE_S8[!I6F9).V:$8 E/'?\05\V&]<E<<
M;?NOJ3BR;7?]_P"R;+<XXXXV&T9%NN^ZK3;I[ <1MA*V^]"DK35)!36H(.>
M/3AP!Y;'\02HCYN7JR4*5#G'8!H#0?LZV_[1[\ :;$DGS5-5$DT) )K[!08
M<5)=34UH13\F ':24JU)-%4I7W?T8 62E(6%4%=0-??7 !52E:CG[/ >SZ,
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M*CH\[Z6R!_X.O[N05'HM!*2"*G--*X 7^[T( ++CCYJI*6T_W>O@-2=2?K.
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MW+PI%]2)Y4MT+A9?'MWWI?MV-V%UQS;MVM;BFVM@KANO)4N8X^V4+EJ.@#,
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MS;:)B[-;)SS=OAEY-"ZW%:0: @D4ZX T^=E:U MZ5(T#4%5"DY TJ>I'MSP
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M^.;#Q38%\6S=N[9L\FRV&]7_ &C'G;WMU@FM*0JW)N3FI2F7'5EO2A8T)\,
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MD\8[1OW'MPBWC;N[]G[9C6:[WB[1*-MJW7=$(,IU#S (*%(*%US]N "F_OF
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ME2R>JA4 ^%0 :?[. #+2?(,JZAF" 3EX'*M1@!Y'/0%244\"LC3U/V?#+PP
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M*( "@"/ 98 D")%N4VVB3&7+>%-;L<!O22<R2<U8 D33MF2QE$F"M0A0<:J
M?IHH4. ',==J*A6/<4@).HZVLR>ASRK08 ?,?A(*E*3-40"1J#1)IGGX&N "
ML!VSR""Y%FU;%4D)9 Z^!H:C $DC.V8:5KB3BA( \Q9;'N.H9^7 #A4BRGRM
M,SD%"BM8#S;@*? 4.9RP 3@/6PTU)F@&I22E-:^V@RKIP 69<M9?T%JXJ2:D
MD=IM)_QM?4]< %6T6BH;#5P*5>8KUM*"3X GQI3 !1G\-)"2U.*4B@42R-0
MI4U/7 "J7K4E0"F)U$+J:!*J ]!Y<J8 /L.V0MH"V9()<(JHYG++4,@, +-B
MR5U=N80H^!;SK3IJSIEXX >LFR-]Q6ATE>H@*4-0^H9 _1@"L2+,!_WG,5_C
M!9 5[P*X ?QS:".\692<J %6?T'/.E< .--LKJ[+V@'S#N$*S)R]@. '(58Q
M0HB3!7Q2YK)SZE)(& *DFSN5K'G@CRC5V@1^7.N .0BW(II9FE8R)HFM?&I
MI7 '&JW%0/9F@@YE0;TGV_:RZ], <AZV$D*8EJ ]X;]WVD9$9=< <A^U)K5B
M52O1+O>/Y#7H, *)<M#YT!B:DA-:T8!(ZG)68P!QV;76H:G>XU8Z8 I6FS4(
M4)94>J5J: KXU/NP V;%I0NB42.N8:4%*^A0II!I@"IU5L\P+<RE>E&PKK7S
M#Z, ,J6JA^ZE$'/[Y8:H*UR(-.F &+C=J6K5V)JD))02R\V$@BH(45$%=#XG
MK@!N^+6VA)2S/)KI!JT?*#E]6 $E(M3C=5-3$*TC(=GZ_P F &+HM  '8F9
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M5#4:>SRC/KBA.K?:52S=,CDJ3IR=C^[SJ!]@R\,7*KJ(&U ZHU<:73^IH6H
M>Y0\<4@H<9"7&J*I4JK4MIK0^(\*>S #<.Z"<D'PS!/C_6%:_P"' ";BW'5!
M6M" D"@&BGY"*^& $WE M@*2EQ2E>&74G/)-,\ -G2H )"0*4J.HZ4_J^[ #
M-8.JFFOESK7J0:G[/B3@!!QY(2!5H4%*%:J]*'+Z1@ 4\^FBJ(;.9S[R1[<Z
M$5& &3E"@%:24J%0 M2@*CP(RZ'  9]U(*M("J @ K14 5R-144&!;<H5Q0.
M2XEPA(;((R))5^8@4I@1JAU(2=6E%4J3J*:KU&OMJ373BEQ?6752F  DR$%0
M5VU*!\Q557CGX94Q6HN@![[Z%)*: #VZ37V5K[<35+HQ #?JNH"D  D5(5TJ
M<S[SBB63H!KVRD5);+8%542:D^-#3!9$U?2#'GV4K(3T4XU0:3]C6WJ2/<K$
M^PH<8]1M!^3TXD^HK>_E4D_J=!4HYYAV6DISR/0C&J/S%)0X=<<,'HZ#;KY?
M80ENX:E547<=GF(3V4JJ2K2@$G,D!(IU]F/-V7]HU+.IOI.,59BDE32NY#S1
MJS"U!1S.?CB5.?G4JZ5,3R<<D)K;5T*U'WZC6GAB]<;EFV1^'3>*1A5Z^&W6
M_3#RDM%5I5MZ<TM-?,-3-*^W';?**4H>H;$(.D7)8'67,I1M< OSHM:B\>DZ
M3S+P$=3)"4:"M(\I!JV$A).749X]6N"2<.'V=.'ACW(\R./[AWM_=<W5J3I7
MM8BI*%@T454)U$J10"OV:J&77'+2^)]IP2Q2?L)KQ,EK]K7$V@_]*_&M:BM5
M?KQ8?'Q^G%))[.. /+E_B!T@_-K]5QT()+G'(+3JRA(#6Q-M/F5J'5"@@HTX
M M%LOUO\;6KBFS<>WKA67;KS!L\O;PW3LZXM(N$>#)B.-JO[D:0TMGXA&M:5
M%*%*\Z37V 577U<<9[S@[?VR+/NRP"S[+O7&UMF7VXVZYP9=IW%;68(OF[V2
MVZJ7-@J07&2VAP:LB49X 3V#ZO>/N.[*Y9XVW-W[A<&PFN);M<VI=N1;416Y
MIU[JL$4%<B'<76-0[*$%#BE"JLL /+_ZR./+MMVR6&W[;WN\QLG:VZ=IV67(
MND11G,WZ(XEN7NY+*79,V3"? 2E"$N)1F-0S  UYVY"T1HNI)4O(/:@$@.4J
MY5-,TE9)'NI@"51[D$-MMEN*XKO5"BVNND5!Z95^C !YJZ IJ(44'5]K2%UI
MXZ5#RGW' !%-V5F/@XF1I41FP.G@ ,C@!XU=/+J5%BJ"U4*51T4U4RJ*8 +(
MG@A*%0H"5K5I!,9%33/P!ZC+ !*-=!FH1;?5*M.E#"0:YC[-"!UP 93<J!U*
MH3"#VTIU=E+>H=<B,Z' #EB;J&CX*,JH!%$AQ5 !E0C !5J<V2$_A\8D>6CC
M26T@_2G,# !=B6V 4B!%25 *4&^@_P!J? 8 )Q+BWW4Z+="6-).IU0!U 9D
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M+T([?I:.'&'NSDPZHUS*67"#[Q0],)13I)2P1BN,/,E1^&N R5$D$ B,\4@
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M1G.'<*/#;D(X246=S\H=I'=<43GDYH[;5NO][9A,1V+M=&&6VVRTTS.?"4(
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M6EU"BGSC-*03IRQK_P X,>'W&\]#[CO'DW-?F$/OH[7\!"1'84DYE":C(?H
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M\-*]2%U<%>B5T"GI@V,%)R"E0&DY?X,8JYO\14$I7)U[&1+DS:UMI1^A%+?
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MK(R&PAU8%$'J*'Q./1?Y=9:>':<J02_0CSU^8.,?S*J6&M]YKY>*P@C45=P
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MO6FBB&\]11?B4ZJYXJA9CO(7-O/IBT7OQ$=K*W>?1-,S_P"%O6OLOB7CVU;
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MP\+@OG9@7.\0=C;R@N6*&^NX;DC-/PU6@/#LLM/NPY9?D,K+@9 :.L.J%<L
M,'N#.:;HXSW>/MSRY]PK)>DJ"+C,40BKBKO-F%T6YZ,VV'7 \H )(IYL $;]
MZ6N;+!9-M[A_4BXN1+K'3-%MALID75J,'C&%T8CKD,/2X+RGT)3(0KMH*:J!
M(P!'KCZ7/4)9F$"\\1;IAL%D,Q)ZX<26J[K?#MS,:/(;EMB[OS([ \R$*,1#
M9 R.8 6S^GOFR95RW<8[C?0R0PEEF.7IDUQYL%5JM4,#3+>;!"UCM:TA)H<
M*(])?J.>OC&WXO#VYW=P/VI[<3UMC6YM"E1F9*(L6:J4\XAZS!]2BKMNJ 57
M(>& )';_ $B<Y3MM[IWAN/9-WVCM7;5IFW";?[ZII;"'[>2T_;8Z8:JE2'6Z
M 4 J<CG@"QO$#JG>6.)%)0I 7ROQJ6VE-!M?EWO8@I89U*6E"^HJ>AP![/>
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MV0HY<"71VVO,7 0E6:< %]X>M#F??Z]E[AO]NCG9_&&Z[5N*";/&G1D1+FT
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MHKF4DDYC+)1'C@!RFB' 0*4Z4RI4>!\,\ %FG2O(J4K3DFJBJG0DYG+/\YP
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M]6=/IP ]9_ED=([?[\M,J:OV@UKG2GC7 !#_ -V;TBO[\.GPK^O_ %\:?[&
M'#?\L_VU:/WW=.5:_K]JKX>^M, +H_EI,Z?ONTT9ZOU^IH\.OA@!PU_+4ZCV
M/WV^[V<^Q^O_ 'NUI-:]O[S3HZ^%, .6OY:G2SH_?3U:4_#ZOV@=S3YM/PU/
MT>M-&7LP M%_ELM<?L?OL_VKOPM?U_T]_P#X7L5S[W];3YO;@"10OY<_\-G_
M  '[[GX=W/\ E+X?]?\ L]VO_AFCR:Z_U\\ ,!_+?T__ %KTH.O[0/8*5]^
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M1J^^[]<J:NNK  Y_^56JYWOW\^YK'<U?M([^BOEUU^\^'KTKY?9@!FO^5/\
MAY'>_?VT:4=_O?M'[W;UI[>O7]YVNYITURK2GA@"1W+^5S_ [/\ B/\ I!_P
M74O\([_[3_AN[I^]^%[OW7?I]K1YO;@"-C^53U)K^_[KJ?[3]I.KP^UKSP!2
MO^51KYOW_*ZOT?VD=:BM*>& )#L7^5D_:#L3]6_W\?UH_7;:'ZM_&_M$_#_U
=B_6.U_@7QW<^Z^#_ !;L]W5Y>WJKE@#T-, ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g214466g24n02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g24n02.jpg
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M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
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M/KV>K-J37JNO!S%1^[KE=3Z_V,(P P_MYO5BRIU5W@5%?_!UROI]?['_ ,6
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M(K04E)+"4^)=0L"N7"M.)& )4.(05?=(56ND@?FRX8 *9:4JFI(J>R@_0 <
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MN@@K1I2.  !21V5[>& (9 KI\L!)KV 'ZJ@X A<U((2HG54E6=/"KX!3L^C
M$2FTY5K4@$^)69/$TKE@");;:4E=4D9U#BBSV&H"U$@T/;VX %!24.#0CQFJ
M!X%Y<<ET\>7;VX !R2=(2G4%*"?"GAGX>'# $+T<?R0#[!3ZN&  G$AI&8H2
M:5I]G  :V6E^)3:20,C0=F  D@ 5H*J KD,\L "D!2EI(!3F*4' &@_)@ )U
MM%5C2GM[/9@!1Y+2U*"FTJ!XU -:'+C@ 9;25+T):;43GYB0EI".[65#L[3E
MG@ %0:$A3"I#:GF6RXXV@)4P$'X2XL^74^XX "66WF@M*&BA"R/,2VE-5$^+
MP^8XHH-<C@ 5:4I0=*4#VA(IP)RJ*@8 $?::\E*_+1JS-=(K^; "IU*2$@I%
M!6@H!^;  ZF&5BBD BM>T9_01@ "0PTE82E   ! S.=3GF3@"'RT&M4C.@/M
MIPP!&I"$G)"!7/X$\?I& !G&T5^$</TG  :F&:G[M'$_9'?@"!3:!JHD"E:?
M1@#8?Z1J$_VHO0"=*:_UGN76=!7*3((SIWX NUZ[S1/JW]:I\NNK?FSZ'OIR
MWV5E[.& -3:4G6I*AP)R[N! R[JX DTI[ORG !#24JK45X_HP 3I IH!X"H[
M_9[/9@ II14%@H"$]A'=GWDBN "6@-)'$9<>WC@"8)2:>'@1F ?IKQK@!@&=
M*4'3IK3+/+\I[< '(2D-@TX*X_3_ !X G9HMRM*D*RK[B,J4RRP [C0Y4Z3!
MM\(%<^YRX\""ELI*G9<M:4,Q_(6"X[5Q5"6]1 [, >@>/Z3?+<\D9/+AZ-OB
M%UK,\KV^<$B0Y#N;G*N389$82HNVVKTQ$=CQ[J(@+RDK(J/"#JRP!@3RY].?
MG5S0Y;<NN9FRMP;*OD#F!S+=Y4O6%+%]MDW9VX_-,4RMQA^(MU=JCOH)\QH$
M(3FO(C ';-K^FUS$W/=N>%LA\U^7:+1R!W7;]C;OO]JV[S#WH[.W7)E(8=@6
M?:VT;'<=R3HK1)"I'D!L4J"1@"P?4UTT77I4YDIY7[AW[MG>]\59;=?I<[:M
MOOT&W,-7=GYF)#^3W#"@W9J2U%6/-#C24MN I40H$8 L%\JZTZ%H<:>0 26U
MZ6J!#:BO42O*F1X\1@#T>=$/I>].W/7I$V3SNW5L+F'S+WGNJ^3+-=6=K\R]
MH;'9L%NC@E=T1%W/-AB[-6^/5XIC%QU9333@#!9OTY;ESBZI^;')+I-W>SNS
M:'*]F=<KONO<\"]S%06X#*5R;*Q:K%#DW/<5WB2:LTC(*7Z52< <<U/2MYZ<
MIX'*Z\;HO=E;M/-K>3>RK(NX;?WALRY6>[2 $Q)5RL6Z+7$N;=K?<-?-"2D\
M!@ >9Z:N_F]R\V=A6#G+RTW'S"Y+6)&XM[[/A6+?5L>^27#"TBT;GW!9X%@F
M/>8:EM"U$'AE@!-;/3_W9'E\G++OOG'RUY<;SY\LC]WVRY^W-_[JN+X45%F1
M=[[8[.NPV03!1* XX4I)J33 $L/T^-]VVS=0.YN8/,S8/*VP].=V9LF]G[ZU
MN_=3MQF3F%*MZMOL[8L<F3+2^A/G!+:%E*315, 5(Z2N6:^D+^LLQSU<?N;V
M\I&V(FW1RTW68ES(;3\LF'J;1/A*4VH+U/-ZE5K0 ' %]N6/HY]3G,/;VQ+\
MFY62V(YF6E=TVS_N.WWN6R1(8!4U)OF\-KVR=MRPNOD42B4ZD@FB@D"N +,V
MWH3W98]O[UYA\V]];)Y<;-Y7[]A[$OC<VV[DW?-W!?6IKD*1'M=FVI$G2S#E
MK"5^:X4-MU&LI3XL ._4.Y1<NN4G,KEI8N5VWX=NL]RY;V2]RE0OG$HOL^9&
M;6Y/:;GI3,@+5JU?*+25J'P]^ ,=>G?D)?NHKFA9>4M@W)M;:]WOREN1[UNY
MV3#L>A*7E-QG%L(+DR:MY ;;88JLT S. ,_.F[HFM&V.K6X\E.=$*W\P7K=M
MF\W"58+IM;?VR6F_P]MYH38Z;[;8+\N(MU.IMYM2D+2 0:8 R$Z0?3NY!<^-
MH\W]X[CY=;]W7N+;O,FY[6V_LW9O,;;&P68MLCRG6R_%N.\I$>W34PD)U.*4
MYV4KJP!9:9T4]-K/7O8NGNT[FW)<]A/PGIV\K!^(-C=6TGXD1,N79V;TRT[9
M[NZPL*:4^PM;9---:UP!W:P>GGR:W1S;W1>-I7.]7CD FS;O7M]^XR_(W!:=
MT;>9D!5FW"E26BEI#C7A5X2HCNP!CQTF])/+/>JM^\T.>MJWQ-Y&['W0-KHC
M;!=^>WG>;Q,FRHD1IB.TPL)@1EA!?53X1D< 6-ZL>FR-TR<[6MIWQK<$/ESN
M-%OW/MV4A)3?']I7!Q+T&,E%S;C:;@XT^&G"M(:!1DJE3@"[?6+TW<C^4'*7
MIVYC\IH.]YC',^U&?N/]L)<%5R*T+U2$14PWQ""RD$-^4I=.W &3G3OR#].S
MG%R4YA<W+YRIY_;/V]RMV\7]R;UF;YV^_:;ON1$=2$6ZP6)ASYXH>F+25:J@
M#MP!I7O[%E7?-Q+VQ^+MV!N[/+LK-V\@2T6TK+T>,^@*TRU%A:4+4A6I)%:8
M REW9TD_NSY6[%YM<W><>Q.6UHYCVYRX;*L4K:V^]W3KFP$MNAR=<-H6NY1K
M0LIJ$>>$I%?%3 !\/HLGHV)RXYF[VYO[*V9MKG%N-C:_+9R5MK>>X7[_ "W9
M*FXDM;.V+;/7:+=)0\V%/S VAHY*H:X [Q_9M\V8NY^=>VMT;WY?;0C<C[ U
MN;=FXI<+<][;F6AQM2X;]AMUFA/R'7I"'$*5'55TUX#A@#M?)3H.DPN9?3-N
MS<EXV;S;Y-<Z+G(CC\.8W3M1M+D9M;\EK<4/<D*+=8*$-TT!M U*% < -+AZ
M:G,#G9S.ZB;UR88LUCY:\JMVNV9%NL-HW;S O"5.K;4E-FVQMF#,O,N&A#E2
MM0 !K@#HNZ?2HY\[1YW<O>25[W9R_ME[YG[?<W'MK<VXHVY-IVF.PC1JM=RV
MU=X;>YX^X"L+2(ODDZQI!. ,0>H_D#?^F_F!+Y<;FO"KU>[;'6]=&U;/WALQ
M<4(5I\]#.\+=;WG(Z60%(\I+GGDZAI&6 %73YR"W/U.<V-L\HMFS;19K]N1<
MQ;=XOXG?@MH@6](?>?G1;>S(FR776 =.CC7(' %^[KZ>^\#RWWYS!V'S=Y?\
MUX?+CF&CEQNZS[=V_OO:UWM=_D25P$Z).[;1"B7&"Q+("U,U*0*G &0/]B1U
M8/V];L278S/9V&[S"5(.T-\JV0+4S;USOPQ/,=VW-;)?O)4@MJ:5*0$$9FE,
M 8:7GHPO^UNFZ/U0;ZYJ;#V/M>[[PONR+%L=>WMX;IWM>;_;9BXLIB*JQ07[
M:Q%@N1U_>NK2VD&I)& ,1;9MZX;@O]NVW:F6G+C?+K#L]K\Q:4)>D7%YIJ,^
M'77&V7&1Y@+@2K4W6AX8 R,ZB^D>/TV[PD\O=[\\-AO\U3:[#>6.7-FVKS <
M06]P-Q50K1'W8W99&U95R4MTZJ2:HSJ, 9GV+T/>K&^6NR.NS;# N>YME(WW
M;F'=E<Q+CM^#:%6IRXIAW7F+:[6]LRV7%3= &WW4+4L9@<, ?6SI.Y36SH7V
M#O'=6S[9*YM1^JR-RRW7?F9<IY]^QL75$"7;BVORH?R+JT+2VL(KI(\6 ,</
M52Y+<L>1?5C=N7_*W;$?:FUFMI[7N$*T02IQN/*FV)F7+*9!<=UK<D&I!4:'
MA@#6JZP0 E+:G%:W-0-<@"10^[ "UU*B A:=":=F> !5--T/A!H#0Y_7@!0M
M12I0!!XT]F?Z, "NT405#Q<":']'9@"A:4AO4!0U_2< 0+2/+U4SKQ^DX "6
M14<>[@< 1%*22:<3WG  ZT)\67\KM/M]N -@WI'*_P"=(Z DYT_K.\NNS+_*
MI.> +P^NX"YZMO6E2OW>_-H5S(X\N-E5X&F -2KBZ.K5G\5%>^@!K]6 )12O
M9]-?T9X (1D13M(K3AG@!@W\!^C\^ .60:&O#^'\/IP <TD:":=GM[*TP 6@
M>"HXA*37M&?8>^F &)^!->/A_-_'@ C3J;T)&=17MR_@, $I06P%^67!4 I&
M5.\BF9.6 +T<BMR[.Y?\V^7N^=^V2Y;FV=M?<]NO5WLEL\I,RXLQ7DR0RTZX
M=--3?EJ0?M$8 W!P?73ZGT=3QYAO[NW6KI25,5:[;R -DL#=R:V&U&5;V;8;
MLF,9)EA8*%@J'@X #B SZ3/5IY3],LGJ?MW[GMW;EV#SNW+>]V<LK>^F',F<
MOMU7-,I,61.CN)4F,W!D/^:E2170GOP!F!Z0&YMU1>GCJGYM1X_,;<V_]Z\R
M(TJ;#Y,7>SN\VV/GYZI)N$.->O,0FWA#E7E"M$BF ,4NL3;W2YTM]:%TW%SN
MLN_^IFQ\QN7Z=PWC;^X;]#E[]V=N^]VY:VHVYI-O>TI1:Y1#BF0"VVA)":#
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MA"5 :JDU!^C+  ))!6%(%:FA('"N1P (XKB#F-1R ]OT8 B6!I2.PYT_+^G
M ;RR. R&1( RIE]6 (*US[\_KP .K3J6"3P)I[:>[VX V%>D7GZHG0*3G_G.
M<NJ&@K_E4CV8 NYZZY/]KAUJIKD=^[1J._\ HUV3@#4NE0\K.A)6H9CX1K/'
MM-, %-I%%*4ZG(A5-/B#=*:U#B4E>0 SI7 $_EN#,1UJH0"?L=E5 \*$\/9@
M QI- XDI6H)0I:A4)(*4$ %?P@5.JG'+ $K(%*"CE FA0D@*7I%10G,'B:8
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M"B233Q) [#E@"?Y>AU!+:M2JE)"2%$ITU4,PHZ<JD5P!,6VUD$MH0HJ 4K2
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MU02OQ'2E))K4I22H))XT!4<N& * AM2"EU&OXVQ5"2 VOXFP*$!I8XIX'MP
M5#W%N2QMW6#8]P7ZQ0[I&;C3XEKN<F*S<(] A3+S,8H2(Y0:455('9@!(MI)
MS45_&' %O!TARGQ%5 E:P/M4%< "K0X@J5&7I=6D(6XHG6H#+2IPDJ*/96F
M PQ367%MEQ:"ER@RU*T^9I_DU4@<*5P!0O4AKS$N)UHTI!20VL:@-0#E*YX
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MY@X 5N)2E54)4@=@[ .X#@*<, "O)4:%-0!2M./U]V %#JBE1S50U%:5I].
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M#A@ L0Y9(2N,]2F0#*^X\? 3@ @P73D8[X%/B"%I[.[2, 3Q[:M)+B6I%4U
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M@6E 0A))0X7ZD>8V*<1F3GVX *0L5CN:UZFQI+@H@42T:):2%E3BAV&AR[<
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M$IUK%0%UT'ZB<S3Z\ ,PMO2CL) J%*;!]U._ !C9^[JGRP-7#,FG'Q4%*Y8
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M%@ 19 <*0*) J#I4,^[A@"@*:H*ISIGD>/;^7 $&@D.D(HDJ.DU(RU$U^HX
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M Z0<\^/$>W #1M.M:%(II135J!XI-32N6 &>M+YHGQ)'8O@2:=F #HPU.!)
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M/0/M;WVBE( /Q#ESLLD^^F -3;2?.+92K14^0-*"Z2ZZ\&6U#0"KXL@@ FN
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M-E.0J*TR''.@IQP!+'BO %=1H3\5:5RRK]/?@"4*;J=04"H'0!YE.  U$"F
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MI*B?,"M'C*LU#,=GZ, "AM6E23D36A4 *]V7 'V8 7/M *4-0)TY@TI7MH,
M)W&U$J "*J2*ZNT#A[:#LP $XTXE#@5H!63H(I4:?BI[\"5<$)EMY@ZA1)*C
MG[CBM]N-*=2,2>,H_;_:9S^FHA8ZNMM$(\[S+#=*:% #X00">_&L_/=N6VW&
M_H&R7(_^9A_G/Q/6M;$.-LL^8D)JT1GF1E6F1SQS&UV&KFOKR\3HQ:_E8_87
M@%HRJ??0^SC7%D'2+ZR2S_B5?W3^G$EB2RNO$EE\:%5R.EEU9X!AQ!_TPR'Y
M<?H;.LFXI]I#N'\HSQ]^IZVY_6KW*G2!IM=L5F>Y)H?H&.EO(?'0QETY(^".
M<7/.;_/)Q?!2EXLURA7A*2DZC7/2Y[>%,;#O'5_*:\W&W)-XX(A40RVH+5IK
MG]Z"D?5F>W&8^)&^)G_Z1Y']J#T$4((/4WR[(IP-9<G,>_% 7<]=7+U<.LLD
MD:-^[26Y3_$'EQLL53G3658 UK<K;A:;#S+V'=KY/1:+-"W5;[A<)+<1-R0F
MUQ'5/21)A.?=O?..:4J"M(0FI!)P!N)WOU(\B;RQ:F-F;PVSL%V#=-G7V9:Q
M(=N<%&VK-?7I&Z&K3N3\.:EW6X7E"D?[3NH2PD**0Y08 L=M/=&S>7MXW0NX
M;BV_L]S=_-A[G!:VT&(\Y?\ E1*GNO2+&X(K"W(%ZE+.I%M%5J0JFJF +RS>
MHGDA*O?,22QO>SQK3ONS,V[E?"<MT-I>P+^U&4B1<;\%15.65M;A 227#0YC
M &O[J*W7MK=.\]MJLET9N\BR[!L]CW->XK;*(T^]1UJ=?E1/(:;1.8=6NH<H
M*C %C&/E]0>?:,Q)^[*VG/(0D(\(J,Z\/KP _0NS#2/EWU$4^&65CZ$T%*8
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M@CG!SNQWR;?7+Q9KPUV1-/#<,N%75 @ 9 C@",;&*C3G\]/C\IK[=^]BNAI
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M!*;/<%&G95"HE0:8B?KW:Z_>V_:%Z>UOT;E>XY_93=Q^+;FXU'M"K)+;%?\
MK -!BQ>O]G2E6Y;KWE+FPZM-)0G7N)&]H;N*VTIVMN:CBDI&FRSBG).=#Y%%
M XCL>O\ :;EW)YENG>6:C8=9&TY1C<3IU">5 NEO5Y5P@S8+I)^[GL+C/)(/
MB4MMU*5:#V98]IMF[[7K\;2A*3/S+6BU>GQOJ2[P0FO:2.S^.F/TK_EU2@DF
M12IF=.%3C$#P="TX()X9$8H"A0TE)-.&?M[?RUP!"4@DYJ ).5<LSW8 CR23
M5-3P!/&G9@ 1:!K)&0.=!V8 @.1([C@"$DU.9XGMP! Z:5%>*2?I5F3@ )2
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M1W]O\!7 "]_P+2BM?*!6/>YVCWUP +4I'$U /YL\  FAJF@S/Y*^[%8\2DN
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M+UP%KT22ELJ#0U:C74ZFGN%#2F!4'$-Q1/A;"NW[].1^KL.*QXC#I!'K>Z5
MJ6T@I6K25K90@5;))*N)KWG$=_',GBLHBVLKC@\QM_\ 2T;<9V[O%"TJ5JG
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ME0DU[.W%Q&^+,_/2.4X?5%Z" K,?UG.78J:5I\W)[>_ H7>]=?\ ]+9UI?\
MN[V?_P"3G9> -46IM3WEJ2J@00:9#CG3*E, $%YT+0H%6ELA5?M&F2*U !*3
MPP 0E8:4=1\:XZ6DII5"T:BH>97)2@3D>. &#>E9!4I1JM)IF,R!6G=G7 #@
M)2V*HH=1J:CL'PCZ, 5PW'0I=*4T)-#E0D]W>:X ?Y@!7%1 _-B:*3C5K$!3
M2BI*:_:H".P@'($>S$4OB8&;7Q(/N_-BE&\$!O0$I! (RP2:5'Q*Y$\:A:
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M]2[C6_G]?E/;91KT,U!JNKVEP>>Z2E1"25T2D \-)^(#&_\ 9@\JZZ'/*_\
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M5RTV;46MWA.=EY/,5'3M/GWK_=-)<VN>6[',[?"IY5K:$K:61J_RR3_L"?\
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MH6/M  D8K+D!Z;C)KW:KL1)+GQO[D^/M8$>N+J'=6WJW!:"XZXZE89LL-*'
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MB-<8-Z+DVV*VX^ZJ4&-RZ6=IQ#&E6'FF]N!!E!TVLV1Z$Y%U+(?\Q#B@^D%
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MK;0%$<< #;:YZ<PMM0;[8VYUFNUNW5Y*K\O<]BAW9V8&FOU9N*F2EY$-+:0
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MUI)#:]*4@CPI5@ G?EWZ6]T6BR6:S7VRM1+-(A'\1DJG#]494GSHS*G5/O\
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M?VHW0,"*?YSO+H$9T'ZW)J.-,L 7?]=1-/5RZU%',?M]M#(__-MLH>W &I)
MT.+]JUY]N:B>. "TN*R!J?I_/7(X D%"H9#B.P=^ #VEKTD@&B<OJ%<A7/ $
MJ77%HJ*T"O$!6G]P8 -014K2/NS\=!F%=I3W'/ #(.ONB,IQQ4@0T*#(DK4Z
MH)4%#R?&542 >& #XDJ9\J63*>46TJ,5MHEE$)2*T\LA21K2"0",Z8 REY6=
M-ZN:?)?F=S<BW<?C_+F? 8A[27$:=_:./-\MM^:F4H@/3$+.32EZQ3X< =SY
MQ=*&X>7+6W6;'>W=Y0+EM>R7.X2)2A&18)VX4,&-8F?/2J:AV/+>\NJ&_*![
M< <V3HPYXWVV2[ZJT;/M$2&[*CK9W%NVWV^0A=G:2J4XE2G4(?B(10K6V2$_
M9%:X ['8NCKFEN2RV)_8DRU;E?EHGNWF?!NJE6&U*8<*DF#<4MQ(LF=(7]WI
M6YY:D@437 %KN:W*#<G)&5MYJ;-F1;G.C2)R50PJVRXEV8<0)<*#<5K4\RHA
M7C6X2RL&B1@"UTF7<),Z=*FSWIKTU"$A^7,DW"6XA  \MQ]]#BO!F,E4[LL
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M^O?A.TD0K+:9%X3=7=[VU5LN,>*RZ_<$;<N4?6FX7"VE@I5%8==6A5==!48
M11.B#J(NMAVU?D;?MMJL.[G8ODR;KN5J!(ASWVVY-OE30[&89C&Z@ZV@*I=2
M?":' '3^?_3ANWIYL>RYV_7?E=T[J?G%RWZ4)9;CM@,M2$)1_EP>^+7GQK7
M%]O2,24>J-T#H405)ZG.70)2*))$J14I!S K@"ZWKMN.(]6[K100GQ\Q-H:"
M!GI'+791H3EVX U+*KI=*J:M7$=GC/"G#+ !/ @ TJ![.P5_/@"=(*>-20:Y
M_P!W ![2ZM+IED>&5?#^4C $K62,LJYFG;D.. "FET2I([?H^GVG !3+A*J+
MRSKJKG7(:N^I& &C8);":I*%D(2I:%K":\:9TU4P!D_R.ZG-Y\BF##VQ9]LW
M2$J[-SI";Q'F.(< 874/,,24!Q(4:T(P!V23U?[UNLJ7)W#L;85^:N!C/F K
M]H8K"YENN?XC&=8#,Q<F*$O!&DJ;>;4D$ )XX 9V7K'YA0MO\P-K73;&U]R6
MKF0N?^.,W:=NKY:Q.7)14M.V&&MPF38I$?)(>#I2H#^937 !NS.L'F?L?8C?
M+W;-LM=LM+$9Z/&N-ENFZ;7N:.@/!:$,WMNXR+@J2V[3[U!4%(R* , =%YK<
MWW>:3&U"M-S=>V[;I#-UN%\EKFSKC='G2Z\\N4Z2\^"E)3J-"5 5SP!:,S$O
M)"B**JFJFZI"P0#[SQS[:X 9Q"5!HMJ*%-OI=%20D-E-".(P!DGLOGLG:.T]
MJVZ%8T3-S;/OT^Y6:9,< LSC=Q;6TXS,CQ7(\J4XWJJC[YDH5F2KA@"XW*[K
M W!LO;>Y[)>[0F_N76!>3;+A<),J?<;5=;@^^YY[4RZR7XJV6@]I: 80M":
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7M#F[=]U[KO#J3]U"MT61*>X(0< ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g214466g25n25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g25n25.jpg
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M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
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M<[I:+[Q?N/U"[UY=L6Y1Q_OVTQ[Q8+LR'E2)<URR1V B% M[^E+ 25>5W=N
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M>Y-WVC9<&)R1>;*PD-1K?,O<5OR9=L=2*T6".VE< 8J;#DQ+7OKCR?<I'Y;
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MW %22*>*@.K,9]#_ '0< ,04H  3X5"H*1F*@5-< %1R":!2^G4IRZ=X'MP
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MR1>MHV?9C?$9M,2)M*59G+4Q.7RZW+;-W95(2MR[1E?,J<2XEPJB)4"$BE,
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M%36I^.HJ>S "LLVQ)T#\PHK-7A10$FI%2NHH< <&-; :!R73LJA%:=E?%UP
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MIT_O@YUP ,\0$)6\VG6A/B!%0HGH.^@!RK@!0ZZ@$A+&E6FFK2$UIW&E:'
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M0I6G[,:R<Q]5XZ753L0N)/'>?7M/T^U.KT_F1A)JBW%TW/ZMKQNLY>IO<%%
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MI(HI2N@JHHJ#3M%.F !'TI"@$)UA0"JZ5=N?V8 @7J2@D)4#2E0WV '+,]F
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M*P34X Q&BA*0&63Y("4H;\1>5Y:$I2@$J)) 2, /6KA*924"0E1-*ZXZ4UH
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MJ5D_N6Y5+WY>+.K7)*3Y>MU^K'P1>VA0  !4 >_[?;7'SVBJ9?!U5'L."@J
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M!;B$$A-"0H+\7>$?HFF #0TL]U3W^$^S+LP 8RTM !40>GZ0)/6F "5@N(T
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MVUMR1\$7J3\)IE[L8&\&S-K;J\2@$U&9Z#^WB!-=2H0R2JJ5)%?$FH5T)27
M#^YB.C_J5FFW.6=S#3W/A/)W]7&2S_2<AIFPEKU[6:3YK+A2G2EMTI"T_P!Z
M3CH[T&_IEK]]\YH1USE*.KGE='1FK?\ S$=>J#+51#68>50Y#I4GKC:[6_>.
MG::JV&VYO?E%ER,)(1\E%4W4YK<<\::]E3W8FE]S\A;6_O$9R;42/V5O/?C/
M^L@](ZJU[?Z*GK9-*_V\6_T?45_I^LO_ /7J?/[73UI5&L-;OXV24I)'EH_F
M0XQ6'' /B(4:@XF)34LR VJ*$MQ9BGEE,=2U*JVM*'2AMZ.V/Q6@DU!6:"N
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MHU+S"CWZ>[ %&M22A61T5Z 4'N%,A@"-9U$JTTJ:@T[^RN (E)KF* ]__<P
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M^*E?EG"0* T!RJ*X .CPY:?-_!D*&JE1&<J1E3 ![$>57PLR 5  A<=T"G<
M.S #=B*^V*EJ2:]=,9T]E*>W !K3$E2@4LR*5% 8[HR[*]>S #9B.\:E4:4L
MI%"4,:0FE>M<SE@!E'C/+(<^7E@CM+( 50]V>6 &?DR<B([ZB<S^'2A]PZ8
M.9B2%)0?)?%2JOX 4/O[< 2-19 5_$23WGY9=#[13*@P 2W%="SJ;D(S[8SM
M>O;3V8 )^5DGX4/%/5/\F>^_K@ QB/(H0IN150_W ]?<37$(4>:NPC%*M:'!
MA2J&C4DA(3GY(S/:>O4XA9=+K6ZI&_@XF4GHTBK3ZC=OE2'VM,513K0$)TEH
MJ('4@$YXUOZ_UAPZY+O-FNA7\]:]1Z,K>X2T#I!J![0?MQS6XNXYYX;V;_Z;
M[J/PH9)\5:@"GLZ'NQXUB.:#;WGIQ?LHHJ4KH,JBOL![<N_$ME9+U7LJ233E
MW%G^:U4X[W<@IU [=N]*=16&O/V8^D\CNO'+?[Q&$\Z>SP>ZEA^S9YC+8RM<
M:0E+:E)3.D#P^-=#+77P]A..J_3K'@$?@7@<M>?<>89I_7EXA9B/4HEAY8)K
M^,TXV :]Z<L9A<]]]YBM9+"I&Y%=51!CO:A0GRV7'1]E<R,5K;22J0\2)R._
ME1E]/L,1P'[1G0_N8J*-9>@$9C/J_P 7(_\ S9S]ZF*5Z$ELP!"J.^DYM/4'
M:ILM#V4IGB$:Y57;0%!CO*^)ARG84)=4?8-0ZXF .["=-%:) _\ <*Y>\G4:
M>W/$U4MP!#$E$T;:>/\ A1E_OC+$$LS(9)/%,I5$EA*JLND@&O@T^^@()'NP
M>#H1V8/:!IC/!*DEERJJ#X1T'0'+$ #JC/C_ !;V664=Q73^^&1RQ+>^CW$4
MW'9O%LEIXJ=5Y3P!BN(_B:'4A-%9'/.F+'6_<R^$];043BWMS&_GZ;PT>G2R
M)H0I4^>""*?XQW*G932/NQS"_,%5<T2O;XW/G.D/09UX':KOMK_!(V).:U+2
M?""DMBO;V5KCX?Q.:_B87+:HJ8T/M>E;<I5>]^(>X-72E$$Y=E1W#'F7G63:
MV5+Q;"@F@4K*J4:L^\YI^ZN+7)[:9"6,&C13]6;1_HZ5\L^\\F9<=+K("P@Z
M1U2<;U_EP2K;3W1CX&G'7J&97*XI5\32Y(CRG'@HM20EUY*EJ^5<\-$52<LO
M'C?)MM13[$:,SSYFJNE19(;D+30LOY ?XAZO2@[,L\2O"3ILJ2I45!+*BOAM
M1$>3U1F&._KUSSQ6BL*[R-!9-BO.,,A$>4DMRXZE%R.&ZTD>7\5<Q1:?L QB
MG-E8<'OM_59E7*/]9L5^NCVE< MUXEV ,TD[0L*B.X?)L'3[@,<HNJ$6^8IM
M?6E^L=3^GO\ QNVOLQ_5+Y=/=CYREE59&;K81N=F(UB1.'TA4>0>WY=S[]*!
ME]F*-BG\?8_>_.>9Q%26DN-?5/)=]71DGU-PD(2M5=O4JE)(%$O$#N\)..CO
M05M\/B]_F?.:$]:%EOSE+;1FJ]4*5J4E#$@C0R/ PX[EI Z9#&UVM]Y=QJW9
MQE-_9 IS3[*V ^R\AE>H(4MOR3KSJ5 $FE<17W7J+:W1W$9U[42K]E5SVG4*
M_M'_ $D)U5RT_P!%;UL#XJ=/;B7Z'J*_T_69!_7J<=/U=?68!58:W;Q[I2D4
M":\&\8$E?\+/KB8E,)]E>K_G/9VUK;LX;L>W)M*#(<>&VMSAV=;'(*F PJU4
M"4R&+45*U%+2BK4GNP ]@>K_ 'O%WO=-\?JALF9,O$1=GN=GG6<NV:;8$Q'X
MMLL9@-NU;MUI=5YL9:-+JG!XED^$ ?;Y]5O)'(>Q;CM"_0]KN2+L5(O>Y46X
M(W([;6G42(5I,E7A1;("=+:*DE/E@',' &.[#:F*+;#R5TKJ7\N"HD5U )-"
M#UJ.H-< -H]TF@'S'74::!*JM)33V*I6F &KEQGO-H6+D44<!TI54]!D5B@5
MTP QCS+BHI(G/@K51!K4"GLP Y3<)RV0IVXFB7-*@*@FG>1@ YJY2D$%N8I1
MK44<*E$Y]49 8 =LWF:I;(=F/*&KH5*'9VBO=@!E'O3R5+2F2]12R*ZE9$]M
M3D*UP S7='R16:Y1-*:B2._LJ< ,8]RDJH&YCA4>J@5)%:G[L '-7.8AQSS'
MW%>$$>,FA-,QG@!VU<'G4I+DB8VE("4!M1I7O5W]< $M3GDKH9,LD_PB<J]*
MGV# #)JY2P=*9#Q3U)4&C3V>+Q5P :)LX4*9<@=HTN,A/O [*X )9NLI%4KE
MR-0R%7,^_L\)Z]F "C,D/)*UR)22G,:5*\?M5TP!PW-G!"_Q9B4H2"BCK82>
M\YYT)/;@ UBX22*EZ2%4_A E/2@J,CGA#Z1&.TD,^< HB6]4D)**E:B!VJ1T
M!Q):^_\ 00OOW:;3)_T8.2'_ %%[>+LMYT_*:3K2TB@I2E34]/MQKM^86*CP
MB<GZ39KH3CK;->Q'HSAHT( !RH.A!%/>,CCF3Q5UN2ILJSH#I?NH]R#A_9]^
M+'1XJFX]2/N(A6K\6M?A)K[?8?8,4KM87:[JE10K%%H^:EC^;G>CU2DLV*XA
M.DTJ%PUCQ=>N/HO3]YN,6F_]1&!\\X<*O+=D9YB;?)D-B40XL?R^42EL4Z/+
M50]^9QU:Z<_T"/;ECX'+/GS_ )#/XY>(9^8R\],B4DDU.M39%>W)52,9I*%9
M,Q4X5<9BAXWU@T *DDA1IWZ2!]V"RK @0F7)*D@/REI.=4J5E[LR<L0E>RX)
MXBA0N3+;51+\D"I *G34]QIB,+V>F;$''S<D_P"^7B:=HJ/;UZXN<L7C3 >!
M"J7*2K*0Z/<LC[AT&)6D 9ZXR@HI\YQ1(K0J.=:YXH_2:])35Q5H]S!DS)A
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M7VST(_3=6L^G&Q,T3Y?YA)-336 9)&7?D,<M/S P<N9U*.R-V7BSI=T/?_\
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M?4A8-5A(2DFG>/,KEC3BYR!QB<WY=J>6N#1M3_?'+FZZJ%?ZPVO-*7UJ425
MU03I.=/XRM ,30Z=<??^3<?RC^^.7:?>HI=W# ( \S(ITG41E_[Y3+%'4=.N
M8LM(69+U$8<Z\NJ6=W(_*8+^OW7=/3WN1BWLR)SY5"4F/$2I]]8$G)3:$+*@
M$]M,?:ND/)7'^&:B-Z=N5<Q\>ZM\Z< XAPR>GC<BW1H\^IL&X0D@[?OH(0V/
M#;9.FND5*2&2*'WG'1/@%FY;X?!7E[?EJO?3$YX\=NVGQ";M_=YW3NJ??JYN
M I6?R&]I4NH2#;Y8/AZ](^1.+N=/,JB@GGM8;: IL%^J=6WKTD5Z_EMP]O\
M!9I]V(W]L>XH6++S8]H!-VYN%Q#G_!Z^E*(SM#^6RBA04DZ4@*8)U4[\\6NL
M6;2NFVA[O#'&Q?BY4IG/0/\ 3=8=L_IML46Y0YD20FX/J6S*0N,^AM;RC0LN
MMI*@-7=VXYU]<^4N.\7XO<NZ>TW#S9973=5T-^NEG.FAX7P*%MM*>2*?;L-@
M:KY;FU:0LD -YJ4V#T'4:Q3[ACXCH^G/,D+?GNRZI;:'U:QU"X>H2G*4*U=
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M0^&M>8[=NCQQBMY-#J!Q.7[.5RXJ85S,^N/,'+BH[T&^;WWR8[@:0AFXW)Y
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M&)!2$LZOFXK:O,#@)\L)25)H,2M)[2 IG<L\H.->6K=6\""7RRX5RH[CJ(J
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M4..)<<4!3(DC$U<*;B;9L*AI2M*5O(25R@ZZ\ZCSEI"!^""352BY_"]N"PV
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M Z98 Z##]:_*UNF)N47;G'B9MQB(9?;%@E>6Y<6M*#=C26M*IH:3\2#I!^W
M%CM[<A;CY,W&_N7<SZGKHT!#\YCR6?F2Z:!QR/4A*TD%"<SX0.W '7M#J7$H
M,:8T)%$!LL.K6D-H5J>#/EZW5JTU.DZ?9@!@@K68I;"%:4K^6=4VVLAX-D&@
M102WGFP4JCI"E)-"4CK@"].U.<N0=O[#V_QM:I+#.U;)NT[MM\%^WIDW*1<
MTKS[<R^IP@,-D56#X4@D=0< 7/<]77+KKR):6]J66VN2&&A9;/8DLV*]RZZ@
MQ^(CRY;CB128GI6NG $>Z?5GR;N.>Q,E#;5K<@6V1;68MIM3<:)"CN^&5 B-
MJ=0R S4^$IU9X 57/U(;SN>UKEMB_P 2PWRV71#+4)5XMKJ;A:U1(Z4:K-ID
MLM,H\DZJEQ2JYZ3@"R+:8RTU0I:62CYA)42X$.*.;AU);==U?P5)!& "DEU"
M?F6DEV2"AIF$@E3ZXZ/@D-MIJY(&?PT\. #T*;\]N.IE:YCWG(3'22E9<;:U
MJ0MH(\UL-]A5G7 !NA92EPU2EU"5^:\TZTDM]$AZ0X@(C$$'*GB[\ <?*><#
M(6A6I+Z/F"DJ:,I32 _'>; <&@)2@9_I+& ,D(WJ=Y)3=-MW"1*L%[;L.WE;
M>CVVZ0@+9.M)C.H0Q.A)2J7*F1ZYN!!;4K]+ #>U^KOENU7&%*E,[;N,6VHT
M0[==K1&5%M9;SB,VR,V\_(C>42/+U(J*"@5@#KUT]2_(]XNTN?.EP_GILABX
M.-(B*6E(>):8\U@_+I=E,:U*20ORBV/&4=, +-Z\R;IW[8H5IW-;]O>9:Y*F
MF]Q,Q%Q9TIEU)HE4M<E41RJ1_%I%.[ %I&78I:AN-OI<B.H>=AK<9+#;7E$A
MY9\QQ25I6.T UP!]YRGFTJ987.0AYGRDML*>96VMTA55M'6P4@YJ "54P!<^
MU<C*LVS/U69BJ<NENW*W?[7+2@.,L+8)TH4VY4)6UTZX -E<Y[\G3%3Y3D0O
M*BF/(?1%+*X_SCR0X\GR5)+KH0C4*9I.> .T[S]2^[]U7NURHA:^0L$:T(9@
MJB.7(R';<RELB?%:<$@1)2DU4::C7Q8 [-;O5WOBWP=W2[EMC:TJYW_Y<V2'
M(M*6=E6,1 'W9C:EK$=5T;53\/7K2K]"N .GPO5CR[:MQW7<STJSS)NY&HT>
M\QY%M<D(NL5@ 1&X[:"CRHK   )H2G+ #.-ZK]Y2N2HO)FZ6(\B?8[7/LT.)
M9HKENL]L8N$133"P-;TI+[A<_P 8"BI\(& $_%WJ<W=QGR#MO=LZ)'GP['&N
M+#]M6ZIJ6NTW.4LR(RE.-I\QQI"](41UP XWOZL9=RW=NZX[ V?:XFW=QK#Z
MK;O=ER^2(EP2A/E3;:I%SCNQYX4D%KP%L@ G/ '1=\>K7E;?NQ9G&]Y1MN'M
M:>EJ1<?E;5)%WFO,:4LNF27)&6E(K1( '93 &-R8=XN#BW8MINTX/D^*+;);
MH=2,U.ET1U!Y &8- #@!4M28#CR)+$IDMJ0T\A^.XP^5)0"4^6KRR4+10)-!
MXJY8 [?QWS#N[B*[7J];-?8BW'<VV[EM2Z+<@J?BKL\UO1*C.*=<#422D?"I
MW0'/T*X [W9?4_RGM>PQ=LVERQB1#;2+?N9=I4[NQZW+.I5N+CH6V[;M/1!!
M<1VYX;=H&ET]7_,-ZVU*VTY#VY%A2Y2';A+A[=6F\7*5$<T19,QP%IVX/,,(
M!U)(**YX ZE:O5=RO8[I^9!RQSHZ7I+MSM%PM+9M$F,] $5R/=(S+Z7BW);4
M"H-"@10_%7 %A-U;E5NN]W*_28,*P3IKSTJ3%AMNM6Q"2-+K<1+ZY#;82,TU
M6E6>>> .GOK4\IMIQ*F5@)5': 02ZVIQ:2I]"5?@-(#B:.%12H &F %SY6W$
M9=4U(4PXZIOYUMEQ;+BD&@;C*;5Y2QEF4YD>_ $GR=RD1@_&LE[F--!7F*BV
M.YN-- YK<*TL$LM)K52EJT9=, =7F^6^ZVT02I8T)DH4VM4210%*W6F A+:-
M3(%1XJ' %S-N<W\@;6XUOW%&U[G$B;-W3N"#N>\N(C:GW+S9UN/PW6'GBY\C
M'*H^86M/F)Z4P!="3ZT.<9"F5V^#M>WK7'9<GL6+;DKY?<LFUI^0=N=V@N*:
MD?F"NLAX(^64V05.+%"0%NZ_63S)O5S;$9]_9]HB;5$]NR0+;M];,6.BY-LQ
M+K(E_*.(0\FZ0WUAAY!+:U)\-#4X ZS;_55R1%LMVVQ=+9MW<=MN4$VQ-JO<
M1R3^4+MP=:A2+"(LV,8US9C.%1D.A3" 3I4"=. ,89+BY,F"7B'5S'I!#L9*
MWDO.%*G'"W+(2IU++25)4IU$<J"1I*JC  E6PO3^(ZE]+[T=44@K"(NA"W5-
M.56$-N)HE3J4Y#PJ[< "R72#JTK"2GSREPT&G5HJDJ2"[4YZ$U]YZX SVVG_
M *J;GS,_ZR+TBY^6K53^BIZV_P#%:M=:?HUKV8 R ^OE_K>?6E_WV\;_ /,?
MQC@#4(E8 IG[?O\ ?@"2M45'\ D=X\1P 8TH(<;4:$:0%5[:@4KWTP 0XM*D
MJ2$&JB=6= H'J*9"E, ,8ZTMCQ@@Z<E)-2-2<Z'KF#G@"9)44Y*2&VU%Y*]2
M@[6IH%*&==6 ,Z?3ORQPG;N%MU<4<MMO,Q=R;TL^Z7KA;K7!<O%M%C7\U%%N
MFR(J42(\Y]I*9C+KBJM], 70WUOSTT<][MD\A[DN-FVW.MD';T5^WQXS]J8O
M]BC6?Y$0H#$*.Y%1<'Y"6EN%3C220?%6B2 SNT[T>0>,]NKVA)XIB<JQY,%R
MZ(W!:-_7 IVY"E*6XJ!=H+UK1,W 4); :+,=I KJ4ZG+ %TMN[X](FZ'8.Z[
M5;;:.3YLR,VY==S7J2U)A?+L)B/*L]L1:7;6BQ+90:^:YY^8\LA6 -:N[W;<
M=Z[N%I<*[.YNJ^R8*5E?D!EV9YE I:UNI'F$Z!7X:5SP J40*,U*-05I.25!
M=2:>$CK[.S #[:*V!N?;,FY)280O]L$U,A7X*HS4D%2B<Z5)J:@U& -A%^Y8
MXCL&X+3;=S6NV7Q<#>GS\!=DFNQHS%G=@I#;$E3+3?SL@)4K4A0<9K3Q5R '
M9OU)]+QWI>)##NRE6E_:+>\EW??$NX/[=MUPN4C5^4385@DBZ.26XX/DH9=0
M$O445T&@@,-L6CT2W^_P[5#9V^[:7X3K89O,O<GZT,WP(4XIU^\-+1';V4\3
M7RTM?.:"!KP JW=R%Z8X>VK/QW;MO[3G!N=<%[BO5J@WMFWVA3)<;B2]E/2W
MG76Y302GPRROH2*$X /O5S]&4'C>V7*UVNS[IY,MEM2W;+5Y-ZA1;LJ2LH>D
M7^KB5LS%(5J4XV:+4.[  5Y1Z6]E1MNP3MNT;FW#NE-JGW)N[-WAZ+MMN6EM
M-SB6$1'PEZ0RA>E*ET1I'3 %_.1..O1SQY<>,9T>U[6NNT;HV9\^XP+W=X]_
MAS9#.L-[@99G2;<FW)4=/\6A[*FCO ZM'W'Z(K7'EW]J!88FYK5=Q/L3D69N
M)]]E:EEI2(CST)MAZT/QA5QMZ-5*\P>W &+>R;KMRY\X[JNU(;-LN]ONCNWI
M<M##$!4IX*^599>(""^RH@JU9%. +_;<W[PANC=$?:VZ[+%\V^[73M:[[@$M
M8C,36G%)$QJWE:&2VI62'"XD@=$8 (M&W/2U;+9N65>OU3%DL&YD;:>9N,^]
M/;KW!:H""$2]IHB.L6V-+7*H$./$(</AT4P YMUE]*EQL>X;@TYQZ_-L:FW+
M&Q<6MW^0;.5!R1&W'$;DL2KEN41JI9$0LQ_-ZDC '6=\;Y],F[]TVMD[=A[:
MVQM^):FH-ZCV^YS+K<4Z4(N,2],MO1V'K6,_()<:EH'4J/4#LF]3Z/'-P[5L
M&P(MKN;%^G0[?NFXN"ZM1+"Q)9*4O6,RE6R1">2QJ0LRRIDK(TJ5@ W:%O\
M2C<N2+)QO)M5JC[=D3;C"D[XFSI3UV7<K83\DF-)-V:M2(:T)#;G\F022:+P
M!V/>FV?2)L[DG=]GO-JV;<&6;?#<V[+MLZZ1[%,B)8U3"]&#UUD1+HXHU;\I
M9;=(\=< =0W#NGTF;?VK*N>Q%V]G>5VLLN&B(RQ)6B6A-4H%SBN-QT)$6@#;
MT=32D5\;*^N -?*2&TC04EI4AYWQ AQ?FJ*JIUI2O14]H& *TN^44J*3J6?
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M@ GLIV=*=F )$K  !J:=?O\ OZ8 +11:@ #V=?A^[I@!H$+  )3E[!E7/NP
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MHVQ[+>_SC>%FW+N-VP*O35@9D%^Z61QHK+<=;7S1*64,@'-5>W &"2#XI2U
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MKT,VVZPH>]F-Z6C:>T+A9+)=8]HW%-:95N820W)NSY<HEZWW-UM>J.@ $.$
M@' &!?+NU$;"Y"W#M*"VV(=H#7Y?J+J'TPW&TJ=<N*VE);<9KFT49JKG@"UK
M[C*7$K0E*F/A2M]KS%#5DA#:7*F/I!IU%, +9:0T$I=6\HI"DNH=>5,3I5_%
M>6W_ ">@;J,M1IWG "QY:T!E*5H"VT.*>>C@MAP:@D>:RI:@XZ$@#-2NE*X
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M4HY )(J< 97+])GU$5V"!&D;^]+[5@CO-KMKW],7TPFWNDU4 IY7)H8>.@@
M)*O#2F .SO>GWU\IOFU;E.NOHA=O,)1C[:MLGU5>E9)=GI<;"9<!!Y19=GW
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M?HCT]E/7WZ/2*>S_ $P=, 1.^@_EI6G1RYZ'DBJ:_P#3]]('Q4[1_.]35@"
M^@_ET$4Y;]#:NHJ?7_Z/OO /+W;@#Y/H-Y=U$GEWT0CXM(3Z_O1X1UST_P"F
M 8 %<]!G+YJ1RYZ&]%>WZ@'H]"3[P.7Z5P ,OT%\PDU_G=]#/3_[0+T>#+N_
MXW^E/W, #/\ H'Y;4E6OF#T+BNB@5]03T=@5[<SS"!7 $!] _,@#@3R_Z&#4
M]3]0;T=5I^C6O,.7AZ>S "U/H$YBU*(YA]"00#F!]0?T;T(U?I4YCI\7?VX
MO9P]Z*?6!MJ;+<X=Y.]&EVN3TV,_(18?7+Z1KX\S<$)2B(QHM?+4EU*U*H4
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,2Y4=ER/"E.- ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g214466g26n01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g26n01.jpg
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M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
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MP2(R%36!D=%2<B,S4W.A0F(4-"7PX4-C)!:"%[(F-O_:  P# 0 "$0,1 #\
MW'ZRGUH/J)^U+ZBG?SL5V/[V;=Q#M?PJQX"_&M@EX%PS>)K*7>N"[5O6XN^X
M[M:37]RUQN-V[^=J** "@P!\P)?\13]6U'E5?<=M1"@T/]E_;SJ344IMQ&6
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M5/\ ;WM8J.A[<\#/\+V$;G\J@_+ &47UW_JA'U-7?O;#1LO]7/ ?@,O^Y*X
MS_?N_4]R/]OFVDTS']GG#EI^2+8Y4_,Q& '$/UW?J>,ZJW?;:J?'^SWBF?S/
M_$'C@!]^_3^ISZOE[][65(!H>W?$Z#///]A G "A^NC]3HG+OOM?6AIVZXI2
M@ZT_XDP!^_?J?4U&1[[[54=?]7W%1_!^P#@#]^_5^II_X=]J_P#F_P"*_P#Q
M?P!^_?J_4T_\.^U?_-_Q7_XOX 77ZZ'U-BM1WUVPDTTT[>\3H?RG9!7^# 'X
M_7.^IT#1^^NTITZ=O^*_FRV,BIP!B_US_J;>G1>^^W:]7WAV^XCT\0*['TP
MFWUS_J<KG_;OMY'_ ,G?$OY-B P!XOUT_J<&NKOKMPIT_P!77%,\_ELF9P G
M)]=3ZFX4D]^=N7P\O;OB51^?8S@#Q?KJ?4X,2%>_.W,32I;MSQ.IR_S=CI7
M"4GUV/J=1L%_MVVYB>I';GB9 /2@ILGA@!NWUV_J=L]!WXV]1\!VYXGX>)KL
M9P!Y^_;^IX*C^W;;V'BW]GO$12A^'["RRP!C^_:^IZQ_[_>WJ*#_ /ISQ'P'
M7/8\ZX 1/UW/J?@G_7YMU/\ Y.N(?_N/  N?Z]'U0HV95[^6&3$5_LWX>1UH
M*?\ $6 &?[^_ZH0R/N"V@'X-VZX<&'R(_80H< >#Z^'U1VJ%]P6S4KD?[.N"
M=!_M]N1JGY@' #&7Z^'U3%8C^\/LHH2*_P!GW 1_!^S33+ "!^OG]4\1RNON
M(VDA6&?]G';XTKX*39#4/R8 8GZ_OU3A.5/N)VN@K1'[9\!1:?[=;&0UP VN
MO\0']5!"WI^XC95("9)VYX+(*F@.3[6G\> $)O\ $"?5441T]Q.U G57_5CP
M#,@G_P#,_"F !8_Q!GU7 QI[BMI8YE5/;'M_0BN5:6-< >/_ (@_ZKRH"WN%
MV<'22:]L^ H,Q\5L)#0'Y8 '2?XA7ZL"J"?<3LR^;JO;?A3'37+^BV&6I/V8
M ;R?XACZKHK3W&[2/#_O:<.K_#QH&N $6_Q#7U7P%_\ &/VKIU_LPX::_P#\
MO8 P/^(<^K$ 2ON/VC_=]L^"(?&M!<;+"Q_(", -/_LB#ZL]3I]R&SFA(R[9
M]OG\2!Y6VN,U_P F $I/\0_]6O4-/N0VH 9$?V7]N_#_ -H>. /#_B(?JUHO
M_./VEZGK_9AV[R!.7_ZO^& &\_\ B)_JV(R@>X[:@/'_ %8=O/CU_P#<^HRP
M!;KCWUV/J<7WT_>[O>ZY[\[7)W)XO[VO;IV@V7?!VZX,J6O >>>W_P!TG-^4
M;.VWK9?@II;_ ))VYVB<3LIFC%L44A7>H%,?\0_YOJY>Z4,20+'M905(I_JS
MX\/"GQ. /BV/,"222U:YG//[< 9ZC\3DNGJ?N_# #OU90*>K+IZ!?4?2!\ N
MJ@P \7S",$DA2"*L>IH2:UJ< /O30= 14"OF;.H%?' "_HQJI(7/26ZDYZJ5
MS)P []-4C?2"/*!DS=* _'XG "L!+$,68D#2#J(R%<LC\L %5<H:BKU7[H8J
M ? $G+ "EM.64I*8Q.35(PX9M'^=IH-6 #$-2I9:A@1X4.8^!KT. 'PB-0V=
M?$BH/0>*G #Z!BQTEF(Z$%B<B1EF3X8 =*TL9/I5%/*$$B1^7^=F&K3YX (V
M8D;4P9G=" ?3G3]4=))#445((S. 'I:<^8RR9TJ1*9 2?E'3+ #RTA=P"*$Z
MFUL5%6(IUU FO\. '<:'0^H Z35<ER;XY ?PX (I$VE:#(@'('Q^P8 S@3SL
MK#J^8S^'^3 !)444 %!D* D?RX 6++ Z@QFATZII)O52)I02FN&+]:L1B&H#
MKJP X!,E:QKK8 (0I6H!ZJK#U&U#/433/ 'JL!<BV62W)8>55G$C1L/O1W$H
M7TU8?S<B3@ B @95 ?)F5R&6JT74Q>TH)8PL7FZ]< )JX8 &13&U"LJ*==#]
MTZ>@#?/ &924DBDBEB%4:5<@CK4 95ZX 4(12T,CPB9KA @+!%T%3Y&C*L_J
M?/53 &:*BRM$-9$1K,/4$DFF:/4GIT*1Z(VZ' &<B&-"5B]24%',;) 9+>)5
M\S7:I*S2(Y/WE P @OIA@)[R"UTH#*407*+(?NQB-$U*['(YT& ,Y()"AEN=
M$0CCC92KI'#I:2@).AF8D=5&> &K%9&]/3#*SDT>VB:-'4=!$9:@LOZ5< -Y
MPVAHXRFJ-D+% NB@^]0TS&6 /*GS4T^>GI^49?SJ99X :73L--*"N62K\_E@
M#)!X+Z(=HFEC]5%]$B'*59334,QX4K@ 4]S+.\*Q1PK))(BOK\D/I4\YM(V4
M,N@_IL2&'3 "$D<J&19,SZK !HEBTJ&^Z"X.2TP QDC9B054@$T\JG*M>JK0
MX 0N8Y40&&I;2/+09&F8&5<C@ 6YF9&=)%8HIBDCCE4$7#&OG!!8,HKE7 #%
MV$GG#+$%95=6G\[%B/NURIGE@!&Z%M;$F21(_P"=ZLB%9&7^9I4UD_@P )GG
M*1-<@K'&R3-ZL<JJX TE?5  \PU9TP UGEB>-9/Q+3K/E471E2W"#RL5)J*_
M/  QC(5D,LD7F4&QT@@.&IK,E>F6 !LLD,18$C5(H*^GK)6G49D^. &Z3"2J
MZI(HA0B125D8BOE-#_#@!I.%9&_6229DT=W8#/H/-@ -+72QJP(J?O'(U\,\
M (:0Z!F%36E3@!-AIR0L@-:A'9 >G4*0#@!!HU())<Y'[TDA'3P!8@4P RI3
MH6H?#4U/S5P C,S(5"LP% :5)SR^). &<KNS"K$Y?'\F +^\39OW4G?PUS_>
M2>T7/_Z*GO;. +5_XA\%OJ[^Y]40A1MO:XRD'[[?V8["5/RI0=*=, ?%LTJV
ME2@U, I-: ,1U/7 "NA?A_"?\N %XE5B0PK^4_R'Y8 (+$XH:"GAG\/\F '8
MKZ@5OYN8_BS^S #D9T!Z'(_83@ @J*T9J*U'Q/P'P^S "T4/D\B^=LDS/7^$
M=, 23VL[<\I[O=RN&]J.'V,=URSG6_[9L&QQ,"\$=W>7$:&:\T&1A;B,L2M%
M9Z>4DX Z%?>C]'[:.VOM0W[FO:+AC;=W-]NNWV]YWDY!=\SV#?=I[H69AMWW
MG=>)[5M-[>;QL']7)972:VOX+9Y'72A)P!0C>_I:=VN.=DX_<M==QNVS]BI^
MUEKW)LN<1MO,$6XWDZ(&X1;[1>6<5_'R.WN)%CD:71!4'23@!5_I>]X-M[$[
M7[C^2]Q.VG'.TVY]NOZ_6V_;GNES:7]Q=,];?BL.PW%O'N\][=.1%ZT4+VP#
M"DFJF /G1:[;=IMMGO4NV2P;5>2M'%?3RW"V<BT,DDO[5DM8K:0JPT(BJ2B&
MK$G %]?IJ=ENUWN#]V/&.V_=C;+C<>#R[7OVY;G;Q7,MG/<_LZSDNDB6>VUZ
MX85C:I0AJ4/C@"]GOR]H'M/V+MOV:Y=[9-EN..;MW0[EW';6QW*QY+>[YP&]
MW**^&WZ=VWZ\L6EV?<H9'&M5C<=12M, 5X[K_2V[C=E'Y^O.>]G86PN>W_'M
MOY')M,7.+>XWSDRW5O'+^Q-CXY;P_P!8+?<HTDJ7O(+>)RH*DUI@!KQKZ:7=
M7=.6=F.#6_,^,Q[OWPX)?]S>,[A<V'(8]MX[L=I;N9-NY==+MCP_CYY%7TA;
MLR1UJ[&M !H_(/8CW XOP_M3R[=^6\5N++O)W4O>TG&X-BM][WJ2VWW:-P:P
MN;R^N+6Q-G:VLDJGR%S+(M-*C &R]POI_=Q>VFT=_-XW_G'#C;^WBXVVQY+:
M[=;[Y<S\BNMXMU>R@VQ6L!)M$T1D&O\ $ ZCTI@ 9R'VO<7VGV==G/</MNZ[
MNO,NZ'<)^&/L5X(]QVBUA,L< O)KZV_#3P+&[U&F)V'BN )C[D?2^[A=KCN%
MOS#O3V/V&[LN"6'<"WL+SFUG+OU_9[AMZWT&UVW';82<B%RL+@M)+:QP*V1?
MPP!NWME]DMQPKO\ ^V.X[OS<8Y3Q/OAQ;=^60\=VS;MWO[.RL[.UD6R?>-ZG
MMK.,+<RJ&6.,.X)ITP!\\>[>WVNU=UNX^W[396VVV>T\OY#MVW6RDG\%:0;G
M+%%!'&S,R1(F0!)RP!](/:)/[;>;]DN9]DMV[/3[IW"N]AWK>N9]XMTL?3V?
MA"QU.U[OM^X07$-M)&'90;;S73D:=(+#  +W4^UNT[<=C."\DX3MO';WC7&K
M6%>X'(8=VB;G.X[QN3+^RKR]MI-#VNQM 1<+;_TYCZL0*8 T_P"GMV#[9=]N
M1]\=E[E6<VX#B/9_D7,MGDM;G\!$;_;;2>:UE>2-RHCC= =*]1UP!IG&/9#S
MKD?#^RO.X.:\4MK#OWS#>N)\0V\6.]WESL[VUZ]E;S[M<6L=3&OI%@R@@UP!
M:?9?:[Q3@OLU]S]ES':>/;MW9[<]V=FX/LW/K"#<YHXS=745F_X.SN+9;B-3
M),&D:<B@Z# 'O93V?R]JN4>XO@/<;:>W7<G<ME]N\'<;;]RG??8H>.?M"VBF
MM[W;[<6*LUTJ24_6$QU_1P!L/=OVA<9[F=O_ &,\2[36'&.&<V[K<2W6[W[E
M$FV;C>6]Q-:*\QO=[O-MM9KE('4!8X_2\W6@SP!&>_\ MWLN&^TA+'?>(<.N
MN3I[DX>VV[<_X_>W=WR7]FQW<<5^84DMEM/P3Q%F10C3*<FH< ;9V^]K?"NW
M/O\ K_L+:;!MW<#8-G[5;ARUK'N5-<6ME+))LS[E#);#;XC-<7,#2KI1A'I(
MS)P!6+E/LKY[<6?;_GHWOCEO9=ZNYN[<.XILVRVV\[I#QUUO91%+O<EE8M+;
M6D:4410QR3$9M3*H&=G[!.=R\Q]R/%+GFO#H;OVU<:@Y7S.ZM7N]QAW>PEC%
MR-NV6SM8A<"^D#A2LPC,:]17 $%]Z_;;S+LIQWM#R[>MYXUNVV]WN++R;8K/
M;1>PW%A8S22I$+EKU(4_$IZ#!A6@-<  O;_V!Y+[D.[&Q=J.([WQG8]YWH7,
M\,_*9+U;*"VV^T]>]EE;:XKJYN&FK^I6)"":5. )-B]FW+&[6=V^[<O+MCBX
MQV7[EV7;?E.T[AM^X;3NV[W#W2+>7G'[FZC_  E];HKAVME(NC'G0&HP!-_U
M*-H[:=M+WLMV4[>]ON.\7L]K[7<<Y=OW.++\5<;QO-YOFU64XM[^><NTD5Q>
M7-!$%5XA2M, 0;[7_9)W&]W6T\LW+MGR7B"[GP.^M8.1\/WP[JNZILLR![SD
MB[C!!/:"VVN#]8\=#(Q! & )/[[_ $NN[W8'MERON]RWN+VXW+M[L-OMK['R
MG8WWLIS:?=KJ-!MVR[)-MWX^VOK&.32\DGD4BI& '/,O9IVXX%W6]D/'TW?D
MFY;3[B;#BNZ<ILKQ(WM"=TN(UOK+;MQ003SMZ+DG1&ND>(P!.OO_ .S?TW.#
MV_(^S'8B\W;9?=AMG<':.(\5X?QW]O<IM-X_$/!:S[AS"^O+0;3LA:6>M#-5
MJ'2#X@6"YG]&[:(/:]+QO9.&2/[D>*<,V[N%R;N=+RW8VX)R)%VS\1N_"=IX
MY!?2\G@WK;BHD,LEG' 7.G73 $%>T;V\^P;8?9]P_O1[S-@W"TY#SKO'>=H-
MOW(V/-=P=MS6[:R L=EXEMNXR6=W#(5(FF'X:N;-ISP 5[-_3O\ ;[Q+WD^[
MG@???99-T[.]G.U$/=C@MI=\FA@2YX[O$$FX[7+R3=-K0RV%O<VBZ2%5[JU0
M5,3FE0(0XOV=^FQWY]\O9WM[V"O.1\U[1WW%][W7O;QC88-YVVQL=RV>R_$3
M6?$=_P!VM([S<4MP/,U 6;("AP!O'!?I]>W?N2WNU[Z\%M-YY#[=..=O>877
M:'9!<7$?*>"]P^,37*2<?Y8/O-%+Z-(97(C*BA))K@"J7M#["^U[O-[0O=;R
MG>>*=P=U[^]D^%+RS;^0SW5G;\0A@NKU(4CL=MLYO6%U;DE1ZOJ!E\*X ^2$
M"O((9RBM-<"=UEDD1%ACTPLL,]OI'K-&KD50*5\< 8O"* ,NHEO, I5"":^6
M3(,M/'QP -O;= &6*+.I/WB?+\":_#  I8WT']6U 210Y?DJ:D8 ;.'_ $@1
M\OA@!,D:6Z=.M>F7VX 8@5Z?;@!&4 MGG04_-E_)@!JZ+7IX?$_$_/ %^N)K
M_P!%-W\ZT_>2>T4TRZ?W4O>V/MZX M5_B'C_ -+I[I<R*;=VM\2*C^R_83X'
M/,X ^+1--;'S5+4&=5HU,\_XZX <> ^8!_. < 9QFDH )\*C[0#\, %)7*$"
MNG(9#,=/X\ .8*&C$L33QRRK^3 #Q K.HJ5JX'QRTU_CP 36$J31LJ_G R_@
MP Y%8RI0Z=;4J!ZAU 4J *D$#PP!-GM[[V\P]N/<[C/>+M[8['?\OXR+R7;V
MY%;I<[?#>74<ULT[VLJ2.CPP.?3D'F5LP< 2[V:]Y7?/LSS7NGS?9=WCY3N'
M>SC_ "CB'<;9.6W^Y;SQ<V'+Y+FYO[C:]IO9[F$7$;3Z59%6@I\, ;?NGOW]
MQN\>T?;/9/N>X\=MNR.S<@BWN9[.UNVY')#?W/XV2QMMSN9YYC96Y)'HDZ1_
M-P!]^HO=;[+.1>V'@EIS[GG9+F?;/A_M_?BF[\"Y!8W[]Z8.XRV+Q;%;[!;(
MD(!AF =K@$@A0*TJ, <\_._<KSKNAV8X-[?=TV7B-AVU[=\CW7D/%-RL=GBL
M>4WMG+-,+:RW_<'C:\N[8VY"L&8@D=,L "^P/??GGMT[@6?<SMG!LTG(]IV;
M=ML2#=X&FM5L-YCDAN_PUMI"-<>F^3A0P44K@#?X?=[W?;LKO?8.\3B\?#-X
MY_\ VE6F]-;N-[XKRZ>__&1/LUP\,D5K&[2LQ0*RY8 FON-]2'W']V.%7'!N
M9<2[,W%_N>Q[?P[=^ZEKP^->[&^\>VUX;9%N>1PK"KSR64*Z\UJH I@"_7N.
M^I=S#MGV>]O/;;VQ[[VVWNXC[(KQ/EO+=PVM+KG7 7O!^$O=LL;DQ?B8UW&-
MV#".5/1-"1@"A?M]^H3[E?;9PO<. <0LN"<UXS=7]WR/;+7N/QN'D-[Q/DM[
M+))>\BX]<L4DL+WUFUQW,;B4'QP!%_\ >I[XWO ^]G MZW+:=YL/<!R&+DO<
M3?MRA>2_O=TCD]2 JLRDR16E:1,WF '7 !CBWNS[Q<.]ON\>V2R@X?OW;#==
MTAWB'<-YV1[CD?$MZA*.E_Q.[U-/9Q2N@U/'H+4S. )4WOZ@WN-Y5VUL^VO*
M./=HM]N[+C"<9N.Z5SQ.UG[G7/&;:!K=-KDN)8V?\/;V9\DWJ/(".@P!M/9_
MZFONP[']O>-]MN&)V[W78>%"2'BF^\HXW'NO--A&YR$/9[?=7;32R6$[O37'
M(/1'WA@"DF_;SN_)^1;YR+>5M&W[>]UW;<]W>UB$,$LM[)^+G]"E(_6%S(Q-
M!2F -]V+O%W V#M-R?LUQIMKV/B?,;\7O+]ULUT;UO'X6:*6WL[;=@$O;>+\
M3&H,>OTR!EGG@"5NY7O![U]X>UW#NS7,!QD<1X9';VMO?;7L@VODO*GVV$1;
M;:<FGB=#<-M,2Y7$LC,\.68-, :CV0]P/<3V\WG+-P[6?LB2ZYSPK<>&;_%N
MEL[V]MMN\EX;R6W9XI&G<QN0%4AERSP!M^P>\#O/L7&^T'%; \>&R]C]\N^0
M\&GFCGN6NMSNYI9'CW)0P=(EO+FBCH !@!WN7O"[T;OQ/N1P6XAXA^Q>[O-[
M7N+SM9;"^_$2<CL;FVO8X;"9KBKQJUMJ$9- 3D, ;5?^^CW%;KR7FW*DBX9'
MO?/^V=GVGWT1V=WK;B%G$L-IZ2^OY[M8(P'#5-?' &[\-^I][M^W_ ]@[9<8
ML^U4G'^'[#<\<XIOF\<8,6[<?7<8/1OKBPO(V%Y;[AI)T2J1G2C8 KG-[C^\
M-WV<@[+7]]97_%EYZG<F2[G-S:<I?EK;C)=3WME>/<-$T:M<"60NRO(!34W3
M $\[I]1[W+[YS_B/<NZV3M8G,N'</G[>[=RNPV:YV^^Y5LLD VM)^22N\LM_
M>QV\>@!E6,4J"<  NS_U"_<CV+XER+B?$K+@')N.;AONY\JV4=P=H7>9^(\H
MWEY6O=WXW<7$<IL[B)Y6] HJLO@1G@")N&>[#OMPZ+O9?6USM?(KSW$;;+L/
M=>^W^V9+R^COG]5I=MCEEFFBCMZZ0SFFD>6F -;[F]^.<]W>.]M.(\T_8XX_
MV@V0<8XK#MD#Q3PV.N:ZMFNV&E6AEN+UDZ9#I@#0.$<YYIVRY?QWGG MWN-F
MYGQ7<3NW'K[4FAIT6*2:WG6(IZ5E+Z8#4-67J#@"RGN!]_WN.]S7&MIX;SRP
M[<<9XEM>XVO*]UL.W&RV]@W+N76%Y&]MNO)(S;017]Y$T ]3UA(TH'D.G+ $
M#]Z^_7/O<-R?9^8=QOV-%O.R;%:\4MOV=!)!#>[;MUO#8QWK0*46.^6TMDF>
MHR>M, ;=[:_=IWH]G^]<UY'V9ON/QW?<+BMYP[E"[U!)>?B-CW"-H_4VB"CZ
M+T!R2[U8'Q P 4[F^]OO_P!X_;_Q/VQ\ZWG8;OMQP3=]SY1MCQPSV^\7=]/*
M+AH+J^6-&G]*0_=+&AZ8 ,7?U N_=UPOM!P*_P!H[;WFW]C-RL]W[;\GO-JO
M%YC:&S18[6Q&YB87#PQ1J RLVA^I!P! ^Z>X#FVY^X*?W*W>V<4O>Y"\JV_G
MXM)[-1LT^\;;(IM[>6V]-H/5NI[8AJ@D4!K7/ &P;+[S?<#QOW%[M[K[7E<V
MY=S]\GWB/<MDW;<MSN>&QVN_)(B[?^R_6_9S6BQ-^KC]'TZ 5& )M[5?5.]P
MO9;B-YP;8.WG8O?^.WG,K[N%;_UVXBV^_L+E-V9)IKVSAO%N5MUM#,'M] "U
MIE@"%[?WU>Y2RYSWX[B[INNQ<AYA[C^'Q\-[BW6ZVJ2;39<:4,\=AQ+;Y?47
M:X[>TD!C! \* $"@%?\ L;WKY=[=.XVW]T^VW[,7ENS1WD&WKN]N)]NCMMT,
MEO<"YC:/6CS255&-/( .F6 )?[/>_/W"=AN#=^NVW![K8#PKW*ON*\[L=UL4
MN[?:[K=;H76Y?U<ME0BUF"W)*$*JDGK@"0?;[]3/O=[6>T>X]CNV7:3L'N/#
M]WLMPVOD=]S3C2W'+]^M+YF9FW^_>.Z%S:02-K@0M)X9#I@#YY\AW>YY+O6\
M;W=V6T;?<;Q?WU\;'8+9+?;K$3G\0T5E'I4VL"L0%1=(T@"F -7;U/3J3(5#
M%U4G)4.8 7)0 /#I@!*:LT9D% :4%,LJ9"F0'7  MD*1DZC2G0!LJCIUSRP
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M$4?0'9BH !*TS-%\< +_ (*T8QS-;1W4ZLI6=K:-9D*UH&F=3(JJ2: &E/#
M!](9)2)GT$2KZ*A*$QD^9B&49@GPR& 'KU5H22P8$,K?\(I'E'G^_2@Z5I@
MA#&78/KJ1I'F-:!&+)D?**$_# !2&U%6:L4E79FM6A0)(9#YYCJ5@9?\X9X
M6BM+>%F%K$$UOK*ZUE7UCE(Y6C%2PR(Z' !06X95'DTA2H4K50IZC2U<OXL
M.S"\RAFD]41T]4-YB549"I\U*"F %8HUED,RLRL$],N*HXB%:1ZETEHQ\.F
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M%J$?>8=2<\ ,V;6KQDAU)4$DZB/38F,K4&C1'[I'3PRP B\3M(TQ(;6H5F(
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MK ]<Z*H(%, (F+9F!/JW#4'5(7Z"E*9BF &<B;. 2UQ=*%+:*P5H"<Z]?C@
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MTKJJ%SRH&_/@ C!$J,&N" =55!SSZ"M!3I@ U%!%(\<U0A235Y<JFF1%,R,
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M^K^!P 2CL;<$NFX0NR_=.@D>&52H\1XX +1PQL*->PG4!4:,OMR'7 !2WM8
M5)O[1#2FIU+T'P">& 'R6\+R ?M.TH#4NBL"WSTE6T]?CX8 <OM\,CH$W"(K
M6@8(6'SZ@4S^S !B&RCB5$-Y$X&:G0<SXG^'XX )0VT)T(MU#J8Z5\C4J/R8
M ("UB;3$;ZT1HW 92IJ#T/4]1@ D+:U]8M^.@Z 55#IZ#I7[,*,"GH6Q#:=Q
MA5P P_5^!/C7$W<YE5KB K;V:+$@FO+7S2,^O[I*$544\!7$N7+ZO4#-K>+T
M9%6_@-7&DA"=))^(!#?;@ DMG %53=AF 74P0T)H#4 =, *QVEN&K^-C7/\
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ML[_<N+[]M]R\2)=6LN].K&30*LH454!NF9QX<W'G/JM-NDX0DU"KZ?*>B/\
MTQ>U=E3C;65Q3_9YPHOTF_IH%@W[#WXE14G]MR9G*IZ4&"YX:JE7)_.4H<C]
M7^[!4^46E^DY],L@";8M]&M1I WR7,FE#4#KBHN=NJ?[S^<F?)C66_\ 35/E
M M_])3Z:5G9W5VG%-[N3'$\@ACWJ4W%YI^ZD1(-47HX-<5=NYUZG4:U6%)NK
MX5)==R?N1TW>.%&EQIVG*%[W>UO .V?N0YWPCMY8V_&N(;9<Q#:]MN7,TUK
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MCC]0(5%*D2"3IU\JTSSQ>V/P?+0IZ/\ II^=EZ>*,O[JKOVU,OWC_M'\/_\
M%7WL^%>E,"?_ $__ !]!:7_$-$R?5M]T=NQT@[=VO=: &O\ JRV YD@D5*X$
MY\P-E]P7>+9-JVO8-NYSN%GLVV&2WM-IM[7;99EC+L5%U<RV4EVVVQMF8270
M^(SP!K'*.6\HYYODW)N4[PF_;\R0Z+]H4MI"$#01[=:QQJD%HKQ1L=041@ 4
M P!KUO&WJA]<D@2N@:@7C3P65A0.RC(D"A.> #D--+'2FER061W!],Y$9.,J
MC%I"Q752GUOT"Y%2TLY/BN!8WVI*R>Y7LU/%.Z7$7,[*.-];O17B(C71JSIT
MSSQJOFO=DMNO0;>6-MM>1T-A\K]OCK=9;4XUK)=IWD<6[T<QVW;+>T:[BNXK
M:UCB'J6D*-5:U+,5%37',[<_%>Z::Y-PO3SYY8JF.+\G4>X-%RST>K@KJLQ2
ME%.F.&'G-P/??E*QBI@J!YD*Q&F5:9(0,L8VWXRW&2K=NS;7^.HN/_5=A22[
MJ/[?I$1WXY0?NQ69'A6*,G_\7GB:]XXW++#+=FD_-]!=7^4VE[J/JQC7HQ^D
M"\@[Z<P_9MS)!^'MY4B\LL,4)=00PKI$53Y:]:XR&U>,MQGN=JW*]/(Y+##Z
M*F*U7*S3Z>TY0C%/Y?I.,GWZ;IN&Z^[;N9=[C<2W%RR6AN99&< 22,KG3&WE
M09CH!CI!R<UD];L<;EQYHJ&%>C%GDOF[LMG9]8[<(I34O6?7@BIZ%3)F[9G/
MP'YAC>MMO^24NDTM)**2A@F@Q AJNER-3:0:FI6G3\^*:5'*A(E3AT!#2XTE
MY6U1M2M:$Y_9F*8H1?WH>/$GOV^SK)WF[;JS,H3D=D[$>-)%I^4'&H>=%R?N
M6:3P[M]AMKE.LN\02_,1UL;:(UL+-HW+ZX@]#_.]-*''*W>XKWO+[3.GGA]5
MVJ*EPRH+DZ@">M 3]N,4H^M)^4S*20A)]^OB *8IVE]]CQ;)6ZNCX B^#L)R
M#4:653_,+1DM0=#4KCZ?:&EKX*.#SHLMXJMLEU]VSEP]SIF;W*]SA&Q4?B8V
M#B@(4@?*ASQTAY*-RT45+'!'-WG*Y2W"2;PJR)HPD;.@1Y!&*E_4<:@3U(#"
MGY,>AM5ZEYY,,30-F*[N/F'>I <PE?\ .GE!_*,Q7%UEB[&:F-"+XBR.K@K2
MG^U\P'V$@$C&+U$4Y0;Q*-MUG)>4EKLC2#N]V^\VH?UBVHTZ:=;T\*?'&J><
M<4_#\HTP[IFYN3?_ .CA%<,R.H/;"46($GRVZ*14GJBUZ_''*7>HI[U>Z\TC
MIWH8J.VV:?EH(K(0 *G(?'X8L;3BE0R-N,>ZS+C0])=@6K\OR#\^)+J2Q1/#
M&*KTC&ZH;:XD(R]-@O7[P* 8S/AWUKZS8^N8S=FHZ65M>RX',W[D8&'N#[BR
M,=2-N2$Q,Q"E2$TG)@10C'3'D17W7#J[I'.#G="$=XE&*I',W^TA]E?7.RA5
M4JI=]3FM#X!B0,OACT)&M'U&@;J3RR?&@Y28Z#28T(SIT/\ L_DQ*L54C5UK
MTC=SK+OZC (BCKX_+H<\"5I/B;YVCGD'=KMK&H#+_6FT:2M22KSJ/C0U"C\V
M-3<X)R>PRA^[W7DZO,;;Y/P4-\@^CO?2=/>R:OPMGYLG@ARRZZ@#\N@QRM\2
MT]ZW)?O5?:=1-IFO<MN75%=@?!JS'[:8^>MYII.1=6Y.3H^!CUK7XG^,8EN4
MCPXEQ))+ $[DCO'+H&8B+]?A(HK3I6C8J;;&/O"U*F.=%IN,Y+;[JZ,C[#F<
M]V()]P/<!BQ=%OP1$*J!2&)J>8Z3GCJ)R)G)[/"+?JY8]B.:G.OXM)]-7VE>
MTGB"FD95170M2P5CUH?$X]$W**;2X5-!0]A>8'FX()&@9$C-Y!_ ' &)"<3]
M1"23&E2:G];*#7J:Y'%&K=VC)%P?G9O':,M_;#VO822*@Y5:A5$I*J7N0&"E
MC6AQJ#G+\)E'H[LW#R@5=XC7K.L/:1)^SMO_ $J1J:EB6J8UJ2U:DG'*[Q>\
MVLNT]KO)=K.D'AZS*6EMM?478A^,J+0 GKXY_P"SCX_3P=MYU5,^P<7D5>-#
M+10U8 #Q- :_D-:5QD[C<[EMRXT13N5=OUNC@,KZ,?AV9*4#5Z ]9$)R/QQD
M-"W[QM?;])CMSDY;3-OBD<E_O,C5/<CW._5$D[LC JY7RGTB*A:#'4CD'>BM
MH5>*MQ[$<VN=TY/<VI<'.7:RJ=U.A(0(NH=!^L4BO@6*E6(^.-]YXRNYW[53
M13K%*"]E] .>9B)8J$&B%J&M>G0T&7Y!B$W6K(T2P7 %7@7TKAA4@("J$D"J
M2T-""#BB/-Q)C]KTKGW+=F7D6)2W,(1"%9V)-PI2WU58TUW)HWR QI[G/\!N
M?I>@W?RG4);C926.9'9WMPI;P-X-%0'I4H)!7_THQRHWAM;Y-+A5]K.E.P)1
MVF%.I=B#+L-9 ^%*?+%E<D^\HN!E(YJB3_H ?,?F&+^PH3PDBH"]QCK8SK2O
MDD?/Q.9!SQ<;9%>]K"Z%>])9:Z,7I-0WQ[OT'&-]0YC)[N.Y9="R1RVX'F I
M_HZDT ID2*XZ<<E?5V:-/KG-?GG-O=+B7U&4?+ERSA0HS U,PJ?CDPKC=^MS
M=[7RF@-M_IU#]UH:W*/)%1F* =5KDQ^-3GF?GB\T[^Z^0BTK4N[AA!O@7GXI
M_P":D[]?']Y)[2%K7P'M6][ Z_EQ,345*=!;+_$+Q,?JW^Y\J0KR6?:Y(V8A
ME8CMEL%8BB^8$J<OMP(D,=G^PW:3NEVHX?OFW;#>+O/%KF\W7N+#>":VEY12
M.3TK#9)9%$%W/01?J06>A)!& *P>Y;@W'."=RA8[-MUWLEEN?$]KW>38KK49
M=FEO;82"QN)=;4C@>@I6HZ?' $$V$(F8K_19A?.?,*9&I%!I)S'R(P >;;'M
MVTQR0$.H!HW^86Z5(ZXFBTGB1N*FCN2Z*EA/:OM\R>Y/LS)KC)'-]G)HU,_0
MU"A'7,_GQIKFLG+0ZA]#M/L-P\F,KUUJJ_?7:=K^V@?@YF<!C(2OFS\VL_''
M+'>7;[^<*I-3EVLZ7;+=4;<8I8**[ Y&ITKI1* "M1_)X#&%G;BK=8M8F9N2
M>9-(]]0 %3$O6@(J!^3/%%V%*-O'#_,7--WZS2DZ@[<G8V5VD=%FFC](,PR6
MA'G\?T6(QD-%8C;W>RTZ>LC%Z_0*.DDW+"AR8^^FWFN/=KW116C9P+ =:!Z1
M9DFH_27'4'D4D_#WD5O#YV<^^?L%#<W%NL<WH15Y-INE"N3'3(_?3^6N/0=K
M^@7G/-4;E5%= 8@L)&"UD4:6&G,9'QIT&(+I*LN.' +MM;,06GMRJT.DMI;[
M6-:$XMH_BKSD"9_;]::>\W;XQO X._6:T$BG,2KT/0XU!SH^$3Z^[?8;;Y5?
M%[;7'O$=9^T%C8655"HL,2M2E<XU!Z99XY8;W\7FOXF=._#S7NJ/7E0</A3I
M3^"AQ8+V9/RF:0B_4?8/Y,6.9J[5<2F_:8,O2JQRU6NE)'K_ #2(VH3\?O8^
MCV.Y7<8+ISHQ^\R?NZ?V&<O_ +E-NFF]R'=%E94*RP(A)IJR!.5:5..E_).$
M7H4VL:(YR<X:?S[\[(C_ &-<223,)D76BJ!44##(CIC?^K;[PT#!>HA9MLN%
M8KZD9IE7U *Y?"HZXO%_3_(0EQ%[?;;A2#KC8,QJ-5?L%0<8J_[4"WM^U+SD
ML]E-NF_M<X"YT$-R#;%(U5):.X4#QJ"!C57./X!*GY3-S\F__P!';^TCIVLC
M49@ O%&%%3DP0 TKF>F.4.]SINMYKCWK.F^DD_=]GR6T/Z_R_P %<8]2BN!D
M[;?<"FH!"HZG$;C]4FA+U5UT!][5+)U+55A*!\C5*?/(XS7AO^H_\S$[NZV9
M?8.:SW'6[-W\[B.'6J[A'$WJ=7 T4">%,=,.1'PR/Z:[#G1SO^,2^TR'WM)"
M77RKZHH"SH*$>!'3+'H./!GG^YPAYC\NW3:=(:%C6H82+73X9#+$L>" FVW7
M.F3./JH'ZQ>@^T'/$0;KVKLI;?N_V\ED:.@Y#8RD!J_JT=:@D$"FH_#&H^;_
M ,#E^EZ#<7*:*CNMN3X.XCIZV)*6=@2P;1&II\ RJRC\A-<<L?$WQ.;\K])T
MVV62>R071E78&P*?:,C_ "_PX^=LW52A?V..' ]6E37I4_R8C=MYG7H9=2X#
M"^6D<D@-%=1#2O\ .DC .)MM:6Y6HOHFC&[G*FAN+^!G-)[K=MFF]P7<.))8
ME]/<=!:5J:M,$7FH33,XZ@\A4Y;9"O"B[$<U.=LG[WFNC-+M*[G9KI-0]2!\
MS32V7V@ TQZ,NJEV7G9H>UC:CYAD^U79<FD9KG]Y<ZYUSS\<4RH(';+_ , *
M5H*24%/E3+%!?B_.0EA!M<3=>T.WR'O%VU4H&]/E-D\@]05#_BO-3Q.>-0\Y
MOA4OT_0;;Y.2<MYC7ZQU;;5*!MMFH4UCBCU9FM#&M*T..5?BAUW&Y%?F2[6=
M-/#M%HK37Y<>Q!!2=88UID:'&"5M94CZ>;2@NN@[U*:_/^"OP!Q/-4N0711%
MG/\ #8QO=*PO&WE+*I7/*I:,U/PQD=!CK[?6KGI,=N2IM$_,<GOO(VZ2;W(]
MS=,L5?Q\63LL8/ZNO4]<U&.F_()M[2Z_4CV'-CG;\5_\WVE3[G9[E9%+7$#:
M6-%_%APN9\H0'(#'H2W&KDWUFC9>TAA)MEQZ\S>I !H2OF\*=.N*KPCB3/B#
MKS:YW1_UT%/, -7Z):M.N*1!$M^V:R>W]QO95Y'A;3S+;M84@L:O$0>M1Y8C
M]F-/<Y_@-S]+T&Y>44Z[K;C'Z_I.RVP8O9VIII/ZY"/GKD6O^^<8Y3[S\<GY
MWVLZ:;&DMHAYEV(+T_6,.N1_./'%M-*M>DRZX51YIJ0?YO@!\>M<5;%RA"34
M?.--P!_#34H=<,N1R  !RQ?[2Z[E9?3WWI+/7M+0WVORO0<8_P!0G;GF]VO<
M^2.2)@9;=: ]#^&%1FU,=-^2KKM$%T9SFOSI2GN\\,<C*0?LR?(.8QI_]44Y
MCQITQOK7VUGP-!:!4MT&-Y#)'^JDFA],CH#^M\/NTQ/!9;.'&A"X_O?E+T<4
MBC_=4=^HZ'1^\>]I'QU?\U;WL#5_MJ8A7U:^0G+5?XA.3T_JZ>YV18U$@LNV
M,:-J#E6_LMV%O5]+,5%0,Q7$P/EO8=Z^Z=MLG']GL.6;IM^R</W5]QV6QM(A
M:1VEVZM%+>SE OXV(ZF'ZS70].F -5Y3S/DO--[W'D'*MVGWO>MPBMUFFOU8
M)):VOW&@8:0 BG(=/B,'P S4Z*-'Y0Y#]:_?H_7\OYL+7K-5*,Y-2HG@/8:L
M69B6-#^D?YCCXXDU+[N[&,,$RXBG/0W5+%5]!8CVK.3[D.RE:Z5YQM=34^8"
MVJ*_83C47-U=WM\U#"MIU^8V[R8CEW*S'HS+M.W';EU[>C#+7-J0'P^/VU(Q
MR?\ %*5O<GDPS7'7RXG3'9_5I]7*NQ!F/RH0W7.IQ;W[<8VX**P:,[.3<E3@
M)2@E-(-,JK]E?_1Q)<BHY%'!(F<4VWTC3<%K9S#K^I_+2E3GUZC%WIU7<8/]
MY96BSUD(7-#<SJM(,Y(??7(Q]V/<8 D&5+)V854Z?N9D4R&>.H'(U*&P0C'!
M.VCG/SVGGU;K[:FU4K-$K1E TC/\*LQRK]OPQO\ M2?=RM_N+H/-SBHT2"D#
M"4&M:=:5/AE\<++<DVRL$5! IK(U#H?-_'7*N*2PO?**$T>WJ-H^]G;0^653
MR6TH& 6A]1>H32,:DYQQ4MDO.2Q4'3YC;?*KXO;^VCK@VHM'9VZM$M"E3H)-
M:1)3(G*GRQRGW1REN-V4G62FZ'3KPZE[JAYD&B:T\/E\,6-7PZ#.+ 1D8!A\
M*4_+EBGDC6M,2C+VF"=R8K!=*":O;O7[:*M<NF66,KL%/>D7_N(QV\_#Y]61
MG,%[H',7N4[FGS4-[;**$C.J!NA_FXZ:<EFUH(TZD<Y^<>&NE3K9#4=QK:1P
M6"B1@/-+0 .13($>&/0=U)WI5Z&: T^-O'H%BUNU2VK6W^>XZ_[BN)E.;62O
MJEO*4N\IT&4?J( 5;(MY*LU0#^49_DQ;ZI0C*"2)Z1BVXDO]C=9[P=O<R5'(
M[-::F(]195:N9/0XU'SB;?AZ;_@H;AY--O?X-\<R.H&RTEX!2@0+U)\8U_E.
M.4?B""6[7Z8?>R.G&V>OMMIRQ^[05]!P*U0Y5SK4'&+I\Y?VI.F7]T0I356A
MTJ&:F0S^&)KCK!9>-"9X-I<!E?H39T/B)&_+5,\9?PZY1U"^V8S=Z+1R?[U*
M'-5[BGU=]>Y:,>FZKJ^WR9UZC'37D1\,A^FNPYU\]*1W23C@\[(::A("K)05
M&K43GG5O-GGCT(N$CS[+&E>H0<&/3D1H&E6J2:?8<@37$JX$SXB F!]1?.[.
M1I!!0!A3+5B) D7M-^O[L]OE84#[S:09M4"1[E?$9'+&H>;S?N2?Z7H-R\J?
MB=K[:.GW9$06EN5&0A@U&IS(*K6E:?=&.6/B=_W::Z*OM.EFRNFRP3^JNP.,
M068_$L?X1CYJW%9C*Z<QQ=.32IT4+OCQ&%^P%O)45\H8?:LL8K_!BWT/Q2V_
M]STF*W=4T5W[!S/>[%%G]Q?<61O+%^T"4",U1^HAH,CGCJ1R$;]TV_LQ[$<T
M^=>9[O/JK+M*^B7RL@4CJJDDUR^T_+'HN]^++[3-%VOPX^9 F5;CUM-9 &/W
M@YI^05H!BF5!-F*,5,DQ*DK]]Z95%1G3%&&-ZCZQ<PM-F\]EF+=Y^W?F;4>2
MVU"22U%F!_+GC47.A4V>3Z<IMKDQCO4:]9U<[5$38Q&O]+8PNHRRTJH%/L&.
M6/B:$/>UU17[\OGJ=-M@2CMUJ3^K'L"WI5 J? 8P6*BF^-#/W7AAP/-)56I^
MB5 /RK3$L\O>0KU(IK*WE?LY!KNM!;L3T44=O$#5'I ^%,7>DS+<;23P<_28
MO65GM-]/@HNAR5^\=@WN2[E)69].X6M:J"""64]7Z%<=.>0*E[J?V%V'-?G2
MV]TK)UK-]I6"[5:)(FD9U%%4,/MH,>B(/VO.S2$O:0(F),CU).M?-F<Z T^S
M$ZQ1%\6#)54^HHU"JC3YFZC[WCXXIW$E' I3SK%,E[VQ_P#.2[+!20)N8V)6
MI)TB".8Y!J]3C3?.;X#/K[KT&X^3"S;S#-C]YZ3LXL_.L=!33,:@9424+)3_
M 'P'YL<J=WQWJYYWVG3O9:>ZH4\@4 ((/Q45_-BR;;>)EDZF0Z?:<\2*3B\"
MG=X5Z:##<EU6SQE:UMIR#4BE*@=",\978W)[GITWAWOI,9N<FM+-)X2A1G&#
M]0:WCB]V'<Q6#T:>WIHE8>8VX->M:UQT_P"322V>#6'KHYQ<[?4\12MV\(N/
M I&T$5.LM?G)_'4]<;^U/K-N1H"TW!M1P0PNF*,J!25(I4T)I]ISQ2M.JRO@
M59)53Z2^?%$/[JWOV/#]X[[1S2IZ?W4_>R>O7KB>BK3HJ2EH/\0L47ZN'N?D
M-:+:]KEDDB'FC5^V/'@ H&;3$Y9Y4;$ 5\[;^R2#DW9[CO<K=>565SN6X;C=
MW]WL>UWL,LT7'[:,W46W_AW<N-VN@DBE6 3(9UP!6;OYV[VCMUS>/:>.SWS[
M3=[#L^^6EENT8AW':GW.V]::SW%"*1QKJTD?+(^.(/@")+>)KB0Q1*JZ6HJ%
MJ* #D%<Y%/YORQ-9XHH3]IAZWV>^9F01QJQ %1<(ZZJ'.BY]#BEJ\;T/.7VF
MQTEU/A4L![8+.>S]Q_9EF"$CG6W5*DF@6$I2A)^&-2<X<-!/])]AMKE!6&Z6
MI+AG7:=M-F?]'C4=%:WTBG36&)_/CD]XL^(X?F/M.F>SI.Q";Z8(*TR%<SEB
MEJ?P[?F,G*3SJG"IBYIG\%R_*<4[W&#+B+>:51CN4H6UF(%28G%?]Q4?PG%W
MI_Z^/F7:6VJ5-!<ZLC.2?WPP//[M.XBQE:_AK-2IZ@H=;CY5#8Z?\D/@,/TX
MG-KGA+-N,X_[GT%;TVZY8%U$:D4"_K!50:&F=1C?MKA-&@KEN*A%T]:@6LML
MG"5;T_\ ?5K\QF,+'LNG I\&&EV^1%1F,3G+QZ#%+_6!,78FV:+O-VVEJNC^
MLUH6 IUUK^7&I^</P._^F^PVYRJ^+P_41UF;0PELK8K_ -;CRKTK&@.?SQRC
MW+^OO?J,Z<^'?A4?,@WTI4> K_%BSZ3-^80G H"/YW\A/\F)>DH2;S,%;DA]
M"=ZYF 4^0:@-!3XC&3V#XI']1&/WI_VRXU[65G,;[H;*X?W']S6C4&M]%(M6
M0  A=/5@32F.FG);^ACYD<ZN<N&X2\[(@M+"[2-E8E"I;4H<:2:DY4)'YL>@
M[GXTO.>?M.O49^_"W!.HRD?(M737PQ&/$MIK[Q"QM974MZL'D KJ/FU5ZL:]
M3BUUC2G%%9])+/9"W:+NWV_)>(G^M5NWD))I13_'GC4O-ZDO#L_LFW^3&._0
M^T=.]A1D1AXI&0?^QKGCEGO]J/O>\DL,[?RG3C:J^[+7Z:"I8JP!-=>=1X?(
MCICYV2IYR]LF)B)]=:U)0?[T8IPJZUZ&5&\6,K\Z;24DY+&X'VU2I^.,]LBI
M?BUQSF-W?^BEYCFD]PRB3OYW+B'_  FYI3_-;R5/Y,=,N0U7M4&^/=1[#G5S
MVK[SD_\ <9$[64J@J)4*5-/-_'0BN/0T>#//KXH1-G)_UP4_S34@_E+8D7 F
M?$_+8RR2HJ@L4%:LR =*DY^%,1($@=K;66W[J=OI -2GD]AH52#I97!-*"G7
M&H.;WP2:_P!LW!RIG_=+:_C1TV\>;5MED.CM'"6KUTZA0'[,<LO$WQ::\K[3
MICL='LT'T95V!Y@%( Z?R8^<M>T9>S1,\ZD@=1BXEP+BM 7N#D1NH/6.B_(F
M2,MUZUQ)MZ3W*U7\PQ>ZXZ&]7CE9S1^Z**:;W$]P]""CWR(M305T1*33IF!C
MI]R(GEVFVE]6/8<W.<D*[I-RZY=I!+V$GJ$&2$4'35F#7X@^&/1]QUFWY30D
M%2*7D!ES8W-=2H[ YZE9-+?YPJU:'$A,,OP5PP9J!=!(*DBIH?$@_P 6*4/Q
MOE(7/P6;YV9M7@[R]MI7T-3D=NY535B)9 0I%>J5QJ/G*LVT7%_ ;;Y,?&H^
M<ZLMH\MG: YB+;D3["56F.5/B";ENMUI^MWLNUG3;9JK;K2?L]W%_L025J45
MO  '[:9_#QQCYP2M5IZU#-N6>*IQ%6IH<_$K^;%BY)W85ZD4XO[QQ?U =NS*
MMNS.30JFH#.M&BH<9304EN5I/AG])::FCVF_]EG)][P;*2Y]R/<ZXC]+TVOX
M>NF-AE&0"6K4@N?SXZ?\@;:]TNB_<78<T^=7Q/#CG?:55FVZY19:B/2"NC]<
MLA )^"TS(QZ :44Z<<31TO:7^.@&S6%P&U#0?"GR^ 'AD<(^RO,3/BP;+93B
MC$* /5ZGXDUQ+=]@F4&R6?;)9RGW(=D6#KY.51.5!&9590#^08TUSF^ 3_2]
M!MSDM)+?(I]%U]IV7V#:8P2K:CZ9Z>(4 ?D QRHW=TWJY]J7:SI]LT/[7!KR
M>@-$@L!\OY,L639DU@J&/@/MQ(^)3O>S\@PO) (I0<QHF4=>A0FGQS.,OLRR
M;EIGUW%VF-W;#13:XY$<9OU!;1[WW7=S'C9(U2YMZB4A9#2W .CXC'3[DJ^\
MV>/DF<W^=+;\2NN/J%(C8W )JJD5I4R(#3PK\\;^U'M-?XXF@(^T_.-;RV>"
M,O+I\E"5#I6C"JCIX8I6N)<3Z"]/%&7]U;WZDH='[QSVD'1XZ1[5?>QY:_EQ
M4_>\M20L[_B%"Q^KI[HS70!M';"(A@,E;MIL#FYCRH90P !->F)0?*7C_.N9
M\5CBAVKDE_M]A;[K%O5M8MN$B-^)2)H5N5B]0!H)'4$@"M<NF !_+.8<FY[O
M^X<FY?N;W^][O"KW\TL+1QS6R,3!'!&J:9)M!J E% /3  VT,;-$VG2K, $)
M/0#*H- &\3D*'%:VE188E"?M,,0.ZS:D8* TA;-ZC3I S!'08M[ZK>A7K+JW
M)QT\DL$RP'M:EK[BNT#I<-)3F-E/I.8(_$/#H\U3XXU+SA2_DYKH[I]AM?E+
M<G_,VYU];O%VG;792EE6HZM;L / >F64#_:@XY1>*(QEN;JL.\?:=/?#M+FW
MK-C2VJ?,&ZG0I\3IK_!BTU7""Z*(OM,L\I9\:/ \E6H ^*G^/%*][4?D+K]U
MOI!NY#19SGJ/1+4^!((^WIB[TWQ.RNAM5+:\\VANU^HSDH]]!8>[+N+(CZ!J
M@7+*@>W%5/\ MM(QT[Y%MR\/)OBK:])S;YT99;S.,OKOT%8;:=X5\[-(& !!
M)R/A4U'2F/0-K^D[S]YO$T%J711R_P",0Y!([Q#2S*5&?F)_C.)K:46TN!3I
MZU!X)I H8.V745.?Q\?$XHK\;Y22ZW%8$V^WZX:3O%VY0D^;DMH2K'[OG7(5
MSQJ3G(G[EN]3@^PV[RFDI;G;K[2FNTZU]@(?;[;2-.D1*6_G?JEK\L<IM]^[
MW:4881<G7YSIQX=;]V07\"#9.K\G3\F,9*4JNAG88Q3?$2F^XOV_R'$N>5>)
M2DEF!6Y'3!/E7_1R:9]000?R5QE_#]7N4&_S$8[>%7;IKHR,YC/=4[?WCNYZ
MI$(V$T!$CQ"0$505 #!CD<=-N2W]#'S(YS<Y7_SY/RLA2UN7D5E>:C+454%!
ME7HA)TCY8]!:QN$ZQP;//EJ35M4Z1?74FK%@%S-?O'^=E3$L6\F;IH'%5KTB
M46IT< D:I!KS/F^VO3&/U4G+))O$-NC9,'8YA'W@[=H068\BC<FIZ!E5?ED,
M:LYN/_ZY/[!N'DPG[]@_XD=0.W$K'; YF5$S^'ZM:=!CEQO\Z;I>?2KC.GFU
MQ2VNQ^E$(O52F>9:A/7_ &,?,W<U73@7<,.'6.*Z9#_-*:3\_P N)+5:/SD9
M/UT@3N'GLYE(_2*_D)2N/H-C_&C3ZYC]ZJM'*G4<SWN'U1]_^XOG-6W-2"/T
M2=%?#'3;D$H/9[6;BX>@YT<]?B3_ %'VD54\SJ9"0J CS'KXFM<;_@ZP;_QQ
M//TN*/S:$6JUU?$%OR^.>(+@3/B,O59FEHSJ?3%"&/7(=<1(&_=I?5B[H]NQ
MZK4AY):R,M:ZB\D(49U^[J.-0<X\/#\Y+VLAMOE/CO$$_P PZ>>.ZA:6P)J5
MABS^=%/\9QRQ\2X[S+SLZ;;!CM$4^%%V&QS"ARZ"M/SY8^>HU)N/69:T_6$D
MJ9"?\W_9Q66*Q+IKU:](,W(#]61\Z?[],-)ZNY6:?71A]US+174G@XLYG/=2
M43W$=P06E##< ZJI-,Q'F*9TQT\Y$QC[GC+IRQ[#G'SA^*7$^N7:5\>?2!(&
MF<N*FKBJU\!4=,>C9>TS0*X#5Y8Y,BT:G_/D;4?M'2N($1F;A4U(&8@$BH8T
MH,LOB,48/[_Y2%S\)F^]F&,G>GMJJLP!W^W8,2>OK+0FN-1\Z:QVB=,*V_0;
M<Y+_ !J/VCJ[VU2EI;QUU,]M;H#7KI1"W\(QRIW3*]YOJ>*[R?:SIIL[;VNR
M_P"&/8@H4K+7XEC\/CBPDZK'V69^,816"Q,SE$?M'\%,6LH0RJXEZRE1>8MY
MT49W%[6(TW)-<$A%%T1FE0#73&&!SK^DM<7ND;CO&GA'V7)5^<QVKG);-<H^
M*Q.3CWFZ4]R'<C5F#?QL5J0"0L7A4#'4CD/ZNTO+]1=B.;G.[#=&OXY=I4QG
M$FD#2IN'"@AF&CTUJ>C >8XWQ%MYJXXLT9+&2_QT EIIO4(,C'*O7^+QIB=8
M)(F?$:R22."KNQ&F3*OC3Y4\<6TW/%5PJ54W1$N>UJB^Y;L>I)\_*8 02<PV
MJHZ^(.-0<YHOW!/])=AM'DTW'Q+;B_8=[TG9;MVHP1NY)#0P,OAF)%#GPZHC
M8Y7[M!>^;E5TOM.H^WMQT-J%K"-%V!H=-7C09_F_)BP<55F42Q:\ID.@_/B@
MTZE*]P!>XM1'0"I8/0_"J'\F,WM23UNFKQSHL]RC&6V7Y/BK6'D=#C(^H=I_
MO7=S(E>0'\5 -8-"I%N :4ICIQR-:]S1K]<YI<X)RGO\I2?K92C[L\:4:1FI
MY0234@=*_/&^=7*:NM)X5?::&MUS,:3JDGJEC(Q?TCF200 !3KBI&+5NL>)<
M3XHOWQ1D_=7]^AI\O[QSVD#QZ'VJ>]<_'X#$N.6O30D+-_XA8G][;[IJKIIM
MW:\HSD$R-_9AL/W5 J%7^/$05D[:^U#B7<7M;QCG$/)M_CNUW6>;EJ?AX9([
M;8K0N;G\/*R&2WEB-&CC"G4<_' %=^_?;C9^UG.4V#B6];EO/$]UV'8MXV2_
MW<20;M^&W:-FMS) ^MD9XD5VT%0"W0=, 1%$)93$50ZTTD^;5YPM&)8T))/6
MN*\?910G[3#<,<]5)2C>>HJW7R5KI%,ZXMKWXT/.39I*S)=%&3W[6HO2]Q/9
M]S&WFYCMQR^Z"=Q4&GB1EXXU/SA7_"N_I/L-O<GUFOPSXM7%VG;C81@)$^JI
MT1N5\  FD>'ACD]XGE+WBVOS'VG3OPZZ:!)<.[78%C)]U2*'72G@  "!BSU,
MO5@WQHC)Z7VIF1- 6/4#^"M,2W77(RJF\DJ\*C'=B#8W+#JL#,?'RA>E#7*N
M+K2_%+'G1:7)?V^[UY&<D?OJK_>M[C"@S_ O76Q.IH5ST!<J@XZ=<BJKPTY=
M.5'-OG.Z[Y/KSOT%90D@CTJ.K5 9'^Z#2E-%<>@X*FC5.M'G_53HH(*VS,@
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M.0JP$9('QRIC)[8VM;IZ?F%KN-/=>H_2]!Q=_4'>>?W:]S94B+J+J$D#( B
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M:I*."5Y)?.=N>W@&" =0854_$@5(Z4QR?\4X;BZ?F/M.H&Q8:%4X=VNQ#]P
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M-CG-F>Z_>8^N^TJM<7$SQR'U'C-$ =6-2"/ ^%<;Z@EZ_G9I&\DIK+P!KO(
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M4BA6:'6-)]1F>$'R]10DXZ7<E$I>'U.6,U,YP<Z(N>\SNR]O)Q*:MNEZD?\
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M:K*O0&"=/@33H.M/EC :N[6_/U/WGUF4M6NJ6!CJK4Z&&*"O-<(%Q*+2PEV
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M"@=2-1_+C)['X,WRWK4[MN62M:4X5,=N/BK2STMVW"4<N2G'H.-#ZC5AN/\
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M!:W4%I=3V5[NFW003,+BX%O$QGT^F3JE7RTQ2>KN/B0R170.NV7;?LMOW$N
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M7()S(+2SN!=_B($BA8-*;6$LZV^JU1:R"E2,3*<H\"5QC+B(OV?[U6;3;7#
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M@+*971991<W UPN6)TAE"("I4C5]XY'Q& !LIF2,3Z1&%>1U>J4B4,T;*RU
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MMG)U9Y_'H< ?EG%K4J*E5$;'U)55X6)*QZ0U-"EC0=<\ -9W,=0BHBL!I](
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M[',UH/UV /3],KZA^G_F7>X:I.?_ "!O?^VY=, 8?NR?J(?^1;[AO_@#>_\
M;< >CZ9?U$ RU]EGN&8#/_W@7E!E_P"N=<\ 8R?3-^H:6%/9/[B<LO+P&] I
MT%/UGPP FWTROJ(L ![+/<0HZY\ O2:GX_K, (-],CZB=?\ F6>X@_/^S^^\
M1GGZGC@!O+],7ZBK@I_<J]Q&FE<NW][F?_OG7 #4?3%^HP(Z#V3^XO4&:E>W
M]]T)S.<AZX 1/TQ/J- L%]DON+^YI%.W]\!0#H/UN &0^F']1X  >R/W'4 H
M/]7]]TU:J9R_SL (GZ7GU'R2?[DWN+&HDT/;^^\37/\ 68 9S_2[^I 6HOLA
M]QS !02>WU\5.=6I23XX LSQCVT?5MX?Q!.$[1['>^K;'':[;:&.;MI?FX2/
M;;I+Q_0F,QD1KTC2U"!6I%, +-[</JD_L&\V"[^G3WBW"VW V%ONFZR]KMZC
MW7<+%2&_9,?X::22TL82H#RH5:@J*8 =<O[!_53Y1N'#]T;Z:_=G9M^X#82[
M;Q3?-LX#R"^N-I@?4K?@YKMM<9D$E2Q&LTS. &E_[9?J:<CMM]O^3_3O]PD?
M+3Q:XVFSWW:^#<DE;<Y;M9E>2]MFG6T:4&;5I"FA\?' %*IOI9_4OD5"?8O[
MDO- 6=(^VFY1J7EN&F=6 E!U5:N> &D7TKOJ8+H;^XI[E@SF3U2O;K<$R.HK
M4"8&E3E7  Y_I4?4S#LP]B/N7;[P'^KF_P#&M3E+F#@!H?I0?4R5U=?8C[F*
MN&UT[<[@* ]!E+X4P QF^D_]3EU:/^XA[G%22>$2&/MUN ;T28A)H82U!<#S
M9T(K7 %I^,>V'ZR/$^'VG"MN]A7N$DV."SVFWN(I>VNX"YEM=BN'EM+*UN(Y
M4DMH[@!?44$:J_# #V[]L7U8;[BL?&-U^F5WLW1IK^VW#>=Z_L[WBVW'=4VR
M9AMFU1RVURDUK:01MF<@PSP 1Y_[?_JY<TY1P[F4'TQ>\.S<UX/M3['QCDVU
M]L-T2[VO9XM!_9LD]W+1HY-  9,WI4DX 8<C]J/U2.9;/RZ3DGTX/<I9<NWW
MAS\<3?MKX'O=\NYS7D3V]V^Y64UXT%J/2.FL7E \, 4C3Z27U08[>&'^X5[G
M8FMJQZ8.W.X^F0?*=+"4:ERZ^(P VG^D?]4)F2GL*]SSZ8TS_LWW$^;U"#4>
MKF= 'Y, -7^D;]40D'^X-[GR0!F.VNX=<_A+E@"Z/&OIA?45MOIN]ZNVUQ[*
MO<1#W!WOW[^V'N!L_#9. 7R\@W+A/%_;9[NN,\DY7:6'J:Y=DV3D'+]JLKF8
+'3'<;A IS<8 _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g214466g26n02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g26n02.jpg
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M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
M   !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P/_P  1" "H DD# 1$  A$! Q$!_\0 U0 !  $$ P$!              @!
M @<) P8*! 4! 0 !!0$                % 0(#! 8'$  ! P(#! 0)!PD$
M!00."P$! @,$!08 $0<A$A,(,9$4%4%1T2*2TE-6"6$R4I.451AQ@4(CT]06
M5Y>A,U07L<%B)"5R0Z49\.'Q@J)C<X.C1(25)B?"L\,TI&5UA48W1W<1  (!
M P,# @0#"  #" ,    ! A$#!"$2!3%!$R(&4;$R%&%Q0H&1H<%2(Q4'8C,6
M\-'A\7*20R13-"7_V@ , P$  A$#$0 _ /?Q@!@!@!@!@!@!@!@!@!@!@!@!
M@!@!@!@!@!@!@!@!@!@!@!@!@!@!@!@!@!@"AZ#^0X _'J+\N/$FN14F1(;A
M2'(D<J#:GI#3:W4("B,LE]'YL :JFOB:TJC/VV;]MQRV6#7;YH]^GB!]^UV[
M8J!IU*EQX:1Q9LBK)6'$1QDIW]'8, =MU+^*)H'9UNHJMJ.7CJ1.ET:G5Y%/
MM>A2)#,5JIR&H\:%4:DVTMJD5)0"CV5P;^:5;=F .QN_$XY8H$2Y9-6NRKP7
M+;HU,J\YMV@5(1GI%02R'Z#2)7 _XE5XCKVX4)S(4, ?DZ]\\MUVM5--;8T1
MM"@UZIWQ9R-1*M7M4*V+*MVT+66]&,*+69,@)<:K=<;6XF.A0"0M&1P!^V_\
M2OENHBKGI5V7BY3;@LFCTZ=<\6C0Y-?C.SW&DNS(5NR(3:VZNB,7$A:T9YI4
M", ??'^)1RO.OV3'-Z5(B^F%U"$_W+-:C46.2^Y%C5Z0IHI@S7NRK0&59*41
ME@#\2S_BA\J=]72BVJ3>M>I\X]X(/>MKU*#3W.[F')*5O3);+;4%N:AE?"62
M4N[N0P!]E=^(?I?4M [UUCT@5-U&J-O7/$L2EVPB.JG3)UY5&2FGP6'4.@;E
M(<DN)4IX$@#,YX LI7/?2]/9-EV%S2Q(&F6L5P0%U*MV_;"I5SVS;U.?94]3
MGZE<<=I4>')F+04)0H](P!S6W\3?E8N83FXEYU2GR:6],1+:J]!J$-#[<1PM
M%R \XRE,AN0H#@J'S\\\ 8LUV^)<UI!J_1].H=C.5:W+RTHB:A69?DV>Y"IT
MVNN24,1[-F0ELI<AS:@THE"E$;QR(P!F>1\1#EYHMDP;ONBZ:I23)I\N7-@,
MTJ;/?IU1IZF(U5HQ2TP2Z]'FJ*&B-BAMP!@34'XK^DPL=%[Z./SKL9H-TT*)
M>])JU"JD6H1[?JS@0],I#/!"I$B*G/\ 5@$D[, 9K/Q)^5U4^WX*M1I!1<-G
M3[R9F-4EUAJFPZ8QQIL"K)=27(U:!!2B* 5YC/ $LM&M6;=UOL*W]3;/D5!5
MKW,PN;0U5"!(ITIZ#F4)<D1I3:%J2O=WDJV;#@#+B%$G:<QE\GR8 Y, , ,
M, , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
M, , , , , , , , , , , , , , , , , , , , , , , , ?))W$@+R)7F
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MZY_TENC]UP _$?0?Y;ZY_P!);H_=< /Q'T'^6^N?]);H_=< /Q'T'^6^N?\
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M&W8!V;)/2=HV[< 4/,/;2ADK3+7%8*M\A>DMT+&]GF#DJ,>@[1X!@ .8>VP
ME.FFN24@9 )TFND #/>R $89 GIRZ< 5_$1;>\%?Y9ZX[R2"#_E+= R(SR.R
M-D2G,Y9]'@P!:>86V203ICKALS__ ,END#-1S*BD1@E2L_"02/!@"BN82UU_
M.TPUN/G*5_\ U'<^14L%*U* B@+*@?#G@"]7,1;:OG:9ZY'S=W+_ "FNG+=V
M>;N]FW<M@\& !YB+;(R.F6N!VDC/22Z#NDY [O\ NOF9@>#(8 ?B(MO-2O\
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MMK;1Q5F3?84@+"E;O<:" 75[%99_FZ/!@"4RJO5DK/\ P.249G(AY&1R)VC
M'&:U4<]MO3"?#_O"?)@"G?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP
M [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N
M],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\
MF '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50
M]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE
M/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [Z
MJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^
MTI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '
M?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WI
MGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP
M [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N
M],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\
MF '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50
M]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE/DP [ZJ'N],^TI\F '?50]WIGVE
M/DP [ZJ'N],^TI\F '?50]WIGVE/DP!>BKU0G90I S.7]]_W< =3OJ947K)N
MWM%,[,VW;E7&^Y+;<\W@#(>8C;LP!E7 &N7GTY?[^U]H]J4+3K4"5IA7VJRZ
MW%O*)=LF@2J5(=CI;"Z11FFGJ?<=8=:WDI1/2&6LPI"M[ $P]([1GV3IM8MF
M5&K3;@GVM0:?2)U<KDQ<^M567#9#<JH39BVF5ORI;^\M1W0,SD,P,R!E5'S1
M\[_OOG?GP!CW4BOPK4LNZ+EGTJ7785!I4VH2:+!:#KE4:W %1$,G-+SVW,@@
M[, 1:L/F4T]N/46T[.HVGT^WFZ[; 3$NF32846GQ)C#*)JK+=6VTA3$EE#G%
M!+F68^9@#]S5Q6]S)\K"AF4<:_1FO8HJ%&;2%$K 420#UX F'VB/OY%U@$#Y
MI>;S&>W+($X MXS/M$?]ZMLC\QWQF/S8 <9GVB?2;_:8 <9GVB?2;_:8 <9G
MVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9G
MVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9G
MVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 MX[7M6?SNIS_/T[< 7[Z=T*WT[N
M8VYHRR/@!X@S^0X <9DY9+3Z:-OR[7-F +>*DN.("V06TI6H%P%24G;M0% C
MS?#GE\F *!]K(9N(/ASWDIWDG/)2=Y0WQEX0!GX, 7!YGVB?2;_:8 <9GVB?
M2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 <9GVB?2;_:8 KQ6OIM
M?G>;']FW+ #BM9'-;8_(\V2?%@"@=;V9N(((R&62=N>W:IP).7R8 JEYD@Y.
M).1R)*FP?_K , 5WV_II]-K]I@#D!3_XOZSR C %F\GQCTE?L\ 6<9GVB1\F
M\C9UK!_LP XS/M$^DW^TP!7CL_38_.^@'\XSV' %W%8]HU]8@_V\3 %O&85L
M#K23F1F5)RV?^<P!3C,C_G4GY=YO;_Z3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,
M^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,
M^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,
M^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,
M^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,^T3Z3?[3 #C,
M^T3Z3?[3 #C,^T3Z3?[3 %W&;'0XW]>CR8 Z-J,ZVNPKP0E;:EFW*OD$+2=G
M RV!)\6 ,AX U?\ Q26$'E^<JYHM2K;]O7Q:U0"Z3<_\-5&DLHDC<EQY"2A2
MN(_DC(I6E0/3@"9F@,JI3='=.9U8BSX51FVG3);\:I3VZG4PE;*"VJ94 IQ#
M\@(4G-2%9$9>' &<T[ -N>SI.>WK). .EWU09UTVC<]N4^J&@2JS3)=.9K'
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M?^N<];  6]2/#$<^O7ZXP!;W!0_9C[2YY< .X*'[,?:7/+@!W!0_9C[2YY<
M!;E(5\UM]/Y7W/7Z, =-OVB08EEW:\RA])%MU<[7UJ&? &>0*R, 97P!K?\
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MALV@;X. +T5.L*R*:"A8V;W^]M)(V9_IIRSP -2K?N__ -(H]7 #O*M^[_\
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M700%[,45::E2[M,?VT7Z]'DP=6O2"[CL':'&<O\ E-^N,5!;VAKZ3/UC7[3
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M!. .IUZNV7;J$/5Z;0*7&<?BQ&U5"9'CJ<E37RS$CI#C@XC[JL_U24[XW>G
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MR:C;W/J1[T.N'EOKM?K\;0F^;$KEV<,M7"W;<YZ9*(4[DM4YMQQ88;0Z@Y
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MI;)\>,5I1QVW-]2KFUJSY>7JPM3=.]/?X>U'NVC7'<JZ_6Y2JI382(;<FC
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MT(6\JOPV-&^4VL7U5--ZU<TR9J-1.XKG55IS<]MJ'%4M9[&I)7PW..^GS-A
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M 6[IV9*( .>6WJ)SVC %"A).\<][P'/YIRW<T^(Y8 % (RV^$9^'(]()\.>
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MO,[S:B3FG-)+>8(!;*DYY';\N6S %PC.!!;4 4[,B,@L9**DE)3T%!Z-FP8
MKV-/$#P4I+NZL))*UH2' -_-M1W=X^,[< ?0EA.S>"2=TIS2G<V$>=\TY99]
M'A& +!&"5E06H@I""E1WMT)&22@G:E0!Z>G %%1B3_>**2GAD* 5DCHV9[-[
M_:RSP!01_,+:G'-U'S3M1TC=R*MI4,L <8A@$G>VJ*@3TG=4V 4@^ $#;X<
M4$3)(0E;B0E.XWNA(#>>6\I'2 K(9 ^ 8 N+&2=Q*^D;,T9DM@!*PM1.:B<
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M' I2W7-Y0_143YJ?DZ, %QE*7FE669WE(R.:E#PK<Z%#,='1@"U41:D=#:5
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M>9_)X, 5P P R_TY_P!F7^C %,NCY/E. &Z/%@"N & *9?*3^4^3 %< , ,
M, 4R'^G^WIP!3=/C&?CW=O\ IP!7+,9;>O;U]. *9'Z7ASZ#U=/1@"[ # #
M# %N2OI?FR_[>> +L , 6[I\8S\>6WKSP R5M\[I^3H_)MP!=@"W(YY[W]G_
M &\ 78 H0#T^$9>'HP!\DDN;H4&EN!*'%;B!M*@"$@CI(4#T>' $&^7#3FZK
M2UEUVN%ZV:];ENW?669M,34J0S!@3)()2Y4($QYXU,MJ1L*.&E.7@P!/# '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g214466g27n27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g214466g27n27.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X00W:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O,#<O,3 M
M,C(Z,#8Z-3,@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0C-!-S9&,#5%-#DX,3%%1#@X.3E!-$4X,S4T
M.30V1#,B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0C-!-S9&,#1%-#DX
M,3%%1#@X.3E!-$4X,S4T.30V1#,B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IC,6)E,S U82TT-3@V+30Q.&(M8C!F-2TT
M8SAD9#<P9&8V8CDB('-T4F5F.F1O8W5M96YT240](G5U:60Z9C X-30Q-#0M
M-F$X,"TT9CEC+3@R9#4M96)D,3!E,S-D9&0R(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3YR<C8Q,S(W-#PO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M($1R869T(#$P
M42 P-#(S,C-?0E0@8V]M;65N=',@35,@,#0R-3(S34)A8V-E<'0N9&]C>#PO
M<F1F.FQI/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T
M:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R
M(C\^_^T 2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,
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M,A.!D<'14A05H347"$)R(S-3<R5B@D-C)#06&/#A1/_:  P# 0 "$0,1 #\
ML/WD?=@]QGI\]S#JIY.<ENK/F+R\Y8;(W)L6'M/9MEMNQ'[98XUSY2[ OL]F
M([=MH7&XK1*O%TD2%>J^X0MT@$)H ',K]>+[M7^?-S9_P1RT_@'@)OUX7NT?
MY\O-G_!/+7^ F F_7@>[-_GR<V?\$\M?X"8"?]=][LO^?'S8_P $<M?X"8 Y
MKWN?=A(J>N'FP?\ \)Y;=Y_>+@)?UW'NP?Y\'-?_  3RV_@+@#A[VGNN>D3_
M "W>:U:<?NGEO7@,_P#Q&I@*V/>S]UM5-76[S65\MIY<>/=L88!A^NN]U?\
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M[]F5P!)]X3W-?6T_RQ>9M*C+[LV!^2/WFX @^\#[F=3_ #P^9G$_WLV!_ W
M',^[[[F"FP3U@\RR>\VS8'\#<!(?=\]R^A_G@<RN!_O9L#^!N D;]WOW+BD$
M]8',HG_:S8/</WFX IOW=O<L4DUZO^95>P_=NPO']YV I_6Z>Y?_ )W_ #+_
M ,%[!_@=@/OUNGN7?YW_ #+_ ,%;"_@=@*D^[I[EU17J_P"95.VMKV"/_0ZN
M E_6Z^Y3_G>\RO\ !NP_X'X"ASW=/<L**(ZON9077C]V[!X<>W9U#@(_UNGN
M7_YW_,O_  7L'^!V ]_6[>Y:./5_S+_P9L$?^AV I<]WCW+$TIU?\RAE_P!S
M-A=P_>=@!U^[U[EV03U@<R@3_P![-@]^7_D=@(Q[N_N9]O6%S,/RVO8 ^C_P
M.P'RO=[]S%*37K!YEUXU^[-@=X_><< O7[P/N9A1'\L/F9E_WLV#_ W 1.>\
M%[F@22.L3F8#_M9L#N/[S< +^N%]S?\ SQN9O^#=@?P-P$)]X?W.:G^>1S.X
MG^]G+_\ @7@%TCWC?<^0X$IZRN9X%>'W7R][_P#$K #.^\A[H"6U$=9G,\&I
MS^Z^7O>?WE8 $^\I[H=#_/.YH<#_ 'KY>?P*P$)]Y?W1:'^>?S0X'^]7+S^!
M. 7+]YSW20I8'6ES1H/4I_<OEWV(01_Y$]A. &/O/^Z70_ST^:7 _P!Z^7?\
M"< O7[TONH N4ZUN:>6JG]RN765#3_S(P"MSWJ_=5 <IUL\U!1)(_N5RYR.7
M[Q\ ,U[UWNKJ80L];7-0J*B"?NGES_ >F '<]['W60H@=;?-4#_:KEQWG]X^
M $?][3W7$MU3UN\UDG52HM/+?A4Y9[&. $'O;^Z_IK_+@YKUU$?[$\MN&?[Q
M<!$OWN?=@%*=</-@<?[T\MO#]XN A7[W7NQ"E.N+FQV_WIY;>'[Q< *_[WWN
MR)*0GKCYLC('_8GEMW#]XF %7[X/NS@Y=<O-GA_W)Y:_P$P'A]\+W:-!/\N7
MFS6I_O3RU[J_^8F W&VY[P7N:2_;HYR<VY/6)S,>YD[?ZZNFKEE9=W*M?+\7
M*W;"WCTZ]6&[=S[89:3LQ,!4"\[DV-:)CJELJ>#D!L(6E!6E8:N>_I_2]]:?
M^-O+?_@/Y88#D&D#2,AV]GC@)P!Z@%,JC+YL 70=P^@8 AI*55J >/[& 8
M9 4P$B "45'%=#\FDFGTC -64H*EI6*IH<A]'>.[ 5MF,E92EU#1 )H\DT5Q
M^JH=F> .BZ'!50#V?%I\) S^UJ&> ;M-HTTTC*G;7\/;PP!C"4E820*=WT8!
MHRR%N+3Q2E&H4&@)/>I1/FS[L 8VRRDA2'89<R"FG9)_.^.G[*AW5P#AE$<@
MJ4%(<4*(2%AQ (R50 =O9@&#: 2@A*2DCB00H]E:<!@#VTIU@4'S?*.W 'LH
M94NC@)2/-05I7C6E1F< 8CST"#Y=1"U.<"D<$@Y<,!*0*MFF>E.9&?UB/Q#
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MFA2CA4X"(5<<*1Y0!]7L!'C@!WE)-0 *!.G_ *(9$_+48!8XD>DXHCS@C/\
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M)VVRFUQSZ0\CC#556Y$8FJRZ?,1F*X"5-ME(0PE%KN$R1+"4P7FK=*0;B75
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M<AVR39(\%MIU]Z1*<>$1QI<92-*2/K# 2;WZ?>;'*W:%CW;OC8-PVSMG>_\
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MJZ$H)0$G4D'2JO%2=5%$*^; *9)3ZCBPB@<(T  T\O$)[< .34+(X%)/TD8
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M#<^CSE8FP73;]JLL_KFF;BMMG>N4)JXP-M_?JD1G7(ZY241(=$!5:)2&^!J
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MBN?CWGNP$$A.C34DD@$ 99'@,O#  2EJ4!1)HE !^6F> WRVH?\ FH.?9_\
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M7-+HTFNE>H# -H\9$= 0V7UK&E+BY2WG'2RFBD(4\\I2UI3E0]V6 8.I=<0
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M1TJ6HN*>0$ (U+6=0-*X!4_:(TEU+CLF[E07ZJOA[K+0TKR);"7FVEIJE*$
M!"JI'93 3/L17FA$"77 DC0I[U%D:%ZJ)<>4LDU^2H\, '<+:BY.QFW)$R(P
MS17I19CD$N>F*H*9<:0QHHH9(XX 4VRK26V)%UCH2L.&0FXS43@FNJB9@E.N
M*545U<2<S@!9-JBICHC^K/D,A8=:>E7"XO3VE!*@A*+AZ@6C2%GR< 3@/(;
MM[LE_5+,F6EMM4RY2')<E'IYA2W7U+?+"_[&@G2GNP$EP;#[%'&WD*&2)#;X
MCOI&D)"RZD!07I'S' 9LZ8NHG<_2;S'7S/VA9[-O5^38;AMC<>WMW?VY;[U:
M;N@-28S\S3ZL>1Z'D0H9)RP&=N8WN+<S]UWCE/+Y:\N-E<H=M<EY<ZZ\O=B,
MDW9B#>IDIZ=,NDF0Z/3D/*=>5I<^LOMP&B.]-WWSF1N^_P"^M]S7+AO#=UVE
M7F]W*$T8&F:M+C^M*@:H05O*T@DT!P%B.16I++X6[-1&?4AV4TJ?-"Y;A !"
MU^MYTJ2* Y"F @E6^.I2W&W+DPXH4C2&+E<(Z[> *+0U/2X72I0R*$T![\ O
M0PXR%>O,F38Z?W-<ZYO2E!W2 5*,SUW2H]J4J!P"F2RZMTO1YUUAN+JW(;@7
M.Y1(K[8"DE3H2X 0M))+9[\\\\ "ZVS%]>.P"A4Q]EX%;KCDE^0TVG5+0\X/
MBV7JIJ"A84>VN 3_ '<T$"1\5.E*<%77YES<E2VM!JREOXE+LFU^C72"E2=:
M1I^KE@%3\-TI5*;FSWI3B=*)DFXO.S' VHH]&.A"T+;CLI)^M5(J:4). $]
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MJ!)! HX :<0GN('=G@&\-"6@JJ%*IP/E41X!502/P8 SUM:J4*0.Q24D&O\
M6DZ:^/9@#TD:$A2@K@FI>-2DYYC.G' .XOU21D*4%%(H>ZH! .7:17 'LZ="
MB=.JH )<SR(((XZ5>(SP#!G20=54N%54JK6N=222H5K7MP!JM2 WK4@YG2D$
M4'@I.DBF 8QU,A%5K.L*JH^HE7;WJ.KA3C@# ^@.I0V4J0D^4Z@I:5<2?+4\
M3XX!F%(<(!?(4*9U2%)X9 J.H8"0-L@$%PJ)XE2DJ).=34J)[<!6SH]2FH:<
MDYI!\HX4.J@'R4P#(N&ITJR.51052. /GJ?GP'FL\=2@1]H+TDT[U!8)'RG
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MR/V<!\<^(![> XX)TO>MB>]$XDJ-$ D#(^3('+MX98)UYFFWL[ CS2S0>FL
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M!@E"G'"ORT],=]#0\>\8!RR4T)4?K4(I2E*4RK@#& %+1I70APZJ_D@5H:#
M.4.HU)HM/"A2 ?+GF"1V8 M2@JF@**2$H\J5$!0-2>WLP!"TJ+NNHIE6N5.
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M"A@$BS0.(R*TE)!TK&1^;++ ?/E(;24I437L2NF1X#\WEG@%<E;:W@?-330
MU%#2G:!P. WUVH/^:HY]C_YD72,*?_M5ZVNW ; ^_EJ5[N?6IF$)_2KEL@I
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M*]"N[\6 E% $5U?6 .9I7PH?# ,F"14 FF?'YJ?CP!&2:%0R)U=]3WYUXD8
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M4:**1P)IVX]3O#7N].I-=\Q'L>:7B+9U*_TAS-E?GTB14OI'F^)4DC17(IX
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MO*M=EN3?W.TT=*6(DQI4SX=Q))*2R7-*@<Z]@. L:,RZ^D)0VFIH3F:#50A
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M&A[, K>>_-L(*7:E2CJ]550>W[5!0X!!(DN!YUC4X:!(2KUEY&M*_5/&GR8
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M$"J>S.E:U'' ,V[8@T2)C"0!]H D<3GGQP%;=J;"B#<(U03Q5](_9P!R8+(
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M)(M^IV[]J1Q+-452"0E5<^)3VG3D3\V/T,[]FY^>(7W%$I/EHI7Y".!_Z&F
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M%EI:4O24K"$T>82-)=8 4=61S)P#!I!!4A=%Z4A/ 4I0#ZM5 >48"O6K+/@
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MH^H H))).G.IH,<T3ISP5M?;,0XKTOF3H1;4G.PT:D0PR%+:F*)H%%M!9-:
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ME!7Y%+]12#VX 2V=4>[K6B4ZT^L/7.1.N#]+K+=T27W5/NH"V2VGT_46:)
M RI@,S;8ZX=^VJP?<T*P/&>ER3.:DV65'BA3$VB753F%1'9]QI4G2AQ%.[ 8
MWY8<^=Q;)A[RA1[/<[TG==\N=R=FLW&9#?$V6%.K:NA<MLI4N*@J(]-TNM@9
M5P%P7OJMW/=]N-6BWVAZWNMJ2PZ[,6WN.R'TTZJ6JV.1$0;*ZA=:..!M(/#
M'1NIZ='L\';KFS)=RM,AI*[Y&N=Z#]P=FEP$N6=P!A=GAJ<&H)HZA?>G+ 6'
MN?G%;-S[3O=FF;6^!N%UNT:>U=DW5F,+9 C._#,QG;=Z;TBZQ#**4AM*@I?
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M@*U)"E&H).> <%;2TI5Y?4K5514@5S'"G'/ $E+&G]V4I9*04E1H.! 'R4&
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MZ>Y72@K_ #4NDWN'&O6;E@#AM?VH:#_+G[E' ?\ LI])_P#\9> (_1?VH_\
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&Y#\8/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839302048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BENITEC BIOPHARMA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-4620206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001808898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3940 Trust Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">780-0819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,981,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839462656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,551<span></span>
</td>
<td class="nump">$ 4,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,395<span></span>
</td>
<td class="nump">4,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,220<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Trade and other payables</a></td>
<td class="nump">2,455<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,153<span></span>
</td>
<td class="nump">2,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, less current portion</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,507<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value-160,000,000 shares authorized; 27,981,161 shares and 8,171,690 shares issued and outstanding at March 31, 2023 and June 30, 2022, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">168,791<span></span>
</td>
<td class="nump">152,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(163,228)<span></span>
</td>
<td class="num">(148,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(853)<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,713<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,220<span></span>
</td>
<td class="nump">$ 5,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716842647136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">160,000,000<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">27,981,161<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">27,981,161<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716837833504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensing revenues from customers</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,167<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
<td class="nump">9,588<span></span>
</td>
<td class="nump">8,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">5,011<span></span>
</td>
<td class="nump">5,093<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,395<span></span>
</td>
<td class="nump">3,508<span></span>
</td>
<td class="nump">14,599<span></span>
</td>
<td class="nump">13,189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,341)<span></span>
</td>
<td class="num">(3,460)<span></span>
</td>
<td class="num">(14,531)<span></span>
</td>
<td class="num">(13,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss)</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,397)<span></span>
</td>
<td class="num">(3,275)<span></span>
</td>
<td class="num">(14,901)<span></span>
</td>
<td class="num">(13,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized foreign currency translation gain (loss)</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (4,352)<span></span>
</td>
<td class="num">$ (3,508)<span></span>
</td>
<td class="num">$ (14,509)<span></span>
</td>
<td class="num">$ (13,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (1.61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (1.61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_BasicAndDilutedEarningsPerShareAbstract', window );"><strong>Weighted average number of shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">27,981,161<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="nump">22,090,191<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">27,981,161<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="nump">22,090,191<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_BasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_BasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716834161232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2021</a></td>
<td class="nump">$ 20,010<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 151,583<span></span>
</td>
<td class="num">$ (130,119)<span></span>
</td>
<td class="num">$ (1,455)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2021</a></td>
<td class="nump">15,475<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">151,854<span></span>
</td>
<td class="num">(135,164)<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2021</a></td>
<td class="nump">20,010<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">151,583<span></span>
</td>
<td class="num">(130,119)<span></span>
</td>
<td class="num">(1,455)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Mar. 31, 2022</a></td>
<td class="nump">7,520<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">152,285<span></span>
</td>
<td class="num">(143,260)<span></span>
</td>
<td class="num">(1,506)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Sep. 30, 2021</a></td>
<td class="nump">15,475<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">151,854<span></span>
</td>
<td class="num">(135,164)<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Dec. 31, 2021</a></td>
<td class="nump">10,836<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">152,093<span></span>
</td>
<td class="num">(139,985)<span></span>
</td>
<td class="num">(1,273)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Mar. 31, 2022</a></td>
<td class="nump">7,520<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">152,285<span></span>
</td>
<td class="num">(143,260)<span></span>
</td>
<td class="num">(1,506)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2022</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">152,453<span></span>
</td>
<td class="num">(148,327)<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts', window );">Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869</a></td>
<td class="nump">16,015<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">16,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants', window );">Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,637,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2022</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">168,768<span></span>
</td>
<td class="num">(153,420)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,809,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2022</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">152,453<span></span>
</td>
<td class="num">(148,327)<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Mar. 31, 2023</a></td>
<td class="nump">4,713<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">168,791<span></span>
</td>
<td class="num">(163,228)<span></span>
</td>
<td class="num">(853)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,981,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Sep. 30, 2022</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">168,768<span></span>
</td>
<td class="num">(153,420)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,809,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WarrantsExercisedDuringThePeriod', window );">Exercise of&#160;pre-funded&#160;warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,171,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Dec. 31, 2022</a></td>
<td class="nump">8,994<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">168,720<span></span>
</td>
<td class="num">(158,831)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,981,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Mar. 31, 2023</a></td>
<td class="nump">$ 4,713<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 168,791<span></span>
</td>
<td class="num">$ (163,228)<span></span>
</td>
<td class="num">$ (853)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,981,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of pre-funded and common warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of pre-funded and common warrants, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WarrantsExercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WarrantsExercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840219904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments For Stock Issuance Costs</a></td>
<td class="nump">$ 1,869<span></span>
</td>
<td class="nump">$ 1,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716837784224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,397)<span></span>
</td>
<td class="num">$ (3,275)<span></span>
</td>
<td class="num">$ (14,901)<span></span>
</td>
<td class="num">$ (13,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncreasedecreaseInAccountsAndOtherPayables', window );">Trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,917)<span></span>
</td>
<td class="num">(11,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants', window );">Proceeds from issuance of common stock, pre-funded warrants, and common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Shares and pre-funded warrant issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effects of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
<td class="num">(11,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,076<span></span>
</td>
<td class="nump">19,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">$ 6,565<span></span>
</td>
<td class="nump">$ 8,630<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
<td class="nump">8,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Re-measurement of operating lease right-of-use assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreasedecreaseInAccountsAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreasedecreaseInAccountsAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock pre funded warrants and common warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716925414000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Business </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (the &#8220;Company&#8221;) is a corporation formed under the laws of Delaware, United States of America, on November 22, 2019 and listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April 15, 2020. On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June 30, 2021, the Company completed an organization restructuring as part of the commercial desire to provide a more efficient structure for the future as the Company transitioned its operations to the United States. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; are to our fiscal year end June 30 of that calendar year. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Principal&#160;place&#160;of<br/> business/country&#160;of<br/> incorporation</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Australia Proprietary Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">United Kingdom</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RNAi Therapeutics, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tacere Therapeutics, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec IP Holdings, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716925453632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Basis of Presentation and Summary of Significant Accounting Policies </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basis of Presentation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June 30, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principles of Consolidation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use of Estimates </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, allowance for uncollectable receivables, foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates, and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.&#160;<br/></div> </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Risks and Uncertainties </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single- source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third <div style="display:inline;">parties.</div> </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Segment Reporting </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Other comprehensive income (loss) for all periods presented consists entirely of foreign currency translation gains and losses. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair Value Measurements </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with GAAP using ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</td></tr></table></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and Cash Equivalents </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. There were no cash equivalents or bank overdrafts as of March 31, 2023 and June 30, 2022. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concentrations of Risk </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and Other Receivables </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and Equipment </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:82%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">shorter of the lease term or estimated useful lives</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment of Long-Lived Assets </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and other payables </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leases </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and Diluted Net Loss Per Share </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of March 31, 2023, and June 30, 2022, there were 40,684,965 and 845,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue Recognition </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue by applying the following steps: </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing revenues </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method and is constrained to the extent that it is probable that a significant reversal will not occur. Revenue is recognized as or when the performance obligations are satisfied. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Services revenue </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div>  <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and Development Expense </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed when incurred. Research and development expenses relate primarily to the cost of conducting clinical and preclinical trials. Preclinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain preclinical and clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with preclinical and clinical trial contracts are based on the number of animal subjects, samples or tissues requiring analyses, patients, drug administration cycles, the type of treatment and the outcome since the length of time before actual amounts can be determined will vary depending on the total samples requiring primary and repeated analyses, the length of the patient cycles and the timing of the invoices by the preclinical and clinical trial partners. </div>  <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based Compensation Expense </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the shorter of the service period or the vesting period. The Company determines employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation based on the grant-date fair value using the Black-Scholes Option Pricing Model. </div>  <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income Taxes </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to Australia and United States income tax laws. The Company follows ASC 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div>  <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent Accounting Pronouncements </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> Financial Instruments&#8212;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840664480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_GoingConcernDisclosureTextBlock', window );">Going concern</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Going Concern </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended March 31, 2023, and 2022, the Company incurred a net loss of $14.9&#160;million and $13.1&#160;million and used cash of $13.9&#160;million and $11.0&#160;million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s business focuses on the development of novel genetic medicines and, at this stage in the Company&#8217;s development, the Company has not established a source of revenue to cover its full operating costs, and as such, is dependent on funding operations through capital financing activities. As of March 31, 2023, the Company had $6.6&#160;million in cash and cash equivalents. The Company has performed a review of its cash flow forecasts and has concluded that substantial doubt exists as to its ability to continue as a going concern. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future.</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840706144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, and restricted cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">4. Cash, cash equivalents, and restricted cash </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">June&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at bank</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840584480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid and other assets</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">5. Prepaid and other assets</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/>2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses&#8212;OPMD Program</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">879</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table>  <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840767280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">6. Pr<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operty and equipment, net</div></div></div>  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 457.391px;"/>
<td style="vertical-align: bottom; width: 33.9062px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 28.375px;"/>
<td/>
<td/>
<td/> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/>2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,343</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,343</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,403</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,404</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation and amortization</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,297</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,182</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">222</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and </div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">amortization</div> expense was $32&#160;thousand and $115&#160;thousand and for the three and nine months ended March 31, 2023, and $54&#160;thousand and $161&#160;thousand, respectively, for the same periods in 2022. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840664480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and other payables</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">7. Trade and other payables </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March&#160;31,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;30,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued OPMD project costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued consultant fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840585712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Leases </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2025. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the nine months ended March 31, 2023: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Operating<br/> lease&#160;right-<br/> of-<br/> use&#160;assets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Operating<br/> lease<br/> liabilities</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(188</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>   <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, the Company&#8217;s operating lease has a remaining lease term of 2.21 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March&#160;31,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded lease liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#8217;s incremental borrowing rate. Rent expense was $0.1&#160;million and $0.2&#160;million for the three and nine months ended March 31, 2023, respectively, and $0.1&#160;million and $0.2&#160;million for the same periods in 2022. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840653424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">9. Stockholders&#8217; equity </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Common Stock </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December 8, 2021, the stockholders of the Company approved an amendment (the &#8220;Charter Amendment&#8221;) to the Company&#8217;s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock of the Company from 10,000,000 to 40,000,000. On December 7, 2022, the stockholders of the Company approved another amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 40,000,000 to 160,000,000. The Charter Amendment was filed with the Secretary of State of the State of Delaware and became effective December 9, 2022. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Warrants </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December 6, 2019, certain investors (the &#8220;Investors&#8221;) were issued 4 Purchase Warrants that were exercisable into 214,190 fully paid shares of common stock should the Purchase Warrants be exercised in full (&#8220;Purchase Warrants&#8221;). The exercise price for the Purchase Warrants is US$10.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (December 6, 2024). On April 22, 2020, the Company issued 37,417 shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for 107,095 shares of common stock. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The activity related to warrants during the nine months ended March 31, 2023, is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Common</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Price</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Stock from</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">(per</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Warrants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">share)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants issued September&#160;15, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,171,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series 2 Warrants issued September&#160;15, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,809,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at September&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,088,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,171,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,916,566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,916,566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On September 15, 2022, we closed an underwritten public offering in which we issued and sold (i) 17,637,843 shares of the Company&#8217;s common stock, (ii) 12,171,628 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, with each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant immediately exercisable for one share of common stock at an exercise price of $0.0001 per share until exercised in full and (iii) 29,809,471 common warrants, the Series 2 Warrants, with each common warrant accompanying each issued share of common stock and/or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant and exercisable for one share of common stock at an exercise price of $0.66 per share. The Series 2 warrants sold in the offering became exercisable commencing December 9, 2022, the date on which the Company had both (a)&#160;received approval from its stockholders to increase the number of shares of common stock it is authorized to issue and (b)&#160;effected such stockholder approval by filing with the Secretary of State of the State of Delaware a certificate of amendment to its <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Amended and Restated Certificate of Incorporation, and will expire on the fifth anniversary of such</div> initial exercise date. The combined purchase price for each share of common stock and accompanying common warrant was $0.60, which was allocated as $0.59 per share of common stock and $0.01 per common warrant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On October 17, 2022 and October 27, 2022, investors exercised 2,004,961 and 166,667 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, respectively, at an exercise price of $0.0001 per share. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of March 31, 2023, there were 39,916,566 warrants outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Equity Incentive Plan </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Employee Share Option Plan </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In connection with its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> to the United States in April 2020, the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Share Option Plan&#8221;). This includes the Company&#8217;s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date for three years. If an employee dies, retires, or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. Since the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> no new options have been or will be issued under the Share Option Plan. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Equity and Incentive Compensation Plan </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December 9, 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2020 Equity and Incentive Compensation Plan and, on December 8, 2021, the Company&#8217;s stockholders approved an amendment to increase the maximum number of shares that may be issued under such plan to 1,850,000 (as amended, the &#8220;2020 Plan&#8221;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are issued under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#8217;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date for three years. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> director options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on the day prior to each of the Company&#8217;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Future equity grants will be made under the 2020 Plan. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Equity Awards </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related to equity awards, which are comprised of stock options during the nine months ended March 31, 2023 is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Remaining</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Aggregate</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Contractual</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Intrinsic</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Price</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Term</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Value</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June&#160;30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">738,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.18&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.93&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">768,399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.64&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">456,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.46&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Share-Based Compensation Expense </div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The classification of share-based compensation expense is <div style="display:inline;">summarized </div>as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;">Nine&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March 31, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">44</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">129</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">238</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">478</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of March 31, 2023, there was $0.2&#160;million of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840544400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">10. Income taxes </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three and nine months ended March 31, 2023, and March 31, 2022 respectively, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.</div></div><br/> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840704480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">11. Commitments and contingencies </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Contract commitments </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Contingencies </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840593888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">12. Related party transactions </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">During the nine months ended March 31, 2023, the Company did not enter into any related party transactions. As of March 31, 2022, the Company had entered into a related party transaction with Francis Abourizk Lightowlers for legal fees totaling $1&#160;thousand. Peter Francis, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director at the Company, is a partner at Francis Abourizk Lightowlers. As of March 31, 2022 amounts due to this related party of $1&#160;thousand were included in trade and other payables on the accompanying consolidated balance sheet. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716837909920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basis of Presentation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June 30, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principles of Consolidation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use of Estimates </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, allowance for uncollectable receivables, foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates, and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.&#160;<br/></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_RisksAndUncertainitiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Risks and Uncertainties </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single- source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third <div style="display:inline;">parties.</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Segment Reporting </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Other Comprehensive Income (Loss)</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Other comprehensive income (loss) for all periods presented consists entirely of foreign currency translation gains and losses. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair Value Measurements </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with GAAP using ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and Cash Equivalents </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. There were no cash equivalents or bank overdrafts as of March 31, 2023 and June 30, 2022. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concentrations of Risk </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Trade and Other Receivables</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and Other Receivables </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and Equipment </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:82%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">shorter of the lease term or estimated useful lives</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment of Long-Lived Assets </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_TradeAndOtherPayablesPolicyTextBlock', window );">Trade and other payables</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and other payables </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leases </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and Diluted Net Loss Per Share </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of March 31, 2023, and June 30, 2022, there were 40,684,965 and 845,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue Recognition </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue by applying the following steps: </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing revenues </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method and is constrained to the extent that it is probable that a significant reversal will not occur. Revenue is recognized as or when the performance obligations are satisfied. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Services revenue </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and Development Expense </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed when incurred. Research and development expenses relate primarily to the cost of conducting clinical and preclinical trials. Preclinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain preclinical and clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with preclinical and clinical trial contracts are based on the number of animal subjects, samples or tissues requiring analyses, patients, drug administration cycles, the type of treatment and the outcome since the length of time before actual amounts can be determined will vary depending on the total samples requiring primary and repeated analyses, the length of the patient cycles and the timing of the invoices by the preclinical and clinical trial partners. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation Expense</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based Compensation Expense </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the shorter of the service period or the vesting period. The Company determines employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation based on the grant-date fair value using the Black-Scholes Option Pricing Model. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income Taxes </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to Australia and United States income tax laws. The Company follows ASC 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent Accounting Pronouncements </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> Financial Instruments&#8212;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RisksAndUncertainitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RisksAndUncertainitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_TradeAndOtherPayablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_TradeAndOtherPayablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI https://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840756976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlTableTextBlock', window );">Summary of entities in control</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Principal&#160;place&#160;of<br/> business/country&#160;of<br/> incorporation</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Australia Proprietary Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec Limited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">United Kingdom</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RNAi Therapeutics, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tacere Therapeutics, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Benitec IP Holdings, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">USA</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of entities in control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716843786384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Summary of property and equipment</a></td>
<td class="text">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:82%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">shorter of the lease term or estimated useful lives</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840727504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, and restricted cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">June&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at bank</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716843824816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Summary of other current assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/>2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses&#8212;OPMD Program</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">879</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(105</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716925320832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment net</a></td>
<td class="text"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 457.391px;"/>
<td style="vertical-align: bottom; width: 33.9062px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 28.375px;"/>
<td/>
<td/>
<td/> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/>2023</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,343</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,343</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,403</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,404</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation and amortization</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,297</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,182</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">106</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">222</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716843765616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of trade and other payables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March&#160;31,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;30,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued OPMD project costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued consultant fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840608208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Summary of supplemental balance sheet information related to leases</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the nine months ended March 31, 2023: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Operating<br/> lease&#160;right-<br/> of-<br/> use&#160;assets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:89%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Operating<br/> lease<br/> liabilities</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(188</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liabilities</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, the Company&#8217;s operating lease has a remaining lease term of 2.21 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March&#160;31,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840140672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants or rights</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The activity related to warrants during the nine months ended March 31, 2023, is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Common</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Price</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Stock from</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">(per</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Warrants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">share)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants issued September&#160;15, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,171,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series 2 Warrants issued September&#160;15, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,809,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at September&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,088,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,171,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,916,566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,916,566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of equity awards</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related to equity awards, which are comprised of stock options during the nine months ended March 31, 2023 is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">average</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Remaining</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Aggregate</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Contractual</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Intrinsic</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Price</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Term</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;">Value</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June&#160;30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">738,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.18&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.93&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">768,399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.64&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">456,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.46&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of equity-based compensation expense</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The classification of share-based compensation expense is <div style="display:inline;">summarized </div>as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;">Nine&#160;Months&#160;Ended</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">March 31, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">44</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">129</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">238</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">478</td>
<td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716837745808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Summary of entities in control (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember', window );">Benitec Biopharma Proprietary Limited ("BBL") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember', window );">Benitec Australia Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember', window );">Benitec Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember', window );">Benitec, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember', window );">Benitec LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember', window );">RNAi Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember', window );">Tacere Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIpHoldingsIncMember', window );">Benitec IP Holdings, Inc.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIpHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIpHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839309472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation Date Of Incorporation</a></td>
<td class="text">Nov. 22,  2019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716833922160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">shorter of the lease term or estimated useful lives<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839235920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">40,684,965<span></span>
</td>
<td class="nump">845,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716842609872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,397)<span></span>
</td>
<td class="num">$ (5,411)<span></span>
</td>
<td class="num">$ (5,093)<span></span>
</td>
<td class="num">$ (3,275)<span></span>
</td>
<td class="num">$ (4,821)<span></span>
</td>
<td class="num">$ (5,045)<span></span>
</td>
<td class="num">$ (14,901)<span></span>
</td>
<td class="num">$ (13,141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in provided by operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,917)<span></span>
</td>
<td class="num">$ (11,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840084064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromBanks', window );">Cash at Bank</a></td>
<td class="nump">$ 6,551<span></span>
</td>
<td class="nump">$ 4,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total</a></td>
<td class="nump">$ 6,565<span></span>
</td>
<td class="nump">$ 4,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A bank's noninterest bearing demand deposits in other banks (such as correspondents).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716837834496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid and other assets - Summary of other current assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CreditMemo', window );">Prepaid expenses&#8212;OPMD Program</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_MarketValueOfListedShares', window );">Market value of listed shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Total other assets</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Less:&#160;non-current&#160;portion</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Current portion</a></td>
<td class="nump">$ 774<span></span>
</td>
<td class="nump">$ 741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CreditMemo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit memo.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CreditMemo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MarketValueOfListedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market value of listed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MarketValueOfListedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716838581920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Summary  of property and equipment net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,403<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(1,297)<span></span>
</td>
<td class="num">(1,182)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716840091856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839414240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables- Summary of trade and other payables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payable</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedLicenceFeesCurrent', window );">Accrued license fees</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedOpmdProjectCostsCurrent', window );">Accrued OPMD project costs</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedConsultantFeesCurrent', window );">Accrued consultant fees</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other payables</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,455<span></span>
</td>
<td class="nump">$ 1,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedConsultantFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued offering costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedConsultantFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedLicenceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued licence fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedLicenceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedOpmdProjectCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Opmd Project Costs Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedOpmdProjectCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716835273104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of maturities of the operating lease liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839329680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease has a remaining lease term</a></td>
<td class="text">2 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839333488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of supplemental balance sheet information related to leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Initial measurement at July&#160;1, 2022</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use asset</a></td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset at March 31, 2023</a></td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Initial measurement at July&#160;1, 2022</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Principal payments on operating lease liabilities</a></td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities at March 31, 2023</a></td>
<td class="nump">623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less: non-current portion</a></td>
<td class="num">(354)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at March 31, 2023</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716837683712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of warrants or rights (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period</a></td>
<td class="nump">42,088,194<span></span>
</td>
<td class="nump">107,095<span></span>
</td>
<td class="nump">107,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsExercised', window );">Pre-funded warrants exercised</a></td>
<td class="nump">2,171,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,088,194<span></span>
</td>
<td class="nump">39,916,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsExcercisable', window );">Exercisable at March 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,916,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding</a></td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised', window );">Pre-funded warrants exercised</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="nump">0.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable', window );">Exercisable at March 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_SeriesTwoWarrantsMember', window );">Series 2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Series 2 Warrants issued September 15, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,809,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod', window );">Series 2 Warrants issued September 15, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Pre-funded warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,171,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued', window );">Pre-funded warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantOrRightsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsExcercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights excercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsExcercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrants or rights excercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of pre funded warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_SeriesTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_SeriesTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716837857984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of equity awards (Detail) - Employee stock option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options,Outstanding, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock Options, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding, end of period</a></td>
<td class="nump">738,064<span></span>
</td>
<td class="nump">768,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise price, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercise price, end of period</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="nump">6.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercisable, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years 2 months 4 days<span></span>
</td>
<td class="text">6 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm', window );">Weighted-average Remaining Contractual Term, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Term, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at March 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options granted during period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716839424064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of share-based compensation expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716833617760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Additional information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 27, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 17, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 22, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 07, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 08, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 06, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognised share based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,088,194<span></span>
</td>
<td class="nump">39,916,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CashlessExerciseOfPurchaseWarrants', window );">Cashless exercise of purchase warrants (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember', window );">Purchase warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_NumberOfSeriesWarrantsIssued', window );">Number of series of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod', window );">Class Of Warrants Or Rights Excercised During The Period</a></td>
<td class="nump">166,667<span></span>
</td>
<td class="nump">2,004,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,637,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssueOfCommonStockAndWarrantPricePerShare', window );">Issue of common stock and warrant price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit', window );">Class of warrants or rights issue price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Series 2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,809,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,171,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,171,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CashlessExerciseOfPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CashlessExerciseOfPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantOrRightsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights excercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights issue price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsIssuePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssueOfCommonStockAndWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of common stock and warrant price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssueOfCommonStockAndWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_NumberOfSeriesWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of series warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_NumberOfSeriesWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_Series2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_Series2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140716838552096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Amount due to related party</a></td>
<td class="nump">$ 2,455<span></span>
</td>
<td class="nump">$ 1,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember', window );">Francis Abourizk Lightowlers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Amount due to related party</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>d214466d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bntc="http://www.benitecbiopharmainc.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bntc-20230331.xsd" xlink:type="simple"/>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_11_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2023-05-11</instant>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_15_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIpHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:SeriesTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_08_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-08</instant>
        </period>
    </context>
    <context id="PAsOn12_08_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-08</instant>
        </period>
    </context>
    <context id="PAsOn12_07_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-07</instant>
        </period>
    </context>
    <context id="PAsOn12_07_2022_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-07</instant>
        </period>
    </context>
    <context id="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:Series2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-27</startDate>
            <endDate>2022-10-27</endDate>
        </period>
    </context>
    <context id="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-27</instant>
        </period>
    </context>
    <context id="P06_30_2022To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P07_01_2022To03_31_2023">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber contextRef="P07_01_2022To03_31_2023" id="hidden78952390">84-4620206</dei:EntityTaxIdentificationNumber>
    <dei:DocumentFiscalYearFocus contextRef="P07_01_2022To03_31_2023">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P07_01_2022To03_31_2023">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P07_01_2022To03_31_2023">0001808898</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P07_01_2022To03_31_2023">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="P07_01_2022To03_31_2023">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P07_01_2022To03_31_2023">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P07_01_2022To03_31_2023">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="P07_01_2022To03_31_2023">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P07_01_2022To03_31_2023">001-39267</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P07_01_2022To03_31_2023">BENITEC BIOPHARMA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P07_01_2022To03_31_2023">3940 Trust Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P07_01_2022To03_31_2023">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P07_01_2022To03_31_2023">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P07_01_2022To03_31_2023">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P07_01_2022To03_31_2023">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P07_01_2022To03_31_2023">780-0819</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P07_01_2022To03_31_2023">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P07_01_2022To03_31_2023">BNTC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P07_01_2022To03_31_2023">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P07_01_2022To03_31_2023">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P07_01_2022To03_31_2023">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P07_01_2022To03_31_2023">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P07_01_2022To03_31_2023">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P07_01_2022To03_31_2023">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="P07_01_2022To03_31_2023">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn05_11_2023"
      decimals="INF"
      unitRef="Unit_shares">27981161</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">6551000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">56000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">774000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">741000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">7395000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4820000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">106000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositAssets
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:DepositAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">105000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">771000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">8220000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5973000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2455000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1880000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">429000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">269000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">252000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3153000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2532000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">354000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">559000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3507000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3091000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2023"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">27981161</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">27981161</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">168791000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">152453000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-163228000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-148327000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-853000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1245000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">4713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2882000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">8220000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5973000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">68000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">68000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">3167000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2171000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">9588000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8096000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1228000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1337000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">5011000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5093000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">4395000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3508000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">14599000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">13189000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4341000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-3460000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-14531000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13116000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-45000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">229000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-391000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-7000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-25000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-22000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-29000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-29000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-56000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">185000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-370000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-25000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-3275000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-14901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13141000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-233000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">392000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-51000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-233000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">392000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4352000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-3508000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-14509000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13192000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-3275000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-14901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13141000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      unitRef="Unit_shares">27981161</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">27981161</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">8171690</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To03_31_2023"
      decimals="0"
      unitRef="Unit_shares">22090191</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">22090191</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">8171690</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">151583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-130119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">20010000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">271000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">271000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-5045000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">151854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-135164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15475000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P10_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P10_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P10_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P10_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-4821000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">152093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-139985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10836000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">192000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">192000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-233000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-233000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-3275000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-3275000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">152285000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-143260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1506000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7520000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">152453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-148327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2882000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1869000</us-gaap:PaymentsOfStockIssuanceCosts>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrants
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">17637843</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrants>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">16013000</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">16015000</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">507000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">507000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5093000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">25809533</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">168768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-153420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14613000</us-gaap:StockholdersEquity>
    <bntc:WarrantsExercisedDuringThePeriod
      contextRef="P10_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">2171628</bntc:WarrantsExercisedDuringThePeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P10_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-48000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P10_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-48000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P10_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-160000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P10_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-160000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5411000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5411000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">27981161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">168720000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-158831000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-898000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8994000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4397000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">27981161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">168791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-163228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">4713000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-14901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13141000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">161000</us-gaap:DepreciationDepletionAndAmortization>
    <bntc:AmortizationOfRightOfUseAssets
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">182000</bntc:AmortizationOfRightOfUseAssets>
    <bntc:AmortizationOfRightOfUseAssets
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">168000</bntc:AmortizationOfRightOfUseAssets>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-4000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">325000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">702000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-47000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-609000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <bntc:IncreasedecreaseInAccountsAndOtherPayables
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">580000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
    <bntc:IncreasedecreaseInAccountsAndOtherPayables
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">512000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">28000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <bntc:IncreaseDecreaseInLeaseLiabilities
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-188000</bntc:IncreaseDecreaseInLeaseLiabilities>
    <bntc:IncreaseDecreaseInLeaseLiabilities
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-140000</bntc:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-13917000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-11044000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <bntc:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">17884000</bntc:ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1869000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">16015000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">391000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-95000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-11139000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">6565000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">794000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;1. Business &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Benitec Biopharma Inc. (the &#x201c;Company&#x201d;) is a corporation formed under the laws of Delaware, United States of America, on November 22, 2019 and listed on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the symbol &#x201c;BNTC&#x201d;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#x201c;BBL&#x201d;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April 15, 2020. On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#x2019;s business focuses on the development of novel genetic medicines. Our proprietary platform, called &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DNA-directed&lt;/div&gt; RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the year ended June 30, 2021, the Company completed an organization restructuring as part of the commercial desire to provide a more efficient structure for the future as the Company transitioned its operations to the United States. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s fiscal year end is June 30. References to a particular &#x201c;fiscal year&#x201d; are to our fiscal year end June 30 of that calendar year. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Principal&#160;place&#160;of&lt;br/&gt; business/country&#160;of&lt;br/&gt; incorporation&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec Biopharma Proprietary Limited (&#x201c;BBL&#x201d;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;United Kingdom&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec LLC&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec IP Holdings, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P07_01_2022To03_31_2023">2019-11-22</dei:EntityIncorporationDateOfIncorporation>
    <bntc:ScheduleOfEntitiesInControlTableTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Principal&#160;place&#160;of&lt;br/&gt; business/country&#160;of&lt;br/&gt; incorporation&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec Biopharma Proprietary Limited (&#x201c;BBL&#x201d;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec Limited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;United Kingdom&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec LLC&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Benitec IP Holdings, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfEntitiesInControlTableTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To03_31_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basis of Presentation &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements contained in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with generally accepted accounting principles in the U.S. (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended June 30, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). This is the source of authoritative GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Principles of Consolidation &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the Company&#x2019;s accounts and the accounts of its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Use of Estimates &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#x2019;s consolidated financial statements include the estimates of useful &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, allowance for uncollectable receivables, foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates, and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&#160;&lt;br/&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single- source vendors and collaborators, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third &lt;div style="display:inline;"&gt;parties.&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Segment Reporting &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company&#x2019;s functional currency and reporting currency is the United States dollar. BBL&#x2019;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#x2019; equity as &#x201c;Accumulated other comprehensive loss.&#x201d; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Other comprehensive income (loss) for all periods presented consists entirely of foreign currency translation gains and losses. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Fair Value Measurements &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company measures its financial assets and liabilities in accordance with GAAP using ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin-left:auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:92%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. There were no cash equivalents or bank overdrafts as of March 31, 2023 and June 30, 2022. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Concentrations of Risk &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Trade and Other Receivables &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&#x2019;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and Equipment &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:82%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:48%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer hardware&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Trade and other payables &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Leases &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic and Diluted Net Loss Per Share &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of March 31, 2023, and June 30, 2022, there were 40,684,965 and 845,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue Recognition &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue by applying the following steps: &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 3: Determine the transaction price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Licensing revenues &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method and is constrained to the extent that it is probable that a significant reversal will not occur. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Royalties &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#x2019;s subsequent sales of products occur. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Services revenue &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research and Development Expense &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed when incurred. Research and development expenses relate primarily to the cost of conducting clinical and preclinical trials. Preclinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain preclinical and clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with preclinical and clinical trial contracts are based on the number of animal subjects, samples or tissues requiring analyses, patients, drug administration cycles, the type of treatment and the outcome since the length of time before actual amounts can be determined will vary depending on the total samples requiring primary and repeated analyses, the length of the patient cycles and the timing of the invoices by the preclinical and clinical trial partners. &lt;/div&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Share-based Compensation Expense &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based compensation awarded to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; to be recorded as an expense over the shorter of the service period or the vesting period. The Company determines employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation based on the grant-date fair value using the Black-Scholes Option Pricing Model. &lt;/div&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Income Taxes &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to Australia and United States income tax laws. The Company follows ASC 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Recent Accounting Pronouncements &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13:&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November 15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. &lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basis of Presentation &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements contained in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with generally accepted accounting principles in the U.S. (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended June 30, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). This is the source of authoritative GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Principles of Consolidation &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the Company&#x2019;s accounts and the accounts of its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Use of Estimates &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#x2019;s consolidated financial statements include the estimates of useful &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, allowance for uncollectable receivables, foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates, and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&#160;&lt;br/&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
    <bntc:RisksAndUncertainitiesPolicyTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single- source vendors and collaborators, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third &lt;div style="display:inline;"&gt;parties.&lt;/div&gt; &lt;/div&gt;</bntc:RisksAndUncertainitiesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Segment Reporting &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company&#x2019;s functional currency and reporting currency is the United States dollar. BBL&#x2019;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#x2019; equity as &#x201c;Accumulated other comprehensive loss.&#x201d; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Other comprehensive income (loss) for all periods presented consists entirely of foreign currency translation gains and losses. &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Fair Value Measurements &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company measures its financial assets and liabilities in accordance with GAAP using ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin-left:auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:7%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:92%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. There were no cash equivalents or bank overdrafts as of March 31, 2023 and June 30, 2022. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Concentrations of Risk &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Trade and Other Receivables &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&#x2019;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and Equipment &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:82%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:48%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer hardware&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="P07_01_2022To03_31_2023">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:82%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:48%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer hardware&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2022To03_31_2023_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2022To03_31_2023_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2022To03_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2022To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P07_01_2022To03_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <bntc:TradeAndOtherPayablesPolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Trade and other payables &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt;</bntc:TradeAndOtherPayablesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Leases &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic and Diluted Net Loss Per Share &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of March 31, 2023, and June 30, 2022, there were 40,684,965 and 845,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2022To03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">40684965</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">845159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P07_01_2022To03_31_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue Recognition &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue by applying the following steps: &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 3: Determine the transaction price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Licensing revenues &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method and is constrained to the extent that it is probable that a significant reversal will not occur. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Royalties &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#x2019;s subsequent sales of products occur. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Services revenue &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research and Development Expense &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed when incurred. Research and development expenses relate primarily to the cost of conducting clinical and preclinical trials. Preclinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain preclinical and clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with preclinical and clinical trial contracts are based on the number of animal subjects, samples or tissues requiring analyses, patients, drug administration cycles, the type of treatment and the outcome since the length of time before actual amounts can be determined will vary depending on the total samples requiring primary and repeated analyses, the length of the patient cycles and the timing of the invoices by the preclinical and clinical trial partners. &lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Share-based Compensation Expense &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based compensation awarded to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; to be recorded as an expense over the shorter of the service period or the vesting period. The Company determines employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation based on the grant-date fair value using the Black-Scholes Option Pricing Model. &lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Income Taxes &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to Australia and United States income tax laws. The Company follows ASC 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Recent Accounting Pronouncements &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13:&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November 15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. &lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <bntc:GoingConcernDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;3. Going Concern &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended March 31, 2023, and 2022, the Company incurred a net loss of $14.9&#160;million and $13.1&#160;million and used cash of $13.9&#160;million and $11.0&#160;million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company&#x2019;s business focuses on the development of novel genetic medicines and, at this stage in the Company&#x2019;s development, the Company has not established a source of revenue to cover its full operating costs, and as such, is dependent on funding operations through capital financing activities. As of March 31, 2023, the Company had $6.6&#160;million in cash and cash equivalents. The Company has performed a review of its cash flow forecasts and has concluded that substantial doubt exists as to its ability to continue as a going concern. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company&#x2019;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future.&lt;/div&gt; </bntc:GoingConcernDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To03_31_2023"
      decimals="-5"
      unitRef="Unit_USD">-14900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-13100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2022To03_31_2023"
      decimals="-5"
      unitRef="Unit_USD">-13900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2021To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-11000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2023"
      decimals="-5"
      unitRef="Unit_USD">6600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;4. Cash, cash equivalents, and restricted cash &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;March&#160;31,&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;June&#160;30,&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash at bank&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,062&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P07_01_2022To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;March&#160;31,&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;June&#160;30,&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash at bank&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,062&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:DueFromBanks
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">6551000</us-gaap:DueFromBanks>
    <us-gaap:DueFromBanks
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4062000</us-gaap:DueFromBanks>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">6565000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;5. Prepaid and other assets&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&#x2014;OPMD Program&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;546&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Market value of listed shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;879&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; </us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="P07_01_2022To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&#x2014;OPMD Program&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;546&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Market value of listed shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;879&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 81%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">332000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">871000</us-gaap:PrepaidExpenseCurrent>
    <bntc:CreditMemo
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">546000</bntc:CreditMemo>
    <bntc:MarketValueOfListedShares
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1000</bntc:MarketValueOfListedShares>
    <bntc:MarketValueOfListedShares
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5000</bntc:MarketValueOfListedShares>
    <us-gaap:OtherAssets
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">879000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">876000</us-gaap:OtherAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">105000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">774000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">741000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;6. Pr&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;operty and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 457.391px;"/&gt;
&lt;td style="vertical-align: bottom; width: 33.9062px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 28.375px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,343&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,343&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,403&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,404&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,297&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,182&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;222&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and &lt;/div&gt;&lt;/div&gt; &lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;amortization&lt;/div&gt; expense was $32&#160;thousand and $115&#160;thousand and for the three and nine months ended March 31, 2023, and $54&#160;thousand and $161&#160;thousand, respectively, for the same periods in 2022. &lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 457.391px;"/&gt;
&lt;td style="vertical-align: bottom; width: 33.9062px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 28.375px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;June&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,343&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,343&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,403&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,404&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,297&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,182&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;222&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1343000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1343000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1404000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1297000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1182000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">106000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">161000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;7. Trade and other payables &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued license fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;116&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued OPMD project costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued consultant fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other payables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P07_01_2022To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued license fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;116&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued OPMD project costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued consultant fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other payables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt; &lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">635000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">422000</us-gaap:AccountsPayableTradeCurrent>
    <bntc:AccruedLicenceFeesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">116000</bntc:AccruedLicenceFeesCurrent>
    <bntc:AccruedLicenceFeesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">120000</bntc:AccruedLicenceFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">53000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">131000</us-gaap:AccruedProfessionalFeesCurrent>
    <bntc:AccruedOpmdProjectCostsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-1560000</bntc:AccruedOpmdProjectCostsCurrent>
    <bntc:AccruedOpmdProjectCostsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1089000</bntc:AccruedOpmdProjectCostsCurrent>
    <bntc:AccruedConsultantFeesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">55000</bntc:AccruedConsultantFeesCurrent>
    <bntc:AccruedConsultantFeesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">47000</bntc:AccruedConsultantFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">2455000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1880000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;8. Leases &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into an operating lease for office space under an agreement that expires in 2025. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#x2019;s lease does not contain any residual value guarantees or material restrictive covenants. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tables below show the changes during the nine months ended March 31, 2023: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Operating&lt;br/&gt; lease&#160;right-&lt;br/&gt; of-&lt;br/&gt; use&#160;assets&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;771&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;811&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;   &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March 31, 2023, the Company&#x2019;s operating lease has a remaining lease term of 2.21 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recorded lease liabilities and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#x2019;s incremental borrowing rate. Rent expense was $0.1&#160;million and $0.2&#160;million for the three and nine months ended March 31, 2023, respectively, and $0.1&#160;million and $0.2&#160;million for the same periods in 2022. &lt;/div&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tables below show the changes during the nine months ended March 31, 2023: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Operating&lt;br/&gt; lease&#160;right-&lt;br/&gt; of-&lt;br/&gt; use&#160;assets&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;771&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:89%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;811&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">771000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">182000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">811000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">188000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">623000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">354000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">269000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March 31, 2023, the Company&#x2019;s operating lease has a remaining lease term of 2.21 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:88%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn03_31_2023">P2Y2M15D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn03_31_2023"
      decimals="4"
      unitRef="Unit_pure">0.0467</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">292000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">62000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">657000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">623000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2022To03_31_2023"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2021To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;9. Stockholders&#x2019; equity &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Common Stock &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On December 8, 2021, the stockholders of the Company approved an amendment (the &#x201c;Charter Amendment&#x201d;) to the Company&#x2019;s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock of the Company from 10,000,000 to 40,000,000. On December 7, 2022, the stockholders of the Company approved another amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 40,000,000 to 160,000,000. The Charter Amendment was filed with the Secretary of State of the State of Delaware and became effective December 9, 2022. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Warrants &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On December 6, 2019, certain investors (the &#x201c;Investors&#x201d;) were issued 4 Purchase Warrants that were exercisable into 214,190 fully paid shares of common stock should the Purchase Warrants be exercised in full (&#x201c;Purchase Warrants&#x201d;). The exercise price for the Purchase Warrants is US$10.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (December 6, 2024). On April 22, 2020, the Company issued 37,417 shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for 107,095 shares of common stock. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The activity related to warrants during the nine months ended March 31, 2023, is summarized as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;average&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Exercise&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Common&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Price&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Stock from&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;(per&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Warrants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;share)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at July&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,095&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; warrants issued September&#160;15, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,171,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series 2 Warrants issued September&#160;15, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,809,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at September&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,088,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; warrants exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,171,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,916,566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,916,566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On September 15, 2022, we closed an underwritten public offering in which we issued and sold (i) 17,637,843 shares of the Company&#x2019;s common stock, (ii) 12,171,628 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, with each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrant immediately exercisable for one share of common stock at an exercise price of $0.0001 per share until exercised in full and (iii) 29,809,471 common warrants, the Series 2 Warrants, with each common warrant accompanying each issued share of common stock and/or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrant and exercisable for one share of common stock at an exercise price of $0.66 per share. The Series 2 warrants sold in the offering became exercisable commencing December 9, 2022, the date on which the Company had both (a)&#160;received approval from its stockholders to increase the number of shares of common stock it is authorized to issue and (b)&#160;effected such stockholder approval by filing with the Secretary of State of the State of Delaware a certificate of amendment to its &lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Amended and Restated Certificate of Incorporation, and will expire on the fifth anniversary of such&lt;/div&gt; initial exercise date. The combined purchase price for each share of common stock and accompanying common warrant was $0.60, which was allocated as $0.59 per share of common stock and $0.01 per common warrant. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On October 17, 2022 and October 27, 2022, investors exercised 2,004,961 and 166,667 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, respectively, at an exercise price of $0.0001 per share. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;As of March 31, 2023, there were 39,916,566 warrants outstanding. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Equity Incentive Plan &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Employee Share Option Plan &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In connection with its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; to the United States in April 2020, the Company assumed BBL&#x2019;s obligations with respect to the settlement of options that were issued by BBL prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; pursuant to the Benitec Officers&#x2019; and Employees&#x2019; Share Option Plan (the &#x201c;Share Option Plan&#x201d;). This includes the Company&#x2019;s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; on each anniversary of the applicable grant date for three years. If an employee dies, retires, or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. Since the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; no new options have been or will be issued under the Share Option Plan. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Equity and Incentive Compensation Plan &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On December 9, 2020, the Company&#x2019;s stockholders approved the Company&#x2019;s 2020 Equity and Incentive Compensation Plan and, on December 8, 2021, the Company&#x2019;s stockholders approved an amendment to increase the maximum number of shares that may be issued under such plan to 1,850,000 (as amended, the &#x201c;2020 Plan&#x201d;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are issued under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#x2019;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; on each anniversary of the applicable grant date for three years. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-employee&lt;/div&gt; director options vest in increments of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; on the day prior to each of the Company&#x2019;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Future equity grants will be made under the 2020 Plan. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"/&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Equity Awards &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The activity related to equity awards, which are comprised of stock options during the nine months ended March 31, 2023 is summarized as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;average&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;average&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Remaining&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Aggregate&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Exercise&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Contractual&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Intrinsic&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Options&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Price&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Term&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Value&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;738,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.18&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.93&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;768,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.64&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,501&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;456,688&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.46&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Share-Based Compensation Expense &lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The classification of share-based compensation expense is &lt;div style="display:inline;"&gt;summarized &lt;/div&gt;as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;Three&#160;Months&#160;Ended&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;March 31, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;238&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;478&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;As of March 31, 2023, there was $0.2&#160;million of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_08_2021_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_08_2021_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_07_2022_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_07_2022_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <bntc:NumberOfSeriesWarrantsIssued
      contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">4</bntc:NumberOfSeriesWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">214190</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">2024-12-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <bntc:CashlessExerciseOfPurchaseWarrants
      contextRef="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">37417</bntc:CashlessExerciseOfPurchaseWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">107095</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The activity related to warrants during the nine months ended March 31, 2023, is summarized as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;average&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Exercise&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Common&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Price&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Stock from&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;(per&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Warrants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;share)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at July&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,095&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; warrants issued September&#160;15, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,171,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series 2 Warrants issued September&#160;15, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,809,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at September&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,088,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; warrants exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,171,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,916,566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,916,566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">107095</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.5</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P07_01_2022To09_30_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">12171628</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <bntc:WeightedAverageExercisePriceOfPreFundedWarrantsIssued
      contextRef="P07_01_2022To09_30_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</bntc:WeightedAverageExercisePriceOfPreFundedWarrantsIssued>
    <bntc:ClassOfWarrantOrRightsIssuedDuringPeriod
      contextRef="P07_01_2022To09_30_2022_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">29809471</bntc:ClassOfWarrantOrRightsIssuedDuringPeriod>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod
      contextRef="P07_01_2022To09_30_2022_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.66</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">42088194</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.49</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
    <bntc:ClassOfWarrantOrRightsExercised
      contextRef="P10_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">2171628</bntc:ClassOfWarrantOrRightsExercised>
    <bntc:Weightedaverageexercisepriceofclassofwarrantsorrightsexercised
      contextRef="P10_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</bntc:Weightedaverageexercisepriceofclassofwarrantsorrightsexercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">39916566</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.52</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
    <bntc:ClassOfWarrantsOrRightsExcercisable
      contextRef="P07_01_2022To03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">39916566</bntc:ClassOfWarrantsOrRightsExcercisable>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable
      contextRef="P07_01_2022To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.52</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">17637843</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <bntc:ClassOfWarrantOrRightsIssuedDuringPeriod
      contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">12171628</bntc:ClassOfWarrantOrRightsIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bntc:ClassOfWarrantOrRightsIssuedDuringPeriod
      contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">29809471</bntc:ClassOfWarrantOrRightsIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_15_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bntc:IssueOfCommonStockAndWarrantPricePerShare
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_pure">0.006</bntc:IssueOfCommonStockAndWarrantPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.59</us-gaap:SaleOfStockPricePerShare>
    <bntc:ClassOfWarrantsOrRightsIssuePricePerUnit
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</bntc:ClassOfWarrantsOrRightsIssuePricePerUnit>
    <bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod
      contextRef="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">2004961</bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod>
    <bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod
      contextRef="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">166667</bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">39916566</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The activity related to equity awards, which are comprised of stock options during the nine months ended March 31, 2023 is summarized as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;average&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;average&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Remaining&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Aggregate&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Exercise&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Contractual&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Intrinsic&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Options&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Price&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Term&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;Value&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;738,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.18&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.93&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;768,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.64&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,501&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;456,688&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.46&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">738064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P06_30_2022To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">P7Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">5665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">45.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">P9Y11M4D</bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">768399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">456688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The classification of share-based compensation expense is &lt;div style="display:inline;"&gt;summarized &lt;/div&gt;as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;Three&#160;Months&#160;Ended&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;March 31, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;238&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;478&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">63000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To03_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">87000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">224000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">44000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To03_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">238000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">478000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">192000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">325000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">702000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2023"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;10. Income taxes &lt;/div&gt; &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the three and nine months ended March 31, 2023, and March 31, 2022 respectively, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;11. Commitments and contingencies &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Contract commitments &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Contingencies &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. &lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P07_01_2022To03_31_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;12. Related party transactions &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;During the nine months ended March 31, 2023, the Company did not enter into any related party transactions. As of March 31, 2022, the Company had entered into a related party transaction with Francis Abourizk Lightowlers for legal fees totaling $1&#160;thousand. Peter Francis, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; director at the Company, is a partner at Francis Abourizk Lightowlers. As of March 31, 2022 amounts due to this related party of $1&#160;thousand were included in trade and other payables on the accompanying consolidated balance sheet. &lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LegalFees
      contextRef="P07_01_2022To03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:LegalFees>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6JA@3Y[%1BIMXL.CM$J,>&A53;R; N_FS&&H.*P9V2V_F@_/JNP_M*PF8*\
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MAM3EX33R<*-%W1[HW0BM1=E>Y@P6KM(8P/N] $8=;\P987<FO/T/4$L#!!0
M   ( !U KU:G>W+EE@(  "L'   8    >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULK55=;],P%/TK5D (I-%\M$VWD4;:BA!#0E2K& ^(!S>Y;:PY=K"==O#K
MN7;2J-W2423RD/CCGN-SKIWK9"O5O2X #'DHN=!3KS"FNO1]G1504CV0%0B<
M64E54H-=M?9UI8#F#E1R/PJ"V"\I$UZ:N+&Y2A-9&\X$S!71=5E2]>L:N-Q.
MO=#;#=RR=6'L@)\F%5W# LS7:JZPYW<L.2M!:"8%4;":>E?AY2RV\2[@CL%6
M[[6)=;*4\MYV;O*I%UA!P"$SEH'B9P,SX-P2H8R?+:?7+6F!^^T=^P?G';TL
MJ8:9Y-]8;HJI=^Z1'%:TYN96;C]"ZV=L^3+)M7N3;1,[GG@DJ[6190M&!243
MS9<^M'G8 X2C(X"H!42G H8M8.B,-LJ<K??4T#11<DN4C48VVW"Y<6ATPX3=
MQ851.,L09]*9%%IREE,#.;FFG(H,R,+2:?)Z3A4(4X!A&>5OR%ORDOA$%SBJ
M$]_@ZI;#S]J5KIN5HB,K?:9J0(;A&8F":-@#GST/_U0+A <.'AW"??3<&8\Z
MXY'C&Q[A6QBTC,?1$+DB'YA XXQR,I>:N?/U_6JIC<)3]J//:L,]ZN>V?]ZE
MKF@&4P]_+0UJ U[ZZD48!^_ZC/\GLH,T#+LT#)]CQ_TO2W2[,#*[)[C?Y([R
M&OHL-SP3QV-KPR8-!D$0A(F_V3?SU[ #F:-.YNATF0MW LE5;0JIV&_(^^0V
M?.,]'9BQYGFD^)3( ]'C3O3X9-%G.]4W6M?]BL=/=$23B_,PC!^G^&G@>3@)
MXXLC<N-.;OSO<K_41ALJ<B;6?9KC4S4_#>S7[.^5,GN-8-58,Z$)AQ4B@\$$
M*513FIN.D96K;DMIL%:Z9H&W&2@;@/,K*<VN8PMF=S^F?P!02P,$%     @
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M_VR\M3RZY*$5-R<!B#9N19K.C?UXZ?0V,C"K 0XC3(<""4QCPC\SX3N9D,6
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MKH/;C.T/'ZVN('//OGF+?ZOCL^KG!> (YW ED2#="M[YV^![QI",51X,G<1
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M19$;-#9YM!&D",R-FB(P4[PI2[*ZW( ;S\%2M<.-G91DX2)D*$Z2[-ZT,TT
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M)1A SY?>]^D+-LA_\>/E_P-02P,$%     @ '4"O5C0R],&7!   % L  !D
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MD03M G!_H93=3MP!W;.;_P502P,$%     @ '4"O5H\15@:. @  IP4  !D
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MPP)TO]':[3?LH/L>6OT'4$L#!!0    ( !U KU:#L?&]2P@  /$5   9
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M^!90D&I+D8 IF%BM!)7IO6T7SK8C]HUKS0MK>I:/\6T 9Q(P";0@4/T)K*3
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MT)70YL&JDB[UELI:E=-R(SBH@ ?@_4HIVSR@@/:6]_I_4$L#!!0    ( !U
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MFDP^G$=@^C'5&TXW832LM:-!$Y8U378T/H#V2ZW=WO 'C/\5V5]02P,$%
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MD#Y,>NH)X0^"U<&0W@ 3&DCJ$E32.-,T]H;Y,D&[%R2Y$RL(RA@P9^E0P2U
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MQ$^QXA9+FGUXB)XW*X.^>!"Y@2.A5.Q#Z0YY%Y 15J_&Q?M$<IR=0[!A][A
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M&$C:#1O0 D&SR\.P!\6F8Z&ZN!*=M/OZ4;+C9D"2%UNBR,-S*)&3K;&/K@1
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M+B)FF[G2;-!4H9=7!FDRA&5)HQBL=Z#SPAC<;7R";KBG_P!02P,$%     @
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M=F&#DO$"I>%*@L;M/%C&T]70V7N#/SCNS=D:').-4I_<YM=L'D0N(1286H?
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M95%H _J_X%RM/W2 H3N>_0=02P,$%     @ '4"O5K2BT$K! P  W14  !D
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MQDA>/^9(4U1N@'V?26F>&VZ"[LYJ^0]02P,$%     @ '4"O5NOE9BJ< @
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MI<G#%4#PJ %. W"Z .\%@-L W*$ KP%X0P%^ _"' H(&$ P%C!K :&B6[AO
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M0XU-;F.36_)YS]AT0Q8)PZRU![\V'GQ^Q'#R3D$J_^Y*M>(>='/KA7HO<Q;
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ML5!$=;ZO!HKGY1%YQ14>N,O+"%@(0@?@\S7GZFF@3]W-ORS^OU!+ P04
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M2*. WQ="Z.W%&&BV??0'4$L#!!0    ( !U KU:BN\!GX@(  -,(   9
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MP0V=SR:[_RG9GGF_->^?RMXLCF:V34YK>:CEZKQ81Z$?C.SUKH%N3$_-S-K
MU6NY>B>Y]#Q @D@>R_,$4 I@7&EUEF!G:-<-#_ ,,9YCQ@M:O. LO(K1%+@Z
M[S YRAATQ@_\ \1NB.N[9L2P10S/0GR</4P5YQ]YJJ*8<F%D#+L 0>@<4!J"
MG,'0C-EO,?MG8<:TY/)<QJ4X6L=^MXZ'*[$;TNN;^08MW^ DW^/><6C"&G3&
M] ]78#>D?V1VARW6\/2^I0(3$\VPLQ>]7J=,W2!W,#C<$O;.E:.N>WEL+_.2
M(P*IE#DW?>F'U5=HW1&TTK?0@@IYI^EF)K\Z@*D ^3ZE5&P[ZF)KOV.B?U!+
M P04    "  =0*]6?#;! < "  #W"   &0   'AL+W=O<FMS:&5E=',O<VAE
M970S.2YX;6RM5EUOVC 4_2M65DVMM#8A@< ZB-123=O42:BTV\.T!P,78M6)
M,_L&VG^_ZR1$%-)T0GM)_''/\3DW\;6'&Z4?30R ["F1J1DY,6)VZ;IF'D/"
MS87*(*69I=()1^KJE6LR#7Q1@!+I^IX7N@D7J1,-B[&)CH8J1RE2F&AF\B3A
M^OD:I-J,G(ZS';@3JQCM@!L-,[Z"*>!#-M'4<VN6A4@@-4*E3,-RY%QU+L<#
M&U\$_!"P,3MM9IW,E'JTG:^+D>-902!ACI:!TVL-8Y#2$I&,/Q6G4R]I@;OM
M+?OGPCMYF7$#8R5_B@7&(V?@L 4L>2[Q3FV^0.6G9_GF2IKBR395K.>P>6Y0
M)168%"0B+=_\J<K##J#3?07@5P#_7P%!!0@*HZ6RPM8-1QX-M=HP;:.)S3:*
MW!1H<B-2^Q6GJ&E6$ ZC6Z <&';.IN5G9&I)])AK@8+&J8<Q,/II-$>1KIBT
M\4P*/A.R##F] >1"GA''P_2&G9Z<L1,F4G8?J]SP=&&&+I)0NYP[KT1=EZ+\
M5T1]Y_J"!9T/S/?\H $^;H=_RU.">P7<?PEW*3UUCOPZ1W[!%[3GZ-?5S*"F
M_^YWDZ.2HMM,8??BI<GX'$8.;38#>@U.]/Y=)_0^-?G[3V0OW :UVZ"-/7HE
MY]<E*BQ0MC:L(_\C97>]J[N5^4C=W5IW]RW=W2;=):JWHSOP@CW=K<Q'ZN[5
MNGMOZ>XUZ>X=Z [WT]U*?*3LL)8=MLJ^5\CE06'(^#.5>&S<\^&AH5Y_SU'K
MFD<ZZM>.^JV.;L$8)I(L1UA0 4.@);#)2/_ R'G0W3/2NM211@:UD4&KD8FE
M3)&MN<S!EO"6\MWD;W"PTT-_?\<<Q@PZG3JFE.WN'$OV2D!E?2520R*6A/(N
M^I1"71ZS90=55IQ4,X5T[A7-F&XFH&T S2^5PFW''G[U72?Z"U!+ P04
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MF(O$/! FA&I1AVH!/KB2>D,CAL1T)&8@,1.)64C,7O0]9'*0W;K'W4XZ>_5
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M!E0SH9H%U6RHYD U%ZIYE798,*4J%\W[ 3%T386#VK/$ ?46#5H+ =5TJ&9
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M3/1+!X0)T-^7G*M-QTQ0OYW"/U!+ P04    "  =0*]62<I)72T#   2$P
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M #1@2!15^^#.?A2N]JEP_2_8\ 502P,$%     @ '4"O5I>*NQS     $P(
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MQ5K>JO10<)?+;GK "&0H7/Y<0X6_[#(C)X\-SN@.[MZ)#])(VRJ1XQ@08$4
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MQ9B4<VIFY\R6GT]['F.2>UW<FUVD&K'!:\HY-;MSCJAQ&OD8DW).S>P<2HU
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M$Q2R)BAD35#(FOPG6=^U7OWU_Z9VC6M5-D=_UOW4FW\"4$L! A0#%     @
M'4"O5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  =0*]6R.<MA>X    K @  $0
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M965T-"YX;6Q02P$"% ,4    "  =0*]6#'2QCQ@*  !<5P  &
M    @('N'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M'4"O5C;G$(5L @  [04  !@              ("!/"<  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !U KU9U7);UKP8  !HF   8
M          " @=XI  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    "  =0*]6<];BI]$$   ["P  &               @('#,   >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ '4"O5I*=4:D/%P  _4,
M !@              ("!RC4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( !U KU8T,O3!EP0  !0+   9              " @0]-  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ '4"O5CLE:W!=
M @  @@4  !D              ("!W5$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    "  =0*]6CQ%6!HX"  "G!0  &0
M@(%Q5   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !U
MKU9E9,INL@(  "$&   9              " @397  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ '4"O5DRC,[*4 @  N@4  !D
M         ("!'UH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    "  =0*]6#E@ 1_8#   ;"0  &0              @('J7   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !U KU:#L?&]2P@  /$5
M   9              " @1=A  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ '4"O5N#E[WG+ @  -P8  !D              ("!F6D
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  =0*]61_-Y
MT3T#  ""!P  &0              @(&;;   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( !U KU;T>3"BB (  /P%   9
M  " @0]P  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M'4"O5A$NWP-^&   E$\  !D              ("!SG(  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    "  =0*]6YNO*!.,"  ",!@  &0
M            @(&#BP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( !U KU8C#*D9K@(  .@%   9              " @9V.  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ '4"O5K?@8W1I @
M<@4  !D              ("!@I$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    "  =0*]6Q=$X/9<"  "%!0  &0              @($B
ME   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !U KU;<
MAABHM (  . %   9              " @?"6  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ '4"O5N<R@KN: @  G 4  !D
M     ("!VYD  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !U KU8#OL+5H ,  +\2   9              "
M@8&K  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ '4"O
M5NOE9BJ< @  6P8  !D              ("!6*\  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    "  =0*]6;<<;!J(#  #)$0  &0
M        @($KL@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( !U KU8E-46Z=@(  )@&   9              " @02V  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ '4"O5EGXKP#= @  >@@
M !D              ("!L;@  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    "  =0*]6!"Q%CI8#  !Q$0  &0              @('%NP
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !U KU9?&&4)
ML (  /D'   9              " @9*_  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ '4"O5J*[P&?B @  TP@  !D
M ("!><(  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  =
M0*]6?#;! < "  #W"   &0              @(&2Q0  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !U KU9X"O %O@(  !@)   9
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M970T-"YX;6Q02P$"% ,4    "  =0*]6(E$R3'0)  "\;P  &0
M    @(&[VP  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M !U KU;Y,KWQV (  $<)   9              " @6;E  !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ '4"O5DG*25TM P  $A,   T
M             ( !=>@  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  =0*]6
MEXJ[',     3 @  "P              @ '-ZP  7W)E;',O+G)E;'-02P$"
M% ,4    "  =0*]6AI&S0_4#  #5'@  #P              @ &V[   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ '4"O5OTLU:6N 0  P1L  !H
M         ( !V/   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ '4"O5B;ZAZ>U 0  W!L  !,              ( !OO(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #8 -@"Q#@  I/0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>125</ContextCount>
  <ElementCount>203</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Going concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcern</Role>
      <ShortName>Going concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Cash, cash equivalents, and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash</Role>
      <ShortName>Cash, cash equivalents, and restricted cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Prepaid and other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets</Role>
      <ShortName>Prepaid and other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessTables</Role>
      <ShortName>Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Business</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Cash, cash equivalents, and restricted cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables</Role>
      <ShortName>Cash, cash equivalents, and restricted cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Prepaid and other assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables</Role>
      <ShortName>Prepaid and other assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Business - Summary of entities in control (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail</Role>
      <ShortName>Business - Summary of entities in control (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Business - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail</Role>
      <ShortName>Business - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Going concern - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail</Role>
      <ShortName>Going concern - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail</Role>
      <ShortName>Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid and other assets - Summary of other current assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and equipment, net - Summary  of property and equipment net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Property and equipment, net - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and equipment, net - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail</Role>
      <ShortName>Trade and other payables- Summary of trade and other payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of maturities of the operating lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Leases - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Summary of supplemental balance sheet information related to leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of warrants or rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of equity awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' equity - Summary of share-based compensation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Stockholders' equity - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' equity - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d214466d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Related party transactions - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related party transactions - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d214466d10q.htm 3002</Log>
    <Log type="Warning">[dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 10-Q, CurrentFiscalYearEndDate value "--06-30", should match the Entity Registrant Fiscal Year End Date "12/31" on record within EDGAR. d214466d10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="d214466d10q.htm">d214466d10q.htm</File>
    <File>bntc-20230331.xsd</File>
    <File>bntc-20230331_cal.xml</File>
    <File>bntc-20230331_def.xml</File>
    <File>bntc-20230331_lab.xml</File>
    <File>bntc-20230331_pre.xml</File>
    <File>d214466dex311.htm</File>
    <File>d214466dex312.htm</File>
    <File>d214466dex321.htm</File>
    <File>d214466dex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g214466g20n20.jpg</File>
    <File>g214466g21n21.jpg</File>
    <File>g214466g23n23.jpg</File>
    <File>g214466g24n01.jpg</File>
    <File>g214466g24n02.jpg</File>
    <File>g214466g25n25.jpg</File>
    <File>g214466g26n01.jpg</File>
    <File>g214466g26n02.jpg</File>
    <File>g214466g27n27.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="405">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d214466d10q.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 405,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 125,
   "dts": {
    "calculationLink": {
     "local": [
      "bntc-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bntc-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d214466d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bntc-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bntc-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bntc-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 310,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 6
   },
   "keyCustom": 32,
   "keyStandard": 171,
   "memberCustom": 14,
   "memberStandard": 16,
   "nsprefix": "bntc",
   "nsuri": "http://www.benitecbiopharmainc.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.benitecbiopharmainc.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:GoingConcernDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Going concern",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.benitecbiopharmainc.com/role/GoingConcern",
     "shortName": "Going concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:GoingConcernDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Cash, cash equivalents, and restricted cash",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash",
     "shortName": "Cash, cash equivalents, and restricted cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Prepaid and other assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets",
     "shortName": "Prepaid and other assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Property and equipment, net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Trade and other payables",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.benitecbiopharmainc.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Stockholders' equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquity",
     "shortName": "Stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Related party transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions",
     "shortName": "Related party transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfEntitiesInControlTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Business (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.benitecbiopharmainc.com/role/BusinessTables",
     "shortName": "Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfEntitiesInControlTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Cash, cash equivalents, and restricted cash (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables",
     "shortName": "Cash, cash equivalents, and restricted cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Prepaid and other assets (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables",
     "shortName": "Prepaid and other assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Property and equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Trade and other payables (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables",
     "shortName": "Trade and other payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Stockholders' equity (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Business - Summary of entities in control (Detail)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail",
     "shortName": "Business - Summary of entities in control (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfEntitiesInControlTableTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Business - Additional information (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail",
     "shortName": "Business - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Going concern - Additional information (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail",
     "shortName": "Going concern - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail",
     "shortName": "Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail",
     "shortName": "Prepaid and other assets - Summary of other current assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
     "shortName": "Property and equipment, net - Summary  of property and equipment net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Property and equipment, net - Additional information (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and equipment, net - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail",
     "shortName": "Trade and other payables- Summary of trade and other payables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Summary of maturities of the operating lease liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Leases - Additional information (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn06_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
     "shortName": "Leases - Summary of supplemental balance sheet information related to leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
     "shortName": "Stockholders' equity - Schedule of warrants or rights (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P10_01_2022To12_31_2022",
      "decimals": "0",
      "lang": null,
      "name": "bntc:ClassOfWarrantOrRightsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail",
     "shortName": "Stockholders' equity - Schedule of equity awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail",
     "shortName": "Stockholders' equity - Summary of share-based compensation expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn09_15_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Stockholders' equity - Additional information (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' equity - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn09_15_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Related party transactions - Additional information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related party transactions - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LegalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": "-3",
      "lang": null,
      "name": "bntc:AmortizationOfRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.benitecbiopharmainc.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d214466d10q.htm",
      "contextRef": "P07_01_2022To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "bntc_AccruedConsultantFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued offering costs current.",
        "label": "Accrued Consultant Fees Current",
        "terseLabel": "Accrued consultant fees"
       }
      }
     },
     "localname": "AccruedConsultantFeesCurrent",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_AccruedLicenceFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued licence fees current.",
        "label": "Accrued Licence Fees Current",
        "terseLabel": "Accrued license fees"
       }
      }
     },
     "localname": "AccruedLicenceFeesCurrent",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_AccruedOpmdProjectCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Opmd Project Costs Current.",
        "label": "Accrued Opmd Project Costs Current",
        "negatedLabel": "Accrued OPMD project costs"
       }
      }
     },
     "localname": "AccruedOpmdProjectCostsCurrent",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_AmortizationOfRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of right-of-use assets.",
        "label": "Amortization of Right of Use Assets",
        "verboseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfRightOfUseAssets",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic and Diluted Earnings Per Share [Abstract]",
        "terseLabel": "Weighted average number of shares outstanding:"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_BenitecAustraliaProprietaryLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Australia Proprietary Limited [Member]",
        "verboseLabel": "Benitec Australia Proprietary Limited [Member]"
       }
      }
     },
     "localname": "BenitecAustraliaProprietaryLimitedMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecBiopharmaProprietaryLimitedBblMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Biopharma Proprietary Limited BBL [Member]",
        "verboseLabel": "Benitec Biopharma Proprietary Limited (\"BBL\") [Member]"
       }
      }
     },
     "localname": "BenitecBiopharmaProprietaryLimitedBblMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Inc [Member]",
        "verboseLabel": "Benitec, Inc. [Member]"
       }
      }
     },
     "localname": "BenitecIncMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecIpHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benitec IP Holdings, Inc.",
        "label": "Benitec IP Holdings Inc [Member]",
        "terseLabel": "Benitec IP Holdings, Inc.[Member]"
       }
      }
     },
     "localname": "BenitecIpHoldingsIncMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Limited [Member]",
        "verboseLabel": "Benitec Limited [Member]"
       }
      }
     },
     "localname": "BenitecLimitedMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec LLC [Member]",
        "verboseLabel": "Benitec LLC [Member]"
       }
      }
     },
     "localname": "BenitecLlcMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_CashlessExerciseOfPurchaseWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of purchase warrants.",
        "label": "Cashless exercise of purchase warrants",
        "terseLabel": "Cashless exercise of purchase warrants (In shares)"
       }
      }
     },
     "localname": "CashlessExerciseOfPurchaseWarrants",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "bntc_ClassOfWarrantOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights exercised.",
        "label": "Class Of Warrant Or Rights Exercised",
        "terseLabel": "Pre-funded warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExercised",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "bntc_ClassOfWarrantOrRightsIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights issued during period.",
        "label": "Class Of Warrant Or Rights Issued During Period",
        "terseLabel": "Class of warrant or rights issued during period",
        "verboseLabel": "Series 2 Warrants issued September 15, 2022"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsIssuedDuringPeriod",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "bntc_ClassOfWarrantsOrRightsExcercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants or rights excercisable.",
        "label": "Class Of Warrants Or Rights Excercisable",
        "verboseLabel": "Exercisable at March 31, 2023"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsExcercisable",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants or rights excercised during the period.",
        "label": "Class Of Warrants Or Rights Excercised During The Period"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsExcercisedDuringThePeriod",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "bntc_ClassOfWarrantsOrRightsIssuePricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants or rights issue price per unit.",
        "label": "Class Of Warrants Or Rights Issue Price Per Unit",
        "terseLabel": "Class of warrants or rights issue price per unit"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsIssuePricePerUnit",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "bntc_CreditMemo": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit memo.",
        "label": "Credit Memo",
        "verboseLabel": "Prepaid expenses\u2014OPMD Program"
       }
      }
     },
     "localname": "CreditMemo",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_FrancisAbourizkLightowlersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Francis abourizk lightowlers.",
        "label": "Francis Abourizk Lightowlers [Member]"
       }
      }
     },
     "localname": "FrancisAbourizkLightowlersMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_GoingConcernAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern",
        "label": "Going Concern [Abstract]"
       }
      }
     },
     "localname": "GoingConcernAbstract",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "bntc_GoingConcernDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern disclosure.",
        "label": "Going Concern Disclosure [Text Block]",
        "terseLabel": "Going concern"
       }
      }
     },
     "localname": "GoingConcernDisclosureTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/GoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease In lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_IncreasedecreaseInAccountsAndOtherPayables": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accounts and other payables.",
        "label": "Increase Decrease in Accounts and Other Payables",
        "verboseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "IncreasedecreaseInAccountsAndOtherPayables",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance and exercise of pre-funded and common warrants.",
        "label": "Issuance and exercise of prefunded and common warrants",
        "terseLabel": "Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869, Shares"
       }
      }
     },
     "localname": "IssuanceAndExerciseOfPrefundedAndCommonWarrants",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance and exercise of pre-funded and common warrants, net of transaction costs.",
        "label": "Issuance And Exercise Of Prefunded and Common Warrants Net Of Transaction Costs",
        "terseLabel": "Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869"
       }
      }
     },
     "localname": "IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_IssueOfCommonStockAndWarrantPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue of common stock and warrant price per share.",
        "label": "Issue Of Common Stock And Warrant Price Per Share",
        "terseLabel": "Issue of common stock and warrant price per share"
       }
      }
     },
     "localname": "IssueOfCommonStockAndWarrantPricePerShare",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "bntc_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment [Member].",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment [Member]"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_MarketValueOfListedShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market value of listed shares.",
        "label": "Market value Of listed shares",
        "terseLabel": "Market value of listed shares"
       }
      }
     },
     "localname": "MarketValueOfListedShares",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_NumberOfSeriesWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of series warrants issued.",
        "label": "Number Of Series Warrants Issued",
        "terseLabel": "Number of series of warrants issued"
       }
      }
     },
     "localname": "NumberOfSeriesWarrantsIssued",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "bntc_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre funded warrants .",
        "label": "Pre funded Warrants [Member]",
        "terseLabel": "Pre-funded warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock pre funded warrants and common warrants.",
        "label": "Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants",
        "terseLabel": "Proceeds from issuance of common stock, pre-funded warrants, and common warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase warrants.",
        "label": "Purchase Warrants [Member]",
        "terseLabel": "Purchase warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_RisksAndUncertainitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainities.",
        "label": "Risks And Uncertainities [Policy Text Block]",
        "verboseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertainitiesPolicyTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_RnaiTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RNAi Therapeutics Inc [Member]",
        "verboseLabel": "RNAi Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "RnaiTherapeuticsIncMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_ScheduleOfEntitiesInControlAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlAbstract",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "bntc_ScheduleOfEntitiesInControlLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlLineItems",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_ScheduleOfEntitiesInControlTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlTable",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_ScheduleOfEntitiesInControlTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of entities in control.",
        "label": "Schedule Of Entities In Control [Table Text Block]",
        "verboseLabel": "Summary of entities in control"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlTableTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property plant and equipment useful lives.",
        "label": "Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Summary of supplemental balance sheet information related to leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_Series2WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 2 warrants.",
        "label": "Series 2 Warrants [Member]"
       }
      }
     },
     "localname": "Series2WarrantsMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_SeriesTwoWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 2 Warrants [Member].",
        "label": "Series Two Warrants [Member]",
        "terseLabel": "Series 2 Warrants [Member]"
       }
      }
     },
     "localname": "SeriesTwoWarrantsMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options granted during period weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted During Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "bntc_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies [Line Items].",
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies [Table].",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_TacereTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tacere Therapeutics Inc [Member]",
        "verboseLabel": "Tacere Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "TacereTherapeuticsIncMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_TradeAndOtherPayablesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other payables.",
        "label": "Trade and other payables [Policy Text Block]",
        "verboseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesPolicyTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_WarrantsExercisedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised during the period.",
        "label": "Warrants Exercised During The Period",
        "terseLabel": "Exercise of\u00a0pre-funded\u00a0warrants, Shares"
       }
      }
     },
     "localname": "WarrantsExercisedDuringThePeriod",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of class of warrants or rights excercisable.",
        "label": "Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable",
        "verboseLabel": "Exercisable at March 31, 2023"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of class of warrants or rights issued during the period.",
        "label": "Weighted Average Exercise Price Of Class Of Warrants Or Rights Issued During The Period",
        "terseLabel": "Series 2 Warrants issued September 15, 2022"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price of class of warrants or rights outstanding.",
        "label": "Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding",
        "periodEndLabel": "Exercise price of class of warrants or rights outstanding",
        "periodStartLabel": "Exercise price of class of warrants or rights outstanding"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of pre funded warrants issued.",
        "label": "Weighted Average Exercise Price Of Pre Funded Warrants Issued",
        "terseLabel": "Pre-funded warrants issued"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfPreFundedWarrantsIssued",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of class of warrants or rights exercised.",
        "label": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExercised",
        "terseLabel": "Pre-funded warrants exercised"
       }
      }
     },
     "localname": "Weightedaverageexercisepriceofclassofwarrantsorrightsexercised",
     "nsuri": "http://www.benitecbiopharmainc.com/20230331",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "verboseLabel": "Entity Incorporation Date Of Incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Principal place of business/country of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail",
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r237",
      "r369",
      "r393",
      "r412",
      "r413",
      "r423",
      "r425",
      "r430",
      "r459",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r237",
      "r369",
      "r393",
      "r412",
      "r413",
      "r423",
      "r425",
      "r430",
      "r459",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r184",
      "r370",
      "r424",
      "r429",
      "r454",
      "r455",
      "r460",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r184",
      "r370",
      "r424",
      "r429",
      "r454",
      "r455",
      "r460",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r235",
      "r237",
      "r266",
      "r267",
      "r268",
      "r368",
      "r369",
      "r393",
      "r412",
      "r413",
      "r423",
      "r425",
      "r430",
      "r453",
      "r459",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r235",
      "r237",
      "r266",
      "r267",
      "r268",
      "r368",
      "r369",
      "r393",
      "r412",
      "r413",
      "r423",
      "r425",
      "r430",
      "r453",
      "r459",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Trade and other payables",
        "totalLabel": "Total",
        "verboseLabel": "Amount due to related party"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r1",
      "r8"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r105"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r111",
      "r390",
      "r401",
      "r405"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r16",
      "r19",
      "r72",
      "r361",
      "r396",
      "r397",
      "r441",
      "r442",
      "r443",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r448",
      "r449",
      "r450",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r135",
      "r136",
      "r137",
      "r138",
      "r147",
      "r187",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r272",
      "r273",
      "r274",
      "r285",
      "r286",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r371",
      "r372",
      "r373",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r65",
      "r66",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r87",
      "r107",
      "r130",
      "r169",
      "r178",
      "r182",
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r297",
      "r299",
      "r319",
      "r428",
      "r457",
      "r458",
      "r495"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r101",
      "r114",
      "r130",
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r297",
      "r299",
      "r319",
      "r428",
      "r457",
      "r458",
      "r495"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r36",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33",
      "r103",
      "r415"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "verboseLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r28",
      "r33",
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r28",
      "r75"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r130",
      "r150",
      "r151",
      "r153",
      "r155",
      "r159",
      "r160",
      "r191",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r224",
      "r230",
      "r319",
      "r414",
      "r437",
      "r446",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Class of warrant or right, exercise price of warrants or rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrants convertible into shares of common stock on exercise"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding, ending of period",
        "periodStartLabel": "Outstanding, beginning of period",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r83",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "presentationGuidance": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r53",
      "r202",
      "r203",
      "r408",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r448",
      "r449",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock Par Value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r428"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value-160,000,000 shares authorized; 27,981,161 shares and 8,171,690 shares issued and outstanding at March 31, 2023 and June 30, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r20",
      "r117",
      "r119",
      "r125",
      "r386",
      "r391"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r39",
      "r40",
      "r73",
      "r74",
      "r186",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r39",
      "r40",
      "r73",
      "r74",
      "r186",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r85",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Deposit Assets",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r31",
      "r168"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r59",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of equity awards"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromBanks": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A bank's noninterest bearing demand deposits in other banks (such as correspondents).",
        "label": "Due from Banks",
        "verboseLabel": "Cash at Bank"
       }
      }
     },
     "localname": "DueFromBanks",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r126",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r148",
      "r150",
      "r153",
      "r154",
      "r155",
      "r157",
      "r311",
      "r312",
      "r387",
      "r392",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r126",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r150",
      "r153",
      "r154",
      "r155",
      "r157",
      "r311",
      "r312",
      "r387",
      "r392",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "verboseLabel": "Effects of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognised share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee stock option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r54",
      "r97",
      "r121",
      "r122",
      "r123",
      "r132",
      "r133",
      "r134",
      "r136",
      "r144",
      "r146",
      "r158",
      "r195",
      "r232",
      "r272",
      "r273",
      "r274",
      "r287",
      "r288",
      "r310",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r361",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r328",
      "r330",
      "r332",
      "r333"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency Translation and Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r279",
      "r280",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expense and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of the operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease has a remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r130",
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r298",
      "r299",
      "r300",
      "r319",
      "r421",
      "r457",
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r81",
      "r90",
      "r428",
      "r447",
      "r452",
      "r489"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r102",
      "r130",
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r298",
      "r299",
      "r300",
      "r319",
      "r428",
      "r457",
      "r495",
      "r496"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r28",
      "r29",
      "r32"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in provided by operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r32",
      "r84",
      "r93",
      "r100",
      "r115",
      "r118",
      "r123",
      "r130",
      "r135",
      "r139",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r152",
      "r169",
      "r177",
      "r181",
      "r183",
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r312",
      "r319",
      "r422",
      "r457"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (loss), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (loss):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r169",
      "r177",
      "r181",
      "r183",
      "r422"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "periodEndLabel": "Operating lease liabilities at March 31, 2023",
        "periodStartLabel": "Initial measurement at July\u00a01, 2022",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "periodEndLabel": "Current portion at March 31, 2023",
        "terseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "negatedLabel": "Less: non-current portion",
        "terseLabel": "Lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Principal payments on operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "periodEndLabel": "Operating lease right-of-use asset at March 31, 2023",
        "periodStartLabel": "Initial measurement at July\u00a01, 2022",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortization of right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r79",
      "r86",
      "r106"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r113",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "negatedLabel": "Less:\u00a0non-current\u00a0portion",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r15",
      "r17",
      "r329",
      "r331",
      "r334"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 14.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized foreign currency translation gain (loss)",
        "verboseLabel": "Foreign currency translation gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r68",
      "r69",
      "r71",
      "r116",
      "r119"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 13.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Shares and pre-funded warrant issuance costs",
        "verboseLabel": "Payments For Stock Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r440"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r112",
      "r198",
      "r199",
      "r416"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r52",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r48",
      "r104"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r50",
      "r91",
      "r389",
      "r428"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property and equipment net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r236",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r236",
      "r364",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r362",
      "r363",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r67",
      "r94",
      "r503"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r33",
      "r35",
      "r78",
      "r88",
      "r103"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r438",
      "r445"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r55",
      "r89",
      "r400",
      "r405",
      "r428"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r132",
      "r133",
      "r134",
      "r136",
      "r144",
      "r146",
      "r195",
      "r272",
      "r273",
      "r274",
      "r287",
      "r288",
      "r310",
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r166",
      "r167",
      "r176",
      "r179",
      "r180",
      "r184",
      "r185",
      "r186",
      "r233",
      "r234",
      "r370"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Licensing revenues from customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r124",
      "r130",
      "r166",
      "r167",
      "r176",
      "r179",
      "r180",
      "r184",
      "r185",
      "r186",
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r319",
      "r388",
      "r457"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r353",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Re-measurement of operating lease right-of-use assets and liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock number of shares issued in the transaction",
        "verboseLabel": "Pre-funded warrants issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock issue price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of trade and other payables"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Summary of other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of equity-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants or rights"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Stock Options, Exercisable, end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average Exercise Price, Exercisable, end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Stock Options, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding at March 31, 2023"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock Options, Outstanding, end of period",
        "periodStartLabel": "Stock Options,Outstanding, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average Exercise Price, Exercise price, end of period",
        "periodStartLabel": "Weighted-average Exercise price, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r244",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end (In shares)",
        "periodStartLabel": "Balance at the beginning (In shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r36",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of presentation and summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r130",
      "r150",
      "r151",
      "r153",
      "r155",
      "r159",
      "r160",
      "r191",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r224",
      "r230",
      "r319",
      "r414",
      "r437",
      "r446",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r54",
      "r97",
      "r121",
      "r122",
      "r123",
      "r132",
      "r133",
      "r134",
      "r136",
      "r144",
      "r146",
      "r158",
      "r195",
      "r232",
      "r272",
      "r273",
      "r274",
      "r287",
      "r288",
      "r310",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r361",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r158",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r45",
      "r428",
      "r447",
      "r452",
      "r489"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r129",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r232",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.",
        "label": "Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]",
        "verboseLabel": "Trade and Other Receivables"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r135",
      "r136",
      "r137",
      "r138",
      "r147",
      "r187",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r272",
      "r273",
      "r274",
      "r285",
      "r286",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r371",
      "r372",
      "r373",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized loss on investment",
        "verboseLabel": "Unrealized loss on investment"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r161",
      "r162",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Expiry date of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r149",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r148",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "310",
   "URI": "https://asc.fasb.org/topic&trid=2196771",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r432": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r434": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r435": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r436": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.1)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001193125-23-144211-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-144211-xbrl.zip
M4$L#!!0    ( !U KU9F0Y//X T   ^0   1    8FYT8RTR,#(S,#,S,2YX
M<V3M7>UOV[@9_SY@_X/F+^N <QS'[?4:7.[@O'4!W"9(TUN!83C0$FUSE2B7
MI)KDAOWO>TB)LF2)>K,J%[,^W%46G_<?7Q]2S,^_/GFN]14S3GQZ-A@?'0\L
M3&W?(71Y-@C$8OC3X-=?_ORGG_\R'+[%%#,DL&/-GZW+ZYOWUJ?S^YEU0[E
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M=^J-(<"9E7O(U(<SFTY*AM98:@AS9MF>EW+J@ZZG_O'4] IFA@*FA#=49D>
MYA(+1-ST^J*4V@!*=OM7KSR&R=DJCJ1:A*KL"LBU7H22>Z2FCJ/,1.X-7?A
M)7_D@51$F(_/)+M8W^"S$6>1C;P>EUV6>C%5WF0IA>DW5F*H#]E,01N+S51;
M7^=.\/IJM0OBY5W$-Q)NJ$;?)F?1=TE5S@65UH6JQ 9L,VF,U&FB'J2=,D[R
MNT(G<'%XNK2,.O,B09Q$?"^:#=4GDW.IDP6#@20R4_87=@U.^>Y^ZUV"J:^=
MN>FS>(!0[R[4MY@B+$K6KX:\AAJ2DQ(R9.52\XJP)/Q>5,1YNQ[6W*1<X101
MRM/H[B+" '(FZU24]]O@7#"!5 G"'NY<+$KG! WX#,!FLEW%P/:3A1J9WKC)
MY98F\6S.;H UDUTS98E3?;(PII(/'=\P!QPC\@Z)@*D4&*"SPM$7DW2IR&8$
MS8FK2I,8[R;"@',F81<EJU.P>K$J!?(*9F-:F^5*>LO=Z.NQ#D-8V@>7D^5C
M]C*3Q(LQZWO72JWO0WQA!'*3W[$G$(B.HSWX(6M!.VPLS(!N)B67UR)Y0JDU
MC[Z=YU)M"G@6':H3?MA.^\:9LPFU60G_ S&&Y+>>[)XL5^DU3P,^ \"99%GN
MQE5ZZ?L8:;!\9C&EHT>R")'P]Q3"YE1&,8?'@& F)58!P>@E4N)[\'* B#M4
MH,;GT%NIRRDPY<JLJR?YB$O K"/# &XF864"-]$;2VU#>>67/"R^T6?A4&$/
M=Q:JTNE1/18#F)G<D@',?N)4[]!_*7I-& T89E)'YD\%_N^1E/^3_<P]7ECJ
MXL!3>:O:V8 3#^:#@^C=BN'%V4#>@SC4=QS^#BX=/7FN)I&2"^X#5.!O1R%2
MK$5$E\T57VPXBK)WL# <:>,'UJ@%AR#B=1U*@_1]N>.B>5UW@ 6[WY\G4+7K
M>K+5&EKV9Y2XXV^4OOT/G/&9L&CN?:2FJS?#JTQGOJW$%+#(7T/--Y2OAN.3
MX61\],2=R+8:!FR\JF> YJMI0/Y=HA55:P:I\U45;88[1O/4<6U<+L\(NX+'
M%T;*-Y6=S;^UM-"$/!;]HZ'R] 6HU;0G>>)?S?0G+DJMI#NF5T_-="8O7*VD
M=,,0/C93N[F\M9)232X?&BK<7.I:3:.F5T^5=6;OA56=+,5+.6VJUH9=QE)<
MLB&_D9W'^,>=3*C8A234BYU5%]^*6]6<I)2KC9":UAFN+ZY4'32Y?*A<&4P7
M$._0LRHQ]0W8OCBXF@7Z9N)0>RRCD?H=%3=J?[DW'YLL*.-4OWF3\31U=7)]
M[+],DH*&X:O:Z->W08, ^B,!6=W1I?!*>7CRT9Y2YY*X ?1;5XA10I?\#C.5
M$YK..2P89;L/I[/JPO53>4Z(+F\$]N1J:V"AB.IL(%@@)[N*"J:7Q'<>%)\3
MA%><#BQ*7%=N<FI:N?J5$^+?*UO" W@D0EVQ_Y;YP5J;!>MR+]=)G7"^>L+,
M)K!HO RD P\K?*=LW/).JN-YWBV0RYNZ5VY#?;]N. _D7%D>2XC$JD.LBX Z
MV FOJ_5\JE6_QT)M;NOU_X7/Y;512=^!&A;^[+EM[]NQM"1"X7.TO7,VL!EV
MB&@C<%W4C]HF-:@N%$(BLZXX_/>&1L>(>?;"I4XJ10U[ZD'OX+D)^4CG9:QS
M^P! M[X7V=&6SU,/!AORAS+I=J'VW&X7'SG6]\9UX6^9#6WY>L=\&V.'7S/?
MTTWJ=A&V'97,AB9UK9J4;DDEK?U;!:050]N*6F)7;_L#M@YG )6LJ-_MI0[T
M=^=-OMK=S-_D]1_PDSAWH9IH3^*_*'(J=%';5;;4DOK.Y1ZU4U^T/._#PVKF
MU'?SGO#/LOU^E+$32&75]^EG17OJ.UK0A-67Q?MPMH9-NSBL#_+>N?(SL<1!
M81CE%H$[(U^C+^'W&X,F9NX2EOKGO;Z#(.UN=/M-9[\#<&2"P2U'G*Y ";.#
M.;XQ.7@>[IS/B ?_..^P-\<LBZ[CRSWUMG,+N:KK8Q3)F0;2)I<@V9@84?/#
M/;I5P9S&KLY<>R](;=0VF%0@&-7P PSA:(V!SX9JW*T7A18TQN)<GSG)XGP^
M=_<!4S6+&CO<-6Q9M0VF>A21?5:] OW-<5C_W7?EWTCMW)LB UH=8F>$JI%K
M.]?7\3";,*.^>S,TCV=SG:*4I[@!.M5O@^P"I#K6[#(MJJ:HT_I9UZ+Z6+]#
M[#,6OR$W@%8P(US^[2B55F\A^1:>(!(%#A9H;RNC=J$V'Z Q^)UXE%376MK8
MMD&)<[OV'!C>_XUMH;9AHD_5.W&KS(26795_@2QPI4W7&._#48,!K>U[16IF
MQ,9 NB<G\[2WYF$F:][I0&C4WF#/&LL]$NQ,O\)<;HGUGN =(W:X,9A6)+<0
ML)-U<QUMG[>^G=W,O/IQN' 1Y_$W8_J3L7@7O8NMV5(3VD8WK3#^3BX,HN'L
MPKXAKV=S1Q&[#83LE.3*H:4XE?=RNQO:47"NGFQ%EIQ0?Z>U*&WJKIU(802Z
MZTB^D7=Y+:^[8T[5;6E>RU%8=7!4==:RZO@+6VKV%_K37Y^%'_[B[9&BNRK>
MU,X&2V<P$!:CC_Y>9CU&[0T<R?T0=2K%+A7=^?.&Y X]RU?J$^3;M?JB[:W4
MGZYI6QW./981"#>RE>L!<A\P\]*-0WO=^A;3'OUK=KXP?2AE2O643G78^G!F
M;MN"6;YH>6RM85!K@X32J85_I$1T-I.H;E #9Q%?N9CSQ%G#@-DKJ'9='GJL
M8D5]W]X'LONY783]4OX**6KFV"8><EO&K5A_Z[.7O1QGKF]3TU'M9(]C6D9W
M?2>V*W2W^0B#\OIN7 ,_X#J=^X#K'Y]G$FW_T<6L6X?*S:CBVBC\FN*7_P%0
M2P,$%     @ '4"O5@F[><A,"@  5(8  !4   !B;G1C+3(P,C,P,S,Q7V-A
M;"YX;6SM76UOX[@1_EZ@_\%U/SO.2Z]W&]S>(;&318 D#ISLW0%%<:"E<<RN
M1+HDE<17]+^7E.W8EL47V3Z1VAZP+[;,(>>9AR^CX8CZ_L>W-&F] ..8DH_M
MDZ/C=@M(1&-,GC^V,S'N?-?^\8<__^G[OW0ZGX  0P+BUFC6ZE_?W+=^N1S>
MMFX(%XA$T.K3*$N!B%:G-1%B>M[MOKZ^'L5C3#A-,B$;X$<13;OR]Y_F#;:&
M9T?'\JO\='+2N4.SSNGQZ5GK'R?'YV??GG]S^L_6?R[N_MOI* 423+Z,$(>6
M5)CPC^VU)MY&+#FB[+E[>GQ\UET6;,]+GK]QO%'Z]6Q9]J3[R]WM8S2!%'7P
M L6[E*JF3.[DPX</W?Q7693C<Y[+W]((B=R$5KU:VA+J6V=9K*,N=4Y..V<G
M1V\\;BL;,)K $,:MO/ES,9O"QS;'Z311:N?7)@S&']LC(J+<E,=G<^F_]J@B
M <>*ODN4**2/$P#!VRU5Z>?AS8;F(R!80#3"=#I!+$681#EUJFS74%?W<%H^
M"OFOZDY\,!Y,5<=3'>B"Q#V:3AE,@'#\ K>4[PNA2D._$[X>XI/KA+X>$LI:
MG?MJ+6M2?Z_^G>$7E*CJI76&P 7#D6Q5_:9&49PE,&_75GKKPEKA/@B$DUT,
MX47-/6W[P&"*<"Q;&H@)L O.Y3AZS-(4L9GLCNI:+V-,MCC_:6?K[-K0WOBH
M'%)B)MM5QINJSGD/XKUAS>][P-RKO3W1/C$4P]+$#VB&1@FLC%SZZ\Y(]VAK
M3Y2W()>G55-W2&0,"PQRTGF:P&(*)<]YL5N,1CC)?]T9Z9[MY6@CE$19DD_M
MMQ+;!FIX$T!BB)>X5:.'6 USKX5&&VTERD^@;-/$JBDNV\J]@3'BH]PER'CG
M&:&I= U.3[N0"+Z\HM@XS9E87/AU/F27E29H!$G>U*_% MVZ=5K,*5;5WLL5
MV;I@F\HB%BTKDQ^WJ-ITJ!8ENESU'55;1_*8+N7'C*;E9EHT2(V:9EPV3:>J
M6B2[&64Q,.E!MUNO@)\G(O]8H[T7"U9Q31,]Q-A,#H^?4)*!@0='^0#X*?2I
M(DV.0,KI._5%WT44T6SNA.1S]A BD+JK:5NN3P[#R$T^?/H<@933=^:+OH5[
M=?4VE;<+L.EEV<ESD@Z?.B<8Y<3]S1=QFPZ^G2I-^?#)T2A>3L<W_L;1W#]_
MD(Z4*#CIQ@%D$@N '/V0,2E>3L[??9'3ARGE6%B]S4*Y@,U?T+3<WM_ZLO?F
MK<U0J3 8?Y8SJU+78'^+7,!\6#0OY^<[;_RLEK=[2B+KVJ$I'S(?Y1J7\_!A
MFX=NX;[[Z[\57PM R.G\4=#HRX0FTCY<3>UB9N@>=M$:^_::,FXJ>^['KG8O
M]O -!)I;^N,P%H"EJC.WR<8N&PIA;JM!*00-8]ZB,&NH[/<2985#YZ1,9PT)
MWF,IB[CW^XUH%+$,XDH45:\J% (=PRSNP#0L>PNY7*73A,X AI"H!;\2K0ZR
M#>'1 8F&.&\A%\VT;F?-)M@0RFPP-'QYB\E4<F*U;FL O%1R#,M*:ICQ%I#I
MT32E)-?4NKVS5=0K*^X\;"NN8<%;F.8BCO%<F0>$XQO20U,L4+*FN,G!<!!N
M"%,N4#3<>0OA#%62 ('X"C$B9V0N_9\LS?*EM ]C'&'S7H!=N"'<N4#1<%<2
M]JG-S5_J.,]?6L_7NR$13?.LO7L0@_$3>C-[^=5J:@BKE7%I-L5+ B#^(GL5
M\C5K78F+EG7H=T:I&D>2;'35&PSZ%LIY'04.%B\.AX+Z@27PO-\6.%%16MHK
M(:6=2'OO8R?"6_CH7<=%(H,3#:NR7DDP="(M%2O5K4DUG=J3,T!:0*5S]>$%
M$IIOC2_T-2=IF.3"8*C8NTH2-DP@ LNCF3\<E$AE+^(4$\R%0OD"=K*LDLV@
MRPHCL$R;H>Q3)#-.;JLB85!@G]-6&@>6.K-0[%J"D[ZL[!J1^!F+22_C0D)B
M$EF2J6?NU%Z[_!.;_<:=:O/*8;&W:8BKABBP=)U[2NAF5[5/?@:9\)TY@_*!
M9>I<4R;;)?,0>S1[8HAPV<6D=I_DC:;"> EC6<8\["K5XI<^6U<L4ED)FG/Z
M3SWDWA !#+C8 +IN 7/NJ)MXL^ATPQ1<NHN*4>TRB]H$FT6>#4UH.2^?"0.4
MX-\@7LX5 W)#7F3WRZ-T!MZLDLTBS@HGM$09EZ#P V6YY85@>)0)E2SR1!^0
M2ZKK/C4W+;:X-^#0TFMT@/2>@KSUS;_-"5L.@0N&N1Q _8S)?Q^ 81H[1,9K
M:=WO7>UAQIYK/SRHX=PSBL+8)EJ=A5'O\[B%9U#=3Y>8&UPRQU2*4!_F_[_?
M!5^]11-$GF$H(5Z-QQ"9IN*Z%:DS!3!O<C!>5V- ]@+\#JV/^91RE'QB-)NJ
M&"SF$272%\@@7FT[FG(, U#.[RKJ901L)4@&0$-@.XWJ.6J)Z('1%RSGVLO9
M9P[2U->8(!*I()M<%UYLCWY4J>2/;EC)7('MASZ@V6(=S3-/;CC/U*-5/<J-
M-W=F,=_1S8H#8.NY72.X ^^C;A_!HZZH9X<C@)BKH/E2 >GKK-+M'AA<9\J;
M^ADQZ>&)19*,_'EYH82^R_NGWF&J;BC%AS- 8%NT&I.\;Z_M,^V75O+'M%_)
M7(%M$#<Q*:QZ%]\I1\SG"0P,(IR;0GY.8'$#?Y&J2,%O^74#56[B#6?0#>1A
M]XXU*_1ZDX-QX3@#[>)KDVHH/T[8 MLW_FJW-O8>93ON=7SPEDOX.$$,+N4J
MGN>) ^&VR5(GT'#B=+ .O!FLF1&7+E7\[E(5SWM;'E:JFQVKU-!0JBKC#&U'
M>-MQUC^F;,S,J%)-0\G>#>R!=Y(MHW6E4_&07=LH-4DVE#!G?*'MZ&[KO#BP
ML0]C8 S*#VZL-#[=*FPH\?O"MN^:UNP2;0,Q'+Y:J1\8Z_GJZ#>BM9_FT/&T
M6>[C?0F^#G;=/A#:F%YO$ZTSY#//BK]$Y(OQS,V-8IYS_=TLOQ6XV8 0V)[I
MUW!.\*[$5#HZN,0%K7=>V_W%&/]/)Y1YP9D;OS*D32F_IZ7NR)OE]+5-A(>=
M^72AZ:7*$9 (KL'4U>:16[U HRFQ@0LL&6.AJ?1?Q\!YKI29/%?!1I/H"C*P
MMT;L/.D'?0CEH<C<[4#*7=,KS//D8)JJ7O4OB$2>X^,V66JE&LV/$T)K,L-!
M4J 66JB\[RP1B CWA4PC\]4PH\'GG-!0K].^WSO>:CS?63U]KM%GMDP*[!M/
M8G2OHLYSJTU*?2:Q2FR6/5/%-B-9]")5WW8%J:_/[TFA%;G=.AI[-\R!!3HT
M^IN<$9U$H]G4H@HT[+'C"UZ]O"W%ZMG6_[K*S7>757UE6QCN0XF%S:]HJS?D
M<(?8%Q#Y(;Z#\2WFZB$]E8RBW40V"(1J9YO>AXTF: S=8Q!C<0<IU5EVO430
MIEQ7U/GFO>Z)=Y]73M<YP_U>K];SK/\G9DY0MPEZ'0 NK#B_-' !*#"/<N,L
M:7MNMA:=.;AYH"8:UQD.!]VZ-AD3%;I*NY%TE7_X'U!+ P04    "  =0*]6
MG6!68:@=   VMP$ %0   &)N=&,M,C R,S S,S%?9&5F+GAM;.U=:6_C2)+]
MOL#^!Z_WL\N2;Q>F9B ?56O %V3W]"P6"X,B4Q:W*5+#PV7U8O_[YD'JS)N9
MS%3/ 'U8$C,9+UZ>D1&1?_K+YS39^P!Y$6?IM_W^E][^'DC#+(K3]V_[53D^
MN-C_RY__]5_^]&\'!S] "O*@!-'>:+YW\_WN<>]O5\/[O;NT*(,T!'LW65A-
M05KN'>Q-RG+V]?#PY\^?7Z)QG!994I7P!<67,)L>PM__2EZX-SS^TH,?X5_]
M_L%#,#\XZAT=[_U7O_?U^/SKZ?%_[_WOX.'_#@Z0 $F<_C8*"K '!4Z+;_LK
MK_@<Y<F7+'\_/.KUC@^;!_?)DU\_BWCMZ9_'S;/]P[\]W+^$$S -#N(:Q:(4
MJH96KG]Y>7F(?X6/%O'7 I>_S\*@Q"H4RK7'? )].F@>.T!?'?2/#H[[7SZ+
M:"$7?"8J%Z]9K>#TD/RXC]259PD8@O$>EO1K.9^!;_M%/)TE""'^;I*#\;?]
M45J&6.N]8_*B?[_.$%]QA)A^*>%_$:?%T_AIAMA'+ [2Z#J;SG(P 6D1?X#[
MK"CV]] ;?QG>K6E@!-*X!.$HSF:3()\&<1KB)H">/=1]T:$=?"]E%OXVR9((
MMLW;OU=Q.3>(B59Y2QQ751&GH"A>JNDTR.=/X]NTC,L8%'<IE**$%=^ ,H@3
M#13R5;?%$!0QU,YS#@JH)TPZY'SQVI?X/8W'<1BDY2 ,LPI*D;X_0_V&4);%
M4\]Y!EM,.8<ED6IG2.7ZT&U+Y%!C@RB*48$@N4O'&42./CC1%%>2EAJB*?\1
ME%QRX._:>FCYOI9H[P&<*PPS*U&G$:F7;:6:P4)(,4%R%21H'GZ9 %"NO'@(
M$C2FOF:D:$ML!M[<4@/;$P):B$15 I[&OP9Y'J!I(Q_&[Y-2'ZS.2RSB(I\'
M/X,\LH.)]@+S>!9M!PH'X"@(\"(%KE!P<[G]1'\"D_B47F@<K]FQ1;'^EFCJ
MOOL<P/'W%3;W(@C)PM(H)JVW&%S%K@Y<;1?B&W596FM?!\7D>Y+]-+EM6*G3
MEFXAP_!=$U#"98U.0Y&MN+7\<$/_'+P#+1$793O;9YE4J]*;#.W 6NRPC,GP
M&HP2T$:2I@)#\AC>:\C4VE+R'QG<H,"F%((\U1!QO;A!6<QJ4KIFA_O4CC>C
M3K$ZPFP,.YIUT;]H?/T($C3P0B&&H"CS.(3C,?I-9TB7JK8#V;7'597*.\"Q
MW"3)/+WUQ<K#VD./&S%;6Y/ +(@C^*8GN&[(!T6AM\9FU&-#.NTFRZW-AJ2+
ML0I_=UWE:'5&?FIACM-[D1VKHSE[HBT)6[06;GTMI87[Z @T)#X'<UTI&?78
MD$Y;D]S:;$BZZ [47[6[7HMW&;$G:YN##;U?NP&L%S=K6W\(RBK'AW>0@@FH
M#U?3=_S8?1R,X@3_:LJBKOH^2Q8^@V8\ Y:0Z30NI_42!IV@0GV 5'/9SZVM
MI:1W*7P-> T^M21;*^UP3Z5O"S'P4N/V=R-&=@MR:6N9796=%8Y9 XK.2S"N
M( \;:/6?J^]=./+$:7D8Q=/#^IG#($GVA;I@N!0U'D'(E^@4JPC7UD8<^#?R
MQ<G2@PB,@RHI#0I'J=N0J!DBT8ZD==6M!,5U'$S!= 1RDU*NU]M&Q F4)@^K
M$3A80#<H*+7V-N*F63DPVF^:"K%0L'7&*>[M]["JM9> SQ*D$8B:UR!IK'O$
M8??(+%P3)$$.B5F^#;=H]#8.BA$&7!4'[T$P@\"/C@Y!4A;--VAT/<+PZR_>
M%D)!X. ._EDT+TB"$4CP:]_8#[^=GYR?'IW5:I02>7N41]^\H9DZA,JXB9,*
M*NLVR%,X%Q?/(,>'Y(-14>9P^4:13J7X6_^\US\[/M[B?9"OBP[;7?.JN@EJ
M]OIQGDVEM5A+D+4!5A50U&Q&IJ[]O2R'L_*W_;X*1:U;U:\ >:" :/ !F_D[
M>*R01FIWA^*I*I%G+G)(QN X#4ZIGEH%)RZXU:-JG>Z6H.F\'_G >ZV0+03J
MS+-JJM5P^@?E7@R;SOYQI^P34^SJ9$;VCVA*@POJIS'<2$*%Q%D$O\^1]> &
MD/]S1G=SE:-1MG=QL1-#OP74]!9RXE\+R7+,2EGF\:@JT4;R-2-N'FV;![MF
MK*5+)U.'!:I;M"4)%=$;TJD7#>E[EL,1-"7G0>&JT0^.S?A3@I?=/R C"/<@
MCPLXCMY4.3+\8.TVJM!H; ;?3K1]] _9(&VHD=YHE38NYO9:V#HFL\_"#Y(I
MPLZ69<4696"V8LA-MMY?PRPMX6[ZEGCGP^T[>)^20;W^/<D*$'W;+_,*L @[
M;T]8D9<K9,%/2Z+@A[?G/(NJL'S*7T#^$8=@\!G3ML2L1PEH.Q,)QV3#(6^#
MBS7BA"CH+%QTQ0*RCM1B%3=K)C\Z%=O/$R26]@4,<^22#*%^F71PD- YN=PY
M3M[6;<+6N%FW:ELE9PF)887I=3KA/**PIV;*YLPW:\^1*?-RI[9)=  ,#KHU
MA5'6-Q(K3$XI N]LI_B1@<-@JUL#UF.69HU_ Y&S#L:2L% (RY+E<'^GF),'
MQ>"O6Q,4>^O0;!:NP!@^P^]]"K40^$[W:?(4T2G60<L@NUMKTB\IW&TF\>\@
M:@1]2N_2#U 07QH.P8*2!*838[(I4F41,HCLUIIS!S>&.11M#>BJ!K"W+)--
MF>($L--SO[:4*L%D\-JMP0,;>)BP108V9D$"TJFQMBV7D@ 9+!JP@IA8$^FL
MA0@TIZO7MMR)L3%H,V V4:!-P8-"5(2LT7?KY$R(A4&2 3M*"Y+J@UX%CNH2
M]4FPTX6H4.5R3&TA8G@V=&M+V912Y+I"?;[&Y'0+:(BE#3P,CKJUM2Q"$^H!
MN9#Q*V"5P?HX[^W4H"<&P^"I6RL+R3N9#-)H$$VA6I&,9?PAL:X0E"0PW1[C
M"RF@4R>+C$%@MV:6(2@ U L*U[T!'R#)L-.\F#YN.0+1Z19-ESPY7 SJ.G;!
MV82H,C82*$Y7[[H4L;$P:.G8H65]1R$XL*$\3>#LUK$-#P:#E6X-&$/8F=-*
M:AVQ^2@&<K9;QS1,# PRNK5#U-)]ASAQSEHHX*]Q.;FNBA(VGARVH:1"3K$H
M"P#\)^+;^#5J(^HX=TDIDR$NH5H@&9QW:\1H\$IT/"*XTP%0CYVEY R5-Y@.
MU\.4G 0N40)1=RI8J7^J9#9@!"LUJ59O/T$>QK#C$-_#UPD@[H<4L:3*O5WT
M3_J73D<8CMK66[$:(!^BDEKX7_9/[)"BX7])H4(@MT'_RV[M!-=)4!2+Q,9U
M7F.&0Z:P#&R*QR<7=NPY+3TS"4M42L5P?(C\H4K)= Z4*$706;*3"MTVY96O
M0-H&,!_"<6S1YMJSTSY_(D?/;HT'BQ&E%APOT@3C)+,,&9#L'/;9&R?%<'R(
M %D53K:?K3Q,L%C:XDB/BF)5<WL5#8^U8(_.N?%EZ#-.DFC$Z]8NL(!']J#(
MOSA+<0(MR5&/5HZLKNT<H7<P\G$A60L:43E"7Q=0V,FHSQ-$EH[XU,= KM+I
MA/%A>1$X8I(I[T9$PY0)8WZZ-7(,PK":5CCO(2N^]F'-!$2A4[H.K *W-E=^
M;Z+3J8[/B^"4(4H^ERZ3BPAYI!<@H)QZ\^F0)@#C1?C),F?@<Q!'=^EU,(O+
M(!%W.%XY M&I4XM6)Y/"Y$4@"4K FJ5XS2ND:NM9HH:=ZTYL'"9"0ACG)G=%
M4:$[DE"JS?K$ "=G'5?HI(JDPH-2-:<*)$9P&8]TG174L!YC=4,=7)R<.'6B
M53M_,0K:GYB1/WIFE[Y;'T7E@Z4NU>)%S,L@^I^J#I5[S1@S&7:#'FU>WC@$
M<# NXA+4"0((RB$(LW?"\U^#I.(=/MI^-5&TAQDP.>VO,YUX$;FCDB=Q.R4@
MAK(;4Y@8A!=!.MII-/IN TZ5>: #\"+\AI8 GV/EW7R8-"@/4R]PO3F8*$Q$
MVYA9HAM:C9/&MAO\M,(GB+_ITL6ON8)S<1O&;5KBBUS@E(J<1;.DONV@;9-:
MN<Y[\PWW'$<^Z;)(N4<G^K:X H1?WK,/J/N8#$7PC^4(!#^\X7?/T=B8SS*2
MN!TWEVMT94@.=]X1;44G61**?WETZBYUL9**U[N"*D(#7H#J;8SE[2=5C@"W
M,S!1G?_:4J*&RB_70$$"NA54>#I\ .4$)1]MLIIL?PO 8S#EI7!L4R51HIT5
MGM1QL2+5:\W$&'AK[H>"QL 2CIN2D%^(8')UM&R,D6VB)6%;<TET1J7KLV?7
MG!IU4V1=W$+6F/?Q%/XO8IZ?,)\EHCJ)>5#H&Y1)E@O&@+<A7]^#"L48)7&
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MPE[@U(M$D@PVS>P%3MEI);LUEQE:59XZ2SS9C@*UQ>0I.UMEMU8S<ZSM[%Y
MCSZC-U[96M&HKV/01']ZZ>$)G?KJ90'%!W/8QEXD?I^43^-?"C" &Y5R-<I"
M]<Q.7!71@U/_K):4*F#TP2JV+OQS,,?#C32C30&"R:GK2$O>MI#X8/UBC!;7
MNCN_Z]4=DH=F$O6!<Q.1#\8N[H"@.UB2=NFAHX/NR+@ Y)%%ZZ7,PM^0\QC(
M"W*MT#)&HKFU_BG'0';/>(6N-#KJF;@B[5> - "BP0?D]QW<?L(-9@R'T#P.
M<3 )^%XA#AJ-W15%M61D,QV85F4$C'=KOX6*U_N#"9SV;HF_3H*B6+3OIGDW
M\C%Y$Q1[.^J?G)^<7?8NG&19UR1)!90!:Y56_UJ7<3$>D09S4^5PO'V=@&>0
MQYEFIU-Y U;GI9M[)ZWT1#WP/EBU7@(T3^$Y[+%"&H,?4/J*6O:[]!4B*H*P
M7#$!TJ8.A6JP OJ[TL7;(31@ C/9WY^JLBB#%-U;:+27K]2+,YZXC>;HHFO3
M$/M@*-,].\(MUM+:2/7P2-03&9(;/#[JUG;V4HV*.(J#?+XRR B.BIAE:NWY
MYR.VY(G.JAB0#[:OU6D@F,(_5X9]H2^GN' -UK6[F 09XEE2A- '8UE'=/IR
M=M0!KT9]R!AKGZV-+__>!,;CM<1.[[)0Z2^4I8L0F1=!IXN)H%Y+2<UOK#+U
M/&+GV,#F_"8&Y,<%0"OBB3.';CU<H[&TN9.?P,3:IM/$0^3%;3^&^/%F1C)/
ME/!&K6XM+%3SH"AM-JM,;3SR(1&4TN@G <B+ZWZH<LIV,UJI&I_KQ$X2^E<@
M;A.:X Z?':?.EZ'2)H?",5/)(L*Z!PCD*(W^STQNV<YXO!;9J851JE=0UNM"
M2 SM*]DX3!J,;S]#_!CO;J;6%=?P[;@R>V0SIF-F4*YD!Y$ZI54B51Z";RY!
M\D>U E0,8KKU"Z*.-/QC'-FBR!'GV#N/+H'Q7QH4XZ3=A"L+_<!_];"7?Y N
M6[YNBKZ%6JG[0O"@,7@RX:32#-(!&:1!/4C/T""=C4,D:C;^68\%69YC68'(
MAZ5=K8TW2-^QW5%ONC. F<%WLZ/UQ7./?!Y 3)$#KSWD6' 50-6A9)!P?T#2
M:"#UO@.2K'7Y2.V$C$6]E_'R:UTY/O"^[-;LM61&*'_! B"?D;WE.XB"'*1L
M-\@MPXIM7$4[>W,IP3(79G=?>X[ MC/T:^9Q-T8DM<'0T?L0M*N/>XDIC5#2
M471R)SXLMO ZHD]+EA#Y>%(JQ8SQPZ86O/"G_,.T*E_,GIXT+[^N9+V=SI)L
M#@!>PC[)Q38SRQ"$;KVQ;8X+]+8B5H<7_IRZ*SJ":-5/E;@MV]@9L-Y%-.G6
MKFM]16Q-:09<4UD',2UE_H'V^>L&G0V#^"(9U76&KEH-RRI(&-FZ'$OTUC\Y
MZAU;NEK)=2/U1K=>N.YJSS&KBBCN4JH.UHZ K*S8E*7 2>0<VQF=#[\6U.F%
MXW);W+>?LYC<@>V\12N*0BS5CN/'O&_7VDKU(1N"P475'9R18KC5#/\:)%6K
M9JS[SN7QA]O0<^=-UH@"_?!H-[&D6O1+T<V_%MY&J/QG>]15FQ>N^FT!4J8(
MBZV0\K9ZTG&; LKW9LC5FQ<A"5C\D1CAB(EPX7TEN;'LB]IIM]+@G8&ES+M>
M-6-':O4BCL/@\L;61LN,!&2?Z]8OT/=!65657@2WM)^)6%VXJQ8L*0%1^S]7
MMR95Z46,CT'0UD_#MMY%5.G6FW>'6N6&TDS$)3E?Z;*G#=8BZ,CB2E=#&K(D
M^P=8&SA2JR#^R[%W].+6'BH%=:KJSKVE%XX<(/^(T?U!U/:1)/6=@D_C(0BS
M]S3^';*'M]/765$6]Q*NTX;?A-OA6<>6]:6'NQ$P\C[5!M]'%&?G8)/K7VVK
M 8B<K6WH;F<=KVW<6PQ58L?_3=,IVPKAU$8FHQ<?W+5MW9\+$5IR4#-T_3&A
M0(F\#7 ^^$7;I,\73V6[//KE@#P$!8 JF@S2Z 9\@"2;(<'K):#0%5FB-$'M
MU(8CU[OHC*H@],'/^ =(X18E@>(.HBE4=5&B,Z</(,NH5'F"V.EQ7QM.U3#Z
MD%FV7B& B+MCXP6O256 ,9\[M6QUNS)75 O?^]7MIGX013$1;.7.W9V[I^3\
M[.+XR'S*%,NY'?INQT*.'M>;O28R'S:+5*DWTO5LIH/A>1=HU?=V?M[K7?B6
M:87.M1F@/NP8;:;.Z1]='/?.?<M8I<$H%90/&T87%Y.@UGONV_U0?%*U\/FP
M@91:L#UFZ0<HT $*3L3RFI5!LOH[6K0]9N5_@G*YG&MKO]=YY]M%_Z37\^W2
M$W[+L:\, _M:QBH--^ZG,91DFJ4D97#:Y$#'<Q-<BF! K&6:= 4D4=6I;\F:
M..LT#6CV(DUY%V,UPOP"%2JWG&:7K['X=J.8]'):!IF!&$H62T$Q24"QN+/N
M:?Q<Y>$$#@:->$Q^A"71JN*H;^M&$RO,*&#R(120NJY;+ 9 "/=F90R*ZR!)
M0'0UWVQQJLM@^9JQFGJ.X_^-K))U,/L01]=(!V> K6O+'H(289G?0 5QVH!L
M%76?V*U-KCHX$^%GC%%XV<A0DNA&-/Y%N+PRM="^I0_EC+QR:/R(O=*\9P^C
MM[-,4;UF3["QI,MMTFO$ W.0_CT<>)BW8RMH<P_'@B?YR6T=CQ>Q-A;N<L#X
M+)G;35S#T>A?@;A-:%X$F5BCSA<O#YL<"J_A,&$\(;/K43.]RES"L?$P.>)Q
M>^ KU2,H:PP!((O7GQBZM1 ;<=V:&L67%F(AZ;G$1;@L7H%B\-[(RQ.G^6=T
M6[\0DL7;2#:M* +E4Y^NP>VF[@6(O+AO9+&<)-XAR-:?I2C=D.Q]G;1R]=[-
MA[37*JME24PF;AII?YRV+J)PP45]OL;D.J&TI-X9QUI\8":N&_&++%_6Q?98
M$ZV*CSHV)"Q/UH1NL5O/UIB<'E0)N@AC]\)&PF"E8W\1UM7FO$F+>1TZ6HR>
MV5EE6)ROA' 83'6<AD*X?9#TYQ'L/=S.84(N&!S*XV.0V7%&AD[(]&:.L\VJ
M<*KK-G[@[OE).,4MGB$0W!X ZEHFV& 8/!A(75WDY0H'\--2__##VQ"E&V!,
M8&N_XXGX\GA7SB(8LC/T;,"50D;/S%:^\40MKZMS!(;N& K>%)FA8@,&!ALJ
M=CWFM]&U:!@_-F <$.C\(?B,I]64J_6U9VK9G9C6F$UV6]L,F1EZ-K"O%^D9
M:DFHY]5GB,QN;G55T3-=9H:>N]V!-_?\"+9WJX\1!);BK>QMZ>@0&"1TN^&6
MOJ-LXU8FC,+Y_HRN6#X)FP 8-'2[FVY)@^M9UAP?PCG7V<98%)$@*D+V(F[O
MNV@1ET3'PB"IV_WMBE&31$T-JG*2Y8(P(DZI>D;=C3@$)3P,OHR$']!#(6X_
MP_H"<1)>_#H!*K'7XGJ6]TKL1N16>Y ,$IM549>9"(8@00D4GH.\G*]8:0H_
M\A$PI+N7R$X@*HJR0IQ==KM(N ?O0?(= )[<BV?>D"?4A=OY1EJ)]!&-@L6'
M9 2#,,PJV&F?@SE:^P_2Z*F<@!Q^G5<@NH^#49R0Z)(JSXD[-8LMU:J((BZ<
M#G0M2=6'[$,V@F5N/];(=S5?^T4ZL:9"?43#=O9>W/"#EM2W VLP9J';+;8<
M6($51+X2HC [!SB:>3"UZ*8V(0TU^) F854XX19_^V&"Q5+PK;2Q14/W8A(W
M /J01,\,6;Z89.RS)C+9F/"Z_PXEA_NBP2B#^Z+??[M'NZ7L9P)R@?^QJ%R]
MNG":&(+3'2@[1WE$ROGJ#M';4#[\/_\_4$L#!!0    ( !U KU;$ \6M=$8
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M9Z0$5#6S%)I82#=>1##7H?.U/YDD#M46*D=R)/#U>L;"8D!: $LU&6J]I8X
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M+V1QPXDC( O56!A,D[WT^:K,,D-B9916G?=IZ/L*RSP :_TRD->1H.\,*<<
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MVP4%IT/<L&:H;A?";D WPCWW?_'AM<K#<1KFF+=S38NQP.+E\8Z%SJK;D?E
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MX"HIZOJ*1 .W"7T80#-<7O;B\RJ@<@<_K_;!G.=PMO!&SG6M&;J#'LL.($^
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M^Z%V["KITH3_W@!FH^^U@]:MVMM\I U[<TE3[E^MX37XEA-;=?FIKT%9Y=1
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M-#242*<[Y=JR2#XP+#,=,QF&P03>NXSX(0BWLL'\7A3R,0^B97+5,B&ITZ!
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M5/?ZF ]\<MKQ^[WJ=%?1S:?I$/3ZO-_/05#JJT()-%'Z'2,E!'DV?\2?%=R
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M)X= 2GU)1>*JZ'+S1F&5QV6,BO,@25!T-M_65M-U3G_D^K8.NA*ADR7/!K5
MKHQ]=+:KG^"N> 6%W' OIL_L.]&%L:Q/[<2'CE759;,!'@$#?8F@6L :I='.
M2]]?@Y+(\?P"4TVR N@.4=/,-^O&')Y )& CK,Z#8I*@8E&,")MDVQ%'(KU6
M]ZRA0]>!,M)N$U0"AOI2A&GM2I6=TT=5.<ERA8DIZ55[TZ$+5QAOVCJ(!+QN
M7I0(T-!;6[%,+;FUKH1&^X/C=V&J<6$)\DPZBOT2K=N\Z==6R'KM1>'JK=F?
MA2WVY@9(;PTWQB9@<4=>2 &+Z81OQVO+$[8U:E J9Z/9 "S.\; OD7Q:3+8
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MP^(XV6-Z ^HR+V-8N7+^\RO&_3>C;L:H@>^>XD^O&'$$]\V<)_[XBC$!9C\
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M<BM4K=G&1_H4J#8>5)6JYFAH,MC:?' :+2G(FU6R#DZ:FV89*/930-I8(&V
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M';=RE@S;212YTD2.LOVP=E1D@QF5([VJV11V%L'>=^7UZ-L]>XQW= E;M81
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MZ0:('8X5:ML!H"*36&,J<8:FS[.0K@2FG9%IXRL 4L ,H'C@ S4"M$*H\9]
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MXSJJ,[OKW,<ETU8MA5?7:FXL-<VZ6M^[0I"Z4*@FRO:EJ>V2T,P_??>< +6
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MJ(2[AG,O',0\93A+O"))[I,@RT3DC/)>&'A.W.\+ J@@*)_ &^ C,HT/\=B
M:KYS$!S. 49Y3';RQ5_M$Y/$)/_^Z\/UEZ?(1SYKG';/&N?'D_T.+!"4*O1$
M&QBE 12;2K)')0@^CE:S\WHWE$DX(^5[]0C\HVE7@PW&"1(N</S&WNH$PZ&
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MPP"7GD>#7+MC//+ $OR"!R)\#'K#_QBXO0!UFTBOT*Z.LMGPP;O+'\X]AH_
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M6!,(-U!?F3W^'1HWBHX1<$*HJ4G;A6XX2_$ >.;?.1AS'&AR?G?'>)W6<*Z
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M.;U.=>=.)TC%Y9%@6@YB[KR-(^!>,HOTY/N%TKII#E.T7FDF! OH!^3WZ?#
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MN[=19+%K98_:!9CD0L6(!!Q['R??F1%5XI.$6)F$HRPM\P%T4OE+?>J]H/#
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M<*F*0K.F<P/$^1R#8%PH!L'_HF&O[)+3]T'D1AZ6#=Z8XM,B&E"0(G\FF4A
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MP_][-Y1X./"X5<OY6-I2P<%@/!=VT"O*1;<(5F20A/$$C@#>NST&VV-P1\<
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M2Z^W+, 'J$J'X566NR/W(''&.;THRD8'4U/S0E33"?7>C%5JS'LQ[9OI-62
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M-4V.>)-#'H-@M RY3XV-= )OE%/%<03<:3^;D@5Z2C3J,;M2:2O>;+Z2FD%
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M?R\$1EW7BT>+UI'YU69@+8*O_O3\2-K5C')()L(="IMQ%CP^KU8$24;==AW
M;WW;'^UZ>H+1@:B.IQVAT1Z2_!M02P,$%     @ '4"O5J8MIZ;?!P  1"D
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M#\C'!F+:QF^.RZ=U@S^FXG&*^\$&LP.OMKV?EW55,W=Y--J_ /\!4$L#!!0
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MNO)R<G/Q 879_R%0_&OW+R'V_Y_R\\$-XF8/_D=;PM[M/W;^ H:@O9FC]7.
MK)9@*S-W>S<J416(A:L3U,G*C4+/R=62@I5"VM7L^<#)H4'! >3BYN)^+ZE-
M\0RPOU%#H:+U%Y6'BUM%TLS" NSLQO:<M]?_&]B_O++_MUC8_Y];]&_2\]7\
M:_N?F?!\^,]4 3L^CQ+7YYGQ= :05[=Q<G."VC@Y4W"S<0#X)154D/^:4P
M-BD""(!$0BM'^CS+$)^_OWFT?_->_]IZ%S'4,NS%#C0'OM#W/'DZ!V#]#1*
MY9=G/L+3*B 8@/!_7XC_M9#^L_[-^YN-\-\Y_\?U] 7PYB5 %Q$'">$- /$-
M M(;A*<^P.US@*C/Q@'_M1 0D9!?H*"^1$-' "#^R^]_>$@(B,@HJ"]>HKT&
M(" A(B,AHR!AHKS&POB7UAL4  [J"TK.EQ)4N'@:9ESX:"Z!U GYDN9:231S
MM#H$A&^G-;FEB+[7?W5-+)@!:KOQA-#Q+@@$6?3.2EO*ZJ;PZ3'PZV\5PF3
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M-LTGX@+<,_834^^ A6\E?W.OQ%&-/\G544LMLSX:[U]@C,)?(E3JM-8WA+)
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MC%FX=1LO=CY**1>J_3,R\F$D0$P/L.&@;<HF_\Y'\O-7W?<\V1&,\&LTK2>
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MBL"V)A7J=B)01;FV  &E1/CG]C*7LB<A>;;)_N)WF^/;(F-CDS;&()=+\,+
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MC V_(ARB#?5K[A:4<56H4H(G&M)*B+%-S<&ID=;"CEH2!;P!-I-\J;<>_+K
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MUQPN2E8,\*PU-"I*">V*HJUZXCE6=G1QV-IJB8.THNB<]63//M5^V_+6M,U
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MV/>/%D%75M._ >8.N7A/2"WAY:8F[!V%T=8 =UL\E?U!M\0?"Y>_EGZ1^&\
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MQ#II;P]I_.)$,[;<^96%T;MJ87EQZM=K6[--5<Z [ #T2+8?MJA;OMR:8XF
MSV)J_Z- <6<3I0OR^F7'+<[S2\GH08ONSX1.0WGFY4\3X(<5^N7;B+WP^DF7
M6#Y$@M844PMAK=3ENJ["%%5G@O5D*AK(Z*8YHF%[V3X(":K?3X#,++2&3C)#
M0NM/V:0G+S,=FL?$&?PC;.GV#? -'G?,]].G>RY:S/^_\XNEHZ<W0'L NK'V
M',ZBL^*DS4!@8=DB-B++9\0G(7AYZ]JR,$Q4^?BGGMXS,VE2G&(_@:D -!+<
M4$3: %0SZ?\Y0%?815ND".:4D43*[D'-_Y3.6L JK:=&@MOVS?U)LM/!ZFBK
M>2H/8KA@Z&<\/*^\X6V4NM_-\^58KMIJP:7^I_1\^67NYR]EAN63@@D!Z"G=
M/OQ+W,2K;MU3MNQ"35VK<SQ+L*VO6L#)*P+O7#]TY[$G;6D+ODV^\Q7X=YQ?
M![7L*S0#!0P_:-8P48[J#?FIC4H35VRO_;8B[_B\6L'2O):.,0;5E(3VE0OB
M=LLNO)/CA>4L+#,1EC"K&=*L91F&OW -1FZX*M-0E$/.<;A/=P,P6#QS"7?'
M,A>63#=090-0K_*DGL+@<2E&Q[EH'=MU_DC 8)_N3./2X-^A:,J'M\]P' =A
M5J@ #%TCE"_6+E(I3*U/REGV*P#93JXP_9ZE@?W^,-H*H?"7>*6%XC3^EPXN
MXZ<3PMJ: ,\8$9F;HZK<?!Z!&F]WQ312NTB"8M?$I*_)ELL67 ,N[;8N3K9P
MB)%7S-1)?-WDSGF5Q!NV=RI)XAS<QDFFME'.8G9GF;)W=RT;&"+D8;)I\ S!
MGQ=-?U *%-\16MOPYW!WV D4D&WOQ>C"LI:0GZKDPU4'Q :6./M"'JDLN&UX
M3YBIUI466ADS+:NM"JQAJ:=XDX#38*J^MM8THQ%7W1[HVF=Q>Z-,.KN5W"CI
M.4.V,KDSM[0;V)4) \]04\&JS?S3*7]$:V#S T[/20[+(C^UTO%._@_T*\&K
M-;F$MA]+%'^:C9@58^'9_'V=X(Y-0^\UMK3ZJ#\[<ZW#9.\83(P68#GS+5'\
M#7+I*_<<>O!RA9G[/X^[DS2-B. /=I=]7)@NK5JK+S,#JTL4]Z4]=\^S$AS+
M!EGN2*&9XBHQ\63?"<B(QUI[C")J]!T*?;16<*'S=@^<[M6FH7PM05?!XFO4
MZ!ZGO#O[VO)+HPOOK]M7EWIZJW5@9ZHR;*$(1_U ;@N-+^UR)8*:66'O7Q/;
ME,45M+7R1\ \B49M(_J5U_0#F83?(\PNC;7+0NQF&M])U[C#<RY9-N>,M=LX
MLG^-@V"LXV,H= 6,]C-Q2:>")JGH%P+02Q.HBX-<+'N=UO%\< #PI*E:%:0Z
M*1\%J%F^,7IFH^J+T8W*TOPF*F(\#9QGFB:&G9;"0EAA)B_<H T5)$%4]T86
MJFA4S?<)'<RF9:W>=SO-U;8IDMU,+#;$LL9&S<!&&,77P< 2P6(<&TY0Y\F_
M!=#M$C-+&_X&R&D#F[6F_>@!1F<=.Q$PDKXN6S"&XUOX\D1V.07*F7U(SE98
M"TF*G)&6UX6/$%'(^;0CF+I Z6Y^YH<&$/3?;VN@A \-^/C$K0BA&*G4LZHG
M \;A#+3UJTC0XVS^Q?A F,><(/Z)T=S?B*745)[0[&5AV&GB#L_*D#/"#&EQ
ME?_IPM35U:A(V+'S+$CK_H,'9X>Z5I2%(G];IH7!1GQYSX<03K1W8AS?(O%U
M-(?75AJI$SV*BL_$IG;<.BNE'%YL*8D6ZO='6*B(__20'GGO@$LZQ'!470<_
MF,$F$+SJ$N7(;CG-U39<]#8F%CG^>24UD^V;M><%J0N).J:/8F=GOT^;(W+>
M84MW;<UR=]6)PXI'OPJO<H>+.EA=EEFM"-S!2?/EB%F3.6SUC^\X_=,K*O;[
MBP.D1_<P];]DUX\ZJ:K?HHE&93M>NWO/Y]\ NMTD?C VT!M@%CQ>-O57>CX]
MS>$ J>+OA<T;8-#D#<":RC?-!7I^=_P0Y?>[='K=Q0!D6MA,Z6U7<,_:*_&(
M%BSB+LCV!L ]_ <W]6.M/I]^_P9PWOR[]?O^L+]EDW@65)ZCKN14&K8Q[O-[
MCYG]_4X/NM^0H?O%2MYX^?UO$HEVAUY'Q^<;>; PUQM@TJ&4JG96=8SW<3JD
MAOE_H'[_02LI':.I-UH_M0;='S:V;!)<3BVJ%;$^T[F([\.KV^3/IN=O]J#!
MW@ >3><[M1(INO_#_ ;XCQKJME)XA-DM9RN9B5ET0^PLB#W-++VX<[)YAA+3
M\3=;_5GL_*I"??FA>Z+(Y/L6SN\2K.8_O1&O17R,*-Q/&&TWS,MJ(>6/=;N=
M783T6-L+?6^ KUU_=70Z?A-7O<:X^)UOOS[9G[;*COXZ8M8H=EN0.=/D.WT#
MQ*<KMWX+[,H:+//#\GRIG.?K>;_P_.[\[NX-T*NDMNYBD@PJKY:?"'A%V<B[
M(2:R.G>2!*_<S/O].I=(D>\5['V=<'WV]ON=[[9>>'EZ2U0^5D9?<,_@]-C$
M2?&ZN5U@77IAT^?7N.7'&E #\7M./?[?Q');ZS<@TW--LJ@55;QV\3S3$)*A
MU_7M,LY+F]__E2?QU#%J2>)OYE'OP3_5$&_PG*.C)EEBWFM<._7L;!FJVZF3
M^E_Z!;_0?PEJVQF;_H5UO'91]ZI2MOSI;2RO5I)XH79N]YM541:P"PQZ R0<
MCKX!.+Q?*IV6'P:E5,G.\@[^9?X]8-TTVEKBG+@B[/TC5ONG/XR0?(??2#9_
M_Q\1U><]W,Y_6EW> !+_JE.[5"NG373T'C2?=TWNW#MK;.MPYJ3'\@9XHA1Y
ML.O=USR?YOK/47YX_\"?JARB*MX X=6*,ZTR#NI/&,'JG3Y$])30A;"_AO_,
M3?6RBW+/L7+ZGXJTI]8_V;P^:H5\9)T;BK/K\0#Q6#(:EEU,H_;^S_SD_679
MGARW<+?5P%^!=,MMOT!)<AT_/ZVL_WUUC5,6MBA5YCBZR&G92&T.+7$3$4KS
MJ3^:T&Z;'0@+IJ-[+0.'V&C"#%EWXV9%>1<$3>QAWE1%8*</Z):QAV5O@)\8
MQ&,/2;Y#Y.$FYQ.DX!=!6"*QWV+"P4G-&R"+2CB'$01M4;8^"RT%TH?Q5N I
M &\L;L'QS7AO "V:]87!EG9/_IOW4W=]$=CF&,<Q;*UIUNC,*3&/X^_?MTW?
M^'E9N$>]YW@7 82ME!#_[_#6U[_   /1]+D&OV"+;Q0^P%[P&X"H!I'^:JY7
M<.1Y\?>P$RT.!_EUM&.WZHL>/.[_.0SD+H)1)].[_:,1F'L]#D"[LQC%FBQ^
M@%6SXY-E?(Q^F;* E[S5@R?4'HG1^:L9\U-B6'5GXB]; .I+D^,T=\^MP*4Q
MZD<+N8*7(O*$OZR.T#;<C*OZ7B'9Y\DWP# 7+0X;^77RIZZ9%]"_Q_Y?Q 7I
MAJ[.$9S-@R/C)T_R9[^]O.O5O^@+(85PY**/=JU2:(*V9W;ZO&B7VW!+F$39
M*U[$@6>QC.W-HD*90\AMN&&I%@V[^#EYLB)I7U^(X?&[FOS^7_$JZ?65?D!9
MF%]$SD,I(@W=2/E+"7'Z7R9W:#IN'E[1Y;_$TC9*G^3_O3A"O_]/W;O7% E7
M^0>V]\QB>1W/5*-5:[=FTF^__A=02P,$%     @ '4"O5C6R5IKJ*0$ 8BT!
M !$   !G,C$T-#8V9S(Q;C(Q+FIP9XRW951<W;8M6D#P0' (KL'=/;A;X1XH
M"G=W$@@>W(,%*=S=":Z!X%*X!=?@]DB^O??9Y[;;;GMS_5ES>.]SC%FKGN>?
MUP$$4IY6Y@" G!P#  GP/^OY$( IZ0:R\0+  %Z][,U>1.NO>"U=71T%6%GM
M75A,S!Q,P2P@!SM63Q-'5G86-E: D*BGHPG(!NQ*;@JVL+(7ICQI[:0DMS(3
MIM3F5F)3<I0 6UK)>CN#U;V5-4#>-B!^,TI1$7(A3P%/.T<[L*L)N:>=K;V+
M@*<PY=_@ B_O?\2LE.1_35QMA"G%_BC(=914R24<G,'D/"QLS" V-@YR7GX6
M=AXN+CX^)G(.-@XV5C9>5G8V9@X. 38> 6Y.\G\MRI=LSF;F D!)Z7_E>MD)
M4_X+E(>'!XL')XN#LP4K.S\_/RL;!RL'!_.+!;.+E[VKB2>SO0O5OR-(@EU
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MBK13>;&PIBK@XPK-%_!,^NMKI_P'#AD5MIA2ET*P"1E,FWQFL/G6M40P=<U
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MY";P_=D[DS.[Q(@\T%I(L\7CXT7))_ <8*:?1+Y2"F.B8=*V5GR_\1&4F\!
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M6:0TPN10M?LXA>GD-?+C!:(S7:549"Z7]V8\D^W2=,#%^9#O\PV:M6FP/PQ
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MQ$I'GG'([-3+@1V>5ZHG9+SK?(Z&(1*E$+BHC)1W=J=M$1<A?*QQ\<5\@5^
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M;0XI'4?CU6<5)A:3!88RUA\I[C+EMB3;I32$24-J[9@"%%+R RMU/F+)W[Y
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M_45ZS*++>>GN2,ESDG'<=<QB;AM'36C&2G&)4!E>&\C8TF+#\F,F#:OAJV<
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M8C1HS,6,VE(3Y:6T-)2V@(]T@=.WIX:N#0BU!CU(PA#;-76LLF0IXHA0(;3
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M\=WB1#*<?5U%Q!5OU_OF/L=_I!>Z_CU/?K""!=<(\*J[(KM_B1C**( @6M8
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MLROL#\6K*E4SSH >+,V^NJ<_.M(/YM=>YX_ECP?F6UP'^=;PIIW/_P"[]O\
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MR-1M[8,WS$/K]6G@URD_QM+Z0T_38&?*Q_H$O]P3R\OAJX?GM19W$<(#$;"
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MN?!^WI,+:Q'E ;<+:6!-F%N,7M,*0B4WLA$4U;!"%'35?3,=ZMUGO2A@'-J
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MTT*%MRD RC2]=291=4[BSYK$$U W^%7AWS+I3C\H"_[.E.'I1\99.2]5W1,
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MHGOQ%N]EF=HS,$[!.J1.H2@JR*GG,8Z/BY.+DT9,'1HDA:T69RJ&0#*KRO=
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MNGL75FI$+E(&6X\K"Z31+XU+FV9SVH]W#MZ67@-T3]\R:,;B_*1/8I7Z@E$
MC4O/SDA$D+82Y0*B;W)2;[8$!/K0J._T'BOR[(PU_1*K_N'VV'-X^:;:H:E
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MD'94A5D?^@#=RVM4'?.B 1I< ^X[G$'/9U/+;P#2%E2KFL5=V*I+CT-;D=>
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M3Q_>>Z,#_F_%_B65[[]TX?N_@O[?H/M,^FO[GQ2^/_RG"-BYWV<^]#[%[U"
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M8+?=,L:VZ("]AQY^G;9B! %N'W>9G$Z[>N8+,B:&A-=90I\*UD6J<=& ;/]
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MUU<P ]\RV@SH-&8)!#S#GW.I#7@G3M@8NO%H>XN#8W\Y3MI.[5;&[9%M*VF
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M4S$07)PR1&[@-*#),#NL5!LO-_$ +& 2HY/U!D&*+;JR;72HI"1"\5K5),#
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M"4HM:H3^H2Y>V% _C?ARO?Q!]'": 1:#2U4-8)T01<5J3A))7:#/\2,!),C
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M;AK]O@.\+4$WG_G!#]7::FR81QDPNX[O !J N&E$=S(>D&#8.IJ&D5L@%'=
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M6::C*B;"BA/'Z9.-+H!2#.Q#6V@5M<&O]1556FF0A)4Z(5-?JT^*$@9P'O
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M"M<2/_BC3J(2GP-/D&7 HQXL^.A( %!0=2PJ3\?'K@3$>ED-0RL0?[9?['3
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MK@\#X5.HTMXSGU+ '\WAB/BV_P!GVCPTL&\0Y!'ICU1*"%&H=0,_CXX53Q7
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MK!5X4*U14R5$-/TC6I^9RQ(^)3:2;H4NHJ"R *<SH4&N?S! ZX@ *>))&%%
MID"RJN7Q\H%< 1!&0D*D=*D5%*'YCX5P!7^',HHR1_=_(/S$8 7-;LC$*8U\
M.B_'YUP!7&&4-5U \:(G]@X &D #.VH:2*#R)F?_ &.=3@!81F<W_)%'3\F8
MRP (WHZF#+G4UJB@UKXT& !Y5C#JXB!  !.>8\#3P-, 0.2S$M!&5"G0?2C)
MIU7,FIR^. %$^DL 66K >7TX_ED?+4?D. %SQ1JYK'",LCXT^VN!#PY/%2!1
M&"TH-&\IR&=!\!6N \*?[3%C)$T;J@*E2RM^KC%2.N84'PP(\,!3-%024/\
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M0_Q?++  $JD-4^/\?Q_*, 1X 'N %4>(.=/AE7PP K9%))U1BIZ%*D?:?$X
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MD34"" IH6:@\>A. &UO+1XF(&3T<CRDK3($@ G/ #VV<:6%&H230LQ\<NIP
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M2JAHLP*XW%_+VD]5!^A&IW/_ #/1W,N#JSEQ)6@5I92K.0:&@-!D,@*4QO\
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MWGMTX>(GV';74R5.U[8S:F&FIM(B<B*]<<H?.:__ &":?[4O:SJ3Y'_ (/\
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M/MJR,R']KW$E58KYC%*": @9XV^_+]AK+:Z*(U0Y]3\'2W*.DI5.7TE_=ZM
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MO>6>YIK;+S7%VZ'CJ^IG<36ON[YN(IGMR]GMKD1-34:,H:N9!T@8Z7\B)_\
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MM9S2N"4$A6H"^GI7KD,F _OO'&Y>KMU:<98TJ:NWDK\%.[C(%GG]340H19
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M[V_=@DC*.]/)(X[@>I'#(T )*'512:EUK]ZE0F//U'+W:K>JC.%F*:]#X_\
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M+NW[9-XY-O7NML(NS\.X0[5L.W;MQS>=ZX78<)WG:9K/<(HA;66W&EO%!+;
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M>5\LL0(E<^Y;O;QP"/=][MXH;2.VC'[5N1<6D=Q,(OP]M' R+!%*LJJS*U6
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M5*Y]26GG0-_C\Y5)2U?4^[AB3G0U;_\FZT7/[,0/*:%V5[LQ8@2(B ;<!Y2
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M%3-7SRZ:P:=*J=[@$F3)L19Y=C]_L&@JRR;LD'S7P>5QRII=PO6+QCQFIR;
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MRWO2S.#<6Q _1SS?Y]8;HRN^^:Z=>Z6ANEJ @^R 34_J]$N] 7.9S'M3)U#
MI=L6/X1[E5A.;0>/BF9*N\Z14 */U"\XIYC404: ^&?IYE?'E>H35$N3NL4&
MEPV[R1AP&ZP1//A/:QOYVY V*.E,DP@E-+/A9*[=^PPD:MPROB8 3?#@V6.2
M&/ :?T,QG/\<Q3^<"Y%>IK=M-V>2C8M!\Z5=;U0?&M$-LU5TW>EC#7T8A?U%
MV6XSI*RVN\S]JH,^6L8\&&TW#D2 C U"0-8A4C'LR*@/U6?JY$E"B+L */^0
MPBP5(&$@H,+ONG?FNTVT!@EH"?',8$@7>ZKI<O%'>6$(S<NY./?-[PNV:IR(
M[O,?H3YJE7M?ULU$_@L#%<5"C'J)&)-TTWN)-ZH5$BX:U;YXU_+#A@^#J$OT
MX:J7?U!K>#NLC_63V-O46T+4,31_ZD8#Y^65-T*56M%L<='%JK2J[:6OX(.5
MN&^9I-$CX/9UN%>7GFV9()M'3X_%B>DU<J'\X28<]NL(&(@/"CXAF5U@RNPQ
M-!.7IZBQ?UQI.LO5)?R@\Y=F"PZX())M.]9@J0G<_)0D56F4@@/$]"\8B]@7
MC@4DJYG5^*2>_.H3S'(UQGJ3S>[KS54/R_O)_)>^_I'PY]-ANQ9Y+6:Y1"+J
MK\#!B!>A14NL,7H?NH[85GNI17@5?F.R::DYQR,??3)3;10(OYY%*QM?^:X+
M$R)HC^G-B'U:@4>I$:.XJ ,BLP+=V<5<T?0OJ-Q+>$3'A+CC5=/L2LY03N F
M@3P MSRH%I@;BTD1WP]9WM0@EDVBZ:\Z@I#)OYJ#M 0@B$^_*=LA!V4?Y'J0
MNQXO-^MGE5@<H=&XSMJ"^ 6Q[P:/^V'N=A$1N/*4';A^(V1I4"KFG40PI:VI
MM:VCC(-7*4<N'W7)7CB-)0,[$=(\NP62YQ!#I",P,KTDKZ>^Y"8T_^KT:Z\L
M$>S&\ MMGK.<]S@;,CKZA)\]N&Q2%_Y)^,&534:"=YGQV\F*8XX3SZY*M;#!
M57M>CCA79%.0IU$,//;@;:(SO%M'.QG2(=@./#3*L"5P3F6K*0KN-$/2VHD]
M2VJ6/&_6L!#';_KMOA/EQ$NV "W+%GQ+I SEM9U7VSRJ=&L2OPV*DLO-VG)\
MT#[JB3B!#=3GBES!M+_/<9H[)SC]6'0PF)6:U"X^&Z1E61Z_)I(^-GO,]V(S
MO(UAHK^'3MM%]-P-]2(HP1!.D7-^[Y<8T)1_RXV%QL)?CVDA8"L*,1JGW*]K
M](?X6&QB-%<D+A:I&J%,B]X6:W6,>2>_A%3PNL-$DUWJU FY]: *,36.UNMB
M]-8QYBO#C>W6D*9L9#WBG[3^*O9WJ'*;SD?\.'\ZWID0-)L@Z[*0E*!20IM@
MVI$PN> ^E-$R2JQVSS"FQRTL:52:)#"S]$G596-(LX/PI8G:;E*C\[%U8F!7
M&G"/+=U2[6S>#HU=2X-XAQ,6\)$HI'(A<0=3&3.BNI2-=6NF?(C\$ )]-^SD
M*NE4R9GN"O C'\564\&?E=!&R]U4T4S(O!RR; CJB\ QY<9T-9JDLRM1Y"W!
M%0%)]M'IIX*L$]L//E )R?3-,#SS(<J)!NKYJQ0OV :E$Z:_//OVK[H@L#=9
M[X*6RYL=<).F!\^U-O-!*LH.]CH%@F^YSO&IZ<U*2]3?$+V@T(1BQ.CM*:H"
MCS76-JS&OD\H<3P=[D>3YYY'BK7-/EYR=)5SFXTK-NS/@2!GX56W;-^[$-SF
MJ/=-RNH"7J2VVF0'++"J,,VH\X\(1P"U.Y\0MXGZU81YLO#>FNC_+OE7+&I
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MS>0=\6M$0CK2KVL^2E$1I3V4-H@AR)9H]*3GX25%HK'^WN?357Q9\_AU6(\
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MV;?=_[&'$>X:]8<10-_I)8V!<.N/ZJ-G?91R!OS#:EU9(GYE?(F]KS.V.LR
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M 04^<[IG5/'O:(_$G6C:7'R492#^:.Y_4$L#!!0    ( !U KU;?!_SYW+
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M1_NLP=-RW]QU/V!;VZUS(#D4%FC9"V!FO%+R!O.YVB?BTZG#C-[.D,6[Y1<
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M%IRSF,),8;") T]+<&S;+@L6EQQL<7^;M@TMNWWBL5STY;W3DZ.!;ZM;J.[
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M8ZD6A+(IT6<73^(U:(32NSV/= CH_&Z7R-AJE<]DJP8(XY#:_*<4'Y>7G?*
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M4?4)4+E(DSU#)M4G0([98"+ERTV3T)]V ^TZ,D,R:Z322<R,:1!<1:!J!QN
M9M&&V%"_[%XO30A'?C$B(W#@-] *]W\FQ$J>I'[>%':M+,H.! DS"LSP*SC
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M&>]O]D[D<O8L=, (_!S?T67QX&C3V9\:T5UP TD0YAHGX1Y:AGJ[+I(_.2,
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MY?LI]@]F "J6Y#8[0BR25>6B6'B$U\"M)"2GV8 (I@S35(BOU" HD,.]0?\
M;CK@ PU!EK4C3#?&20G[ET@5]@U99X +,19*%D"-("D"A(C/@"O@#J&6>!0E
M+57H"28TNH(C/:3X!EX'\E12N!=BTGCD%6VY+:4%<*5I5D%)CNDU)R).JO3
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MK<:@Z5:QEO>Q5%1DKZ<0#V;L >7%_$$KI\VWU8=/(KCM20/$_LZL.9'2OTX
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MNFI\'S.O7;'!IJ-4DF=6J,C2VI*D^9LR3]XXHK"0\KMI4:]4>'LQZE>C)O\
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M!\,0XQ>:1-7ULLORAO3;>]MP#<&WMNR]O&1':%R9D2_C%274I #X=Z"IR"?
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MK39>0I=QVR]:E[CDH<+%VNSDB1)B-K<#FTF9#269-N?6D=WX@*6$FJ#JQ&A
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MSDXVYNTFX-!F*H!$-; :0PEH:4./*2-8"](Z8 *V[U6\@V^1;9T:Q[88E6I
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MUP 3WM'VBSQ3MJY;'A\&63<L>]6\[JMUQFVZ9>8-C:2A34^$6D%YR1,;2''
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M_P T_P ?]I%/SX =_P#NK_\ ^_3_ -8V %6_Y6.HT_OY5IE7]HO^]_QOHSP
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M=W7YNNOSUI[?=@!LK^72KG^^;U\/U[TURZ4RP!P?Y=*A_P"N=T\/U\K]7OP
M@/Y<ZII^^A6N?_CW@!-7\N7K17]]#5YM-/U\I[ZTRP!4?Y<S2K_KH4\:?KW7
MZL -S_+D4S_?2I_Y>?\ 9P R7_+?:O-^^EJ_\O.GN]V $%_RW5?-^^I6GZ/Z
M^TZGV>. $E_RVV@Z_P!]73X_^/OOI6GUTK@!!7\MGH'_ %V:4'V?U_Z94]V
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M5/\ AY'>_?VT:4=_O?M'[W;UI[>O7]YVNYITURK2GA@"1W+^5S_ [/\ B/\
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M-MI;/7) 'E#<GM\1W%8?>UNTJ3\7MS8$,WZ>TD?RNM5[KQ2QYWOQ,#E9S5F
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M0MV5NX:G&H:.^2%G5<LH(G@!5VH\5P"'O (^0#'+P RFU"W9F''4&8$1R@A
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MUM^7 %B3%NQY.>QS[CSNUT)H&SQ]W[$AD?O:/!J@1D!U/0L@,Q2<V/02+CR
M_"3U$-;&2ULM.LI]5@G&P.(IB%1Q[3GP-["0XG CCGPPM\5(UK : %8F8;7B
M5   A?Y-_4R;)8)7-;03CZ4@>QAB$&UL6'ILB/DUSN]S-8#F^\B+,+<K=@"O
MD*;XHL9=WL9GB8!J!J^$A<@H2PWX$9SO0'E5U ID<%8<9ZY/>E+W/@D5Q@0!
MS1;- Y3;BY/%ASNE04[G#.?(13A\=QDE*H;.<("^!2/WEQ3ZFAK VIS[EQC@
M[BBL9-PXYB<69PN<"EKBDK[*O"U^S@)JW%!4V GY?)8?<P.0A!I5)T]F6)
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M!VTS=0<"IWG5]>8I&E8_[@66U3CYT/=(<:O$%C,H.,&RXU \C_2?BSSW-]B
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M1G^6"V!:.%\2&JHKO)RU]A@ PI.,-L)8%1R*1?%_]@%@35PK#>KB'$:W<G6
M8*7A]<=Q)&3VCR5!$AXZNB-#GG\+"VJIDB .5T$)%;XP D)KA]KD*P#2,JDD
M0AE"3%WF@0OPPSC?(J@H YR0=3:(W X/;5N'R7X$[_OO)%R5TSL4-M)?U#A(
MWP!YSQ-0HGR)9-Q2%$8Y'_^J57?5C %4,ZI4!5+I[PQ%_K[V+*PE967U X0+
MW'"NS5X+TCOD %F?IPTA[6&_3BPAM-J0"$[34-V"(@.64/1=T(MV7)T2]SX
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M&0E%+3<?3IZFW"4(YAP_G&U,"P-7<^EK01KH:1T$(&HYVKJXQ)PO4^XF3OV
M*BD^)7T H)72*Q/+'V>SC.DYGV Q1/0X=,#$.Z'DK+X6+Z(1 A/Z:6Z-\U\0
M%5-XF<B99&YH&-Z@=;44+JP!;.M<[4!AK6%#Q(*OFVM$$30 HL*2ID2)HA01
MP\\A>KP21OCNIOJFWJ,U6'Q!W)4WG-]D1#D0>5J8ZMU(8X!BOG6B5"R+BXKZ
M<.[V?5D\% V\G*^"?7DP.ADK8V%J'UOR2JO<+Z 2U&]JL^54ED)[V?&<M\$A
MKE.2R!)"[9KT&=,7K$A%8)RJI#\'ODT"HQDK&?<330?<QT9AK!SX/SB$S@5
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MT9!VQM]:8PA)B&B*^S]TA;*H(&ZJ<?VI)<AEYH+?(&1' WHW_O*"+L+<CQ\
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M=+ZR)?\P0[SFR)9DC%(K+B"U:]I"2)RF>QS?XPL4SB'PH![&:C0TZ(F#HV*
M;IA;&5E!!6$BU;N;!7GTX> 4Q1NY_4YS4'%] BC5%JZ"&;\M+ <H_YL8IJ1M
M M548$,X6CA['76"_#1%%=P("Z!>VM-Y=]*:?@Q ^^8DK0%$')DM?Q7*74F(
M(O'H)((2Z*<4H7,%>53BRL6(>^VV.[$BIU!JDE3&- #/4@80]!'D<0"@2.2S
M)=]##!K> YQN]91Y6-Q%,;L'V%$-[VL!G#5-=E)<>USK[>=I],'< <?LIN2?
MG#9)\_]+*<QM6FU<B =/QJFM<=UWS-O)%1?02K4L_,?Z\XSW!<1>&_LW#E;
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M[:_XVH52([\Z\G"'*ABZCX)/Z"RM7T+@:?*=995"J]H&V%^:WU<'-\@F[*[
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MYARO+WX [!H+7ME3-S/[@M3R.0H3B2[?YEJ4$I3[-[J]X1WI_G4TT7O*="Z
M[<%W9;#PVXF%+3.)8$3.6_2GL,<46\MP2>-WL_6OW\YU6V\_WA.^\<\N&EB"
M!H7S4V+MI-O?M077N)$6EK2ULO+EOL#2_+9DB6J$6S?=+Z!QP15P F[L:F1F
MP)?==IJ$/V\\;54^_TEY !3:+?)OR9[Z=-"<N5T]93K8Z ;(Y0LUI;BX?&V#
MV[S*,PS]C:EO*(Y5>*Y#'X#GN?/!O'NZC&+ZZ:/(J1K@'0 2&V2<<U7YD$&K
MP(PR[C=(AR)WF#Q>=T[)>]#T0 A_$>#$L'PS'4D7+@']2&,<@L;4[_!GU50(
M>HI$35B&3B7,*YDX<4RX$HW'35(B\M$721Z7:T9^?]<;KB<BM6;?V;$>^F5>
MJ3P >C)ONM7 +MU:$:*<=;H"WH:;-NLY-5XW[B=V2J(=$Y4^*M](:CF7,J;B
M/G5A\S,$0]D1]O(K]O#]HYLO-I3O>80\>YC 5LVX$N"_><%6;K)=4H[5:[I,
M)I=:&)8US.3ZSFZK=QX++G<4D-E 5&9,PSS=YC:.F3@[X^W%<!__2TFM/8^C
MC&C,O8(E^[OZ(FWLC5ICD+Q&T,<Y,YOZJRJ\5M/5UJ3F[6%VMA@V2M6Q-$*Q
M_8.>;I=8D;-Q24TFF'D85BW3M$>&57%:R7#_P5%GOD^[US]?:O!"/0"M[;D/
M0&IV!D),J;1>9J.4.T\![Q.IY 2W+D!N[LE'A&MLPJ)WJ_SI>3U F=H%D*=%
M(KV8Z-=01<5IBF-HM%]:/P1GW7<%CV3'"!>B4S8._S@4:NQC9PJLL//%%$3I
ME*+WF0AN!'%=%SW!GBA1MM$-12T?ORH@Y"/(%"9_-YL)EIBJD->%<$,<+] $
M^\P,H8Q#2@+1H9\M*,E:SZR0+CAXYSA%Y 2#.)FP0,BZ%GU$'F!"KT0H1DWW
M]S5^!E.12!PR@P!,7S<E%?#2HT>$S016C1YX/KDA/2P*'0 Q!(K]7HJ)ZX.7
MXA2Q^2K+^US 9A)\:4B=\XI@H\&A2_]234/,0&2?J2>6RB_;]_%<N/4&[+V)
MUQ(I%'D\WMZ]=N9#M!EBD[(#"R%/,>.XE!&J#SXXZM:F\DG2D( YY#_9VMI]
MGI(]< =YM\VYL[G.7AB3H@F9/Q*O^:ZW(28/WBC903.X_T#9V\FQE+[HG'\]
M8,"V$9?*/A[2?M.12/G=7<<0.4Q7]21%1YZCO7/4%9]\*=LAARNZB[+K#W4]
MH[[S+OH!6'SY!>4N5UI5E(#/I+VAJ=?VK>CKB6\.ZTQ#ZAR_P0/P]%BZ;FYD
M429-SCA)I?;(( 'M_QQ^X(:!2@;ML:U]U<0L#=TVQ2M;!H5H!<M4%2Y[^A8.
M+J;TM4:3U^^I@<0P5+U/7)V;_<D&FU &4SHY]91Y6M1$"0.A%OVQ&^%,.GSH
M#MZ.=G[86=<;+ ]A"R.Y%8R &_V7XY\^(=T"7NOWD=].6=C;>KP+Q].^Z$6.
ME_=H!>G]3C#8?7Q"%23Y*U9*(T\-SG*A/15"<;D*;EB+_L1($'IT(>=R\I8J
M8GNT2/9P*P#;-^@[VH.>VK%SZC^F(&7#^TKLJB/G=MMG1QO\ FB_Q3VM!T#B
M:4IG0<8S%/TF=\DT";Z7<*^RWV-Z.(ULV+'DR8CX=$/VOPB*]6)#9_5#.^1.
MUNSK*J\UZ'NK4@P*%=FKHJZ^O-4M+_Q>5/ZD($5MU3$V@]@W64SY^^]>V]=]
MO%]1J&9*DX1KE>[T;&-*,Q7WT31ZAF#EL_+(L"%,&V6$UL*<>-,A?5,7GLL6
MTCRU[?UFSN!"*^HKW/FEQTRLIT%Q%^1[%R4#H4DF.<HZ,].@E;Y_M\J[Z^U4
MJU#S*>R6/<>H73/-_(L+O>?S0S(E?H4B9IZLE]5@UJY\$IR8DUO#D^1[=6='
M NYOKKUY,=)5917Y'G*:N/AC;TO6)X,O7R@PC]>Y2 5@U72/WK]V3BM,O$K[
M.X/)]YDE/BK88DZB5A&[I*\5+3/!;$A4E?]YV:ST73!>4*]0N*ZM/K;"QGFM
M<$>Y^E[^YN4&&43<K.7BV]+,\*^ =E-=VK<ON(7P:(1]7H?/#$%I+/")@SQ&
M35<7V[4(*LJ@3F[2TP_ X+9]WJ$:A*)<++!2;3*E78E%C9L..XWP66=6T-_'
M9K,\&5PE;)_--'(Y)N?C8\=K&=[2SGP9Q0G=B&OUN&M*BCC!]V'.M-%]E<[#
MR(Z+*>TIU: ,0[84RHN,DZOB=T2R3 8MQ@0Q-3BKCW]1,G'Q&V^)Z,=5,IH1
MZ?9Y*R^G<][L?63L7F++^^L!F.A.71@WA;&N.!L1<1NKW:JJL=9&$?F\56\X
MSVWGM6WQURBN_Z[**GLT()3+>?1B0O>Y" 3LS4 =(Z6*%ZW V/7::CG5BR>K
M/FL1LR^^P3108ZK87KB^3L]X=W(@0\.P,!S7YL$Z>#/\ .2;A^A<,8IC?DHL
M[=[FD=UBO$5U!CI$DRU*5?9ZC:[])X-X<"=29 DV$C$=Z\*W6CW9;QX ^J?0
M'7132^AQ)I6&^;=$.V++7"OIUU\YE_$N/]#0PTYD5^#GQ*;:^K5F1NNP$ Y>
MK_A><SH'&DZ\EKCU\SDV+YL&+E]C?KF_3J(_:L[^.I[VO^@=O(_L.641&"K(
M-=H3Y]8]W=:WW)&\#:RC>'4DL1DT$"P<XOROL7W-?@!P<<>2??$O5TU2,HS$
M(A?TP-)4!\;E!Y>KGSJ\YC4\+AZ5A)[N,8<DB%U$)JEL_# ?3G808:M]TE)\
M]\E@FU%*1K-3QN2P6NX"M^D!N!:YP9-2N_&.2W\_E-K+?:PBY;=C\7-K^<X(
MDVSL-L)[4ML8M-T\2&<0734CT=L,^JJJ^$%43*Z$H@I'.=A?V6XW:E126DO7
MM.4!:"A:S6N3;7EK4!YEU!43XM+PP5 FS_V7S;H@7CF?\N+Z+=2%5#4"[K]"
MUSP4B?,)CAA/+W74UJE00NOP46_J(<2='J&"L_G?&36N+&4-10PNS=G->Y>+
MQ2^(OFEQ,MGSA?C/D0;=$VF[Q5=\GR5%R5%^#SWHI*U%R@COFPS]V\BGF0&U
M[C]BK3;9OL*<)$W<<6BXS4_=G&N=4]V=OFT^@J)3RC:S0,$9H[]XUYH]Z]27
M;RNSOPUHQ_9*T"[RV-?*65[;R/X/ "Y T;_2MLNY.RY[C:0A:%"A<57LP!AU
MSZY=[;Y=;^MMMV?<KG<MF[GVM#WAMP7=MI&XFX]P 6U#NJ&ON&&6DY%234TX
M8 LNE!9?-27"0 H!'EH1D#H\-=82>!P Q9=4NE7$J' >%T$9\*E(SQ/'X4!P
MV-#:EA)6$H'8Y2I/$9'$=^#C#.ND> PC>8I2:HHDIU:E>8 DTX9B@&,&W?BI
M8RQ+E7J&K7F+1J5H!U?9*ZCN["<955+WJD$H7FVXUI48-A20DA)60<LG#3##
MK+?+O]%1FQJ!KY9"B*'-P$CNX<,8CG%7&LW23QLW6DVL>X.2"&P4M>5H75&D
MN"I/%5:95QD6W553P*_AY(8-@AMM10HDD5T^82.TCAB0HTX^Z^*&[ 2X%U;*
M2E5$E2W4GZ13(X -;!UTH0,\@IRG9PRX8MCQ9)8XR72%I)2I:4IR\E9(4%GQ
M BA&7U8_+W#B_LDUC^9CWF^CTP@5<L[V5I"0;HX0:'.K3A)J<\R,<^?U!2S:
MVY#HS,WT_3K)RM47T4;58I_5F:G/0G/Z..-4=-"FG;7&AMAD:<NMDU:9=O97
M_0Q9%M6U7C0I"#RU.*FAJ3EPQA7[C391RHZ%D.?X:5RPW3YJ%'_:*\94J%?J
MB\R!CZIRH;>[6W]='C/76.RW/\M^!Y:K:4+0O0TD?K<@'Q.))'FN<12E<=4O
M0[7Y7%=B.6WKZMO?)-81<GXC'0*TTT'L4Y3\V/?7J9:GCG<JNPJT'L;'L.IR
MO_0\<8T5'-P11K.NT,82HCQ"JCPJI=*4X'P]^+;GPR)81I!IF0_2V-'/?E^D
MAJIN&@Z=:M*52FTJ04J &:30X^%\[G__ "%[[#\#8+D4E^<PHL:H])]O $5@
M"E"@*R%!53CP)IV5"1]6.5NJPU,E]9^)T@T>&GMKHR+P&)SQ9/@9B(G/L_P[
M,1QBG--K$MC\$^]BYY5$.ZE'1Y:P,_M)C.J '^"L5]^,W0N2WJUCA4PKW]/N
MOIHSSM=9ZE?OXNRCI4EN/'JHE84G4WJIJ2":!9KCI1R*A711?U%X'/[GM%1U
M6=_2?B8MG4"1IKF?$EUVA[:BH!H3C9K3X0FGQ3-6-4\U^+932N9;/_7'/XL(
MQ;BF9BI1'!(2V\2#4!.G-SPUH: TQ3I(GQ?>%PTK5*M)0H(4+E!!65K!T*>5
MJ!-/A(2*^['@_6OF_E5^>9TC%GK?0WF3WB$56GF4^2IZ?^1DQZ'L+;!@RWFE
M)LT$J1&?<2%+T(U*TU JHXY1\S-7*YZBG&K:SRZ>UG2/T/LEJ_M$7*,:T71V
M%[6[W?%I0HS)"=2EY&0L*(J:!0U<:8\W9G>C:BHS2C1=)[C\@VN.$K47)<?=
M1 N]7C60;A-'AJ0)#E*T[,\/-U*;_>+VE/\ ;^U]%J/_ &HB3>KV4J_7Y9%3
M0JD.$T_U5<5DM1?X7%F1):V;9D\JLPS=/NHT\>IZJ4_MK:KC^J0H[C>)+I+B
MJE&HZ2HGBHUQM5^GNYK_ ,?&TY)Q5.DUUYZZ?1[9H)7-/9I@W@C3;(UA1HAQ
M-200/,^HT!QT$LS;@L_Q4Q- []QWK\[K^=)OVL$J?AU#(\#YE1[#EQ&,Q<"$
M@=2<E"IIP35RAR[,L71X@#=4I(*@UH<.84WK436HJH* S(X]F(=1]VRJ6*[S
M<=Z592BS;\0=2%*N3-&RFA42<RD_9KCG]^HC"Y=?3GEXLWQ_3E<S:*BXY5X&
MYU*0%CPTH*4XD4 RK[,:;:1)1=,.)MA'",BOMQ?5YWWE\?A7<<*J$J]HS]M.
M&*78552Y/H+4<Y"4<N-U.)5H6FS3M*N)%8[P(K[1CVO+G][OEJ+QI<I_B>;]
M:?T*\OJ?L/&Q?W$F^7T'Q?[;W?XD.!O_ "M':D'+'5_T'5;';M_-I'#Y$<L_
M7W_(I=69^+$#JB!I3Y834D!+3A0.^E4YU/;VX]S1+!<#Q,OB?> O:R*)4T !
M2GE.]W$^$X%!6MMPZE $@<0E#@!/L\/#%VICD5:?,7@6:::FY1[69P>FX5_U
MM=II\L@&QSR2C6HDU(J00,Z4QJOS[;>@?4[2\#9+D;%PW)/M/6A (5%:IK/P
MA7F<<RRE5.X$''-F]AK9I?3EXLZ):=_P<*_0CX!XX8K=XD]CBCGL3])^FG'$
M5IMQ:?#_ -R:YP$]S)$=RA(S?X?_ (I.,[;O=O0:PK(Q]6EY$G]0\=WJ:(>_
MK;;M<0WYVJUVXI20L@*3J"J99''3']/<<FUU?#)'P1SFYZ?UN?>_%FO0U-3]
MZDGBD-.T2>-!EP%<;)<8NO"IKO.E8]R()9 :5X%-_!XEI<2#EF14 4)Q:N!&
M^)L!])$)'JA] ND  ]3/+LY=OZU)Q4H7;]=;2/5OZSU*JD#?&T=)X#5^[C98
M!'M/?QP!JLM4XV:XVZX_AMLNQA7*)/:A76*B5 G+C/>>8$Z(L>7*9*D@JU"A
M&6 ,Q9O6AS-N]^N5\F;+Y)1)$RWVEINR0]AQ&;8[)L02WMW<<6$M+46!N';J
MT@QY#* @$5<=3@#AOJPO>W)SLC8FSMJ&)=H,.3N-_=5IA[AN$CF,XX].E\R(
MCKAE-)W&Y(=<2TXT'8P 2%K2!7 'SO6GSE?,*7+9V;,N4E:&MT7B98(AN7,R
M)Y90W9>9C[>IZ2PT@!+34=10OX3X1@"RW,'F%?\ F=N96X=PL6J&MB$Q!A62
MR08EJLME@IH&X-MB-)"(K$<C2E I0#// '4X\A]M\%IQ20WD%-*U>6 >T?"O
MZ,5+G3*NL[0Q>+I0%$I3HX!Q3#:2L=^GL."DRBXC!BZ793S*#.;8+KS2#YK+
M"V$M+4$*4MH@ZE)*JXQ-SW&&CT<KL^$8,SM)I7K-1#3P7O-F_#D=Z+VXN=NQ
M-M[XLO4KMRVM7^S1KD_9KA8W77[9\TE*TJ=4G2WY -0E2,\:H^H^=,-FW.5E
MS>5-])]KVKEJ[NVN]<MMS?30O>G_ -7XYA-I)/4OLM1U?"Y9'F%#_"4@TJ1G
M[L>?_P#L1"#IYDJ?:#Y:7:O+;E3HP9S_ & ?,E-"CJ1V;3+A!E:?H.H5Q7_[
M&6Z_'+_N*?VUO?\ CE[ YOT#.9C5=74ALOQHR*[?)HDBM2DI)(Q33<_K4K[N
M7+DG&3K3,2KEW>:R*U*J^JS!WK2Z +GT8[%&[;QSFLN^;NN7'98L-J@N@+8=
M5H4ZM4BK3+(KDY\1/''U+TGS?L[Y=C:M8U/P]^]%7]JT_FRMI8=*Q^4UO,7B
M>$GY:6ZMM2$+J]\L5QW5)"UI6Y2BVTUH",??-%?_ !.FA??SXIGQ_4)QU<H/
MAF#$7JY+7E=5_P"F:8*:TI7,4I7&45G1#.-=KBHJ_7E.E.6I#49.GMS\/BSP
M+4VN& 5^)SU,.+5*U*%$A9;C:M)(RR H#C\S6I.3K]$S-,EA+YV8WK>F,\\]
MRXW*IYTJ(NRRG30?["NIHCPCZ,<^?U#PIN4LN%6S?3].J2LU7'*C:S%_R5C*
MGW2,NW@,:F0<HR44WE-K9-YV$&G</TXFN95@E@6^:E@? <<J9GCC\Z[&+;=%
M0IYD'Q2+(=02E(Y9;G*"4G\$O&8-/^PU_DSQ]1Y7M1W:TEA^\1X?U].FS7*<
M/+9Y;K7=KBVB2B/)J&Y+X% THM4=6**0M.9'MQU4]$J/Y/!TQRKP.7GK_P![
M>)-_2?B.DW:[9%4E2P14GR&FP?\ !*.(/LQ[N[\"/$0M.BD^#*_Q>94#S'$U
MXE1J/>/9B"/$FSJWB$HNTY.H(EDDY@:F:?0"":8LE\=.@EC)2@Y=#+\]+=SF
M.\^=A-R)* #<S]WY+BB:/-G):*) KW98^$\^_<]-SA#"+CPZ#8'D5AO4>]'I
M/MV4:*.&0%,^ <?H,ZFGOQRSUJ7XV=%AG?B=']'%_AX/HR+P&6=!7/Z<18-O
MJJ96=<"A8X'%MU*,XJ.!17(^7)]XOE(28R\@111.0XE2D$TSSTU'NQG[>D]V
MLMI5P,2]./Y=/#H//=UIRG87/2XJCE*0["2%A-!4H.E.K+/2G(8Z0<BKC6DB
MOJ+P- .?33U:IPS,Q35>K@%* =*2"157B!]H%,;/6*.W.7::L7TO/2*1>I]<
MY*?;]WV_5BU2E1)-F;P[CY5UG+.LR?!\*@&DT) _+2F*&/+XGWDD.ZW!4^UH
M$AK3^(,@^8T.*74:<B.RI^O'@?7%NZMGU#J\KBSVWH.Y&.\VE3_Y$>G#DNMQ
MSE_M@K4VIPV>!XFD>6D)*$4)'VU=^.3O,F*7J&35*YI>)U!]!RA^30:2KE7@
M7=3D!G73P/ $GB0.RN/(2B_+374>V<U7M.>.++=IMU98[A"<D.4[S^?&3&4;
M=Q))(QK3:O2D^#DS4%ZGKKK.U=I+"U#_ &[U#22#4R%)K4=NC+W8VZ_3Q;S:
M]2[C6_G]?E/;91KT,U!JNKVEP>>Z2E1"25T2D \-)^(#&_\ 9@\JZZ'/*_\
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M5RTV;46MWA.=EY/,5'3M/GWK_=-)<VN>6[',[?"IY5K:$K:61J_RR3_L"?\
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MH6/M  D8K+D!Z;C)KW:KL1)+GQO[D^/M8$>N+J'=6WJW!:"XZXZE89LL-*'
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MB-<8-Z+DVV*VX^ZJ4&-RZ6=IQ#&E6'FF]N!!E!TVLV1Z$Y%U+(?\Q#B@^D%
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MK;0%$<< #;:YZ<PMM0;[8VYUFNUNW5Y*K\O<]BAW9V8&FOU9N*F2EY$-+:0
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MP!J884-2D]ZE#W4*OJX8 -""#4D4&?;V8 K\P53F0:BGLH<O?@!FFJLAVYX
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MIXU)!KG_ '< 'M+JTNF61X95\/Y2, 2M9(RRKF:=N0XX *:71*DCM^CZ?:<
M%,N$JHO+.NJN=<AJ[ZD8 :-@EL)JDH60A*EH6L)KQIG353 &3_([J<WGR*8,
M/;%GVS=(2KLW.D)O$>8XAP!A=0\PQ)0'$A1K0C '9)/5_O6ZRI<G<.QMA7YJ
MX&,^8"OVABL+F6ZY_B,9U@,S%R8H2\$:2IMYM200 GC@!G9>L?F%"V_S VM=
M-L;7W):N9"Y_XXS=IVZOEK$Y<E%2T[88:W"9-BD1\DAX.E*@/YE-< &[,ZP>
M9^Q]B-\O=LVRUVRTL1GH\:XV6Z;IM>YHZ \%H0S>V[C(N"I+;M/O4%04C(H
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MZR>;";LY<3(28S$>&VU:IUYW(+&XN.@-L268#5U4Y:;H$K3^L>8\IT\4)X8
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M4S&:92VD@+.6 !>9_5;N;>>Y=V;@L^THUIVGN&V[.M,5IYJ7%<C/[7DMEM<
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M?Z6^B =W^?WTA#_^KN (QT(\WJ?^%OHAI7LZ_.C^E>W_ (7^. (U=!_-[/\
MI<Z'J]E>OWI!!I7_ .=XC  JN@SF\55_>_T.BIR!Z_NC_(^S^E_ %(Z#.;X2
ML#F[T.D$FI_M .C_ "__ )OY9X '5T%<WZ&G-_H<K0T']H!T>Y)]_P"^#A@
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M;MK[. ?8VZGZ>+I#_TFBE//_,N[O?VO95M#&7EA U)I71%1"C%=$4,*&UT;
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M(S< 4X:/VD'+LF/.R:Y6#'0!3'FR=5$ @U9B\;+9W@Q+G-D@[W@1-T0EHF5
MPB\L$BM (C*7CKHWP)<? Z(,KZHG>K3#?@+:B;7\H[AEB>M36)60!,DI@#;P
M1=:E*B 0%OB\C$LM2W)XI("6]G!N>#L3P?,P"UP[_>5$=OC]W_,I)["B[G(_
M:H'M9* 3R7[59JG_KF-DM+1@^V>H<ML-@%4&GCV_119FK<>9L!81,.Y<<-\
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MBHNIW6K7V$><FUIK*F&ALS= T^!8;/E2_,>6&6%%'=H_:F]B])3\,IWNZ(^
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MJ5D_N6Y5+WY>+.K7)*3Y>MU^K'P1>VA0  !4 >_[?;7'SVBJ9?!U5'L."@J
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M!;B$$A-"0H+\7>$?HFF #0TL]U3W^$^S+LP 8RTM !40>GZ0)/6F "5@N(T
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MVUMR1\$7J3\)IE[L8&\&S-K;J\2@$U&9Z#^WB!-=2H0R2JJ5)%?$FH5T)27
M#^YB.C_J5FFW.6=S#3W/A/)W]7&2S_2<AIFPEKU[6:3YK+A2G2EMTI"T_P!Z
M3CH[T&_IEK]]\YH1USE*.KGE='1FK?\ S$=>J#+51#68>50Y#I4GKC:[6_>.
MG::JV&VYO?E%ER,)(1\E%4W4YK<<\::]E3W8FE]S\A;6_O$9R;42/V5O/?C/
M^L@](ZJU[?Z*GK9-*_V\6_T?45_I^LO_ /7J?/[73UI5&L-;OXV24I)'EH_F
M0XQ6'' /B(4:@XF)34LR VJ*$MQ9BGEE,=2U*JVM*'2AMZ.V/Q6@DU!6:"N
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MHU+S"CWZ>[ %&M22A61T5Z 4'N%,A@"-9U$JTTJ:@T[^RN (E)KF* ]__<P
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M^*E?EG"0* T!RJ*X .CPY:?-_!D*&JE1&<J1E3 ![$>57PLR 5  A<=T"G<
M.S #=B*^V*EJ2:]=,9T]E*>W !K3$E2@4LR*5% 8[HR[*]>S #9B.\:E4:4L
MI%"4,:0FE>M<SE@!E'C/+(<^7E@CM+( 50]V>6 &?DR<B([ZB<S^'2A]PZ8
M.9B2%)0?)?%2JOX 4/O[< 2-19 5_$23WGY9=#[13*@P 2W%="SJ;D(S[8SM
M>O;3V8 )^5DGX4/%/5/\F>^_K@ QB/(H0IN150_W ]?<37$(4>:NPC%*M:'!
MA2J&C4DA(3GY(S/:>O4XA9=+K6ZI&_@XF4GHTBK3ZC=OE2'VM,513K0$)TEH
MJ('4@$YXUOZ_UAPZY+O-FNA7\]:]1Z,K>X2T#I!J![0?MQS6XNXYYX;V;_Z;
M[J/PH9)\5:@"GLZ'NQXUB.:#;WGIQ?LHHJ4KH,JBOL![<N_$ME9+U7LJ233E
MW%G^:U4X[W<@IU [=N]*=16&O/V8^D\CNO'+?[Q&$\Z>SP>ZEA^S9YC+8RM<
M:0E+:E)3.D#P^-=#+77P]A..J_3K'@$?@7@<M>?<>89I_7EXA9B/4HEAY8)K
M^,TXV :]Z<L9A<]]]YBM9+"I&Y%=51!CO:A0GRV7'1]E<R,5K;22J0\2)R._
ME1E]/L,1P'[1G0_N8J*-9>@$9C/J_P 7(_\ S9S]ZF*5Z$ELP!"J.^DYM/4'
M:ILM#V4IGB$:Y57;0%!CO*^)ARG84)=4?8-0ZXF .["=-%:) _\ <*Y>\G4:
M>W/$U4MP!#$E$T;:>/\ A1E_OC+$$LS(9)/%,I5$EA*JLND@&O@T^^@()'NP
M>#H1V8/:!IC/!*DEERJJ#X1T'0'+$ #JC/C_ !;V664=Q73^^&1RQ+>^CW$4
MW'9O%LEIXJ=5Y3P!BN(_B:'4A-%9'/.F+'6_<R^$];043BWMS&_GZ;PT>G2R
M)H0I4^>""*?XQW*G932/NQS"_,%5<T2O;XW/G.D/09UX':KOMK_!(V).:U+2
M?""DMBO;V5KCX?Q.:_B87+:HJ8T/M>E;<I5>]^(>X-72E$$Y=E1W#'F7G63:
MV5+Q;"@F@4K*J4:L^\YI^ZN+7)[:9"6,&C13]6;1_HZ5\L^\\F9<=+K("P@Z
M1U2<;U_EP2K;3W1CX&G'7J&97*XI5\32Y(CRG'@HM20EUY*EJ^5<\-$52<LO
M'C?)MM13[$:,SSYFJNE19(;D+30LOY ?XAZO2@[,L\2O"3ILJ2I45!+*BOAM
M1$>3U1F&._KUSSQ6BL*[R-!9-BO.,,A$>4DMRXZE%R.&ZTD>7\5<Q1:?L QB
MG-E8<'OM_59E7*/]9L5^NCVE< MUXEV ,TD[0L*B.X?)L'3[@,<HNJ$6^8IM
M?6E^L=3^GO\ QNVOLQ_5+Y=/=CYREE59&;K81N=F(UB1.'TA4>0>WY=S[]*!
ME]F*-BG\?8_>_.>9Q%26DN-?5/)=]71DGU-PD(2M5=O4JE)(%$O$#N\)..CO
M05M\/B]_F?.:$]:%EOSE+;1FJ]4*5J4E#$@C0R/ PX[EI Z9#&UVM]Y=QJW9
MQE-_9 IS3[*V ^R\AE>H(4MOR3KSJ5 $FE<17W7J+:W1W$9U[42K]E5SVG4*
M_M'_ $D)U5RT_P!%;UL#XJ=/;B7Z'J*_T_69!_7J<=/U=?68!58:W;Q[I2D4
M":\&\8$E?\+/KB8E,)]E>K_G/9VUK;LX;L>W)M*#(<>&VMSAV=;'(*F PJU4
M"4R&+45*U%+2BK4GNP ]@>K_ 'O%WO=-\?JALF9,O$1=GN=GG6<NV:;8$Q'X
MMLL9@-NU;MUI=5YL9:-+JG!XED^$ ?;Y]5O)'(>Q;CM"_0]KN2+L5(O>Y46X
M(W([;6G42(5I,E7A1;("=+:*DE/E@',' &.[#:F*+;#R5TKJ7\N"HD5U )-"
M#UJ.H-< -H]TF@'S'74::!*JM)33V*I6F &KEQGO-H6+D44<!TI54]!D5B@5
MTP QCS+BHI(G/@K51!K4"GLP Y3<)RV0IVXFB7-*@*@FG>1@ YJY2D$%N8I1
MK44<*E$Y]49 8 =LWF:I;(=F/*&KH5*'9VBO=@!E'O3R5+2F2]12R*ZE9$]M
M3D*UP S7='R16:Y1-*:B2._LJ< ,8]RDJH&YCA4>J@5)%:G[L '-7.8AQSS'
MW%>$$>,FA-,QG@!VU<'G4I+DB8VE("4!M1I7O5W]< $M3GDKH9,LD_PB<J]*
MGV# #)JY2P=*9#Q3U)4&C3V>+Q5P :)LX4*9<@=HTN,A/O [*X )9NLI%4KE
MR-0R%7,^_L\)Z]F "C,D/)*UR)22G,:5*\?M5TP!PW-G!"_Q9B4H2"BCK82>
M\YYT)/;@ UBX22*EZ2%4_A E/2@J,CGA#Z1&.TD,^< HB6]4D)**E:B!VJ1T
M!Q):^_\ 00OOW:;3)_T8.2'_ %%[>+LMYT_*:3K2TB@I2E34]/MQKM^86*CP
MB<GZ39KH3CK;->Q'HSAHT( !RH.A!%/>,CCF3Q5UN2ILJSH#I?NH]R#A_9]^
M+'1XJFX]2/N(A6K\6M?A)K[?8?8,4KM87:[JE10K%%H^:EC^;G>CU2DLV*XA
M.DTJ%PUCQ=>N/HO3]YN,6F_]1&!\\X<*O+=D9YB;?)D-B40XL?R^42EL4Z/+
M50]^9QU:Z<_T"/;ECX'+/GS_ )#/XY>(9^8R\],B4DDU.M39%>W)52,9I*%9
M,Q4X5<9BAXWU@T *DDA1IWZ2!]V"RK @0F7)*D@/REI.=4J5E[LR<L0E>RX)
MXBA0N3+;51+\D"I *G34]QIB,+V>F;$''S<D_P"^7B:=HJ/;UZXN<L7C3 >!
M"J7*2K*0Z/<LC[AT&)6D 9ZXR@HI\YQ1(K0J.=:YXH_2:])35Q5H]S!DS)A
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M>TVY?LR:A%4[B4H436JB.S/L[,>A+/EVLAFE]7$'=%%ZLU*TTSZ4[E?9BS\
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M.TTZE;C:4*;?+:"XYD24@J%:]XP ?%D&2XXXE9*4#4#J)&LYJ()S^+$); -
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M"3=2L)J$DZ:T!ZY]G[N(%M?FDV#R\F%T_P#;/W$)I[Z=F&AQXG;K]8LKC_\
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M&HQ+*<KGT54BDD=-Y%V'Q9=>+N1F. ;9MNQNW*%!O#UEF[NMTB;:F[3.=C7
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M+:;M.#Y/BBVR6Z'4C-3I=$=0>0!F#0 X 5+4F X\B2Q*9+:D-/(?CN,/E24
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M2;A*@N[=D;GA;3DI*6A#_-GV(:KO+=821H*BWI/Q%> ++^IF?Q[,E;+<V,S
M9AN6135;9*,V,MMK2IMN1+>8CRGG4Y?&A))Z@8 Q>=D+=HI1)U5-%YD5(5XL
M^I. !)#KY<9(2 %ZT.25T1I:2""@:?$M-/OP!G)M7G-GBH\=JL^ZHUBLUPXP
M,%]<-J#-4WN4);*'KAKB+>B:F@0V =6=#@"*Y;UX!YPWM&1NZRV:WSKGY5LG
M;JM\67;+LZM$03'[O<A*N:[=\V\\"HK;9;%5'2D#+ '6[C.]*C6Z&K!;+/L^
M):;3:UR85VW,SN298]Q7Z(ZN&\=P.V":[)DIF1W"XA+3*$I= !.D8 [ML]/I
M$VI&VGOZ>G9R;>+W?=5HDMWQW>Z$LM-B(-LPF)+L.%MEYPU7\PAV4$FB4C-6
M !-M;O\ 1#N63=[YR)MVR6I^Z2+HB9#:.ZHWE0EJ/Y?.V_(<>GN1[JMD@OM/
M$,ZB0E0& +:38?ICW QR?<+79+=:;3QLW$C<?NQ)$F!=-[,7/2EQ5]5,GW!'
MGL!_PI:3YA(^$]< 7=X%VAZ-N4'=W1[IM[8UJD;2M24;9CW>7<HUOW,I<99E
MN7=#EXCOJN;#B-.J.X$%7Q-TRP!;AF9Z((6V&H=XLUI;W+'W4^]N-R?>;N\I
M(CR5-QX\!"Q\A-VY5 UCS ZV:!"598 Z7ZC-W^F);W"FW.%X]O18K+?&[]O1
M$:/*CVUNXS9:!(:A3+E!B/S( ?4?,+F;9R I@#O>W?58>,-S<C[)O.ZH3FV%
M;R:59;%"MUNN-EE;9>M+:V8#MR0R\MN,N6LIE)T)*Q\*^AP!:G;0])_)ERW/
MO'<MKB;78L>W/UUD6FQ.7&%9KK<8=P?BKM$>/.FSGG43DI\Q55)73.E< (8%
MX])=U7O.[(V[LNRV_P"?>CV^RS8.Z)][FV 6]@M(X_;AR7HZ;V\Y)%%7%M;8
M;\PH0"I"@!<F;N'TB\*6C>"8EGV)N7<-]V+;H6V;8Q"W5<93?YW'0[=(?(\X
M.-VU;H<31+=JS3D'"FF *;+*^G*C9;R-QVV!(NC+#,N):XD>[0[O9K@Y#=5^
M0H<><NS;^U!-6A 0LHD%LU"]1K@"S :]*+^S>.=^7[:]LC7C?.Y+M:+OQ_ 1
M=D6"TVNPM/KCRXS3E[7=X<:Y-M-%:7Y)+RB2E )I@#(';VP_1UO'TQ;GY0@6
M38$/?@C*5N/:;UVOMH8VW*A7)ORY6S[>_?DS69,RS1@274S09*J!('A2 JAS
M/IFN7#;J;E9+(-KO6*&ZY#N=TW6_<@(3BO.EWWY*+IA;I2^L*;^72]%4 "XK
M &"'J]WCQYO+F^^7'B*67^/(%JA6.Q!SR4.N1HS:"RM2@RW\Q4)TE9 U4K3L
MP!>?:91^RGY\/Z'[27TBGLTZ?Z*OK;5T^'1I[*4I@#(#Z^:P/J]>M,9__.WC
M?_F/XQP!J!!J*X )[*=G2G9@"1*P  :FG7[_ +^F "T46H  ]G7X?NZ8 :!"
MP "4Y>P95S[L $,(TZED"@\2M1U(*>@'EGPTK[.N "V5IS#R"]YI )0^AA(:
M34MME&D5*"20,\ 3(4YI0W)>4ZV'%$M:F?*3%;%64IHC45M*/V8 8-.MK#*%
M(7K;2JCB5ZDEE('EI)H!I2D 4]F &SDE10VM2U^ MNT13PZ1J;TD&HU*2.G:
M, %MRFBZEQ96@A2]2EJ)4I3CI6X5=Y*E8 /^:C.%M:EJ);&O(D)).55)'4^_
M !D29K\MMP)4UYCREH(*6Y"2 4M!T?B,R$$UU"F #4);C%84E;HTNZ3)TN*2
MRH:P@O\ B6L(<R!/?@ ^+(2W'4?EQ)&;I2Y(6&W7Z_Y,^V2=,1API4VL"N1P
M!L_X_P#2GQWO?:?!>]7E761;KS!D3>8RM\Q6F#&<6+.A,A"@_'C>:D!"DYJ&
M +*W+TR%S>5YMRMWPK/;(ER3<FIUPBOAJUVJ9(=;BF8\VTH+6XSI T(4I61*
ML\ 7#N/I&V=M+D/8>R[SR3^M%TW; NEYM.V8]H?C)>AB(3&GNW'S2RB"B0H%
M.DK<[T# #*^>C*-L>RWO\XWA9MR[C=L"KTU8&9!?NED<:*RW'6U\T2EE#(!S
M57MP!@D@^*4M0*W%59"TR7W"EQI102AIYQPH^'O. #&IU/*"6BEJJ4O)4D%U
MYYL>!U-,T:2<N[ $92V\DH6\\A@I $)]Q1C%S4=2_-2HN-K/:GX3@!@I0=*T
M?,A*W'HZE):2"M>@ (\:NA3IR[J8 ?[?@0YU_P!OP):B[&D7V)#FLA0!CLON
M@2G72DD*4XASK@#9-=_27QXS/WM+A*NK>W7=M6E7'<Q:M+46_P E257'YE":
M-R8P?7JU*JHH& + ;*]*K^Z[HQ;Y>^+580_>YUDCN22ZA^Z2[?J\YR/$> ;5
M&#:_ KJ58 [58/2GM:Z;IWEQW:=]1]T[DVTJ*W*O"K>_"B;=7*>;6PPXV"V^
M9D:0DK2L-J94C-2L =8YC]/%KXNV4Y=8VZK9NJ?%W (5VNEE?C2XDA24^8N
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MF/BT_HC^>JNK]W !8^GAS-56GFCT"5JJNCZCOHEIUS_^FROOK@ QKZ>'-'F
MCFCT#?"==/J.>BHFG;5*>:?A P!./IY\S@D_SS^@17P5K]1KT5_#GY=1_/1D
M.[]S !C?T]N8:*\WF7T#:M6?_:,>BSX@<Z_Z:/BKUKG7 !J/I]<O)*B.8?0.
MKPIK_P!HQZ+J 4RJ/YYZ4P 8W]/KF+Q%',GH+2M3601]1+T8*4E ^( CF:N@
MCKV8 /\ V?O,'RZ0GF3T'5I^C]0_T94T5&JBOYY::-5/97 !'[/OF!:0G^>C
MT)M*2ZA:%I^H;Z,U*4L5)3_QQUII[.[ &7&U_1[]0:'M%RW[3Y$])#FSOD(#
M*Y-O]:OI4FVWY)M95&=7,C\I.10TMPT0=6D]F .R+]+_ -09C:#MGN^Z/1(_
MMUF[1ITF;=/6'Z4%*D2TE AQYMU>Y/TALD#0R5:2>@P!V?>OIQ^HMN!_:<+=
MM[]$]EOT5EV7LV>QZN/2I;MRJM/D)8$"T_-\G(7-M'E^-2F04:J'K@ 2;Z9_
M63)MU\M6][CZ*%[F_(/D?S-OUK>E:U[C1"#:@)U[D.\J(?>26C4J71&GV8 P
M_;]!'+011KF'T,+22HI4U]0'T=I1J)\>D)Y? %%UK3 !,;T%\NA2!_.]Z&LM
M5"GZ@'H]42GV:>7ZX F;]!G*P4HCE_T.DU-0CU_>CL]]:_Z8 < 2CT&<K%/_
M !O^AXC4G(^O[T?(33]&A:Y@/9@ ^T^A/F%JX,N6OE?T.B0Q+96T(OK]](DI
M;[R7$J0%-#EY2U*.0"2*G &5R_29]1%=@@1I&_O2^U8([S:[:]_3%],)M[I-
M5 *>5R:&'CH( "2KPTI@#L[WI]]?*;YM6Y3KKZ(7;S"48^VK;)]57I6279Z7
M&PF7 0>4679]P)"2K0DJ).8P -?_ $U_4!O6Z[Q/E[G]'T'>J/+>W:W9_5?Z
M5+-<)2TE#B8E^M[')_G1F=" G4XVE:D$YT. +=<B>ESU+;OV+<+?N2Z^A_:Z
M'+^7MP7.U^N'TGVFR&XI;0GRY27>6$-19ZE)22E2RY4X QW7Z#^7E*2#R[Z(
M4Z&4I*AZ_?2'J6@ 4)KRZ"4D]^6 .!Z#N6PF@Y>]$!309_T_/2'0CL/_ !NT
MI@#@^@[EJ@_TN^B#IV^OSTA4K[/]+N *?Z"'+6G_ (VO1#IIV>O[T?Z?^=[I
M@"I'H0Y9T_\ &WZ(]/93U]^CTBGL_P!,'3 $3OH/Y:5IT<N>AY(JFO\ T_?2
M!\5.T?SO4U8 @/H/Y=!%.6_0VKJ*GU_^C[[P#R]VX ^3Z#>7=1)Y=]$(^+2$
M^O[T>$=<]/\ I@& !7/09R^:D<N>AO17M^H!Z/0D^\#E^E< #+]!?,)-?YW?
M0ST_^T"]'@R[O^-_I3]S  S_ *!^6U)5KY@]"XKHH%?4$]'8%>W,\P@5P! ?
M0/S( X$\O^A@U/4_4&]'5:?HUKS#EX>GLP M3Z!.8M2B.8?0D$ Y@?4']&]"
M-7Z5.8Z?%W]N +V</>BGU@;:FRW.'>3O1I=KD]-C/R$6'UR^D:^/,W!"4HB,
M:+7RU)=2M2J% (!)I05P!=*Q>ECZCUFW#/N*=X>C6YWZ0#'EPKEZPO2C.\EU
M86&7Q$>Y16\U.2"2DD CLP!.SZ=/J(1>,]VV>-=?0G)XZDW=#F\;@]ZN/2&N
MR(OSDG4L7NY*Y55:HUQ0\1H2\4+"J!(&0P!UJ-Z6?7G:[7"C;RW)Z'[YLEU^
M*Y':W%ZS_24TTE*7=3+-GNSG+K:6'"I: @H50D) '3 &-G*7H2YVW'OO<-[W
M=R;Z&[!=Y\I#K=DN/U"_1K E6^WA@)::6Q,YC:D);';J3177 %M7OI[<RE5/
MYY_05Y)IYY/U%O1>DII\.K_31FHCK7  LKZ>G,2EMEOFCT%Z@GP ?47]%*24
MC^#JYI!*2, +)'T\>9%*:*N:/0& $JIK^HWZ*0>N61YIH:GNR!P!2W]//FL.
M-_Z9_0$AU1 "U_4:]%#Y:;2/QM+:^:3YGG-!7^ ":98 R6XK]$WU%[+LIRV\
M8<G>D&?LIZS7*/(?VSZZ?2'=;9%LBI\=R8I%R@\N2(SD94A(#[JUZ4+-*@T&
M .T6_P!)_P!1FW[-W+9&=V^A^;MNXO)FW6Y2_6EZ.I"X-M:FQW)\.1=7.7U-
MLV1;@2EU!+85D%&M, /=Y^F'ZE-]VML6R[HOWH4M5AUL*XLEI]9?I MTB(J,
MI9:<V/?7>667I;4YKR]34;SP@9 G "QOTM^O!BY08>_+AZ%+UN!NUWAO;\H>
MN?T?V?>#2)4)3#$EF2[S$R_/M<-*2YH\O30FM,\ 8&R/IT\T%VY*7S5]/M4E
M]>N:5?4E]$;2D3#+<<>\UK^>VC%%DC0<@<NHP M=^G+S40G1S;]/D)J/+!^I
M3Z(<E=H23S=FJG:,S@"G]G)S5_RW?3XZ?_:4>B'X?_'=TP!FKMGT&\LL?39Y
MKV.OE[T.KNEU]?'I?WA'NS'K]]($C94>VV#TU^KVQR[9<]]L\O+VE:=V3)6Y
M&'H-FD2V[G<(3$N5'9<CPI3C0'__V5!+ P04    "  =0*]6#1=(<L?N  "P
M\   $0   &<R,30T-C9G,C9N,#$N:G!GC+AE5)7KUC!\+QJD!9%.Z45W=TJG
M='<W4DN4$ GID))NI#N4#@%I6'0JG8M8Q,O>9Y_SG.\=WWC&.^\_U^RX<MZ/
M\X_KP$M9/WL; %!49 ;0@/^!QP, 3\;;TM$?  %(3[C5$VD=B=_.R\M-B)W=
MQ9/-W,K5PIK-TM69W<_<C9V3C8,=$!'W<S.W=+3VHK*PMK5W$:4Y;NNBH;*W
M$J71XU7A4'&3MK:S5WCK8:WU5E7;\JVCI: 5C;@8E8B?D)^SF[.UESF5G[.3
MBZ>0GRC-W\:%GL9_D=EIJ/X6\7(4I9'\BT&EKZ).)>WJ84W%Q\8!MN3@X*+B
M%V3CY./A$1!@I>+BX.)@Y^!GY^0 <W$)<? )\7)3_0,T3]X\K&R$-&7D_O'U
MA(G2_).4KZ\OFR\WFZN'+3NGH* @.P<7.Q<7^$D"[.GOXF7N!W;QI/VW!1EK
M3TL/>S<O>U<7JK]P<PM7;R]1&II_I^#LIJ+R'\/_O]5R=F;_M[2GEZ:US?\N
M[:GM[V;-KFGMZ>KM86G])$[[7Z[^=]5_"UI9_D?.S=O#Z>\\K2S9K9VLG:U=
MO#R?9#G_EGV*7$C&U=+[+ZJBC"C-$X7-RMY*B%=&1D!&4(9+ED=0@)-35D:
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M0H)ZG%OEU9>;#R] =2>TKMDYF6L(XEW5>U&>%.M\WW B+A$A I26P<.$=SV
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M*H0Z+<4C;CA KV0) '4K1G3*$<@+UF]"[XF_3I79TU]JTB?A9ZQ_NBS'BW1
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M+7Z/_1_VZMTV?5I0C_;< .!RQ[\7=+3:=(=C=ICZLNY0.S,DXH!?Q#/*]<O
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M)8Q>$V*A76RCG@DZ@R.OV$N(TV#KVY=%@Q@.M-4[5=1+-Z ]62N[UY/,E\@
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MT4-6%Z5G+XM[WM4^ @YMG.9D2RR?N-GLY*;,9J(O2N]$L?U^=%H>86E6=7K
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MH/X:'\E6 _BQRQWJ?]WNM\<S.G&UY/=EG]-=@4\,8).N)-%^LZ<#RE:5^?\
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M "_PX^=LW52A?V..' ]6E37I4_R8C=MYG7H9=2X#"^6D<D@-%=1#2O\ .DC
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MX[[1S2IZ?W4_>R>O7KB>BK3HJ2EH/\0L47ZN'N?D-:+:]KEDDB'FC5^V/'@
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M5J0"0L7A4#'4CD/ZNTO+]1=B.;G.[#=&OXY=I4QG$FD#2IN'"@AF&CTUJ>C
M>8XWQ%MYJXXLT9+&2_QT EIIO4(,C'*O7^+QIB=8)(F?$:R22."KNQ&F3*OC
M3Y4\<6TW/%5PJ54W1$N>UJB^Y;L>I)\_*8 02<PVJHZ^(.-0<YHOW!/])=AM
M'DTW'Q+;B_8=[TG9;MVHP1NY)#0P,OAF)%#GPZHC8Y7[M!>^;E5TOM.H^WMQ
MT-J%K"-%V!H=-7C09_F_)BP<55F42Q:\ID.@_/B@TZE*]P!>XM1'0"I8/0_"
MJ'\F,WM23UNFKQSHL]RC&6V7Y/BK6'D=#C(^H=I_O7=S(E>0'\5 -8-"I%N
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MHH:L,G7Y*!C,^&XQ]Y0?3WB,7N^&W3:X]VSEW]TA];W)=SFD2X!-U$/U2UJ
M44"N=13'3?DW)+;X^9'.?G&\VNEF?2R&X75"R>C-FQTZHZM2I U9]:8WG?DW
M?G5^K4T!:2[M)=0MZ8!KIF!^+1^6OV9FF)HQPQX$XO$BLZZI4).H%0D@8#X$
M:" <1C;66;9&'!LEGL,='=_MBI>H'+(BH]-E;*A'G- 2#\L:9YJU7AR^^G*S
M<W)CX]#KS'4%:HITK3[RQM0FM1H4YTH.N.6'B'#<KS7'O&=-MM^&V/TT%R<Z
MCY?Y/XL8NRW)TEP+F/'Y3\69>AI7(],4]3A7R,B^/R@Z_80V\Y0:F9'R/A4Q
MY5\!C+^'D_YB/VS';M_0OS'-=[G(I)^^W.Y)()M(NC71F&(T$4\:8Z<<B8KW
M5#K[I=ASKY[_ !.7ZC()7H"8YE!'1HB2!X T/PQZ"C&.5X'GQ\5_CH% 5)_5
MB0RT^Z5D T?'[IHU/#$D/6EE705KD/53$&C;6K:&*G,>4J:>!U,,SBI=B[:J
M4[:2=#?NTZM_:OV_H"&/(+<G4*Y":"@J* Y,<:7YM.NR77UVWV&Y.5MM>]+;
M2XW$=1&THKV$#DZ72&$ *!GHMD*]0<@<<LM_^-S^T^TZ5[!-QV>"7U4%NAJ!
MI/P'SQC[]803Z*&?CC%=5#P@5!\?Y<65NYF=&3(&[F*QL3X*M/E5D_\ NCC(
MZ"%=PL]3FBVU7]%>^RSF9]TPD/?_ +BD E%W5C4(Q*_JHFR\#GCICR+5-KCY
MEV'-?G9\;E]J7:5T5@=8TS$>'ZLCJ?M'7'H^?MOSGG\8E(222LU223^J)SK\
MP<2@29(QT6X_WK8A;A6\F37_ ,#Y#>^S:LO>+MDR)))_RIM*ZXS'I_TOIK-
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M]I]IU!\/?#K?V$'#TR^%?X\8A\3+0=5B(DU)!S\@;\IR.+>\\JS,IWH50-W
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M+8H[$F"%B#3J(U7X?S5 _)CESO$%/?)]69]ITIV;U=ECYEV&R-4A:]:#\_\
MU'&#U+4;DH]";,QIW@F>5.+6*CFJ7@QOM+($IFP-?F \?7&4T,E_/6:_619Z
MU_\ !O?89S$>[563W"]Q/31@O[3_ $4K_P %$PZ@^..G/(NCV6'4HQ[#FASN
M5=ZE]J7:5V1Z,VH2>4,1^I=Z5.9\E.HQZ$EQ-#1]E>830%<U#T8?^QI17[06
M)%<0)ADVHR.#ZE-3"GX>2@ )Z&OAB-K\4GL1=VW-]$6;MV?K_;5VS9;28A>1
MVP,@!4%DN%HU"<C7&I.='P67F-I<EYI^)(P7#/Z3K1VMC%8V?IU35:1ZJTJ:
M!0*UKT&6.37C"'_V%M?FR[3I[MD5'1VH+V>[B_V(*LH#2Y?=;+Y8M-Q;63S(
MSL75"GC^;%K'\6'F11XVYKRL&[NU+72!D&7(=3YV.7C^B,9?;_C=KSF-UK<=
MJN2CQI0Y*/>BCO[F>YD2QN%_&125C)KG$2(R22*KTQU Y$X;/5?EQ[#G)SP>
M;=DGBL[[2JLZ2A7#07" J6H5$E:Y] *BF-[V^$O.:-U,8I1IU("2,44:E=A0
M:U-H^=::0:4/EKBK'@O,6H-D9R=(256?U-!%NXTTKJR)(SQ$$Q>U5)V]S/9,
M4=D3E\14-;R(!1)6'F)S\R]<:?YX8>'*_P "[#<G)*3EOV5?7])V@V$A:W$9
M73H54'7(*#0#\K''*K?_ (Q/SOM.F7A^L-'%OZB[ PA.A,\P?XSG^?&'C[#\
MYG,'B*4H5IXL1^3%M;_&*-UN@.W1F%K+3)=!!.50#U^./H]F_J+;Z5>?:6>N
M2>@O_I>@XQOJ)11_WO>Y_P"$]1M3VPG<J3YOPRT )%1IKE2F.EG)&O\ UQ?;
M.</.:+][3Z\A1?T9(V5'$S:@U<CF1T-?MQZ,C2B\QYS7!#.6,44&-F%*ZW!!
M5B*FG2HJ?'%-\2Y7 OCQ1!^ZG[]IKR_>0^T@:LNG]U;WL9=*=,L0(EK/\0PN
MOZMOND\-&U=KR*C(D]L=B!;[2!2O7 %"NWWN?';S@.P<(VWMEQ.\?8-\W+=9
MN0W5_?I?\D&ZP_A;S:=QV^%B#'';R>69**!USP!''=3N;>]V.8OR:\VC;]EL
M1L]EL&W[%M3%[7:=OVQ/2B$,K 2L/3) K4^;Y8 CJTO?0U,D964L?38D2-I#
M$*#&00,ABHDFBC)8L/Q;S?9M50:("!:4I76#YB*'I\,8V]=7\W&VU@GQ+R,U
M"PO*6']JVZ7LWN6[)QRHDB_UUV\@E$3060SDC2H8UE.K,]<:SYQ6H2T;2Z;+
M[#;/*62N[C&U'V<Z[3MDL1IAB S/I1L2,_,9&%?S"F.3?B!Y=QNYXYLMR5'\
MITT\-6LNVVZRQ<%4,G/K^3IBVAJ%<MUG"M%AQ,G&U&U+[N5*O$Q+:2**?,17
M_*<L1>6Y%-X*6+1<J%4ZR[ 1O#.L<NE0WEI^0Z01\LCBZTUF,M;9QP4U0EDE
M#176ITEE;^4Y*O?K/,GN^[D*JK&M+5"/3:3RBW- 0#7'3;DBVMDC&N&1>DYG
M\[GW7B"<JUCWC]!5Y-SNT!8S(OZI=)%LP)H"HK3,&F/0UARE:E;7LKH-%ZFX
MKMN+A[03MMTN9$\UQX"H$,A\!2E3\L36ZY&Y8R+99E[7M!&VW>]1%].4D DD
M_AR-)SZ'J>F+:#:OX=#+>[*;;QP)N]O^YW<O>;M]Z@+%N1V11C$6)82*-5&K
MI-#X4QK'G#*FRW,W#NWV&W^4=Z'O6$*>OG6)UQ;0_P#Q5:(%TLL,)8>FRG48
MU).IB1G^;'*CQ';5W=WDE3%G4#PY5;=;E+AW:"K,=((J,@,B"/LK3/&%DW:?
M=N.9KI,Q"*>*E1":L2QJ?T:>'3&/U=]Y:9,/E)YVU3VAM>$+!<R,/-^&GTGX
M&B@'K3&0\*6XSW&,GA]XC![W*$-#<5*T@\>LY=?=)>2VON4[IQQM11<0'1Z
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M1]M,:UYKZ>[KMKGI[:K+(^PVURNNZ30;I;O74E62;^<ZW+&]AM[2T6XN'/\
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M;LP)!4T4Y$@USQ1ERWVG-C:@GYF26^:6YVYY9SFZ>;Z S/[OO< H(_KO?9Z
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M^;T23V(#&59'L]R()X>!KH";<GMW.M#%3-0WCKJ_?HS3 MVG%W+M6&T7\#]
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M<@L01&<A'-KFJ,V-?2-EUI\A>&]JRROPF4$_CV@?@N6+T2$GC'_[S_\(N-W
M2*F.;[^+FK&RB.OPX$S5%RO6NTM+D(=C747C(IE^%#CSGRQ?E,6R4@A,?]8)
M(Y,]?E8%Z$2B$E\?;@L#GU1RDD@5L<PC&$O>J:UM#.ZG!E]T7AC_56X(F]1X
M"XLQ/>/7B&Q?)L(==;(<D\<)LGD69X,+YKQR([%"4GXTCQ+V8D_X)@Q[,L\3
M3O+J&U_B"6L9\1]S,X2M/S[\DE/ET>EZ36?O_0DW>W5KE'\8F]E?BLC-*\"M
M7Z O1'D><@4(N?B[1 B<KSJGC#[V$M>.YF6ILIGW_*\.\;_S+ZKM8"U*Y0V2
MPK;W/Y3-/5ZZ+-L@2[>D=_$7I"SG#K''TW. '3_NW.6LEK2;;#Q,NNL>>6JL
M*N,\\4H91"Q:%+"2+U0XB,EE[F",T.[GL7+&]%:UX)4+Y=;_7!"*#PL+IMV4
MK\/<.QF2C=7RL#MQMSV\[EB'E/H%B'U>H_D+1:S6NMQ="8U?1EZHP%I\H/V$
M!H)*\8G[@/)==.%M@\S;%G/!=M.R.[8CE<>*ZGX4BZ2C$Y%5=T[>P9]-;SRQ
M#?7$AD-R:G4"Y/N8M8^74)H:LL SYEEO@[SC7K04U<6#WC*6H!F6UBO [TA7
M%#M\)![M4KH@S3EGL?YQ_L^#?J:*,X_()WRB5\!0&T:UML9Z#7H8J/CY(@3X
M<R'?6WH6M>-$X*[8O0+N0*+PG4']7&\.2VH2+G5[U_M.J6!7 *B?/[W*9?Z1
M_-*R)]*#2NMBS?F9^W_X!L\ K\3GE/>Y;2V7M9"?6G__XODN^=WRI(01*(R4
M[RV3 ?@G-88D#DJ 'K'JS;,I(#927K,L^ K(]T3&'E_.$+OUPLZ*52BZ^TQ<
M:NIB2C!U&+T"&[E5W$[4^:XC,!]Y_TTYY4,6M\N-$UIO&P09>WUJ5_ @^J:6
MB5G-=QG.Y;O(OLX*2P2Y_QES[ F2XL/9BPO]:  F3.9[)*&U<$$VM:_]U/>M
MGZZD<G<^(C.J4QG94I.E@SXGLCE> 7;1MV?^H,X^<)2="Y)Y^VFHBU==;JDN
MU!IJJE!.':6#!*QQ D-L[_#\H[!]-&\("E2:!EYQ*7R7#NHR'OTCIG#[9I/!
M[/P=ZPI+0 :'T:S5:H8H,?15FX4B&$#]/QT(A?4]C;AR+)3AEF"?V^BI5T7F
M[ CK9_6:YS52DM%\ 9=?+ZS^ZJT/DO7.?,B>'JM(IG<H"/NJTC>JL;N-2GD"
M%HBU'13(/Y\Z6T:OS>0;X!6%S]WW&L,CT)=F?XC_?=&RZO:;7FVK(;U,XZ*@
M;PX=^<[&:(\B$/<SCX4*R=*CHW[V+Y#*DOE>W<>1R>>9QX_L9C57P.:U86!N
M3VO*9\'/ZXH!+\Y9U+YK%\]Y$BR'<<?,J@F,H![;EWXF1INM:@,P1U7JST^I
MW2,)$YQZ?PGL[UP!(QVJQGDJ%*5GSR)-LA>6?J9W)B%!0?AO:Q(LVA][V?L9
M/<[,+IXZV6L1! G^%H;KK%SGP4C:/X:)AJ7O.FCZCST?2SM2>)V.P@7JT]G6
M29^DP:1;!%;3- :-*MR&Y'_7GR$?%"*=D#,[L;BA:F'\F@"XF&MSU_WJ9P%?
MM$3:0I#U$:^"S]RA;4%>37@$TV[XY3=R,F@TV+35@\=C@1>^)*G84'$3[GEG
M4!W0+SF/.NL,?&H^V/E1P,3YUR%F*19OUG*49MI!&@PR[FGR3-:^*!0A!_PH
MSWI$D:5<::A"D2!,*C\QV''0DLO*C%31F+ +P),3M'A-SWW68-C?A$#G)R0R
MI-/.-/2[?;K!7KWS,_5[-,)F%;D+M&JA+R[7G7=?^GB/5C%C")KYUR:"FC]Z
M.W:=I@ K4151"]?S)0^E,<=[J0J7TV2VG1,Z1?Y&ST<"68!B5 5DX<:'**1R
MY^]'M]-6"'R!I\8Y0)>ZSU[<R2WX&9A<!U_BG^@9TL'P$5?[X/QKOO^4GE)$
M=,<&K*N[H#U1C0KCJDZ5";6-3EEN6[Q]WJV=>7SW,> ;DM,CP-7R_P%02P,$
M%     @ '4"O5ELJ_.&)C@  ]Y\  !$   !G,C$T-#8V9S(V;C R+FIP9^RX
M!5!<W[8W>/! "$D($MP]C33N"4[C3>/N--!(T[@FA(0@P=V=1H.[1"#!@P77
M ,'= @0^[O_=>]][WS?UYDW5S#<U4W?WJ5._O6ROM;:MT[=3M\O 4WEON"T
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M4;[0TMH0QN34/'T0'E-IH W7>^NK.1NKB3R,4]C][%Q\%:Y]GT#O,8MX'QZ
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M@P>_DGN#V>D<&=+#I*C/XS)7,XZ@7@G"/::/< ,),5Q]LNVSE3MGS/$H_B\
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M?/(@C9?]V.P^+%1$6.6Y.6%QV59 I56SN1$B.1-I<@*F;X#%*T+"!C^W@8%
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M>%E(?"H%]L'(DCA_5U,W&<M]0[3QY)S6OJ396W>XH&["3CIT*+@42O-64)Y
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MB(JJ"WEQ1P6MV+LL<5"$SE-_/DMJ$%5OB-%<QOD4HI7=$<T/QW:2XJNE9OO
M#3EQ-FZM_'%C;4<N[/E3 _U[D2[LT+#"7HRI^T%Q#6P\+A@J[%TR59>5.7YQ
MR5>QK__IS(G],N7W;.7@5$_=N[8%O3SMA\]FGF]7R[VN+Z[3 ;V[9Q3A5CAZ
M3]M9(*2:AX5@N0I\3U/D1-K!(.H]K?A"FG^L>(\@M31;0-FJO+,>95WG<']H
M'QWH&!5'"@GPN="K1YP5CCLG?T=#?%PSX.([\AZR?FZ?4_%H2&I!QJ9//81
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MQYMP\G<]T>-]-[^9"X$8O/;?7=_,V3?'2G1I/*Y;'9U[R4:CTXJR&0S0Q(
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MP?FQ7V'C7H8KW]"SBE<E87D>E%\C5S\15D?]:50G&$C-JNZ8MN;H :"ES&"
MYO'<#A\ RVXYOW'"Y+G(WJ?3)T_>:V;Y;>5Z*4_(]$7/"A".3[6%XA*'46 =
MYQ*$(+>40;2K++R8[+F8WKWMMU^O:OD3'(U^R4E]5%\C3)\ (A=2U\SWU)X]
M"2X%J0M.;J'5H< 23D D?VXY+V%;O6I25U.DFZD1P?JOUF8^^-ZC<YIM"FV@
M%*=H4?AM)::2X3WO%RV.$)7L^CMQD]V85VYR-N:7I?4MY*U+[S=;^@]&=#0E
MKE[I_P"J;2M&DBEED-@. BVW-[= \W(GI&.K^RDN&<'7=M^)T4_3@TC]>T\[
M'P5AGS=:[MNMNH4Y;$Y6\ZRV,AW_ "CN!0*@O8!L1D<<G[4L7+&8Y-.NYG.<
M+BW)77Y*TJ_YD@OCY+(TOTJ+3*AOU^HH6&VT(&X8NWM2E >8=T='G8E?=\K]
MZUMATH9.5\BEL@_2;)?AU,I>Y,M"W SN-O6A"</0L.M .!12I)WD).0V ^#&
MU[:G=M\:W*M3+CJX[57^'\#0[RLUVXC\7B[:9*N.X)5+7?MZ(<I,RK2WZ6TT
MAA"8K#5/XJDHR\!<2!B"Q,[(GRU)5VU,=J]?=S;73\C;A\95H_@PN)(9 4[=
M- R"TH;:22IX'SO- '^O$A[TLWKN.I03W&[RT+ERQ7]1U[X)D5)Y+*(A3390
MU>]U[V\H.M#.2O-U"@59  [!X,9_]?6,BQ!NY\?@:G"8[;GOKIT_B:I.<0H7
M\7ZT&&DAQ3MZ6 D9'S4H6(S:G=U8!'#2=HQSW+V93]Q_<I>I/]A&WXWGR%-&
MCT+\^303R;Z\.,I0 =/:@=Y+;:$K2$, NH<4,U  ="L=M[FM7LWB8[NJ6E#I
M.2M*[@;)?4:K?@#Q4*T^UU#@45"Y[;XZELH2A*S *PT5!2M[,H&('VGBRL2\
MSCZS2X/%=E-1Z4(W_')(8YH-$'G$.!A="I#/#:2T6UI3<$7YC;A"D$.?J]G2
M3GB(]VJ[?S?*E6?Y&+FX5N^GX'HW::;/+RTZ&VT*.E9W%9-YI;5;&UTNY9[!
MX,=_>\N-P:MVUZME-=="55M?:?L/.%\#9A(YI=;\]UW>H-5R6H!:%%-=DY9)
M22H?-&.(]CXUW%S)6=M+<GK\2$XBS*6=6?T$EOC[-).G6BG#:;2KO^X"D9\-
MI1[ID?J0I9 2H^/$A[RMRCF05E.CZ]S8Y^TYOQ_I-G_(<UQ>2?05PLI"V],:
M<59@+#6<*3O9K .\/^3B;X[$N1X[R:[C-@V[SP/%^D\[G(NPIOXKM64[&.1N
M_4I"""D)6T7QPI :62K=!"ORX\\Q[-V'/^6*>^IH\9:NJ]ZOB;7_ (Y+('*%
M X:$DKU.MG<"&1O[^3J>#NDI1F4H&W'9>^[-W-XVU*C;_ EN1FY+8^AVOX*Z
M$?@GH"N"R'A=]V(=7PVP0OMX_5+V%"E#QXK[,Q)8_&M.N_\ ,PX_]I>DTS\P
M4=?_ %P=+04.H9.M%E^:9KR&F2ZU(6XMEL.AI2E*W?U>[ECE,R7)+F*PKLK\
M##=S;T7^'Y'K0O6FW#4[6J\&U9-.AW$_3)+5+=J<9*H*JBIIY#:9ZMP[B,OT
MQTJVX]@PI7()5I4G[+<UZC'&AMI:I6]0*I(U=J,"KW15:C'&4']:AF!#S2E*
MEE(2Z.%M 3EYGF]&)F2W=2EU[?I/.3\91#B>=[2,L'>;;H-CJ*&TI"TA5UQ6
M=QY*2.$=\[QS!QX][HM7%RW]O0YG.NSM9.VUI'\3T;:S,I5RY:@$!L\+3&J-
MH6-Y)6INW]Y.60V,#HWO%CHN0Q)3X6BK2A+9-KRXN[N>;SX*)'\7<V"LEI6Y
MIXP$I6 VXI:I\E:DMMDJ_5 _IJQQOLG'<,FEQ,C>+M.VZ]SUOX]Q.E& & &
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M5+7N2EUZY?J+S$:673I+?E;G-6G=C;,6>[2\HTIB,A7:&RR\Z4A2E.A.:SM
MSQ=R'%N_2-%MH;]V*NVU%]DCHW*ERCV%RCZ=3-.]**W4W[??JCE;DO5-Q$ZH
MJGY<$\1;*E#L^8SR&TXW>.P+>+#5/0TOMY6U2'0PKK[\-C1GF"UMMO7._P"X
MZZU?=#<I+E$9@3F*?!DN4E]$EML17EI,A"5)\X)!4!L.-'*X:.7?5YJJ4JK]
MYI_XZYY?*WZJU)JWI8+5\6)<.G%<J<A=NW!1'[?GK8;#<MB ZQV5P15>:'5<
M/],G)&)NY8A+!^WDNU"7N6:V%NZT_D10Y0N0K2/D]=NR5I!<E7F-W0419PFS
M8=1[*METK67#'6L)R#IWC\Y.7CQ$<1Q"X^Y*<-%-NO<T\+!\;=Q]:EW-M\/S
M2OG-J%H535*HW%VVS&7FZ4_1'U0F2EY:2X9&\4IS2M!V'YP(QCY#A_N[VZ2K
M0LR,5W;OQ)96MI\BT+(HEB4VL35T.A4%FVX")"$K>=I,6$8"G)#GM@@C=/CZ
M,2/V*CA^"GJ2H;$;+A:HJI$(^7CX:^C/+?K'7=;-/JU="KQN-=2[Q-3F(>I#
MJ:K+,B3V5"BK)UI:SYARSQ#87!1Q\KSI4G6OX$9C8*CE>5I[J_L,P\V/)G8'
M.-9%)L;52MUU%)HU775XKU&=3!?3O-[B4RWO,"4I7XMH&S&;E>'>==C*2K%$
MM>L*XC(^@^@]+Y?=,+9TEL&KSA:MM1'T0UU#<DR5H<=*G%NOMDEY!5M!&W+$
MGA8D<7$=IHOLV?$J(B;0/A=Z$VWS)-\T<2K78G487%/N()>EI%,5*FM$.&/#
M4KB+:2HYD^+'-Y'MRW+/63VZFO'"4KGD?U5T)+\R/+10>:/3:?I=J+7)Z;;J
M$B/,>%"(8DH=8(_364J#:D[2KP8Z/-XNUDX"QFJT+LZT[]OQ]3KW*YRI65RD
M:=OZ<Z65^J2+8E5>74WWJH\S59+<@H2$IWVRLED*^<1M'AQ3A^,6#:<(Z+\1
MA8LH6VGV,#ZR?#1T4ULUV@\P]X5RZ&+W,VW)+;#4QN%3'9EONAV&\U&=6DK;
M_5C(J&\?%B%Y+@ON<GR)539COXT;EZNM29VJND\75?32Y].;FK,A%NW/0G*-
M5'&>&T\S'&3"%H)*0ETMGI^:3MQ)Y6"KG%.RTZTH9;]F=VQX^Q&GE!Y -,>3
M'^,)&E-=N:0N^%1%5%5QNM2FV$QPHH2RJ-D$J4#YJLRD Y'&#A.%MXF.[C5)
MFE@X?AOU5:'X7-7\.;1GFRONSM0=5;AN*-7K*@ICT)%+G-0HC8:D-2BX[FI.
M;Q6@9 $YC&'E>-C?OQW=M4;<\:-V3;JWJ35@V9*@6C&LE%6>70X]"-LM.]C*
MY3D$P#!/&<^<9*VUYI(\W$TL:W+"V->NAL;(2AM(8<L?P[-'.5346]=3-+K@
MN-^Z+NAJB5QNJS45" P')QENAE@+<$96^\K,'=5XL1.!PWV]S>E1C"M6[*;I
MK4[/S?<D>F?.%0Z10=9[CK;,.WIKDNEII$^-3(Y,I!:*7''7&FW',CGNYDX<
MEQ_W,:-5-3)P_/<J9YT6T;IFAFE]K:96=5I"K6M&!%@4MZ>LOOKI;2"% OIS
M*WDI2-@Z>GPXS\?QMK'Q796C9DM8L8VJ*M2)6G_PR-&+!YDYW,_;]<NM5^5>
MI5.L24S'VU4UR54AYX0@'SB,AD#T#$?B<#:CF?<):&I#&2O5)'<RO+7;7-'I
M9.TLU(K5610)=1IU3?71%(9J(=@E7^ZI6LI:4IQ2L@$G/$ORW&K+ALDM"1N0
M5VUM9^;RM\KMK\IFED/2O3.NU>1;\2MSJNHUTMR9O;ZADXJ&XM'G".',RXD^
M<$_-Q3B>-6"J1T,>%;C:N-?'J8$U'^&3HWJAS$4_F;N6MW:WJ#!JU.K3;5/D
MH:I"9%-"0VP8Z2J0W$(;'3B'R^#KE^>FAKO"4[OF:]5?V$P-4=)X>L.F=Y:6
M735)B;;O*@3+?F*ISC?;^S+4A!6A:B-QP)0/-V9XG<O%A<PO#3X&U=@[JVKH
M1_Y0>1W3?DMHUWTC26LUYV%>=4ITZMJK[Z9BHC]/CE@%:2XOLSN1^8.G&#C^
M-^WM^E(K8@K3I$Z;S3_#JT<YL[\M#4#5*M7 W7[289C4]%%F)8CO1VIL>5$?
M<0ZI*?U;Z0I[=.1\&(G.X%Y5[<U5FME8GG>Y]2;0L1UFT%62U6I!HXM\6ZE*
MV4*<["*<:<I(61GO$G/>QT>1C*YB>*:UH;4XN%OQKZ:$).5?X<FCG*;J!=5^
M::5^X)5>NB#,AU-51FLS$,.2YKTT);;CK/9AFX!FH8CN)XF.)D>1*DC%BXL;
M+T6IWCF]Y&]-^<JBVK0-6:Q7XT6V),V13$V_(1"<[1+B+:?,@2"5R&PVL^<@
M%8/@Q9RO$?>Y$;DM6O@8\VSYKE9F?-*=)H6C^FME:56U5I9MJRK>B6W3W)""
MN5NQ6%QW'59><=XN9YD=&)3&P8VL/PDC9C;L6=JZ$-])OADZ$Z1<P;G,1:EP
MW1_'LJ56I?!GU!MZ$MZL+<<D!F+\Y*0MP[%#S<<N^ \>=]S0U+&/&WZJ49G;
MFIY4++YK]-F=-]6*]56K:@5ZFW 'Z7+:I:T3*<E84T9CRT;RR5%S-1"<MF.@
MY+CUE8:L43IT,=[&=_J?I\M/+/:G*QI9 TLTOK<U5K4^HU"KH76%B6^\_5G.
MUJ+SZ=Y &[L"@2G/PXP\=QCQ+6U:(I#&:T[$9;U^&9H->W,LQS(UBOW-$U/%
MRTJ[8L5$Z.S ,ZDM($4(ICKO&"5A*N(I*2!O#&O_ (2W._ODO489XK?5$\[S
MM&NWC;%4MIN[Y]N=X-]G[]HJD-5&FN!9#2XSK@*'&TM*S/C7YN)=8[CTJ25M
M.VM3J6E.D]QZ:P)D"=JG>-[N3)C3G;;Q<86^>#QPMMII&>Y"=R2EMU) 4D9*
MQM1E7\Q<6]$6.97X<>C_ #3:I6UJYJ+5KI:N:T8E*CP54:>Q$IC2J3+$]';&
MB4^<7D)W-XJ0K/:=BL<AS/#/(S//+4B9\;*]/R2^LFA7+*?N&S:U9%1JKJJ+
M5;<7:K_#93VU4"= $13C:QL2\6EC8.@C/$U<Q5+CO TR2C;K9\;ZT(6\JOPV
M-&^4VL7U5--ZU<TR9J-1.XKG55IS<]MJ'%4M9[&I)7PW..^GS-A SQ$<5PKP
M9[TJ2,%C%=OJ]39]CKC=& & & *9#//I.SI\&7B\6 .)3"%%9\Y*G-W>4A12
M3NY9?V#%KBFZOL#A+.W/Z05Q"  2V4D(23X0WX/%B[\ 80I.BL:FWNF^7KTU
M)J=31*ER&*3.NMY=JL,24'=B-47LP;<X/Z)*LQBB26@/W=2],*?JA;J[6J]:
MN.BPI%1AU";+M6K/T2HRUP' ZB.)S 6]':0X!O-@9*&PX74KR2G^GH#[M.K(
MEV);S=M/W1<%UMQYK\EBIW$^'ZSP'%YM1%R0$J?CQQD XK-2@-N*KT]"K>Y4
M9B^N<M=#KVJ4+5:=?6IJ*[3J@B="I<2Z)$6U&XS8"78#MO-M]DD)>&[NK7YP
MVX=ZAR;BHOHC,]WVHU>%NUJVY$ZKP8];A/Q')M%J3M,J44N %+D2IL!3L!]E
M0!WTI.]EEBJ;70LE%2I7L8WT+T61HO:LVVTW9=UZKFUA^INU2\9_>%3(=.8B
M-NO9K<:;'Z9.:NG+%M-:ZU9?72G8^#5;0=6J5:I<Z?J%>-!H%//:#;-O3$P(
M;]=CJ9--J2I<<=I2VVZVKC,G>0Z#D<L))2Z]BBTZ&95T-3](-(?FSSOP683\
MN.M#$UU*(W 6^EQ"<FY"5C>\WH(Q5ZJG8=Z]V8#TCY?YFF-YWG=L^_KCO>;=
MJ."INM(0RQ AME*([3B&W%*FO(:0$<4A*E ;<5W-QV=BJ=.AVW4?1.DZFU6T
MJI5:_>5&59TB=/I";9KTF@OKJLP ;\UYE+I<C);&6XL%*O%BRW!6Y;H]2G1U
M[F6*5394."Q#?F2)2XS!95.D;KDV22 $ORE;H#LDE.:E9#,^ 8R.3=>FI6NK
M?Q(OZ=\K3.GNLE>U48U0U N!-P"HOR;5K]3$RCPG):S^JAH4H[C#(5DA.0(Q
M9M5:]RG?=W.^:\Z+-ZV60_9;MQ5JV69C\9<N307U1I$Z(RX5N0WTA2-Z*I1)
M!!S!R.*ESDY=3O6F]@LZ=V?1[.BU>M5N%18[++$RN352YC[303N(<DJS6YN9
M#/P$#+%KBF6U[D*+FT_NF1S6P[^@6MJ;)I[59IL*94N A5"538\3)YUB:BH(
M?12G%_-:X&7# !5C(I-+:NC%632U+#[=CUQR%#NJH/NQ0G@V7+13[C>2#NI;
M@OO)<1'7N[-\ XM6G0&'N6JGU>#2[G54+:U2MQ$ZNL/-)U6NI%S5AYEM"@KL
M3G";[,RH]* ",5;;=7U*UTH8SU\M:O5+4BEU>W;9URJM3$.*W%JEFUYJEVI2
M$)>;3(+U-7OLRQPADX%!*NG+;BNYA-Q6U="7E09?_@^8ATU9IXVZJ/G#6VW6
MW'A$*5,Q5G-/;5N9[I_17BE2V*4>A%'ECLV?:]SW6IBRM9;7I=5I3$AZ=JI<
MAN2)6:F9RW77:;O+WJ05)7O!M*2G+(8I+U*CZ%%!)[EU9]G-O9M0NVC4&#2:
M1K-49K,E,A#VE=P)I+1#3Z5.,UN/+4B/,;=2G)PJ4DI_1Q2B:HRXD19$5]-@
M4%N=3:Q1UJHS$==*FR%5"IPG\FFSOS-]+QG%*  ,]W?Z<\5[4^""5-417T8M
M>[H>LM2N&X+;U@W5IJM/7=-XS(T>W>[N(X(4:-1HQ*$.);4 AX9J6,BK(XI<
M2N4W=O@72DY=3+?-%1KDKVGLNFVK!ON;5ILE43M%A"*Y4(D=QA\K>E1J@ZU&
MEQMY*4*2DA2%>'%8^CH-SIM['[G+G1:I;VD=GV_7:1<E/G4EA#*F+JWGZVG-
MU2C)EN%;B4J5TI"20.CHQ6NM3&X1DTWU1A2E4>JVAK]6*A1[+UMEFXJNAVL7
M'(ND.6*_%45;F5"=:4PVTG/,%)2<LL\5<F]&9-S4=NE#/VOU$=KVE5V42"S>
M#\BH16F6(]AO\*Z@^Y*;4XJFOE6['W0D@Y^:<6OU4KV+5H8PY0;2K]F:<5:W
M[@IFHU-<B7!(=@KU+E,OU^;#W063QHSKAX06K;MR.*MU5'T*MU,6ZZZ?UJJ\
MP=H7U%MW6.O]Q""W3E6G46X-J0GWG0W(<?!6HO*X6:EMK0$$;=[/%(?VU2/0
MH]29M\19,NQKDCQ(U7D3W[>D0$0J=*:;JP<E1=K+4A.Q$E:E9%2?#M&*-5ZE
M6VX['T(A<F-BW+8ANRFW7;]YT:2\4R8C-P< TQMA:G2@Q7&Y#[DZ>^A?Z]Q1
M!4KI Q5Z]2V*451=#NW,O'NR;4;:BT2T]6+BI+,*JO7$_IK=35KB(K<08SLI
M#C3HJ$AMSSN'L3N>'#O7N5TK7N2/MEM)L2CAM-7"U6Q&0VQ4Y/:*\08F:4RW
MBE*7*EQ0?/R&:L7;G6NA5NJH^A##E_MJZJ/JE6.]K=UCHE+J(K<H(N>Y36['
MJBI$GC-RF6)"!4*?7$G=*8Z<F0C:#BC>Y[GU+4DG5=3)W-E0JS<EDT.CTRV=
M0KE9=J*53XM@7,[:\],7,<9:ZE&#CQ=1F=QHC=7X3@G0N3:=>YEK1* Y3]-;
M8@"'<5-[$RJ.W"N^2J778J&]Y"&ITE9"I<@A S4>E69Q2?KZE7)OJ0_H=KW>
MUS7B\)UIZOQJ*_-F4RFR*K>,F?9R'2THO3Q2=Q,>G1'T[&F?.3MS)Q9.W&YI
M*NA9%*/0E)K\BZW=/JNFS(UQOUPO1F80MKA-5+)_)#T+]?D@MNH.U?Z)VXN2
MI\0E=5U9-)N+&OUC%C5%HA<=* XQU4QP6D,I4:$1\U ])^I(*X943&T-;8]2
ME(A08HXAB"+&T-Y4JXU20T35K,9&42W5ZN3VK'7OXUUK/WT/>^UO?VOM_?C9
M/8AZ8E]LVQQ8[50Q1_RXR,,FLN8^83W6Q4D?[XZ=B9M.GO AGC_/R>0)9O^R
MS'1/JQ43H) 2S>+VO/-="QW*O(+S>^4!83K0+2UF"Y_LMGG-7-.EX]4GX5'J
M"JTI>=O<GF&D@];R5/5M"-*OF_3-DWYOO'7]8\H,.-,!.Z64HW3[#*DS.DW:
M? 1]HLVHJDHW0"_CCGG;U\KF'^K3Q?#7O?[U1I%<NLEE=%<HSJ4VW=9'MA('
M>S8^PD$7 4QK.K1JUSXF%'WAI75QD8$O=SXM5(!'#ESA]5&70E=>)LP6)I[(
M%<5,2&65F](^W;T G;IL=5@)#KDH0UE]H/+US'$1[XD2DV[2O-;6A33OK]%G
M%FAM.KXR7+_:]H^ZO9/!SWDL#CKH5DO*>UMUAIT1-Z;YOCK,?J0"J5>;XE_K
M/>&26?N9\.D;P0-^;Q;/NXRNGC59YH71&RHN\^\4-*53+H[+4;#:T99=6"D]
M_$,D W;8KG.G.7@NGY$6SMVXZ_F6==FIS@S1">W*Z  K EK1'M#(RM1Y1%PZ
M,LWU+G2D>CQ@MM^LTJT.LVG(5'[UAA<Z[DCV;L"H>F#+^9L<72'(N_L-=!X4
M6RKS[.0A[8#$N*BKF!-M3#FW]2-/G7-\FC]1<H+1=6,>4FOU%VR#&0:_4CNL
M"*>#49=%)5HF!/7M+3!^J!>I=L<0$#L: C6>7%:&;P!X@Q5,Y$1]HSQKU)IO
M<+RJR;A5R(2[-P?!)->.G*5"#/O&]0+S[$>65JJ/CDF[J+8EL%G\?$6MDW7^
M$H\(T?'UD5\&#);,3,IN([->R&?G2Y<NF<O7TC[KT2+'M?6VZ3M'PV>,BP0]
MU\D<&-(VH'MAG@0WC897P4^>EO&-I)[!-;BE*/H6(]Y3MPO=,3GQN2C:*.]M
M(\_XZ\8]<+Y_+3+GW'7),49\0<4$K6=!N$89\^KVOUHZGOGUBT)#3U7)%XL]
M[W=AW/"3SUPZ]T@W8?TV^L9B#CH]_-VM&=(Z9O)C(%$55Q#EA4OJA4Q-9,]Y
MSC1')7@<MDV'7SVM7=A]^?R6'XE7[?N*2/-_-4:H;?-EOAKG](ED2I7+7\;A
ML'F&0GM/A51-SJ+"NKAED=[]?5L!SKGE)F;8$Z]#6HW<HARKU"B*!"*]3U+H
MV@=NPUYI/AX.1UBTD#Y%*W? ][)JQMIBW+>F?W)Y8"OGC(C:*'P\-<YXUSIL
M85%F.78H8MS WR"W7,6O1J?9OK)NW8-5O%94%+]./P $/3:F37_V-"K=\/_,
M;[K2W?SNDK&H6DV$1YUT2UY:E>!J2S-%;^9==]<5RCX^'WU^$H4)\=GC%?;@
M\BSJ"L]<6GO<8'&LKMHGG?PHK<4- N7WGXV5SI?_%!S8//55\0<WP(*GY6IJ
M)KEV:GJ\UC0O>+U;'_=9_06.,MUH^DU%!":K1Z_==K89I+XN+YADBA\ D>@
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M%G"PB4S E^)TWF=PE=:P5?(;SB'4]M]G5;L7V/):B@$S2QKI9DBJUDMAI.U
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MG/>Y%&9@HF6G'W2.).Z<)R9W+)8W@'/HS5)TS[\)N!X"'4S^!U!+ P04
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M[!W_K>OZW[IB_ZNNC#+<T=;'$V[HZ>GQE%7/X)\"BPLX>'@P&SO"$7^76EQ
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M."/%%-5I*/"]LK1O0#) 8_8$8L\?24$05T&&DT;B6;G2V&([+%#.+[>X6_$
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M^KAF_K&1F>^TDDTIXQU&@*6X/H^\K%B3J%QZE;*3R/241<'PC80;A9L+H2N
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MX=-"XH?J&7(_*"]Z^;R, E$-@!AJ3-9IL._Q<K[)H6*3ER+6U(,HG1F( (G
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M0CY),Z@'\'$=,(J7V/AEG8A+TZU*3KG._30Z/164/&#?H]R[:;L;54VNR_W
MVISK/:[EC2JA;$!+:XM',H_=._ #MDO73\E^THK)HF@WR^&0$QQ/%@E_T*>I
MBZ,N;]956'MW-#.O4<)/<5[PIW%)%E@JN7,4MX4ML^0!7D7R.#"[Z=@@*['I
M\""<O^;D,J*M4*M^)0]K9?_\-3'U[BM7,JMY3&U1M(@@=6;(/!^QUH&9.:1;
M@PKM*B@AF:3C@! ,\72IZJ!F_.UCL@">3'KNQ.^R_]S5 (E3]W"2@I'H9K"R
M+HV$;IF[SMA,V?. 5R9'08\YL=C>V/G%^ [:@KQ:%Z!DCZZHH+I,XH[%B2,
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M"R5J2$T4FIS(R&?' /(9JI0"%"K7TYGOX9X!FVK2EE"DE02[J4"212F65:8
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M=]4LTM\^0E7E:5GYA@->]Q[=N.T=P3]N7YN/%O-K?1"N49+R7A\0XT74)0I
M $4H3J0\?*4D8 5HZ30K],5('JIIJ*:I(2!V"F1X'C@&# J352:_DA*C2I':
M!3/]G 'MH<(2$I5I0L+62DG4GAEWT. =H<24 #4DY 5;/VCE\F :-_NC245)
M0=2BE"LP1W$8MFN-VT'M$)<35*AQKY37,]W8,5GT!DVL:C3@37,D'YP,1&V
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MVB^NH+/^36P+J3YQOC;H&7;0+%,:NKYS]+C5M&G>G!G9MC<Q5\"\Y-8G@O\
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M)2Z236H*12I![<!O5M3^BIY]Y*_I(>D8T^U7^2IUM&G=JK@,_>_A_2\=:/\
MC7RW'A0\C^6/9PP'(QD*5H2VA 6O6$@I0H/J2D$(4VE2=2  /K YX!E%<]-L
M>HA;;JSJ <2E3A4"HD4"]:4)6HT373PRP$VA82"D+!"= *R/4![ 49Y!(R%3
ME@&3"T@T\VI0 .H:55TTSIF*XM$UCL4]Z;;]@UA+@U5K])[ZCB>[$3MG,;E\
MP*C(<+I% 3Z9*:YTS.0!Q6(M%IS\)NV]A]0EL)2@:S3)( (R%<;,4T[5C\2L
MZD3LK&T2-:0 0I)[ D$TI3QQ2::,3BV)LUYG6SLW&D0ZJ$>H:$9&M,J=AX8M
MP:4QBF,L<ZFO$XVGX5P !!IV ?Z.(CE;VG/%B);-=34X8S,CHJ""I1K4MC,G
M/B?V,8=;EM2L^[J86X[]YPVH(2D$DE)"B,LA3Y.W&I_:5]V;YEAM;6F9QDVB
MN"K9-12I3DG*IKVJ%?HQEI:.VVUFI,Q6)OO,PI*E4J H9>9%?P5(PU../?I.
M:LE=2EIQ$#FT.*0:!"DZJ^4 5X&M.S/&2EXO6)QM3:DUGBGX3J*"#4UU)33/
MLSX=V+*YB=L;A8K1(%,UJ' ?U4K@#FR?02FOFJ#44K0'/LX' ,6U:@ FAR'8
M/V1@*]"N[\6 E% $5U?6 .9I7PH?# ,F"14 FF?'YJ?CP!&2:%0R)U=]3WYU
MXD8 @5/G3]6E#3@3W^ . (;_ '-0J:$=Y'?W8#P4 H D#C]5-:]Y-*DX#[C_
M *%/P#+ 3(;=6/*2G+C4_BK3 5EAQ/UUE8[JU^BF I6E6F@2 /F!'R=N A*2
M!0@4\0#])S. \%=0[@*4H*4RR^G$S,VT;1.W"]8B)C&]2\=27$CBX4I3X:4/
M\*\,:TS;]-U=/^AP;FYTW3B.LZ=HW\3N![=1IR9CG,!-TE)R)!U:J',9DX\R
M_/JO^OS$?#QS[7H[Y)Q$=)G4B/?Q$9^AT5<%5GMK0 D5-!PS.9QUJYB][Z]J
MWG,1#L%IS$5B>W#T-&ASXYD?U#+&31F/E5SW*3,Y?>EP!5P^7]O&57,]Z1+3
M8%*#AGPSQ++&<0@7J"RD-U2$Y9G/Q^C$,G%.&I?6,3_$7OXD4)VW,0>!HG43
M3Z<<O^4$S^M4_P S[7%'FU$3T2^?\/['YBXQ0;='23Q H/%'$^)RQZH>%+6_
M3ZQG_AQ[(>87B:L_JMY_HYGVAWZ.)D%(!]1#0'E!\PI4^!Q]J?BGUO@1&(B.
MX"^1I9![%+'$C/M-*Y4Q"2)Y(2ZK+BG+\-, O?;6M.H(%*&G$5!%,J=XP ;H
M66:9 CC0#AW'PP"F41H:-*I"NX5[!\N 62?-(\N0SK3(YU[>.6 3S4GUDK[&
MTJU=E=0-,P0>& 456?-4]M<QW9X"-P^4_EG@?#QP"68I02XD$@A*54_TU*^%
M*X!0^E:F1I3EJ40:G@:Y_.#@ '$J2EM)J#Y]1J<TIR ^:F "<.O049Z,Z4K0
MD>:IXFIP _U2:)2"23]5)X_*, MFJ)4G/NSR^7(X#?#:G]%1S[X_TC_2-VY_
M^JEUM=O&N V!]^_2/=WZTE*4E.C=O+10*ZT4?XC^6=4$"ATD#CWX#G-<.6L*
M#R4VSS?A3I,M=ZW1(VW)AKA*;:85&4TJ68;I&I]U#*TT(_*([,!M!;^E+9MU
MV;:N9E@WS,O>RE;>1-W,[%M"G;O"W$AV)%7MVUMJ25N2DRYC:2XL>B4Y:@HY
M!JOS(V6=@;]W?L1^X*NKNV+E& FML*B.)CR&5/!R2A9);+ TI6W4EM=14@8"
MUXT=V2^/2;6JI*@4K]2J230BGFII.7ABL9XI[EIB.&)[3]JVS!J/HNGPT4_!
M4&E,;-(]UKWF>(5#@2_5*UL.^5*ZCTU>9(4@ ?6\3C%,Q:\UCL99I:=*)[&6
M^4O*+=W.3F'M7EIM2.A6X=T2/AH"9"@PTEU3"U)#RU*'EU4./S?7NL4Z/ISJ
MWG&'TND]-U.;U(I$9AU1@^QCUL+6I8L=B*4'0AQ<X%+U4A56J+ IGCB/G/-O
M0T->U>*)B)WY?MX\$:]].+XM&?08M>QYUL(!2=NV-:UG)/QR01G3\KPQ2OG'
MRM-LVK'TL-_ _-Q,S%9GTX,&_8^ZUDA)7MFS@TSI<$FA_P#KXR3YU<K$9K:O
MUM>? W/3.>"4Z?9%ZTPH_P#@Q:"F@'^R*0:>/FQA_C/R^I/Q5SZX3'@;GOP3
M^U*GV4.M1"S3:5K5E0DW)"J@=FD*! SP_B[R<[9FN?6V(\&:U:16U;1;U&37
MLM]:2$DJVE9RL:%T$E.H#/4G-68 &+4\UN5O;W;5^N&'4\$<Y>,UK/"TEYY]
M.V^NG3?*.7_,%F''W&(8GO1HCH<]*.X2$!1"B/4!QR-X.\4Z77;<,6SE^>ZM
MX?U>D5B^I&)EB=N%(TY1G0%5H:A5:95TBA%<?OM3EYT=3.ZKYDWB_+Q^+ ^-
M EI\Q:=((^J6C^&IJ..(M,3:9C<TZ?! ]NWS%4(C/'S$C\TKM[1G3%5Q@MTP
M #X9P>&FGX":C &,090I^96. ^SW9]OTX M,*8LJI'-$Y5UMYGO-5UK@)T19
M/[FJ-]4_ZHBE>\Y*[_' ',V^2KS%)JI6>8\,OJ^& E?@OZM 0*C(9Y_/@)FH
M,D-!H,N%:E5*JI"?E%>. +3;IJ 0620?JT6FM,^/=@*3!D!.;2P:"M"D\?HP
M'B;?*7FE"M*>PD9]F?C@"41GTC28ZUE5*!*J$95& K$:6#G&4!W%2=0^4$<<
M!0N/).26'%'/(%(X=G;7 0*AS",XZT^!(_:XTP$?PLE(_.,N#4/*HD4/;4>&
M)K_=616TVUZUA"Y&>2G4.#0*R3WJ! .7@HXU/_P:F?P/K<E$TZSIYW<3M_[=
MS7I<G&T*.L+O+Y [$ZE9@?/CS4\^OW__ +T^UZ->241;H<SVXAT4<"M8)\/Z
MLL=9>8K_ -3;U2Y[C9H5F-^85U.*:<S%(CT(F<3*GZ?I.,G%9#W$<5N]LU^&
M/4\.9KVTI\V)XK=Z<0U)ZQVUJY&\P0W5Y0V],JA*35.I9 !/ TKCF+R=G/6J
M9_Q?M<2^;-_]&O'=I_8_,E#MLTVV*LLA);4O4DG,ZL@#W''JEX5_["O^7'L>
M9GB.LSU6W=M0I@3=*TF*Z?2&I1""10\*$&FG/Z,?;G>_-S&)P7R($HA-6'T$
M5.;1R)S53,<:XA!._;Y9=TAO4=(H%'2?&M.!P SENF! ;+*]1%:A0*0D<1X4
M& 7.VZ8E*P&E9@@::.&AS&7&N 32+5-++(2TZHE:@=31&8/=4X!8JU7 *J6%
MG+L2*_(1\W# *)D*8H+3\,YJ.7[D<Z$4%0?Q8!6;?-;:!,=T5.=4'A7+M':<
M O<A2U.'1'=-":4;-!X?6I@%<NWSBI]:F'D>1 HIHD$]_&E*X #[NFK9HEAW
MR4U:6U >)IGE@$\J)-!I\(\30T.@TH3V GMK@%Z8,T))$.0 .(2D4_9/#Z,!
M J+*40/A7P*=J#6AIQSXX!3<(S[105LN(349Y$T [1Q& WMVH/\ FJ>?8SI^
ML?Z1C3MI_)2ZVC3AQI@,^^_>5CW>NM!24I/_ (5\MDGU "@I')#ED:4SRS/T
MX#02-U&\PXO+W:W++3MY_:>U+A.NUFBN6"&^XQ.F+"2]*D*0E3S04L^953V=
MF NVT=5_.6Q2MOOVFXV2UV^P1[A:38V++':L4^)<V%M&6_&;;*9%U9DJ#K2Z
M* 4VV3F"<!@BYWJY[ANURO\ >YCUPOMWG.7.ZW!\ZG)LA^BGPZ:D*0I9- >'
MA@(65O)>*FG"THG42T2@#5YJ )I0"N(QVF3=AY^I_MI?C5]VM?FKC+IVQ.)W
M(X:[Y@QC./*=452E);2$()#KA5J6H&@S!H:"N,T5THFUHB.)FBV:12O8W+Z%
MB\]U7\HE/RWX[[5PU)EL2' IM#<4K;.E*QYQEC@?S?Y^^AR5HK:8]V7*OEIT
MBW4>HTT[UXJ3.[Z7[<[7SKW?'MS4=FY(DJCNA!<6EXN>FVRVE)-#2M!W<<>=
M_7O$/-QSLXUK1$V]#N_R/ESH6Z?IWC2I'N>G[QZ.=^\E. ^N  *A25+"L\SQ
M-1GC\_S_ (@YVNI6*:M^&?2C3\MM'4G$Z=<_2)'/'>25$IEN$U[4*7^'6 <8
MK]?ZI%N'3O/!&[;Z&>?++0K./E5V>M*.>F\EU"I*@1V^E3/L^WB:>).?T_BU
M+9]:/X9:&_Y=?V_>&<YV;S[)M >T%23^ U'TXO/B;GIGB^;?$^E&IY9:,1&-
M.H=SG1O,M.>G<0A]2"D+===T)"DD$IHK]TIWU&/I]+\3\Q?F(K;5MP]V4:GE
MKRVEHVM?3KL]?WORA^Y/=;C.ZIW)4R=+ER7;(RZ^XZXI:U K6JA*L@D*&5.S
M'>KR"YRG,Z<7F<SP[)^EU0\Y>E:'(:GR:TB.&<-(6YDA5'%/N@*S%%$*S/;I
MI3/':>VMJ:TVXYF8C=Z'7;F,4BE-+9$FT>8^IN@?=2-0H2\[7B#F*9<,8F/&
M-@UN9,2HI3(<(!-"9*@>&>1-1@"_C9#8;4\Z5EQ9H?B'":$9 T21E3 &,J<4
MD.%9JJA_UP[3B:?9SP$Z7"G65%2B23343G_ILBKAVX U@J4@N%2@*9)*B/F&
M> .CN2"E2TO%+:4A6D$^7/L!J>S %.O56ASU7O,!F<L^^A!H< 1\4_5(4ZL@
M #C2HXU-*4K7 >_$#415W42?/K6?H -,!6%N*_[8=^=1_#WG $-+* 07GLSV
M'+MX95SP%27ECB^\*?5(.8^3(X"I;[IS5)="3VZO,0>!/C7 55>*042'> H:
M)S'?76*DX =:WDG.2Z#VU53Y^)& H6MY8J7UJ"<LR:'YL9]+AG0O-HVPIH[.
M;B9W9#_%/E,E#?GJV=6JA^H,Z?1C2OPQR&ILV\#ZE+VCK6GPSB,NWWMTN%WD
M\VI7UC=Y*Z=WFR^2F/-/SYX/U_\ WI]KT<\COW!.=NR/8Z.+H5_33YJTQUHU
MYC\S;U.?(^"M>S"FF-6OPPM,1EYBS+%*XW/L2MN4ZA@-3.L9&OD9S"(>?9+F
MWI("FP@:?36:D'54ZODQS/Y-UC]9I/\ S'$?F[$1T.]NWA^Q^8R/(D*@)H\Z
M:%)!4:**1P)IVX]3O#7N].I-=\Q'L>:7B+9U*_TAS-E?GTB14OI'F^)4DC17
M(IX CNQ]V^R\Q'>_+3OR7*D.K%?BE@I-322X0H<0*A)&DT\<5 3LI[4%*<!*
MOJU4:Z:99\3E].  ?EO J'K+"R"!11\OA\V 3./R5U7Z[GYL>8:BDJH,B:9]
MF 6O3G@U'4XZ[I2MS6%270#J.1HD9  ]^ 6/W$-C4IU9R'U)+I-?&H-< CE7
M!U2=2)*DD9IU25-Y?9JI1IE@$SMQD+2=<A9H"2$3 NI'$@  \< $W(>?2I2I
M#J FO&2ZFH\:#*ORX!?,D.*0YHE2%E(1D7UFE.%*G,#QP"[XV6RE92ZX0LG6
M?B71\H(":95X8!2](?<_..2EM "B$HDN9TK2I*>-, O4_):!2W*?6',U$NK\
MI.9%:@$ X )4F4"=3SJJ5 TO+J0.%:GB< +)4IUL*4X\5)-2%**LCGV\:<,!
MO7M12OU5O/Q6=/UD72-E3.G\E'K;&FO?7 9_]_'^EWZT1V?I9RWR[/\ </Y8
MX#D4EDO---H&HZED@>G12J:FVE54%%"PE1([P, T:6A28_G"D%*FD+5IC%N@
M#B0G4JM2H5\M!7 5AUM@ALCS^F'VT *"%@>50+@!;-5 G+MP!["P6RM!R510
M-=7UJ$BI K0FF&8W=H/:;JC4%J3X _BS^G$6G@C.Z0RCM_G HJ*@$H(!.63B
M/VSC)R]OF5MG;9:LXG,[FYG0NI2NJWE&%$4^^WDMZ:!0TP10$BA53QKCKEYW
M1:O)3B?Z,^QV"\DM6ENKZ<6[_M?LCA%(];T_*@ZZ '[7H GY22,>:'B+5M7J
M/#G^F]%^6U9_(Z<5CW>$<L)- !YB!0YU&0![<:'.WGCIB=C+R]YX\Q#Y+82:
M]G=_5XXR:F^9[6[:]LYPG\A&0 ^BOSXU;S;'H4BTQV!EM%1/FRXT X?1BE/F
M3$QG9"_S8F.&8VP@?9\@ 54^>HR%: TXY5QN=)Y?5MS46V[9:?/WO^4ML['Y
MG/<?0ACJ=)4%)4YMJ-F"#VKXYGMQZ(_RZ<O>G*UF?P?;+H+Y^SCF)MNF;?9#
M1B('!Z1UT2217(U X<<=M-/?;.]U:MMF,[X/XQ*P4E:EY5%30:JG/*F=!@7^
M.1C0(4FJAGQ\FH',<5',X*G#"4A*-0'UU$5%!PRH*Y5[L 4V2JB0=(R'UJ#
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MP%9A2,AHKIX9@</GP'WP;^L*+2ZUXG@3PJ*'A@"4Q)2W /*A( -:\#W&IXX
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MNNI)25K<J/,HJ*B,N\UX8#?':A_YJ?GV:_\ ^D/2-YJ#A_)4ZVA6G#A@,_\
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M59"@\Q^FE<!/ZGA7QKQ_!@*PH*RI0_/^W@/B0.. C4NN0X?CP%*3I-:5Q'#
MD]3P_%^UEB=P\64J12@\J?HRQ&MC\M;A^)&9F\1V/&4I3'<4>+@105(S"'Z\
M,8-+,=&U.*<QPLO(7M^NZ=8G9%G<GVV6=?)A]T+*2Y=)9 H/RC48\U//^)_7
MYX=TVGVO2GR3B8Z-/IB/8Z+"FH <!P^G'5G5BWYJ\>B78*/[N/5"?&32]VD3
M&_#'$8G,;U/#\.,LSQ;V??&WN?8-:WQ3ZU+J0$I=XD$#YLL0JU+ZS%$\A>8C
MYR2WMZ31)IYO45I4/D RQS-Y.6B.M4C_ )GVN*_-C]RVKV?+S^Q^7UEQ2HZ
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M98!.\ G2$B@*03] P JG=-4!-0>)I6E< *XV7*45IH/H X4H, &\D)6FM54
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M<</T_>W;>?,1;%;9KZX&H]Y6$I;O^2*>IA%55-Q0E8S( JHT(KX8G_U[UO\
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M37&Q&Z/4(7DP@R2E<HA1*45":ZCVYIXUQ(#(AEM.LRD*02ERH2-1'::BG$8
M*6EIO5Z+<DMT11Q>D-E9IJ"\J@5P&]NTZ_JI^?GF:U?K).D4?:].O\E7K;\M
M:UTU[:\,!L%[^*BGW>.M.E!7=G+@'(5(/(_EA4$D5H:8#D AL+U-G5J*%*U%
MQRI8(2E<<#530HHKEF#@#BXR6BG6XG,*R4X%)"M)T)="@XEL%(HD'2.[ 3-!
M+:4^FIM"0E00DZQ3U$Z5DC2H$J!.>9SP!C)4RVA2G$9J4 358IH64^7RJ U
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M8KL[&;3O%*1$3,; L':.X[I<K9:F[%<DNWGU$6YB7#>MBGWV14L,&6RB0E8
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ME_8G,>.HK?V!N9"6:EUX[<O183ZL8NLF1$^'#K2 D@U"B0OB,6$HV!S!5-5
M9V3N=;P@L70L/6:>[)@Q*%;EQ=CML-K?CNC@WY5I&>?# (;MMG<UKM+%\OEB
MW#:;3/==1"N]QL,^+:Y4QCTQ\&S(>99+I47*C)(':3@+.D.J4E"DE:?6"EN(
M<<#E4G,!M"3I" #0<3XX#?7:9_YJ+GX<Z?K'^D7[(U4_DI];?93ZV V#]_+^
MEYZTO\;>6_\ P'\L<!R ;/YVF=1D,NPBN1[<S@"5'2E1K4ZA4 C+Z/EP$^HJ
M -5 4%!J(I]!'' 'I0A::%13K'IJ.G6I*O340X*K!)TFF VBY ]2$_D39-Y[
M?A6*]7=O?+MKFQG[=N%C;H;E6A*5>I=FU5>N$!+Q%&%$(<J4I)*J8*S6L[9;
M%Q_<<YA'9KMDC[=%KNBX%QM$Y^RSTV3;K4"7*]-0?L;=L9NK<]*WE%)4\6T=
MU:G$8C.>U;LQV+0B]9VZ9.V4;-N&V6I<*/;?N]4]F^/,2IJX\AN2W*5*DZA]
MX.%*0'W$KHVG2<J#%IF9C$[E>&N<]K)&\^O>[\QMA7/9FZ=KO3=O;C@I@;D@
MV_<IL[,^Z0V4LP+M:G(]NAR8[S*4)48^H-/&N=:XB-D8C<LPSLWJ<W#L+ELS
MRUL5O_M-^XHE(NK5S<$MMIJ1\0B#*;C);>*0 -9!XU!KGAD](SF'SYM7-^VV
MV+NS:UQ:O5IA*MUODVO<HCVAQM;98>D2;$EIH/.C+SK6I0K7%N*V,&]<=LZB
MIFT]M;.C;2=NMLWI;-H7?9,Y]N:ZT&%.SPI4F)*84AQM:FO+Z@(<IEJPX[(Q
M V^=5',2];.O.T-28Z;XU"BW2^O/+?NDKX.VKA+2F6I9EZ7G5@J.H%1&=<5G
M;.9WHX*[\'W+WJQW;RZV3;]FQ+'9)UOL4+U6G[DMY*V9(<2E4VVLM?N-S4ZO
M-8.HI-:X'#7N7UM/K%G6B:U?KIL?[SW2E<Z"S=[7?_N]V#:WW"ZZN/ <CR%*
M]1>2G$Z%$CZ8F(G9*\3,1B-R3>'57%WK+V[='N7;EKE[3NINEE5$W)+9CRI(
M4%F;N&,4L,SG5R?R$ASTZYX1$1N4BM:SQ5C%I9%?ZYKWNZW1+7N2R3[<Z8=S
M3&^XYUM?LCSDAM2''(MN9C_?'J*[5ETY<3B5YF9G,[VB[<H2RY*+R4_$2I+F
MA*GFM.MY:@@ME ++@!S3GGVX(9!Y:<Q+ORRW5!W=95.*N,9N=:&"%+:>CBY1
MUJ^*:<0HJ:<20!J20H]^ S_R\ZL-Q[$^ZISVWWKSO&TS[K.V]N1Z^K]*(NXI
M=4^+M;"DKN:4%?D4OU%(/;@!+9U1[NM:)3K3ZP]<Y$ZX/TNLMW1)?=4^Z@+9
M+:?3]19HD  #*F S-MCKAW[:K!]S0K \9Z7),YJ3994>*%,3:)=5.85$=GW&
ME2=*'$4[L!C?EASYW%LF'O*%'L]SO2=UWRYW)V:S<9D-\3984ZMJZ%RVRE2X
MJ"HCTW2ZV!E7 7!>^JW<]WVXU:+?:'K>ZVI+#KLQ;>X[(?33JI:K8Y$1!LKJ
M%UHXX&T@\, =&ZGIT>SP=NN;,EW*TR&DKOD:YWH/W!V:7 2Y9W &%V>&IP:@
MFCJ%]Z<L!8>Y^<5LW/M.]V:9M;X&X76[1I[5V3=68PMD",[\,S&=MWIO2+K$
M,HI2&TJ"E\ 0<!=U@ZD!M/<>WMQ;?V$\C?-LL3&QYZ[K=$2X%[M:6_6=,&WM
MMHD15$#R:UK#?=48"Z-G=7\W9"-PBV;=NL2/?;PJ[OK5?8TUQNZ!Q2O1<N<Z
M,XB0V%F@C.(3I H%8"6U]7NX(R-SN[@L#M[:W--5/4S]YN,1P^"MQ,6ZL3$2
M3*C,Z1^;:"0FE0,!=C'7YO!M=ODQ+$8<541,*XQXDVVBV*T)TMJL<E^(\Y%D
M(/\ 9%H&KOP&GO,3>C^_]T73=5S3+8F7!X".N<\U)E!*E%5''XJ64N*5VE85
M7 67$F&'.@W%M"%2K=,8GIC?%)CE7H.!82\ZI!:+9T^1)%1WX#=*)UL[C@7B
MW7FW[?=:=;@&#/%WNPF3(I1#0T3M],MB0Q9W3H%7 D)4.&+<5MV=BL5B)S&\
MDO/61O*Z;AMM^?@S*0[;*@LQ;Q.8F6\^HH%N:\(R&H4E;X T#T0XGM5B)GBV
M3N3,1;XA=FZT=Q6.ZN7YNPS69<V!\%<PW=FHJY4MI5(CD.?/CW*'!<9X>DAL
MO/#@H8B)Q&(W*?*T^YB_?W4)-W3OW;O,ARRS6]Y6^2T[=3)O*FV2P@N^BJ)'
M+;4.++3&2E1+=?55FH)X8;UHK6-RX6>K+<"KO>Y,VQR;E#ORF8<QB/=4AZ-#
M?:)2F)/4%JCE6K,H XXG,IQ#$VT=][/VQO1.XF+#<H=MD1;[9[BVY>G+]=')
M-UC+*O1F*"'%):U44RE/YOA7#,F(%[5Y_P![V7.VK,VW:H"7MI1;]"M<EQ)>
M>9@S_B%L/%I=&''EIE#6T 2%YJ).>(,03[(Y\[TV5N_<>^"&K_>=S?!F:Y<"
M6XJX<)Q4IR([%:2IL,JUZ#Y:$#MQ.3#(4_JYN&X[I(9W5M*+=;&\W-*K-:KF
MB%'AQH[X?MD>*LL(48["P*@DA(&5,.*4<%5Q[KZSHVZ;-/V]?N7BUMW.,(UT
MN;6Y):;I&B1DZ(46RWN+ :9A,I2 %H&NH^L5<<0MOC'80[/ZW[_M;;B]F-;:
MFQMN,VN-;;>FQSFF;S;(SDI39FSKI<+0XC<;89&HMQO14*YG :P<[=]1.9.]
M7=T0"M<)RWL,1#)8$=[U&#13DX"A4L_9J37MP&'I12$OLM@I CN(2FH 62E]
M8U4 %3K37 ; GJ8WDW,V49S4JY;:VCMF1M%>SFKO)M\>599\4Q9-RBS$/*:M
MTU25%+93I67=5"*X!YNKK!WE>W-I-VBWKLMHV%8[A9[&PFZ+2MG[P"U_$2WV
M4I4^\VTT-(-3@)[!UU;]VW?+??%VPW-I\J0KXN<A$Z'%7 #!1 N%PCSQ:ECU
MBI82A2W",BG )-]]4O,?F;OWEIOE=AW%>FN5[YEVFVMMRKFU<E?%K2PXN3%M
M[ 9<"@:O@J+=!7A@+O<ZX]S6W<MPG7'8&XT1+E"7":=7OFX1]T%IYU4MMJ1N
M)5O7,N=IBRW-3\8I<JP0D:<5X:]PQ+8>K7>=HWA?-RS-I)N\Z.J4U8-O6L_=
M%EBS+BVI<Z/N)J!&9E;@M4J4AAYJ/+82@N-J4%U%%6%4OJYM]TNEDNM_V!;I
MH?N$._;PB0[[.@1+[?+-"DP8DB)"?MP^Y(<%4@!*$J45D"H& Q! YP;:;D<Z
M4WCE\[.VES64F?=K=#O3D6X6-<&07(C3<GX>(LM)<7^=2Z5)6:Z33 9.N_6I
M>KJ[R]N$G9,LW[E9<[7&V-(@7@BWM6EIM"5?>]CAQ2U?)18BH*9"W0U&'D<"
MTK% ?;Q]PGF#N>][9GIMUY8L>VMQ3-Q_=<_<$+6_)7$=;DMR&H$&'";87)U%
MELI)0*"M1@+@A^Y!?+:_?EV_EL[:VMRLM&^7Z'?(J-XS+S&7\9"=;NUP@7&U
M*MK!T@-J"GBK4GA08#"/4AUE[SZC-C6[:^ZX?I3G;E&N=X+$J%<-O3UQ*)^(
M9M<&WVV8U,C(2V7G%*])?DT)%#4-)7 S5.A9(2-* IU#A0BGE3Y$=@\3\N W
M\VHD?JI.?@KE^LAZ1AV\/Y*O6V./'A@,]>_I_2]]:?\ C;RW_P" _EA@.0J"
M0D4\?EX]_' 4-J/FS.1'XA]. 9@U )[A^+ , !09"M :T%>!&9I4Y' $* 57
M5Y@4!LA684V*4;4#DINH!TG*HK2N GAJ4I:]2E*&@-9DFK?UM!).:=6?RX I
M! 6E.G4E%4@&NG20D$ =U , V,H..!:BI2]*$*7K672E!JE.LDJ"4G@*Y=F
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MAPP'A?!!"LZJ"U9DU4*YU()[<!0MU&E/E!HNH! 4 >^B@1E@(U/(5J+I<\X
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M(T]B$RS#?9?D/Q@__]E02P$"% ,4    "  =0*]69D.3S^ -   /D   $0
M            @ $     8FYT8RTR,#(S,#,S,2YX<V102P$"% ,4    "  =
M0*]6";MYR$P*  !4A@  %0              @ $/#@  8FYT8RTR,#(S,#,S
M,5]C86PN>&UL4$L! A0#%     @ '4"O5IU@5F&H'0  -K<! !4
M     ( !CA@  &)N=&,M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    ( !U
MKU;$ \6M=$8  %4-!  5              "  6DV  !B;G1C+3(P,C,P,S,Q
M7VQA8BYX;6Q02P$"% ,4    "  =0*]6#K'8Z\\R  !1/0, %0
M    @ $0?0  8FYT8RTR,#(S,#,S,5]P<F4N>&UL4$L! A0#%     @ '4"O
M5K?<MTWQ_@  -H$,  \              ( !$K   &0R,30T-C9D,3!Q+FAT
M;5!+ 0(4 Q0    ( !U KU9HUB" SP<  "LI   1              "  3"O
M 0!D,C$T-#8V9&5X,S$Q+FAT;5!+ 0(4 Q0    ( !U KU:F+:>FWP<  $0I
M   1              "  2ZW 0!D,C$T-#8V9&5X,S$R+FAT;5!+ 0(4 Q0
M   ( !U KU:Y#B084P0  )@.   1              "  3R_ 0!D,C$T-#8V
M9&5X,S(Q+FAT;5!+ 0(4 Q0    ( !U KU9*-O&*!P0   D,   1
M      "  ;[# 0!D,C$T-#8V9&5X,S(R+FAT;5!+ 0(4 Q0    ( !U KU9/
M!2^!0'T  ,Q_   1              "  ?3' 0!G,C$T-#8V9S(P;C(P+FIP
M9U!+ 0(4 Q0    ( !U KU8ULE::ZBD! &(M 0 1              "  6-%
M @!G,C$T-#8V9S(Q;C(Q+FIP9U!+ 0(4 Q0    ( !U KU9YZ&:;8.0  (3F
M   1              "  7QO P!G,C$T-#8V9S(S;C(S+FIP9U!+ 0(4 Q0
M   ( !U KU;?!_SYW+   .*R   1              "  0M4! !G,C$T-#8V
M9S(T;C Q+FIP9U!+ 0(4 Q0    ( !U KU83*XWJON\  ,KQ   1
M      "  18%!0!G,C$T-#8V9S(T;C R+FIP9U!+ 0(4 Q0    ( !U KU;H
MV>[V</   '/R   1              "  0/U!0!G,C$T-#8V9S(U;C(U+FIP
M9U!+ 0(4 Q0    ( !U KU8-%TARQ^X  +#P   1              "  :+E
M!@!G,C$T-#8V9S(V;C Q+FIP9U!+ 0(4 Q0    ( !U KU9;*OSAB8X  />?
M   1              "  9C4!P!G,C$T-#8V9S(V;C R+FIP9U!+ 0(4 Q0
M   ( !U KU;T<)CQ#*T  .VN   1              "  5!C" !G,C$T-#8V
@9S(W;C(W+FIP9U!+!08     $P 3 +L$  "+$ D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
